data_2eyc_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2eyc _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.0 m . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 121.016 0.436 . . . . 0.0 109.933 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.7 t -98.99 122.65 42.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.518 0.675 . . . . 0.0 110.526 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 61.9 m -121.43 122.49 39.89 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.08 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.9 t -147.52 141.0 15.3 Favored Pre-proline 0 N--CA 1.448 -0.561 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -103.0 40.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.05 2.5 . . . . 0.0 113.957 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.9 t -158.26 135.52 10.09 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.622 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.8 mt -69.34 -28.0 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.356 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.7 t -83.5 -25.29 7.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.875 -175.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.36 -50.23 8.01 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.055 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.454 ' NH2' ' H ' ' A' ' 4' ' ' CYS . 7.3 tpp180 -53.5 -39.83 64.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.358 177.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.406 ' O ' HG22 ' A' ' 15' ' ' VAL . 24.4 p -62.41 -61.71 2.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.644 0.259 . . . . 0.0 111.222 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -64.52 -24.07 67.48 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.469 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 56.7 t80 -59.17 -58.14 9.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.064 173.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -70.2 -30.56 67.7 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.898 -179.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.406 HG22 ' O ' ' A' ' 11' ' ' SER . 72.0 t -65.2 -30.16 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.351 . . . . 0.0 110.707 176.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -71.74 -27.16 62.8 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.297 0.57 . . . . 0.0 110.574 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.589 ' HA ' ' O ' ' A' ' 21' ' ' THR . 46.5 tpt85 -76.49 -17.71 59.14 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.205 -178.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.403 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 77.9 mt -68.57 -52.29 19.94 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -175.252 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.403 ' HD2' ' N ' ' A' ' 18' ' ' LEU . 56.4 Cg_endo -69.72 -6.28 18.19 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.262 1.975 . . . . 0.0 113.271 -177.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.92 25.87 4.94 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.2 OUTLIER -103.19 128.65 27.15 Favored Pre-proline 0 N--CA 1.439 -0.99 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.457 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.74 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 12.7 Cg_endo -58.43 121.99 10.9 Favored 'Trans proline' 0 N--CA 1.449 -1.146 0 C-N-CA 122.577 2.184 . . . . 0.0 110.752 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.516 ' H ' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -50.67 -29.19 10.5 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.937 173.459 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.16 -46.95 87.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.976 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.74 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -67.5 -46.69 72.16 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 120.971 0.415 . . . . 0.0 109.992 177.841 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 6.9 m -62.66 -35.54 79.97 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.828 -177.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -58.41 -40.45 82.46 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 111.266 178.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.6 m -66.28 -22.75 66.31 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.528 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -86.11 -47.03 9.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.124 176.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.444 ' HB ' ' SG ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -69.39 -36.99 77.31 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 -177.28 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.67 -22.24 36.28 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.141 -172.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.557 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 3.2 m -60.94 116.31 4.38 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.2 pt -91.68 150.5 3.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.925 0.393 . . . . 0.0 111.866 -172.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 69.4 mt -116.14 107.93 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.37 0.605 . . . . 0.0 109.617 174.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.75 HD13 ' HB3' ' A' ' 38' ' ' ALA . 15.3 pt -116.0 152.81 48.06 Favored Pre-proline 0 C--N 1.314 -0.95 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.91 -175.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.38 -64.71 0.1 OUTLIER 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 123.049 2.499 . . . . 0.0 112.41 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.39 -142.47 8.94 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.75 ' HB3' HD13 ' A' ' 35' ' ' ILE . . . 62.52 80.37 0.23 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.388 0.613 . . . . 0.0 110.939 177.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.63 96.63 0.13 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.745 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.638 ' HB3' ' HB2' ' A' ' 44' ' ' TYR . 62.5 m -59.59 144.11 85.3 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.181 177.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.58 ' HD2' ' HD2' ' A' ' 44' ' ' TYR . 57.2 Cg_endo -70.96 -175.13 1.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.974 2.449 . . . . 0.0 113.25 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.41 7.1 33.4 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.488 -0.778 . . . . 0.0 114.428 -170.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.542 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 16.7 p-10 -108.45 -17.51 13.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 176.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.638 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . 22.2 m-85 -102.74 0.73 33.35 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.612 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.01 18.38 18.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.424 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.5 t-20 . . . . . 0 C--O 1.253 1.252 0 CA-C-O 118.251 -0.88 . . . . 0.0 110.215 -179.213 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.1 m . . . . . 0 N--CA 1.476 0.844 0 CA-C-O 120.782 0.325 . . . . 0.0 110.375 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.8 m -89.08 123.92 33.81 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.817 0.341 . . . . 0.0 110.47 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 63.8 m -124.25 106.7 10.49 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' HB3' ' HB3' ' A' ' 10' ' ' ARG . 7.8 t -100.76 132.6 21.97 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.054 -178.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.607 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.7 Cg_endo -86.05 34.21 0.47 Allowed 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.97 2.447 . . . . 0.0 112.982 -177.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.505 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 38.6 t -164.88 133.28 3.35 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 120.983 0.42 . . . . 0.0 110.573 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.31 -26.7 34.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.186 -0.916 . . . . 0.0 109.113 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.1 t -82.77 -47.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.088 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.505 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -61.78 -43.24 99.24 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.966 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB3' ' HB3' ' A' ' 4' ' ' CYS . 6.0 ptp180 -65.41 -28.23 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.095 0.474 . . . . 0.0 110.69 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.514 ' O ' HG22 ' A' ' 15' ' ' VAL . 42.4 m -72.62 -40.59 66.34 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.357 176.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -65.8 -28.69 69.19 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.632 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.24 -50.63 72.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.972 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -66.0 -26.42 67.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.192 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.514 HG22 ' O ' ' A' ' 11' ' ' SER . 84.5 t -68.2 -34.49 66.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.699 -179.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.481 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.0 t -82.26 -24.5 34.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 121.371 0.605 . . . . 0.0 110.393 -178.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -80.5 -13.05 59.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.482 -178.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.432 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 8.2 mt -71.76 -52.1 8.38 Favored Pre-proline 0 N--CA 1.444 -0.745 0 CA-C-N 115.998 -0.547 . . . . 0.0 112.447 -177.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.481 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 6.4 Cg_exo -75.01 18.39 0.54 Allowed 'Trans proline' 0 C--N 1.358 1.051 0 C-N-CA 122.538 2.159 . . . . 0.0 113.11 -178.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 78.9 40.15 18.14 Favored Glycine 0 N--CA 1.443 -0.897 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.526 178.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.458 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 3.0 m -107.08 135.96 19.53 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 175.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.567 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 11.0 Cg_endo -57.24 116.65 3.36 Favored 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 122.938 2.425 . . . . 0.0 111.411 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -39.83 -34.94 0.3 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.903 170.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.62 -49.32 73.76 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.183 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.567 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 45.0 tp -68.55 -36.4 78.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-O 120.852 0.358 . . . . 0.0 110.199 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 36.0 m -66.78 -42.37 86.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.237 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -61.65 -24.64 66.86 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.657 0.741 . . . . 0.0 111.653 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.2 m -76.13 -22.62 55.27 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.984 -178.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -109.52 -42.69 4.25 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.332 0.587 . . . . 0.0 110.784 -177.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.5 m -62.86 -37.88 88.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.186 -178.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 108.65 -15.85 34.49 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.753 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.496 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 34.5 m -71.05 133.4 46.27 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 176.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.4 pt -103.96 141.22 20.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.233 0.539 . . . . 0.0 111.383 -175.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 68.8 mt -108.15 107.73 23.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.977 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.788 HG21 ' H ' ' A' ' 37' ' ' GLY . 5.0 mp -89.86 130.21 43.62 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.05 -179.347 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.55 -13.31 38.61 Favored 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.836 2.357 . . . . 0.0 112.235 175.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.788 ' H ' HG21 ' A' ' 35' ' ' ILE . . . -91.03 -137.35 7.22 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.903 176.013 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.45 15.9 0.26 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.613 0.244 . . . . 0.0 111.387 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.9 m -120.02 105.51 11.11 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.093 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.7 p -134.47 135.96 24.79 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.51 173.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.459 ' HG2' ' OD1' ' A' ' 43' ' ' ASP . 53.3 Cg_endo -67.15 176.6 4.47 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.748 2.299 . . . . 0.0 112.802 -176.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.24 24.94 5.82 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.589 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.459 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 11.3 p-10 -112.22 -18.29 12.57 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 170.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.607 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 17.7 m-85 -98.4 3.6 48.47 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.789 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.56 18.82 21.39 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.824 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 . . . . . 0 C--O 1.246 0.904 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.732 -179.123 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.476 0.827 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -98.26 136.4 38.5 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-O 120.921 0.391 . . . . 0.0 112.017 -176.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 96.9 m -134.18 112.72 11.34 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 173.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 41.4 m -101.56 152.5 38.06 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.911 -173.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -99.74 24.67 0.18 Allowed 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.722 2.282 . . . . 0.0 113.598 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 t -174.03 132.5 0.41 Allowed 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.118 0.485 . . . . 0.0 110.269 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.478 ' HA ' ' HB3' ' A' ' 10' ' ' ARG . 59.3 mt -69.79 -19.97 23.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.154 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -71.36 -41.99 73.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.509 ' HB2' HG23 ' A' ' 30' ' ' THR . . . -66.08 -48.17 71.84 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.8 174.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.478 ' HB3' ' HA ' ' A' ' 7' ' ' ILE . 4.0 tpp180 -50.97 -41.78 59.56 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.167 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.405 ' O ' HG23 ' A' ' 15' ' ' VAL . 41.5 t -58.76 -55.19 38.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.522 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.0 p30 -71.04 -26.89 63.29 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.246 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -62.22 -50.44 71.75 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.615 173.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -54.98 -44.19 74.22 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.674 178.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 11' ' ' SER . 57.7 t -67.5 -27.11 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.455 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.536 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.2 t -83.93 -43.18 15.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 121.01 0.433 . . . . 0.0 111.035 -176.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -76.38 -10.88 59.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.021 0.439 . . . . 0.0 111.409 -177.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.4 mt -69.95 -51.12 15.34 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -176.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.536 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 48.9 Cg_endo -71.8 -8.78 23.72 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.292 1.995 . . . . 0.0 113.131 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.11 19.1 5.27 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.347 -0.93 . . . . 0.0 113.312 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.489 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 3.1 m -83.66 137.33 41.48 Favored Pre-proline 0 N--CA 1.431 -1.383 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 21.0 Cg_endo -63.74 125.93 16.42 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.564 2.176 . . . . 0.0 110.511 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -42.14 -26.5 0.1 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.412 170.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.435 ' HA ' ' CD1' ' A' ' 34' ' ' ILE . . . -51.09 -54.14 27.71 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.769 0.319 . . . . 0.0 110.934 171.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.2 tt -67.69 -41.29 83.88 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 109.85 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.0 m -81.51 9.05 8.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.3 -175.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.422 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -109.64 -49.2 3.13 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.859 0.838 . . . . 0.0 110.302 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -64.37 -33.26 75.45 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 113.859 -1.518 . . . . 0.0 112.37 -173.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -96.57 -15.19 21.73 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.228 1.014 . . . . 0.0 109.527 -176.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.509 HG23 ' HB2' ' A' ' 9' ' ' ALA . 55.7 m -96.32 -25.89 15.59 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 113.791 -1.55 . . . . 0.0 112.279 -172.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.66 7.33 57.89 Favored Glycine 0 C--N 1.328 0.093 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.422 ' HB3' ' HA ' ' A' ' 27' ' ' ALA . 19.8 t -92.92 157.85 16.13 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.2 pt -118.43 160.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.573 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.435 ' CD1' ' HA ' ' A' ' 24' ' ' ALA . 69.9 mt -122.31 137.37 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.599 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.418 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -130.66 157.27 78.19 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 176.268 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.418 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 45.5 Cg_endo -70.54 -28.12 21.89 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.497 2.131 . . . . 0.0 112.263 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.73 -140.5 11.29 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.006 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -152.65 12.93 0.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.685 0.279 . . . . 0.0 111.353 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.2 m -90.54 104.98 17.5 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.254 0.549 . . . . 0.0 110.0 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 94.9 m -129.43 131.68 23.77 Favored Pre-proline 0 C--N 1.311 -1.085 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.954 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -69.81 176.09 7.27 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.697 2.265 . . . . 0.0 112.499 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.51 3.06 26.92 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 116.069 -0.514 . . . . 0.0 113.755 -175.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -94.36 -22.34 18.39 Favored 'General case' 0 CA--C 1.513 -0.481 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -121.17 20.71 11.37 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.273 -1.331 . . . . 0.0 109.661 -176.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -99.37 16.37 23.28 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.031 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.737 -0.649 . . . . 0.0 109.566 -178.7 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 60.2 m . . . . . 0 N--CA 1.476 0.874 0 CA-C-O 120.835 0.35 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.608 HG22 ' CZ ' ' A' ' 13' ' ' PHE . 26.8 m -104.27 118.37 36.46 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.747 178.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 62.6 m -108.87 128.14 54.65 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.344 -174.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.5 m -128.98 132.55 24.44 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.548 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.775 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.2 Cg_endo -90.84 23.82 0.62 Allowed 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.899 2.399 . . . . 0.0 114.245 -177.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.1 p -171.01 149.38 2.92 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 122.07 -0.394 . . . . 0.0 111.438 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 58.7 mt -65.22 -29.45 47.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.156 178.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.5 t -76.63 -38.81 31.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.833 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -72.88 -41.99 64.11 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.463 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 10.7 tpp180 -54.4 -36.76 64.29 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.721 177.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.49 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 4.0 p -79.52 -55.09 5.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.66 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 p30 -60.88 -24.27 65.83 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 121.218 0.533 . . . . 0.0 110.787 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.635 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 71.0 t80 -61.39 -60.51 3.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.586 173.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.49 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 8.5 p30 -69.49 -28.59 66.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.673 -175.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 93.6 t -71.52 -23.61 22.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.394 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.501 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.5 t -76.86 -32.06 57.25 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 121.996 -0.44 . . . . 0.0 110.595 -179.157 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.6 ' HA ' ' O ' ' A' ' 21' ' ' THR . 1.7 ptm180 -87.19 -0.06 56.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.194 0.521 . . . . 0.0 110.697 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HB3' ' HD3' ' A' ' 19' ' ' PRO . 63.9 tp -70.32 -53.32 10.56 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.662 179.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.518 ' HD3' ' HB3' ' A' ' 18' ' ' LEU . 91.1 Cg_endo -82.2 28.03 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.171 1.914 . . . . 0.0 113.759 -177.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.94 39.53 8.57 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.317 175.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.6 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.8 OUTLIER -115.37 136.56 22.74 Favored Pre-proline 0 N--CA 1.437 -1.093 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 174.917 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.836 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 17.7 Cg_endo -63.2 120.99 8.67 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 122.617 2.211 . . . . 0.0 111.047 175.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.635 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 11.0 pt-20 -56.88 -23.71 46.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.243 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.498 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -63.34 -41.95 98.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.729 173.277 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.836 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.5 OUTLIER -71.8 -39.12 70.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 120.903 0.382 . . . . 0.0 110.215 176.795 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 34.3 m -66.97 -36.96 83.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.041 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.4 -36.15 73.13 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.785 0.802 . . . . 0.0 110.898 176.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -69.04 -23.79 64.1 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 114.093 -1.412 . . . . 0.0 111.129 -176.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -102.65 -46.07 4.84 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.626 0.727 . . . . 0.0 110.02 -176.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.5 m -59.95 -44.36 94.45 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 114.626 -1.17 . . . . 0.0 112.172 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.78 -9.16 14.49 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.28 -0.962 . . . . 0.0 112.037 -176.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 94.7 m -71.38 158.8 35.68 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 175.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 26.3 pt -126.39 139.59 51.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.963 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.498 HD11 ' HA ' ' A' ' 24' ' ' ALA . 71.3 mt -112.32 103.28 15.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.791 177.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 34.1 pt -107.83 148.28 37.07 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.142 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -76.93 12.06 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.997 2.465 . . . . 0.0 112.387 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -130.45 -147.39 6.13 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.74 21.86 2.14 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.163 0.506 . . . . 0.0 110.273 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 m -79.98 72.25 6.74 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.396 -175.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 90.9 m -128.29 131.51 23.82 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.287 176.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.411 ' C ' ' H ' ' A' ' 43' ' ' ASP . 55.7 Cg_endo -69.23 174.55 8.88 Favored 'Trans proline' 0 CA--C 1.531 0.348 0 C-N-CA 122.595 2.196 . . . . 0.0 111.903 176.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.98 26.21 1.47 Allowed Glycine 0 CA--C 1.521 0.424 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.236 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.531 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 24.7 t70 -115.38 -29.78 6.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.775 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 10.4 m-85 -105.91 5.18 30.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.967 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.61 17.11 23.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.913 -174.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.0 t30 . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.086 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.591 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 23.5 m . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.465 HG23 ' CZ ' ' A' ' 13' ' ' PHE . 21.9 m -134.16 124.16 25.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.011 -176.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.451 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 82.6 m -128.16 142.84 51.06 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.647 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 0.5 OUTLIER -128.42 151.66 76.96 Favored Pre-proline 0 C--N 1.32 -0.676 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.505 -175.716 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.647 ' HD2' ' SG ' ' A' ' 4' ' ' CYS . 88.8 Cg_endo -82.05 1.66 9.06 Favored 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.955 2.436 . . . . 0.0 113.958 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.8 p -160.9 155.55 23.64 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 121.88 -0.512 . . . . 0.0 110.94 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 59.2 mt -73.05 -28.58 26.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.421 178.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.6 t -67.87 -44.43 85.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.766 -178.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.34 -45.2 81.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.961 177.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -54.2 -39.27 66.53 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.38 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.504 ' O ' HG22 ' A' ' 15' ' ' VAL . 70.4 m -60.5 -55.07 37.88 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.641 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 11.3 p30 -75.28 -22.62 57.62 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.02 0.438 . . . . 0.0 110.906 -176.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.465 ' CZ ' HG23 ' A' ' 2' ' ' THR . 44.8 t80 -58.16 -53.41 58.62 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.086 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -61.96 -29.89 70.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.783 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 11' ' ' SER . 79.5 t -65.26 -33.23 62.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.89 178.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.532 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 39.8 t -75.71 -21.35 57.63 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 121.469 0.652 . . . . 0.0 110.151 -178.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.632 ' HD3' ' HG3' ' A' ' 23' ' ' GLU . 27.3 tpt180 -74.68 -26.45 59.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.013 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.556 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 97.6 mt -62.52 -49.22 84.35 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -175.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.556 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 13.7 Cg_exo -70.54 -5.41 16.62 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.226 1.951 . . . . 0.0 112.995 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.69 28.92 7.62 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.461 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.657 HG21 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -90.68 140.87 26.6 Favored Pre-proline 0 N--CA 1.431 -1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 177.769 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.685 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 14.4 Cg_endo -62.05 121.76 9.95 Favored 'Trans proline' 0 N--CA 1.443 -1.462 0 C-N-CA 122.941 2.427 . . . . 0.0 110.857 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.632 ' HG3' ' HD3' ' A' ' 17' ' ' ARG . 1.1 mp0 -45.93 -32.35 2.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.059 173.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.2 -48.11 82.82 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.066 175.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.685 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.2 tt -66.68 -44.49 81.67 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.095 178.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.483 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 14.0 m -66.76 -40.4 88.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.508 -176.017 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.02 -42.21 93.84 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.519 0.676 . . . . 0.0 111.021 178.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.3 m -68.22 -21.87 64.82 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.353 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -100.7 -38.09 8.45 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.674 0.75 . . . . 0.0 109.847 -174.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.6 m -75.65 -57.68 3.74 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.596 -1.184 . . . . 0.0 112.024 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.0 -20.38 2.14 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 119.705 -1.236 . . . . 0.0 112.527 -176.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 30.7 m -66.83 155.91 37.01 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 175.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 33.1 pt -120.55 148.84 23.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.331 -0.547 . . . . 0.0 111.814 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 50.8 mm -102.13 139.22 23.77 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.344 176.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.591 ' O ' ' HB ' ' A' ' 1' ' ' THR . 3.1 pt -146.31 151.37 43.87 Favored Pre-proline 0 C--N 1.316 -0.859 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.25 -179.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -87.75 30.99 0.44 Allowed 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.498 2.799 . . . . 0.0 112.233 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.51 137.79 4.81 Favored Glycine 0 N--CA 1.446 -0.676 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.699 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.29 30.17 0.34 Allowed 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.057 0.456 . . . . 0.0 111.58 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.8 m -80.38 48.66 1.05 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.511 0.672 . . . . 0.0 111.632 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.574 ' SG ' HD11 ' A' ' 35' ' ' ILE . 76.3 m -94.29 126.38 48.6 Favored Pre-proline 0 C--N 1.313 -1.003 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.699 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -75.03 176.36 10.02 Favored 'Trans proline' 0 CA--C 1.531 0.352 0 C-N-CA 122.762 2.308 . . . . 0.0 112.36 176.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.95 -8.69 74.17 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 114.572 0.589 . . . . 0.0 114.572 -171.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -94.99 -22.12 18.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.831 0.824 . . . . 0.0 109.294 -179.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.451 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 20.8 m-85 -107.23 18.07 22.12 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.278 -178.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.01 33.46 0.79 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.261 -177.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.412 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 16.6 m-80 . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.791 -0.623 . . . . 0.0 109.497 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.521 ' HB ' HG13 ' A' ' 35' ' ' ILE . 7.5 m . . . . . 0 N--CA 1.475 0.798 0 CA-C-O 120.782 0.325 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.414 HG22 ' CZ ' ' A' ' 13' ' ' PHE . 7.3 m -90.57 115.02 27.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.103 0.478 . . . . 0.0 110.785 178.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.4 m -115.08 144.56 43.45 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.599 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.4 t -156.28 110.82 2.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.012 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.568 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 96.7 Cg_endo -84.61 45.4 1.68 Allowed 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.971 2.447 . . . . 0.0 113.881 -173.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.411 ' HG ' ' C ' ' A' ' 5' ' ' PRO . 19.8 m -158.17 127.28 5.69 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.4 mp -64.85 -36.96 78.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.9 t -62.59 -38.8 82.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.326 -1.307 . . . . 0.0 110.251 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.4 22.07 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.26 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.3 tpp180 -50.89 -43.45 59.65 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.833 175.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.503 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.7 m -53.7 -55.01 29.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.423 0.154 . . . . 0.0 111.378 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -76.65 -23.03 53.29 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.398 -0.521 . . . . 0.0 110.608 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.414 ' CZ ' HG22 ' A' ' 2' ' ' THR . 34.7 t80 -65.48 -49.07 70.44 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.114 175.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -59.97 -32.64 71.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.127 0.489 . . . . 0.0 109.843 174.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 11' ' ' SER . 92.8 t -72.82 -24.0 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.99 177.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -86.26 5.71 33.09 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-O 121.753 0.787 . . . . 0.0 109.62 -178.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.46 ' NE ' ' HG3' ' A' ' 23' ' ' GLU . 13.7 mmm180 -106.3 -23.53 12.53 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.556 0.693 . . . . 0.0 109.185 178.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -56.92 -47.62 98.77 Favored Pre-proline 0 CA--C 1.547 0.846 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.131 175.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.425 ' HG2' ' OG1' ' A' ' 21' ' ' THR . 82.3 Cg_endo -79.61 4.16 6.91 Favored 'Trans proline' 0 C--N 1.36 1.17 0 C-N-CA 121.779 1.653 . . . . 0.0 113.037 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.72 20.86 45.64 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.505 176.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.709 HG21 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -81.06 142.46 51.62 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.206 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.709 ' HD2' HG21 ' A' ' 21' ' ' THR . 38.2 Cg_endo -70.85 130.44 17.99 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 C-N-CA 123.156 2.571 . . . . 0.0 111.494 176.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.46 ' HG3' ' NE ' ' A' ' 17' ' ' ARG . 51.4 mt-10 -41.83 -36.08 0.96 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.485 171.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.71 -52.1 50.96 Favored 'General case' 0 C--N 1.33 -0.266 0 O-C-N 123.381 0.426 . . . . 0.0 110.857 175.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.503 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -68.19 -41.62 81.12 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.167 179.063 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.577 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 7.5 m -80.57 12.17 3.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.523 -176.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -108.05 -48.28 3.41 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 121.894 0.854 . . . . 0.0 110.104 173.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.0 m -62.73 -29.62 70.81 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 113.817 -1.538 . . . . 0.0 112.117 -174.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -95.86 -22.5 17.42 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.885 0.85 . . . . 0.0 110.117 -175.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -93.21 -38.61 11.46 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.528 -1.214 . . . . 0.0 111.82 -171.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.74 -18.68 8.58 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.433 -177.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 6.6 m -64.9 150.48 47.73 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 32.9 pt -122.3 149.09 25.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.085 0.469 . . . . 0.0 111.495 -177.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.5 mt -111.28 110.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.829 176.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.873 HD12 ' HB2' ' A' ' 38' ' ' ALA . 5.7 pt -108.52 129.36 24.11 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.907 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.09 -32.31 17.43 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.435 2.09 . . . . 0.0 112.68 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.07 117.91 0.83 Allowed Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.873 ' HB2' HD12 ' A' ' 35' ' ' ILE . . . 165.2 102.0 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.741 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -172.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.41 94.39 0.01 OUTLIER 'General case' 0 N--CA 1.435 -1.216 0 O-C-N 123.884 0.74 . . . . 0.0 110.377 172.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.41 ' SG ' ' HB2' ' A' ' 45' ' ' ALA . 4.2 t -65.92 120.52 69.8 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.356 -175.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.41 170.27 20.66 Favored 'Trans proline' 0 C--O 1.236 0.379 0 C-N-CA 122.766 2.311 . . . . 0.0 112.473 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.75 20.7 7.39 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.008 -173.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -119.1 -11.53 9.61 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 174.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.568 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 19.6 m-85 -113.81 0.11 14.38 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.756 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.41 ' HB2' ' SG ' ' A' ' 40' ' ' CYS . . . -135.9 64.99 1.55 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 120.962 0.41 . . . . 0.0 110.431 -177.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.7 m120 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.582 -0.723 . . . . 0.0 109.304 175.608 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.0 m . . . . . 0 N--CA 1.477 0.897 0 CA-C-O 120.554 0.216 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.444 ' OG1' HG12 ' A' ' 34' ' ' ILE . 31.1 m -97.33 112.49 24.28 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.129 0.49 . . . . 0.0 110.274 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.625 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 74.3 m -105.98 146.63 29.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.082 -176.821 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.426 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 2.1 t -136.8 141.99 37.13 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 5.4 Cg_exo -78.59 17.12 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.789 2.326 . . . . 0.0 115.043 -171.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -170.29 150.78 3.66 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 118.975 0.807 . . . . 0.0 110.755 177.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.736 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 3.3 mp -64.66 -33.52 63.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.893 0.854 . . . . 0.0 109.107 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.16 -51.09 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.754 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.84 -34.15 69.03 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.4 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.736 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -68.21 -25.22 65.11 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 109.93 -179.675 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.471 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 69.8 m -67.91 -47.42 68.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.903 172.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -55.27 -39.66 70.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.195 0.522 . . . . 0.0 109.879 176.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.424 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 5.8 t80 -53.0 -56.65 14.47 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 114.954 -1.021 . . . . 0.0 112.097 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.471 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 11.9 p30 -74.8 -31.39 61.71 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 121.2 -0.2 . . . . 0.0 111.213 -174.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 11' ' ' SER . 96.6 t -70.52 -30.9 44.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 111.131 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.41 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.2 t -74.64 -22.9 58.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.935 -178.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.671 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 74.2 mtm180 -77.98 -22.22 49.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.579 0.228 . . . . 0.0 111.172 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.6 mt -54.45 -50.58 84.37 Favored Pre-proline 0 N--CA 1.443 -0.816 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 -176.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.41 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 55.6 Cg_endo -72.14 5.0 2.87 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.099 1.866 . . . . 0.0 113.089 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.71 28.14 9.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.936 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.67 133.48 24.48 Favored Pre-proline 0 N--CA 1.438 -1.037 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.672 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 18.2 Cg_endo -62.01 124.44 14.44 Favored 'Trans proline' 0 N--CA 1.445 -1.381 0 C-N-CA 122.755 2.304 . . . . 0.0 109.798 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.671 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 9.4 pt-20 -53.63 -20.2 4.94 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.269 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -64.56 -47.09 80.03 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 173.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.672 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.5 tt -63.74 -44.12 94.47 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 120.871 0.367 . . . . 0.0 110.347 176.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 14.9 m -69.21 -30.97 69.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.309 -177.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.461 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -65.71 -31.14 71.97 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.749 0.785 . . . . 0.0 110.334 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 m -74.75 -20.59 59.76 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.78 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -98.12 -52.99 3.51 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-O 121.91 0.862 . . . . 0.0 110.244 -176.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 52.0 m -70.58 -47.47 60.07 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 114.013 -1.448 . . . . 0.0 112.161 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.1 0.79 10.56 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.953 -1.117 . . . . 0.0 112.753 -177.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.461 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 25.5 m -71.46 161.34 31.2 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 174.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.1 pt -132.42 141.25 45.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.967 0.413 . . . . 0.0 111.301 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.444 HG12 ' OG1' ' A' ' 2' ' ' THR . 77.4 mt -97.0 112.66 29.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.817 177.154 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.578 HG12 ' HB3' ' A' ' 40' ' ' CYS . 2.4 pp -105.72 147.53 34.87 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.869 0.366 . . . . 0.0 111.5 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -78.56 28.91 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 123.409 2.739 . . . . 0.0 112.999 -176.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -133.27 -151.08 6.49 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 177.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -148.39 22.38 1.05 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.608 0.24 . . . . 0.0 111.361 -177.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.0 m -133.0 -46.48 0.85 Allowed 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.828 -179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.651 ' HB2' ' HD2' ' A' ' 41' ' ' PRO . 24.1 p 48.92 164.92 0.03 OUTLIER Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 124.904 1.378 . . . . 0.0 113.187 -174.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.651 ' HD2' ' HB2' ' A' ' 40' ' ' CYS . 31.6 Cg_endo -65.82 152.55 81.24 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.253 1.969 . . . . 0.0 112.682 176.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.11 12.2 7.1 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.753 -0.658 . . . . 0.0 113.997 -172.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.44 ' OD1' ' HB2' ' A' ' 41' ' ' PRO . 19.1 p-10 -106.49 -12.31 15.66 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.625 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.9 m-85 -117.67 5.53 12.35 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.616 175.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.06 35.5 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.06 -172.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.8 m120 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.579 176.712 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.477 ' HB ' ' HB ' ' A' ' 35' ' ' ILE . 9.1 m . . . . . 0 N--CA 1.475 0.819 0 CA-C-O 121.041 0.448 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 31.7 m -135.54 142.14 45.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.804 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 58.9 m -125.06 132.27 53.2 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -172.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.0 m -126.47 123.28 24.03 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.377 174.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -80.74 19.67 1.08 Allowed 'Trans proline' 0 CA--C 1.532 0.406 0 C-N-CA 122.416 2.077 . . . . 0.0 113.441 -174.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -157.97 136.42 11.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.786 HD13 ' H ' ' A' ' 7' ' ' ILE . 4.1 mp -57.51 -38.66 64.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.326 0.584 . . . . 0.0 109.672 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.6 t -72.88 -36.78 52.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.271 -177.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.13 82.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.477 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -71.64 -39.68 70.21 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.23 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.579 ' O ' HG22 ' A' ' 15' ' ' VAL . 5.9 p -66.38 -37.39 85.17 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.557 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -66.25 -41.98 89.21 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.379 0.609 . . . . 0.0 109.834 175.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 23' ' ' GLU . 13.1 t80 -60.86 -42.99 98.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.123 179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -61.54 -34.29 75.29 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.156 177.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.579 HG22 ' O ' ' A' ' 11' ' ' SER . 47.2 t -78.57 -6.18 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.475 178.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.665 ' O ' ' HB ' ' A' ' 21' ' ' THR . 1.8 t -108.96 14.94 23.79 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-O 121.888 0.851 . . . . 0.0 108.855 176.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 21' ' ' THR . 6.2 tpt180 -120.9 -42.84 2.48 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 114.979 -1.01 . . . . 0.0 108.365 175.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.14 -51.35 57.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 CA-C-N 113.727 -1.578 . . . . 0.0 113.372 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.05 35.46 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.813 0 C-N-CA 122.641 2.227 . . . . 0.0 113.203 -175.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 66.51 46.68 75.1 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.935 178.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.665 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.57 132.23 24.27 Favored Pre-proline 0 N--CA 1.441 -0.899 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.857 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.684 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 30.1 Cg_endo -63.83 122.45 10.51 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.745 2.297 . . . . 0.0 111.156 177.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 13' ' ' PHE . 1.1 mp0 -51.9 -31.48 28.49 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.142 174.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.63 -48.82 79.72 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.573 177.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.684 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.9 OUTLIER -67.26 -41.9 84.8 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.204 0.526 . . . . 0.0 110.177 179.219 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 86.2 m -74.52 -14.12 60.77 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.82 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -70.27 -32.47 70.29 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 122.052 0.93 . . . . 0.0 109.883 174.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.6 m -72.05 -23.21 61.33 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 113.885 -1.507 . . . . 0.0 110.418 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -99.57 -49.42 4.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.352 0.596 . . . . 0.0 110.608 -176.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m -66.7 -44.92 80.41 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.567 -178.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.51 -15.17 14.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.429 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 82.6 m -65.89 145.43 55.94 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 176.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.8 pt -116.62 153.59 18.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.74 0.305 . . . . 0.0 111.487 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 67.7 mt -102.06 133.54 45.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.956 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.477 ' HB ' ' HB ' ' A' ' 1' ' ' THR . 45.7 mm -93.13 123.43 60.94 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.843 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -55.76 -40.04 87.59 Favored 'Trans proline' 0 CA--C 1.528 0.195 0 C-N-CA 122.829 2.353 . . . . 0.0 112.073 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.41 -125.4 4.67 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.999 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.24 72.8 1.34 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.561 0.696 . . . . 0.0 110.376 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.419 ' H ' HG23 ' A' ' 35' ' ' ILE . 11.2 m -145.78 108.94 4.6 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.112 174.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 16.8 t -153.89 123.01 3.15 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.129 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.54 164.83 34.47 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.918 2.412 . . . . 0.0 112.84 179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -74.41 6.72 21.69 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.584 -0.734 . . . . 0.0 113.314 -175.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -92.8 -21.28 20.0 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -108.44 5.99 25.82 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.892 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -122.88 18.88 10.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.872 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.307 -0.854 . . . . 0.0 110.909 -174.719 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.414 ' O ' HG21 ' A' ' 34' ' ' ILE . 8.5 m . . . . . 0 N--CA 1.477 0.914 0 CA-C-O 120.958 0.408 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 35.5 m -118.19 132.68 56.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.456 -175.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.556 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 98.3 m -106.82 126.38 52.23 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.702 174.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.456 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 1.8 t -115.15 140.45 25.68 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -91.74 22.79 0.64 Allowed 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.646 2.23 . . . . 0.0 113.652 -175.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 51.5 m -150.86 143.0 24.11 Favored 'General case' 0 C--N 1.332 -0.18 0 O-C-N 122.044 -0.41 . . . . 0.0 110.71 -179.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.0 mt -71.16 -27.01 28.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.256 0.55 . . . . 0.0 110.547 -175.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 80.0 t -87.27 -51.91 12.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.709 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -50.16 -42.53 51.16 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.348 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -26.3 68.31 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.286 0.565 . . . . 0.0 110.881 -176.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.514 ' O ' HG21 ' A' ' 15' ' ' VAL . 22.2 t -77.81 -56.16 4.73 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.464 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -68.03 -21.76 65.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.067 0.46 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.448 ' HZ ' ' HB2' ' A' ' 23' ' ' GLU . 21.7 t80 -57.97 -56.01 27.54 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.033 170.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.416 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 12.1 p30 -69.59 -25.16 63.84 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.679 -177.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.514 HG21 ' O ' ' A' ' 11' ' ' SER . 84.8 t -66.99 -22.83 29.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.758 173.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.6 t -83.64 -22.92 32.04 Favored 'General case' 0 C--O 1.221 -0.431 0 CA-C-O 121.35 0.595 . . . . 0.0 109.892 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.559 ' HG2' ' O ' ' A' ' 21' ' ' THR . 3.5 tmt_? -92.26 -29.57 16.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.902 -172.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.663 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -54.87 -44.83 99.7 Favored Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 114.599 -1.182 . . . . 0.0 113.179 -177.802 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.663 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 64.7 Cg_endo -73.52 14.0 0.67 Allowed 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 122.046 1.83 . . . . 0.0 113.808 -177.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.96 27.08 8.03 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.779 -0.724 . . . . 0.0 113.096 176.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.559 ' O ' ' HG2' ' A' ' 17' ' ' ARG . 4.5 m -104.73 138.34 19.48 Favored Pre-proline 0 N--CA 1.429 -1.49 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 17.4 Cg_endo -62.02 123.53 12.73 Favored 'Trans proline' 0 N--CA 1.441 -1.58 0 C-N-CA 122.335 2.024 . . . . 0.0 109.889 176.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.448 ' HB2' ' HZ ' ' A' ' 13' ' ' PHE . 14.8 pt-20 -45.22 -30.2 1.15 Allowed 'General case' 0 C--N 1.324 -0.54 0 O-C-N 123.816 0.697 . . . . 0.0 110.03 174.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.506 ' HA ' HD13 ' A' ' 34' ' ' ILE . . . -58.13 -46.74 85.11 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.704 177.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.62 -37.77 73.86 Favored 'General case' 0 N--CA 1.444 -0.765 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 85.9 m -71.55 -33.44 69.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.651 -177.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.84 -46.12 91.8 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 122.073 0.94 . . . . 0.0 110.245 176.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.7 m -67.18 -20.43 65.72 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 113.607 -1.633 . . . . 0.0 111.729 -178.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -100.45 -45.88 5.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.599 0.714 . . . . 0.0 110.175 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.432 HG22 ' HB2' ' A' ' 13' ' ' PHE . 99.8 m -72.58 -40.73 66.37 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.616 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.64 16.39 4.6 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.082 -1.056 . . . . 0.0 112.67 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.3 m -98.44 170.81 8.58 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -129.86 148.1 33.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.818 -0.353 . . . . 0.0 111.569 -177.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.506 HD13 ' HA ' ' A' ' 24' ' ' ALA . 31.3 mt -101.5 140.64 19.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.231 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.8 pt -129.83 142.78 46.54 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.758 0.313 . . . . 0.0 110.99 177.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.53 39.85 0.85 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.255 2.637 . . . . 0.0 112.331 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.25 149.05 20.34 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -176.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.71 -1.83 58.22 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 120.847 0.356 . . . . 0.0 111.143 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.2 m -99.72 106.29 18.18 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.494 176.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 14.3 t -123.5 131.2 24.29 Favored Pre-proline 0 C--N 1.309 -1.17 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.931 179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -59.36 143.14 99.82 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.791 2.327 . . . . 0.0 112.127 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.57 -8.35 25.87 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 114.563 -173.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -83.86 -24.17 30.99 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.556 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 7.9 m-85 -117.86 3.79 12.21 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.313 -176.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.43 34.31 0.52 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.41 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.456 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 22.3 m-80 . . . . . 0 C--O 1.245 0.823 0 CA-C-O 118.457 -0.783 . . . . 0.0 108.896 176.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 41.1 m . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 120.711 0.291 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.664 HG23 HG13 ' A' ' 34' ' ' ILE . 27.4 m -105.03 125.19 50.71 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.524 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 59.4 m -128.96 120.15 25.59 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.048 0.452 . . . . 0.0 111.288 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.563 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 78.8 m -107.36 166.31 11.27 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.386 179.177 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.516 ' HD2' ' HB3' ' A' ' 4' ' ' CYS . 83.6 Cg_endo -82.21 8.78 4.3 Favored 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 122.507 2.138 . . . . 0.0 114.574 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.4 t -176.09 145.13 0.62 Allowed 'General case' 0 CA--C 1.518 -0.281 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.667 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.872 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 46.2 mm -65.76 -27.24 40.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.561 0.695 . . . . 0.0 109.293 176.114 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.2 t -74.16 -49.75 31.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.844 177.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.93 -40.39 94.98 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.298 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.872 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -65.59 -27.72 68.62 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.111 0.481 . . . . 0.0 110.434 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.558 ' O ' HG22 ' A' ' 15' ' ' VAL . 6.3 t -64.86 -47.59 77.38 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.669 177.275 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 54.4 m-80 -67.26 -26.69 66.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.567 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.479 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 57.4 t80 -66.6 -51.63 54.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.578 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.442 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 10.9 p30 -66.82 -23.79 66.08 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.908 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.558 HG22 ' O ' ' A' ' 11' ' ' SER . 55.7 t -62.57 -34.53 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.792 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.536 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 75.8 m -66.41 -25.03 66.57 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.432 0.634 . . . . 0.0 111.319 177.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.635 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 18.2 mmm180 -75.04 -31.71 61.37 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.722 -175.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.987 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -66.72 -42.87 47.44 Favored Pre-proline 0 CA--C 1.546 0.825 0 N-CA-C 114.054 1.131 . . . . 0.0 114.054 -173.761 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.987 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 94.9 Cg_endo -87.55 -6.18 7.02 Favored 'Trans proline' 0 C--N 1.356 0.939 0 C-N-CA 121.806 1.67 . . . . 0.0 113.22 -177.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.03 23.0 7.95 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.074 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.459 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 5.6 m -84.53 126.42 69.01 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 175.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.772 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.32 120.48 8.36 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.404 2.069 . . . . 0.0 110.557 177.404 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.635 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -45.98 -35.33 4.64 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.035 169.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.08 -51.41 67.97 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.989 174.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.772 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.0 tt -62.39 -53.36 56.08 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 120.685 0.279 . . . . 0.0 110.355 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 13' ' ' PHE . 33.7 t -63.27 -38.26 90.48 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.593 -174.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -64.76 -34.33 78.08 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.356 0.598 . . . . 0.0 111.626 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 23.4 m -76.55 -20.71 56.56 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.306 -177.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -97.54 -46.17 6.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.94 0.876 . . . . 0.0 109.678 -175.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 55.5 m -70.59 -34.86 72.62 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.748 -1.569 . . . . 0.0 111.755 178.52 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.18 30.49 7.38 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.352 -0.928 . . . . 0.0 111.331 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.524 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 42.4 t -109.31 159.44 16.97 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.8 141.26 44.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.878 0.371 . . . . 0.0 111.587 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.664 HG13 HG23 ' A' ' 2' ' ' THR . 4.3 mp -109.95 132.08 59.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.892 174.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.464 HD12 ' SG ' ' A' ' 40' ' ' CYS . 24.5 pt -134.82 156.8 78.25 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.848 -178.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.51 -25.49 41.18 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 122.855 2.37 . . . . 0.0 112.689 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -113.06 -147.12 9.91 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.803 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -135.05 30.22 3.35 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.373 0.606 . . . . 0.0 110.386 -176.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.1 m -79.73 54.51 1.83 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.865 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.464 ' SG ' HD12 ' A' ' 35' ' ' ILE . 30.2 m -98.82 135.0 21.1 Favored Pre-proline 0 C--N 1.309 -1.176 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.81 -178.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.859 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 30.2 Cg_endo -65.1 165.96 20.25 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.779 2.319 . . . . 0.0 111.875 174.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -66.23 -37.9 93.33 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 121.283 -0.484 . . . . 0.0 113.788 -171.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -84.03 -18.24 37.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 122.022 0.915 . . . . 0.0 109.44 -174.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.859 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 16.3 m-85 -112.13 23.91 13.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.797 -176.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.5 22.47 12.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.048 0.452 . . . . 0.0 110.908 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 27.9 m-80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.459 -0.782 . . . . 0.0 109.524 -178.385 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 N--CA 1.478 0.928 0 CA-C-O 121.131 0.491 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.523 ' HB ' HG13 ' A' ' 34' ' ' ILE . 8.9 t -115.62 145.63 42.53 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.425 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 m -136.96 115.67 12.1 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -175.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.407 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 85.1 m -103.58 125.3 35.22 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 121.137 0.494 . . . . 0.0 111.219 -177.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.617 ' HA ' ' CB ' ' A' ' 44' ' ' TYR . 18.8 Cg_endo -60.24 -7.12 6.09 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.892 3.061 . . . . 0.0 115.606 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 p -161.55 162.14 30.12 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 118.771 0.714 . . . . 0.0 111.17 -177.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.577 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 60.2 mt -67.63 -34.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.115 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.03 -50.27 55.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.25 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.57 -32.63 74.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.253 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.577 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.41 -29.48 62.62 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.825 0.345 . . . . 0.0 110.533 -178.662 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.479 ' O ' HG21 ' A' ' 15' ' ' VAL . 70.1 m -68.67 -53.04 24.75 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -55.13 -40.11 70.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.099 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -57.0 -62.92 1.41 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.083 175.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 35.5 m-80 -59.41 -39.0 82.02 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.479 HG21 ' O ' ' A' ' 11' ' ' SER . 69.9 t -60.95 -37.46 77.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-O 120.551 0.215 . . . . 0.0 111.363 -178.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.457 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 18.2 t -70.28 -42.21 72.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.787 0.327 . . . . 0.0 110.808 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.71 ' HD2' ' HG2' ' A' ' 23' ' ' GLU . 0.0 OUTLIER -91.3 20.62 5.01 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.961 0.41 . . . . 0.0 111.811 -177.597 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 15' ' ' VAL . 4.5 mt -73.02 -50.33 6.81 Favored Pre-proline 0 N--CA 1.445 -0.71 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.693 177.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.65 25.96 0.63 Allowed 'Trans proline' 0 C--N 1.36 1.152 0 C-N-CA 122.221 1.948 . . . . 0.0 113.208 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.24 37.78 6.99 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.113 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.478 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 1.7 m -97.65 141.01 22.34 Favored Pre-proline 0 N--CA 1.43 -1.432 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.628 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.3 116.34 3.12 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.905 2.403 . . . . 0.0 111.178 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.71 ' HG2' ' HD2' ' A' ' 17' ' ' ARG . 36.8 mt-10 -51.11 -28.8 11.57 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.901 172.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.73 79.6 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.763 173.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.628 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.1 tt -65.36 -42.97 92.22 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.246 0.546 . . . . 0.0 109.927 178.504 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.457 ' HB3' ' HB3' ' A' ' 16' ' ' CYS . 61.0 m -77.34 -0.4 25.47 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.021 -175.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.53 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -101.57 -41.02 6.75 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.686 0.755 . . . . 0.0 111.113 175.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.0 m -65.82 -23.91 66.79 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.184 -1.371 . . . . 0.0 111.61 -174.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -100.47 -15.23 17.97 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 122.176 0.989 . . . . 0.0 109.88 -176.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 89.1 m -99.93 -46.81 5.24 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.075 -1.42 . . . . 0.0 111.874 -172.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.12 -20.96 6.23 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 119.944 -1.122 . . . . 0.0 112.287 -178.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.53 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 42.3 t -73.61 158.54 34.58 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.25 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.0 pt -131.64 143.68 39.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.441 0.639 . . . . 0.0 112.104 -175.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.523 HG13 ' HB ' ' A' ' 2' ' ' THR . 4.5 mp -104.25 136.16 38.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 168.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 46.7 pt -120.64 142.23 33.81 Favored Pre-proline 0 C--N 1.317 -0.807 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.035 -178.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.1 38.48 0.69 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 123.081 2.521 . . . . 0.0 112.304 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.72 -138.64 2.64 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -178.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.62 13.68 0.74 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.661 0.267 . . . . 0.0 111.244 -178.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.9 t -91.74 103.07 15.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 122.159 0.981 . . . . 0.0 111.991 -177.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.453 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 34.1 m -149.92 112.62 3.36 Favored Pre-proline 0 C--N 1.305 -1.351 0 CA-C-N 113.806 -1.543 . . . . 0.0 110.688 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.453 ' HD2' ' HA ' ' A' ' 40' ' ' CYS . 33.7 Cg_endo -63.89 160.59 36.55 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.49 2.126 . . . . 0.0 111.114 172.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.37 32.55 3.85 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.916 -0.659 . . . . 0.0 113.574 -171.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -108.19 -29.8 8.72 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.617 ' CB ' ' HA ' ' A' ' 5' ' ' PRO . 4.5 p90 -128.13 22.11 6.19 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.462 173.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.96 37.76 1.14 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.312 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 6.0 t30 . . . . . 0 C--O 1.252 1.19 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.234 -179.248 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.411 ' HB ' HD13 ' A' ' 35' ' ' ILE . 17.0 m . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.835 0.35 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.1 t -113.33 119.2 36.87 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.457 0.646 . . . . 0.0 110.138 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.415 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 33.6 m -104.91 108.88 20.61 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.747 -176.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 13.9 t -136.72 99.86 10.23 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.209 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.879 ' HG3' ' HA ' ' A' ' 44' ' ' TYR . 64.0 Cg_endo -85.35 61.24 5.58 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.954 2.436 . . . . 0.0 113.975 -169.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.731 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 1.4 p -167.39 120.96 0.96 Allowed 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.218 -178.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 68.0 mt -48.11 -38.63 8.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.604 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.5 t -77.53 -48.6 23.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.701 -175.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.97 -37.67 88.28 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.27 -178.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.731 ' HG3' ' O ' ' A' ' 6' ' ' SER . 60.5 mtt180 -54.27 -51.69 63.78 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 121.151 0.501 . . . . 0.0 110.284 179.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.517 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.9 m -70.63 -42.27 71.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.261 -177.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -62.69 -38.25 89.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 120.81 0.338 . . . . 0.0 110.581 -178.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -51.39 -51.34 55.51 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.412 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 36.6 m-80 -65.11 -37.87 88.85 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.452 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 11' ' ' SER . 90.7 t -61.98 -41.89 92.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.378 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.516 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 26.1 t -71.52 -32.11 67.82 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.398 0.618 . . . . 0.0 110.018 -179.225 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 17' ' ' ARG . 39.5 ttt180 -73.3 -21.86 60.48 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.342 -176.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 19.3 mt -64.61 -52.89 48.68 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -174.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.518 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 16.5 Cg_exo -69.9 0.5 5.65 Favored 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.427 2.085 . . . . 0.0 113.137 -178.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.25 26.27 7.87 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.182 -1.008 . . . . 0.0 112.407 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.487 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 1.3 m -89.89 137.88 28.07 Favored Pre-proline 0 N--CA 1.428 -1.55 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 176.113 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.482 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 8.3 Cg_endo -55.45 117.49 4.11 Favored 'Trans proline' 0 N--CA 1.444 -1.408 0 C-N-CA 122.869 2.38 . . . . 0.0 111.058 -179.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -47.21 -28.76 2.0 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.457 170.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.47 -42.16 98.6 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.885 174.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.482 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 41.3 tp -76.69 -36.17 57.43 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.053 0.454 . . . . 0.0 110.52 178.444 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.487 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 17.4 m -78.28 3.03 16.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.976 -179.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -101.2 -56.44 2.31 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.852 0.834 . . . . 0.0 110.328 174.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 m -62.77 -25.41 68.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.047 -174.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -94.39 -17.75 22.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 122.087 0.946 . . . . 0.0 109.551 -175.1 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 84.5 m -97.61 -44.62 6.71 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.542 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.25 -7.34 6.33 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.62 -175.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.524 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 5.3 m -82.39 148.13 28.41 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.8 pt -123.4 143.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.451 -0.5 . . . . 0.0 110.683 176.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 78.9 mt -112.95 120.83 63.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.022 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.411 HD13 ' HB ' ' A' ' 1' ' ' THR . 2.1 pp -120.08 139.85 28.99 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.637 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -82.09 22.42 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.234 2.623 . . . . 0.0 113.145 -175.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.48 -139.96 3.74 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.214 178.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.21 62.39 1.53 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.049 0.452 . . . . 0.0 109.943 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 m -152.44 106.05 3.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.275 0.559 . . . . 0.0 111.099 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.0 p -148.46 140.83 14.81 Favored Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.064 171.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.479 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 11.0 Cg_endo -53.81 143.71 58.1 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 123.005 2.47 . . . . 0.0 112.568 -174.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.13 -13.07 47.18 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.841 -0.618 . . . . 0.0 113.674 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.85 -17.37 41.11 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.879 ' HA ' ' HG3' ' A' ' 5' ' ' PRO . 16.9 m-85 -121.67 5.94 10.01 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.094 -175.022 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -105.3 38.0 2.06 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -171.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.692 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 2.9 t30 . . . . . 0 C--O 1.246 0.893 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.07 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.564 ' HB ' HG13 ' A' ' 35' ' ' ILE . 22.7 m . . . . . 0 N--CA 1.477 0.887 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -120.55 147.49 45.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.806 0.336 . . . . 0.0 111.605 -174.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.492 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 2.1 m -151.34 123.29 8.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.886 176.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.548 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 40.0 m -110.2 162.12 21.72 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.044 -175.705 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -91.13 13.95 2.03 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.394 2.062 . . . . 0.0 114.825 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.5 p -167.3 144.02 4.41 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 118.505 0.593 . . . . 0.0 111.115 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.444 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 35.9 mt -60.27 -29.32 43.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.763 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.5 t -72.55 -51.51 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.475 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.53 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -69.77 -30.35 67.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.725 -177.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.548 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -69.94 -26.09 63.96 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.149 0.499 . . . . 0.0 110.339 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.424 ' O ' HG21 ' A' ' 15' ' ' VAL . 25.0 m -79.79 -42.25 24.82 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.434 175.324 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -59.88 -30.26 68.87 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.541 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -52.9 -61.38 2.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.664 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.3 m-80 -63.21 -33.1 74.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.267 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.424 HG21 ' O ' ' A' ' 11' ' ' SER . 72.2 t -63.99 -34.84 71.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.079 178.272 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 41.8 t -77.5 -16.72 58.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.436 0.636 . . . . 0.0 110.67 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.473 ' HD2' ' O ' ' A' ' 21' ' ' THR . 7.8 mmm180 -82.66 -19.32 38.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.027 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.586 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 85.2 mt -67.14 -48.84 47.73 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.586 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 22.9 Cg_exo -65.58 -19.01 60.35 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.927 1.752 . . . . 0.0 112.391 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.4 24.44 5.64 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.586 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.553 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -90.56 134.06 31.6 Favored Pre-proline 0 N--CA 1.438 -1.054 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 177.615 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -66.46 129.55 21.61 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 123.065 2.51 . . . . 0.0 111.168 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -46.35 -25.58 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.197 171.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.95 -47.65 71.09 Favored 'General case' 0 C--N 1.327 -0.398 0 O-C-N 123.293 0.371 . . . . 0.0 110.629 172.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.8 mt -79.08 -38.46 36.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-O 120.93 0.395 . . . . 0.0 111.0 177.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.553 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 5.0 m -80.28 10.41 4.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.285 -176.15 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.73 -43.98 5.43 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.96 0.886 . . . . 0.0 109.731 170.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.2 m -69.76 -24.89 63.59 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 113.96 -1.473 . . . . 0.0 111.517 -177.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -91.36 -31.12 16.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.72 0.772 . . . . 0.0 109.759 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.53 HG22 ' HB1' ' A' ' 9' ' ' ALA . 0.3 OUTLIER -99.12 -14.78 19.23 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.555 -1.202 . . . . 0.0 112.596 -171.469 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.93 16.48 63.19 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.462 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 19.7 t -94.25 159.43 15.13 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.25 148.97 33.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.125 0.488 . . . . 0.0 111.871 -176.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 4.4 mp -96.42 135.32 30.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.898 176.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.565 HD12 ' SG ' ' A' ' 40' ' ' CYS . 5.5 pt -129.64 164.25 41.27 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.716 -179.627 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.41 -57.24 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.995 2.463 . . . . 0.0 111.252 169.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 171.47 137.69 2.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 116.098 -0.501 . . . . 0.0 112.028 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 64.43 18.08 11.15 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.256 0.622 . . . . 0.0 111.373 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -98.18 27.93 4.34 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.685 0.755 . . . . 0.0 110.904 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.565 ' SG ' HD12 ' A' ' 35' ' ' ILE . 16.9 m -112.86 107.28 54.69 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.466 -175.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.439 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 43.6 Cg_endo -71.3 174.27 11.05 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.59 2.193 . . . . 0.0 111.142 173.015 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.97 -34.74 66.22 Favored Glycine 0 CA--C 1.521 0.408 0 N-CA-C 114.754 0.662 . . . . 0.0 114.754 -172.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -83.98 -22.84 31.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.849 0.825 . . . . 0.0 109.772 -172.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.492 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 16.2 m-85 -108.75 20.09 18.91 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.314 -175.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.83 27.11 6.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.847 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 37.8 m-80 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.116 -177.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 37' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 121.004 0.43 . . . . 0.0 110.226 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.492 ' HB ' ' CZ ' ' A' ' 13' ' ' PHE . 86.3 m -137.97 140.38 40.18 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.928 -176.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -114.98 111.14 20.69 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.053 -178.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.558 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 100.0 m -102.0 111.84 64.67 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.202 174.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.666 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 91.1 Cg_endo -86.98 35.89 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.851 2.367 . . . . 0.0 112.923 -177.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.1 m -155.43 131.28 9.95 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 61.2 mt -56.18 -36.8 46.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 123.537 0.523 . . . . 0.0 111.143 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.9 t -83.28 -31.12 8.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.223 0.535 . . . . 0.0 110.382 -174.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.52 -37.21 71.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.394 178.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.558 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -83.78 -22.86 31.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.15 -175.468 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 61.3 p -74.24 -30.1 62.0 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.318 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -92.88 -26.48 17.61 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.876 177.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.492 ' CZ ' ' HB ' ' A' ' 2' ' ' THR . 27.4 t80 -55.05 -52.4 63.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.551 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -61.71 -29.08 69.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.65 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.605 ' HA ' HD23 ' A' ' 18' ' ' LEU . 57.3 t -75.73 -24.28 16.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.711 176.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.815 ' O ' ' HB ' ' A' ' 21' ' ' THR . 48.6 t -88.37 0.38 56.26 Favored 'General case' 0 C--O 1.214 -0.782 0 CA-C-O 121.684 0.754 . . . . 0.0 109.623 -178.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -109.32 -21.95 12.29 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -175.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.759 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 3.4 pp -74.5 -36.54 2.58 Favored Pre-proline 0 N--CA 1.436 -1.16 0 N-CA-C 113.785 1.031 . . . . 0.0 113.785 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.759 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 5.8 Cg_exo -78.62 7.24 4.31 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 121.835 1.69 . . . . 0.0 112.604 -175.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.97 33.05 8.47 Favored Glycine 0 N--CA 1.444 -0.81 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.042 -178.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.815 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 1.1 m -106.11 134.14 19.9 Favored Pre-proline 0 N--CA 1.434 -1.253 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.065 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.763 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.9 Cg_endo -56.29 117.22 3.84 Favored 'Trans proline' 0 N--CA 1.446 -1.285 0 C-N-CA 123.167 2.578 . . . . 0.0 112.183 -179.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -46.34 -31.52 2.63 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.839 168.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.09 -49.99 75.77 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.17 174.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.763 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tt -65.28 -44.31 88.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 18.8 m -76.17 -0.07 20.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.765 -177.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.512 ' HA ' ' HB2' ' A' ' 32' ' ' CYS . . . -94.68 -56.8 2.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.934 0.873 . . . . 0.0 109.885 168.423 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.1 m -58.28 -33.17 69.12 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 113.531 -1.668 . . . . 0.0 113.302 -173.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -96.43 -19.58 19.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 122.073 0.94 . . . . 0.0 110.324 -171.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 m -92.46 -25.1 18.59 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.518 -172.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.28 10.71 27.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.958 -177.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.512 ' HB2' ' HA ' ' A' ' 27' ' ' ALA . 44.1 m -95.11 167.69 11.22 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 176.171 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.2 pt -123.82 131.57 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.233 0.54 . . . . 0.0 111.334 176.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 16.2 tt -94.55 138.5 20.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.227 178.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.698 HD13 ' HB2' ' A' ' 40' ' ' CYS . 14.1 pt -119.58 160.85 40.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.348 -174.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -92.2 24.18 0.52 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.125 2.55 . . . . 0.0 113.176 178.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 1' ' ' THR . . . 177.01 -135.98 3.0 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.514 -0.851 . . . . 0.0 112.26 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.41 13.69 17.75 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 120.635 0.255 . . . . 0.0 111.534 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -77.64 88.25 3.93 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.296 0.569 . . . . 0.0 110.509 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.698 ' HB2' HD13 ' A' ' 35' ' ' ILE . 23.4 t -155.43 125.01 3.15 Favored Pre-proline 0 C--N 1.31 -1.135 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.321 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.31 167.98 25.92 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 123.003 2.469 . . . . 0.0 112.056 177.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.21 5.19 51.62 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 116.033 -0.531 . . . . 0.0 112.941 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -88.6 -20.85 24.45 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.666 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 14.7 m-85 -108.9 7.89 26.24 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.971 -178.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -116.53 52.32 0.94 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.736 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.8 t30 . . . . . 0 C--O 1.251 1.157 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.758 -176.574 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.53 HG21 ' HA2' ' A' ' 37' ' ' GLY . 12.2 m . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.775 HG22 ' SG ' ' A' ' 32' ' ' CYS . 3.9 m -139.5 134.03 31.69 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.019 -174.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.6 m -129.26 129.23 44.67 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.2 m -111.2 127.44 26.89 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.254 -171.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.811 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 75.8 Cg_endo -92.35 43.94 0.36 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.108 2.539 . . . . 0.0 114.113 -176.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.682 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 6.8 p -173.02 135.17 0.59 Allowed 'General case' 0 CA--C 1.517 -0.301 0 O-C-N 122.11 -0.369 . . . . 0.0 110.187 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.574 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 49.0 mt -56.29 -31.01 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.216 0.531 . . . . 0.0 111.003 -171.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.86 -53.09 28.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.956 177.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -62.06 -40.14 94.75 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.708 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.682 ' HG3' ' O ' ' A' ' 6' ' ' SER . 4.5 mtp-105 -59.01 -37.54 77.12 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.53 178.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.7 t -76.05 -35.72 59.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.565 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.9 m-20 -57.72 -42.87 84.7 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.994 174.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.627 ' CE1' ' HB ' ' A' ' 2' ' ' THR . 40.6 t80 -47.56 -46.01 27.59 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.202 -179.019 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -61.76 -48.61 79.9 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.33 0.586 . . . . 0.0 110.116 177.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -72.8 -12.55 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.026 -176.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.705 ' O ' ' HB ' ' A' ' 21' ' ' THR . 69.3 m -100.63 14.83 30.15 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.547 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.552 ' HD2' ' CE1' ' A' ' 13' ' ' PHE . 36.1 mtp180 -134.27 -39.87 0.83 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.325 0.583 . . . . 0.0 110.011 176.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 tp -49.62 -54.79 27.58 Favored Pre-proline 0 CA--C 1.553 1.086 0 CA-C-N 114.709 -1.132 . . . . 0.0 113.427 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -88.5 39.29 0.49 Allowed 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 122.075 1.85 . . . . 0.0 113.794 -174.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.57 50.29 26.43 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.302 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.705 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.82 138.25 31.03 Favored Pre-proline 0 N--CA 1.435 -1.186 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.665 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.528 ' HG2' ' CB ' ' A' ' 25' ' ' LEU . 38.0 Cg_endo -70.1 126.47 13.12 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 122.763 2.309 . . . . 0.0 111.544 174.366 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.47 ' HB3' ' HE ' ' A' ' 17' ' ' ARG . 11.2 pt-20 -50.75 -32.27 19.2 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.064 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.506 ' HA ' HD13 ' A' ' 34' ' ' ILE . . . -64.7 -39.26 93.35 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.255 -178.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.528 ' CB ' ' HG2' ' A' ' 22' ' ' PRO . 34.1 tp -69.63 -46.79 65.4 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.683 0.278 . . . . 0.0 110.831 -177.273 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 17.1 t -67.98 -29.41 68.43 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.258 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.53 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -56.9 -46.89 81.61 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.643 0.735 . . . . 0.0 110.906 177.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 47.2 m -67.07 -28.43 68.19 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.924 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -102.7 -35.11 8.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.311 0.577 . . . . 0.0 111.435 -171.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.481 ' HB ' ' O ' ' A' ' 26' ' ' CYS . 4.6 m -87.01 -19.79 28.17 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.144 -175.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.94 25.86 8.23 Favored Glycine 0 C--N 1.331 0.292 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.355 177.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.775 ' SG ' HG22 ' A' ' 2' ' ' THR . 5.8 t -102.6 161.74 13.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.6 pt -112.25 140.92 29.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 C-N-CA 119.928 -0.709 . . . . 0.0 112.644 -174.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.506 HD13 ' HA ' ' A' ' 24' ' ' ALA . 25.3 mm -98.91 132.7 43.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.274 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.459 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 44.5 pt -141.88 159.5 59.22 Favored Pre-proline 0 C--N 1.32 -0.682 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 53.8 Cg_endo -71.06 -16.02 32.19 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.71 2.273 . . . . 0.0 111.801 175.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.53 ' HA2' HG21 ' A' ' 1' ' ' THR . . . 111.59 130.21 5.54 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.811 176.044 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.55 -87.46 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.333 -0.434 . . . . 0.0 110.008 176.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.5 m -140.91 -15.17 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.944 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.461 ' HA ' ' HD3' ' A' ' 41' ' ' PRO . 91.4 m 64.91 139.5 0.05 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.521 -171.421 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.809 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 17.4 Cg_exo -65.09 156.95 59.94 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.934 2.423 . . . . 0.0 112.503 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -27.65 63.8 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.264 -174.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.7 -31.65 13.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.678 0.752 . . . . 0.0 110.075 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.811 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 20.1 m-85 -91.75 -7.99 48.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.968 -174.125 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.442 ' HB2' ' CB ' ' A' ' 40' ' ' CYS . . . -105.97 30.35 5.93 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.608 174.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 5.7 t30 . . . . . 0 C--O 1.247 0.929 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.996 -177.341 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.57 ' HB ' HG13 ' A' ' 35' ' ' ILE . 92.3 m . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 120.831 0.348 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.2 t -101.53 108.12 19.6 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-O 121.914 0.864 . . . . 0.0 110.656 -179.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.563 ' HB3' HG13 ' A' ' 33' ' ' ILE . 15.9 t -103.65 81.82 1.94 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.438 -173.38 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.43 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 60.2 m -105.54 134.35 19.74 Favored Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.436 178.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 61.2 Cg_endo -94.91 30.83 0.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.545 2.163 . . . . 0.0 115.245 -172.587 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.6 p -179.04 139.55 0.15 Allowed 'General case' 0 C--O 1.235 0.327 0 CA-C-N 118.846 0.748 . . . . 0.0 111.395 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.477 HG13 ' OD1' ' A' ' 46' ' ' ASN . 75.1 mt -58.37 -30.38 40.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.068 170.389 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 67.0 t -54.39 -58.66 3.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.52 175.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.04 -43.15 96.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.041 0.448 . . . . 0.0 110.666 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.421 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 21.4 tpp180 -55.06 -38.57 68.19 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.211 178.286 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 31.7 m -78.62 -10.44 59.74 Favored 'General case' 0 N--CA 1.466 0.375 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -94.55 -17.09 22.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.414 0.626 . . . . 0.0 109.778 175.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -69.22 -37.15 77.88 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.855 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -63.94 -26.05 68.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.955 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.9 t -64.81 -48.92 82.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.549 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.823 ' HB3' ' HB ' ' A' ' 21' ' ' THR . 55.8 m -67.2 -24.76 65.88 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -176.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.472 ' HD3' ' HG2' ' A' ' 23' ' ' GLU . 22.3 mmm180 -79.15 -8.76 59.25 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.976 -0.452 . . . . 0.0 111.703 -178.204 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.567 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 72.7 mt -78.02 -56.95 1.0 Allowed Pre-proline 0 N--CA 1.436 -1.148 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.281 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.567 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 81.2 Cg_endo -85.52 -4.99 9.23 Favored 'Trans proline' 0 C--N 1.359 1.131 0 C-N-CA 122.117 1.878 . . . . 0.0 113.451 -176.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.29 28.37 7.66 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.088 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.823 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 1.4 m -74.07 133.79 78.23 Favored Pre-proline 0 N--CA 1.441 -0.887 0 CA-C-O 121.208 0.528 . . . . 0.0 110.016 176.341 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.864 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.1 Cg_endo -62.61 120.82 8.51 Favored 'Trans proline' 0 N--CA 1.444 -1.415 0 C-N-CA 122.941 2.427 . . . . 0.0 111.008 177.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.472 ' HG2' ' HD3' ' A' ' 17' ' ' ARG . 24.2 mt-10 -45.49 -33.99 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.613 172.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.83 -47.78 84.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.405 176.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.864 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -65.06 -41.03 95.48 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -179.923 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 29.9 m -87.91 23.95 1.91 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.443 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.33 -46.25 3.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 122.171 0.986 . . . . 0.0 109.245 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -65.89 -29.24 69.64 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.259 -1.791 . . . . 0.0 112.388 -175.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 t80 -99.73 -21.51 15.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.872 0.844 . . . . 0.0 110.123 -173.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.22 -6.62 37.68 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.949 -172.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.32 36.0 28.27 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.465 178.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.3 t -127.61 153.01 46.93 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.563 HG13 ' HB3' ' A' ' 3' ' ' CYS . 25.2 pt -122.66 148.89 26.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.326 0.584 . . . . 0.0 112.033 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.2 mt -106.4 116.85 51.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.552 177.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.57 HG13 ' HB ' ' A' ' 1' ' ' THR . 25.3 pt -121.97 131.34 24.44 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.898 -178.589 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.86 -12.14 23.96 Favored 'Trans proline' 0 CA--C 1.529 0.259 0 C-N-CA 122.903 2.402 . . . . 0.0 112.282 177.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.92 -141.24 9.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.133 177.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.66 12.95 1.17 Allowed 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 -176.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.5 m -86.02 97.55 10.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.377 0.608 . . . . 0.0 110.818 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 39.6 t -158.38 107.39 1.68 Allowed Pre-proline 0 C--N 1.311 -1.103 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.536 -178.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.498 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 15.1 Cg_endo -59.55 161.92 16.38 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.851 2.368 . . . . 0.0 112.851 -177.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -69.97 1.14 18.4 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.723 -0.671 . . . . 0.0 113.594 -174.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.03 -15.49 18.23 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 19.3 m-85 -115.44 8.05 15.16 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.029 179.307 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.05 39.56 1.77 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.347 0.594 . . . . 0.0 109.573 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.477 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.4 t-20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.03 -175.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 120.77 0.319 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 28.5 m -132.65 121.22 22.83 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 174.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.579 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.5 m -124.53 117.19 23.8 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.254 0.55 . . . . 0.0 111.244 -173.006 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 20.8 m -108.55 166.74 10.31 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.704 -177.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -91.33 6.02 3.76 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 122.104 1.87 . . . . 0.0 113.351 169.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.1 m -155.62 141.5 18.12 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 121.914 -0.491 . . . . 0.0 110.993 -172.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.4 mm -61.38 -32.19 52.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 121.187 0.518 . . . . 0.0 109.74 174.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.4 t -62.78 -43.27 98.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.889 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.559 ' HA ' ' ND2' ' A' ' 12' ' ' ASN . . . -69.4 -39.84 77.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.671 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.419 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 19.6 ttm180 -64.73 -27.93 69.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.658 176.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -79.03 -48.18 14.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.368 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.559 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.1 p30 -73.78 -15.99 61.18 Favored 'General case' 0 N--CA 1.464 0.271 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.168 -178.159 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 23.9 t80 -48.81 -44.36 39.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 122.02 0.914 . . . . 0.0 109.286 165.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.37 -39.4 53.92 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.345 -1.298 . . . . 0.0 109.941 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.51 ' CG2' ' HA ' ' A' ' 12' ' ' ASN . 92.0 t -57.92 -46.51 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.748 -176.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.563 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 68.2 m -61.07 -38.05 84.87 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.644 ' HD2' ' HB3' ' A' ' 23' ' ' GLU . 45.9 mtp180 -79.27 -5.62 54.81 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.574 -172.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.607 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 31.9 mt -75.94 -53.6 2.32 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.607 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 6.1 Cg_exo -76.18 -24.34 11.11 Favored 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.178 1.919 . . . . 0.0 112.517 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.53 13.49 2.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.051 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.422 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 2.4 m -80.96 124.27 81.51 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.777 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.5 Cg_endo -59.94 123.54 13.44 Favored 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.236 1.958 . . . . 0.0 110.765 177.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.644 ' HB3' ' HD2' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -51.26 -27.94 10.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.738 169.866 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.79 -46.42 89.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.92 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.777 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.7 tt -66.63 -51.61 54.33 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 120.664 0.269 . . . . 0.0 110.426 178.321 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 26.6 m -66.82 -25.43 66.44 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.28 72.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.984 0.897 . . . . 0.0 110.435 174.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.4 m -81.85 -22.11 37.16 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.358 -174.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 19.9 t80 -106.18 -39.5 5.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.348 0.594 . . . . 0.0 110.707 -174.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.0 m -72.2 -31.93 66.33 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.498 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.3 18.59 38.55 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.24 -0.981 . . . . 0.0 112.287 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.6 t -105.5 139.59 39.89 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.409 HD12 HD13 ' A' ' 35' ' ' ILE . 22.6 pt -104.79 139.98 24.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.286 0.565 . . . . 0.0 111.794 -172.353 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 80.3 mt -100.6 124.92 54.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.917 176.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.79 HG22 ' HB ' ' A' ' 39' ' ' THR . 96.7 mt -129.18 137.4 30.91 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.372 -175.509 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -47.25 -48.51 14.82 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.697 2.265 . . . . 0.0 112.384 176.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.77 137.71 2.3 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.6 177.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.01 65.29 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 123.45 0.7 . . . . 0.0 112.401 175.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.79 ' HB ' HG22 ' A' ' 35' ' ' ILE . 8.9 m -151.03 26.21 0.72 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 122.224 1.012 . . . . 0.0 110.091 175.115 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.487 ' SG ' HD12 ' A' ' 35' ' ' ILE . 62.9 m -108.64 116.42 56.13 Favored Pre-proline 0 C--N 1.314 -0.965 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.342 -172.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.428 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 40.3 Cg_endo -69.38 162.35 42.23 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.391 2.061 . . . . 0.0 111.963 175.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.61 -28.4 67.74 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 114.947 0.739 . . . . 0.0 114.947 -172.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -87.78 -20.05 26.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.734 0.778 . . . . 0.0 109.778 -174.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.579 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.5 m-85 -114.16 25.31 11.22 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.185 -176.09 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.33 23.7 13.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.812 177.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 65.9 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-O 118.096 -0.954 . . . . 0.0 109.681 -177.602 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.929 ' HB ' HG23 ' A' ' 35' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.473 0.711 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.91 110.59 16.49 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -171.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.567 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 46.5 m -150.38 156.25 41.14 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.102 0.477 . . . . 0.0 111.768 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.1 t -144.82 143.01 19.59 Favored Pre-proline 0 N--CA 1.453 -0.301 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 47.6 Cg_exo -58.82 -27.91 85.41 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.138 2.558 . . . . 0.0 114.205 -177.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.0 m -142.01 141.93 32.89 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 -176.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.687 HG13 ' OD1' ' A' ' 46' ' ' ASN . 87.8 mt -53.39 -40.35 39.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.956 175.481 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -67.49 -34.3 67.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.099 0.476 . . . . 0.0 110.49 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -74.53 -36.23 63.16 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.245 0.545 . . . . 0.0 109.775 177.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -63.97 -42.13 97.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.4 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.499 ' O ' HG22 ' A' ' 15' ' ' VAL . 6.7 p -67.73 -37.65 82.48 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.032 178.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -66.86 -34.38 77.67 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.277 0.561 . . . . 0.0 110.734 179.144 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.593 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 50.6 t80 -58.85 -53.24 60.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.117 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -55.39 -30.85 61.18 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.398 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 11' ' ' SER . 90.0 t -63.57 -34.18 66.05 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.476 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.52 -23.36 42.97 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.946 -0.471 . . . . 0.0 111.176 -175.386 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -74.61 -18.27 60.58 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 177.155 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.465 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 95.3 mt -63.77 -53.21 52.09 Favored Pre-proline 0 N--CA 1.442 -0.839 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -177.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 61.2 Cg_endo -73.25 2.99 5.01 Favored 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.054 1.836 . . . . 0.0 113.181 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.32 36.76 7.96 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.485 178.28 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.57 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -97.6 141.05 22.41 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 176.621 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.57 ' HD2' HG22 ' A' ' 21' ' ' THR . 13.3 Cg_endo -61.07 117.74 4.55 Favored 'Trans proline' 0 N--CA 1.446 -1.309 0 C-N-CA 122.962 2.441 . . . . 0.0 110.944 178.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.593 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 9.7 pt-20 -51.81 -29.75 20.46 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.854 175.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.18 -41.74 97.34 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.554 174.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.556 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 50.7 tp -77.52 -39.44 46.15 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-O 120.737 0.303 . . . . 0.0 110.427 179.591 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.502 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 26.6 m -64.69 -39.74 94.18 Favored 'General case' 0 C--O 1.22 -0.455 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.041 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.561 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -64.98 -23.59 67.26 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.57 0.7 . . . . 0.0 111.58 -178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.5 m -75.59 -22.35 57.0 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.673 -1.149 . . . . 0.0 110.316 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -104.03 -43.46 5.27 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.862 0.839 . . . . 0.0 110.13 -178.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 93.9 m -64.89 -55.37 19.74 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.24 -1.346 . . . . 0.0 111.849 -178.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 131.1 -24.92 4.18 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.547 -178.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.561 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 38.2 m -64.34 158.85 22.44 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.3 pt -130.16 139.55 51.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.427 -0.509 . . . . 0.0 112.293 -175.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.0 mp -85.68 125.7 40.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.929 HG23 ' HB ' ' A' ' 1' ' ' THR . 9.2 tt -129.65 110.35 17.44 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.46 0.648 . . . . 0.0 110.784 -171.057 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 34.9 Cg_exo -62.24 -32.38 82.3 Favored 'Trans proline' 0 N--CA 1.477 0.544 0 C-N-CA 123.785 2.99 . . . . 0.0 114.331 -174.248 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -153.41 -163.4 11.75 Favored Glycine 0 N--CA 1.44 -1.071 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.434 -177.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.56 25.97 12.22 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 123.06 0.544 . . . . 0.0 111.634 -178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 49.3 m 42.28 -99.48 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.0 -176.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 79.8 m -158.51 137.86 8.33 Favored Pre-proline 0 C--N 1.314 -0.949 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.32 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.573 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 52.5 Cg_endo -72.55 148.23 47.43 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.865 1.71 . . . . 0.0 110.796 169.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.04 10.39 14.97 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 121.364 -0.446 . . . . 0.0 113.529 -173.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -112.67 -16.28 12.83 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.628 0.728 . . . . 0.0 109.252 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.573 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 21.4 m-85 -119.93 18.67 12.48 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.352 -178.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -113.19 45.85 1.32 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.672 177.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.687 ' OD1' HG13 ' A' ' 7' ' ' ILE . 15.6 t-20 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.211 -0.899 . . . . 0.0 110.481 -175.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.517 ' HB ' HG13 ' A' ' 35' ' ' ILE . 86.1 m . . . . . 0 N--CA 1.475 0.794 0 CA-C-O 121.061 0.457 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -123.37 142.42 50.98 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.023 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 44' ' ' TYR . 22.1 p -152.48 147.96 26.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.912 0.387 . . . . 0.0 110.682 175.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.652 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 15.2 t -141.36 144.03 32.54 Favored Pre-proline 0 C--N 1.328 -0.331 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.699 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 3.6 Cg_exo -39.25 -51.86 2.5 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 124.474 3.45 . . . . 0.0 114.694 -177.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.464 ' HA ' ' HB3' ' A' ' 46' ' ' ASN . 3.8 p -147.74 160.6 42.53 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 122.29 -0.256 . . . . 0.0 111.394 -176.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.485 HG13 ' OD1' ' A' ' 46' ' ' ASN . 80.2 mt -53.82 -39.59 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.429 178.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 84.5 t -59.87 -52.92 55.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.652 0.263 . . . . 0.0 110.611 178.248 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.27 -35.46 80.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.746 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.527 ' HA ' ' HD2' ' A' ' 13' ' ' PHE . 1.0 OUTLIER -67.27 -41.01 86.23 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-O 121.231 0.539 . . . . 0.0 110.103 178.194 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.509 ' O ' HG23 ' A' ' 15' ' ' VAL . 29.7 t -57.87 -42.55 84.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.867 174.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -46.03 79.37 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.313 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.538 ' HB3' HG23 ' A' ' 30' ' ' THR . 0.8 OUTLIER -72.54 -35.19 67.99 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.856 -175.699 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -59.85 -43.15 94.8 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.921 0.391 . . . . 0.0 110.019 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.509 HG23 ' O ' ' A' ' 11' ' ' SER . 63.3 t -67.26 -21.37 27.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.046 177.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.426 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 14.0 t -80.99 -25.4 37.29 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 120.929 0.395 . . . . 0.0 110.749 -176.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -72.0 -41.51 67.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.052 0.453 . . . . 0.0 110.741 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.949 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -56.55 -40.5 85.42 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -171.093 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.949 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 59.6 Cg_endo -74.1 0.6 8.21 Favored 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 121.522 1.481 . . . . 0.0 113.377 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.29 34.08 4.63 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.476 178.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.528 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -104.36 135.82 19.27 Favored Pre-proline 0 N--CA 1.436 -1.143 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.677 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.633 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.0 Cg_endo -63.74 127.71 20.33 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 122.848 2.366 . . . . 0.0 111.053 176.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.411 ' H ' ' CD ' ' A' ' 23' ' ' GLU . 1.5 mp0 -37.56 -40.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.346 172.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.43 -50.07 72.72 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.162 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.633 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -63.98 -36.42 83.91 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.107 0.479 . . . . 0.0 110.088 177.812 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.528 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 21.5 m -79.02 10.83 3.11 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.249 -179.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.25 -38.85 5.86 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.847 0.832 . . . . 0.0 110.359 171.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -69.59 -29.56 67.12 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.975 -1.466 . . . . 0.0 112.324 -173.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -103.77 -31.74 9.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.732 0.777 . . . . 0.0 109.913 -175.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.538 HG23 ' HB3' ' A' ' 13' ' ' PHE . 15.6 m -78.51 -33.1 48.3 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 114.426 -1.261 . . . . 0.0 111.684 -175.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.85 0.55 36.39 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.913 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.1 m -85.69 155.02 21.26 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.412 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.6 pt -120.43 144.98 27.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.398 0.618 . . . . 0.0 111.965 -176.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 79.5 mt -107.87 127.44 63.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.178 175.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.524 HD12 ' HB2' ' A' ' 40' ' ' CYS . 24.3 pt -132.32 134.11 24.55 Favored Pre-proline 0 C--N 1.319 -0.76 0 CA-C-O 120.936 0.398 . . . . 0.0 111.476 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 -9.81 15.7 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.625 2.217 . . . . 0.0 111.176 173.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.01 -142.34 7.76 Favored Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.62 15.34 7.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 120.732 0.301 . . . . 0.0 111.181 -177.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.5 m -80.29 86.32 5.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.51 0.672 . . . . 0.0 110.751 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.524 ' HB2' HD12 ' A' ' 35' ' ' ILE . 42.1 t -158.29 116.26 1.78 Allowed Pre-proline 0 C--N 1.311 -1.108 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.672 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.96 166.65 28.94 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.415 2.076 . . . . 0.0 112.692 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.46 10.9 14.9 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.084 -177.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -98.43 -18.84 18.04 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.699 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 17.4 m-85 -120.0 18.4 12.44 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.827 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -115.09 47.25 1.31 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.212 -175.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.485 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.3 t-20 . . . . . 0 C--O 1.246 0.885 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.389 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' THR . . . . . 0.487 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 88.7 m . . . . . 0 N--CA 1.473 0.685 0 CA-C-O 121.131 0.491 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.408 HG22 HG12 ' A' ' 34' ' ' ILE . 40.2 m -128.92 112.01 13.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.729 -176.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.572 ' O ' ' HB2' ' A' ' 32' ' ' CYS . 73.2 m -75.5 90.82 2.75 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 176.124 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.52 ' SG ' HG22 ' A' ' 30' ' ' THR . 1.4 t -125.35 87.8 55.11 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -177.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.63 78.73 2.99 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 123.418 2.745 . . . . 0.0 114.025 -167.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.67 ' HB3' ' HB1' ' A' ' 9' ' ' ALA . 29.2 t 172.21 132.87 0.03 OUTLIER 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 171.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.643 ' H ' HD12 ' A' ' 7' ' ' ILE . 3.7 mp -62.93 -31.57 52.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.051 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.2 t -80.08 -47.26 21.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.173 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.67 ' HB1' ' HB3' ' A' ' 6' ' ' SER . . . -60.75 -48.4 81.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.68 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.406 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 1.8 ptp180 -62.75 -25.09 68.03 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.621 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.47 ' O ' HG23 ' A' ' 15' ' ' VAL . 67.6 m -69.09 -56.49 7.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.029 178.195 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.492 ' HA ' ' HB ' ' A' ' 15' ' ' VAL . 11.2 p30 -64.32 -22.38 66.93 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.634 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.406 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 61.8 t80 -59.12 -59.69 5.05 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.653 170.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.434 ' O ' ' HB3' ' A' ' 17' ' ' ARG . 2.3 p-10 -71.73 -27.1 62.77 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.877 0.37 . . . . 0.0 110.903 -178.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.492 ' HB ' ' HA ' ' A' ' 12' ' ' ASN . 78.1 t -70.31 -17.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.006 0.431 . . . . 0.0 110.263 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.655 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 3.8 t -84.66 -29.03 26.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.417 0.627 . . . . 0.0 109.707 177.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.434 ' HB3' ' O ' ' A' ' 14' ' ' ASN . 6.9 tpt180 -58.42 -40.72 83.23 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.383 175.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.564 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 86.1 mt -61.08 -50.29 85.09 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 113.775 1.028 . . . . 0.0 113.775 -172.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.655 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 7.9 Cg_exo -73.39 13.56 0.69 Allowed 'Trans proline' 0 C--N 1.358 1.079 0 C-N-CA 122.581 2.187 . . . . 0.0 113.507 -177.712 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.23 36.85 9.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.897 176.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.58 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -108.79 134.9 20.17 Favored Pre-proline 0 N--CA 1.434 -1.27 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 176.887 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.726 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -60.18 122.51 11.48 Favored 'Trans proline' 0 N--CA 1.446 -1.29 0 C-N-CA 122.951 2.434 . . . . 0.0 111.121 178.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -35.84 -39.56 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.398 169.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.56 -53.39 58.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.192 176.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.726 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tm? -63.71 -37.2 86.46 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-O 121.004 0.431 . . . . 0.0 110.782 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 23.9 m -65.04 -37.43 87.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.358 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.52 -32.4 74.02 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.804 0.811 . . . . 0.0 110.462 176.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.8 m -74.89 -22.5 58.6 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 114.47 -1.241 . . . . 0.0 110.761 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -89.45 -45.58 9.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.864 0.84 . . . . 0.0 109.024 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.52 HG22 ' SG ' ' A' ' 4' ' ' CYS . 85.0 m -70.89 -37.79 73.01 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.002 -1.454 . . . . 0.0 111.061 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.04 16.89 17.65 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.904 -0.665 . . . . 0.0 113.017 179.11 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 3' ' ' CYS . 10.7 p -114.24 179.53 3.93 Favored 'General case' 0 C--N 1.327 -0.395 0 O-C-N 122.725 -0.279 . . . . 0.0 110.721 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.4 ' H ' HD12 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -127.77 141.88 45.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 111.563 -173.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.408 HG12 HG22 ' A' ' 2' ' ' THR . 60.3 mt -99.44 140.17 19.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.777 176.477 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.841 HD12 ' HB3' ' A' ' 38' ' ' ALA . 11.2 pt -137.91 129.14 15.94 Favored Pre-proline 0 N--CA 1.448 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 111.388 -177.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 32.6 Cg_exo -61.62 -27.77 81.94 Favored 'Trans proline' 0 CA--C 1.53 0.307 0 C-N-CA 123.029 2.486 . . . . 0.0 112.639 176.608 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 39' ' ' THR . . . -132.94 -153.46 7.22 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.927 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.841 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 71.69 -29.04 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.904 0.881 . . . . 0.0 111.898 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.482 ' H ' ' C ' ' A' ' 37' ' ' GLY . 52.2 m 65.81 5.45 3.41 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.331 0.652 . . . . 0.0 112.512 176.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 66.9 m 65.59 137.46 0.05 OUTLIER Pre-proline 0 N--CA 1.468 0.465 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.141 -175.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -74.62 175.85 10.54 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.418 2.079 . . . . 0.0 111.698 175.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -73.94 -0.82 57.49 Favored Glycine 0 CA--C 1.518 0.235 0 C-N-CA 121.363 -0.446 . . . . 0.0 113.12 -175.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -98.07 -22.25 16.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.193 0.52 . . . . 0.0 109.612 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.528 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 16.0 m-85 -121.44 19.95 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.679 -173.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.11 14.8 29.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.393 0.616 . . . . 0.0 110.77 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 18.3 m120 . . . . . 0 C--O 1.247 0.971 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.681 179.404 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.0 m . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 121.016 0.436 . . . . 0.0 109.933 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.7 t -98.99 122.65 42.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.518 0.675 . . . . 0.0 110.526 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 61.9 m -121.43 122.49 39.89 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.08 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.9 t -147.52 141.0 15.3 Favored Pre-proline 0 N--CA 1.448 -0.561 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -103.0 40.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.05 2.5 . . . . 0.0 113.957 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.9 t -158.26 135.52 10.09 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.622 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.8 mt -69.34 -28.0 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.356 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.7 t -83.5 -25.29 7.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.875 -175.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.36 -50.23 8.01 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.055 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.454 ' NH2' ' H ' ' A' ' 4' ' ' CYS . 7.3 tpp180 -53.5 -39.83 64.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.358 177.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.406 ' O ' HG22 ' A' ' 15' ' ' VAL . 24.4 p -62.41 -61.71 2.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.644 0.259 . . . . 0.0 111.222 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -64.52 -24.07 67.48 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.469 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 56.7 t80 -59.17 -58.14 9.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.064 173.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -70.2 -30.56 67.7 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.898 -179.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.406 HG22 ' O ' ' A' ' 11' ' ' SER . 72.0 t -65.2 -30.16 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.351 . . . . 0.0 110.707 176.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -71.74 -27.16 62.8 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.297 0.57 . . . . 0.0 110.574 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.589 ' HA ' ' O ' ' A' ' 21' ' ' THR . 46.5 tpt85 -76.49 -17.71 59.14 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.205 -178.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.403 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 77.9 mt -68.57 -52.29 19.94 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -175.252 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.403 ' HD2' ' N ' ' A' ' 18' ' ' LEU . 56.4 Cg_endo -69.72 -6.28 18.19 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.262 1.975 . . . . 0.0 113.271 -177.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.92 25.87 4.94 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.2 OUTLIER -103.19 128.65 27.15 Favored Pre-proline 0 N--CA 1.439 -0.99 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.457 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.74 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 12.7 Cg_endo -58.43 121.99 10.9 Favored 'Trans proline' 0 N--CA 1.449 -1.146 0 C-N-CA 122.577 2.184 . . . . 0.0 110.752 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.516 ' H ' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -50.67 -29.19 10.5 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.937 173.459 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.16 -46.95 87.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.976 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.74 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -67.5 -46.69 72.16 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 120.971 0.415 . . . . 0.0 109.992 177.841 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 6.9 m -62.66 -35.54 79.97 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.828 -177.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -58.41 -40.45 82.46 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 111.266 178.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.6 m -66.28 -22.75 66.31 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.528 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -86.11 -47.03 9.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.124 176.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.444 ' HB ' ' SG ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -69.39 -36.99 77.31 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 -177.28 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.67 -22.24 36.28 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.141 -172.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.557 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 3.2 m -60.94 116.31 4.38 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.2 pt -91.68 150.5 3.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.925 0.393 . . . . 0.0 111.866 -172.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 69.4 mt -116.14 107.93 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.37 0.605 . . . . 0.0 109.617 174.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.75 HD13 ' HB3' ' A' ' 38' ' ' ALA . 15.3 pt -116.0 152.81 48.06 Favored Pre-proline 0 C--N 1.314 -0.95 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.91 -175.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.38 -64.71 0.1 OUTLIER 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 123.049 2.499 . . . . 0.0 112.41 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.39 -142.47 8.94 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.75 ' HB3' HD13 ' A' ' 35' ' ' ILE . . . 62.52 80.37 0.23 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.388 0.613 . . . . 0.0 110.939 177.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.63 96.63 0.13 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.745 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.638 ' HB3' ' HB2' ' A' ' 44' ' ' TYR . 62.5 m -59.59 144.11 85.3 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.181 177.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.58 ' HD2' ' HD2' ' A' ' 44' ' ' TYR . 57.2 Cg_endo -70.96 -175.13 1.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.974 2.449 . . . . 0.0 113.25 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.41 7.1 33.4 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.488 -0.778 . . . . 0.0 114.428 -170.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.542 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 16.7 p-10 -108.45 -17.51 13.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 176.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.638 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . 22.2 m-85 -102.74 0.73 33.35 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.612 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.01 18.38 18.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.424 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.5 t-20 . . . . . 0 C--O 1.253 1.252 0 CA-C-O 118.251 -0.88 . . . . 0.0 110.215 -179.213 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.1 m . . . . . 0 N--CA 1.476 0.844 0 CA-C-O 120.782 0.325 . . . . 0.0 110.375 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.8 m -89.08 123.92 33.81 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.817 0.341 . . . . 0.0 110.47 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 63.8 m -124.25 106.7 10.49 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' HB3' ' HB3' ' A' ' 10' ' ' ARG . 7.8 t -100.76 132.6 21.97 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.054 -178.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.607 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.7 Cg_endo -86.05 34.21 0.47 Allowed 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.97 2.447 . . . . 0.0 112.982 -177.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.505 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 38.6 t -164.88 133.28 3.35 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 120.983 0.42 . . . . 0.0 110.573 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.31 -26.7 34.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.186 -0.916 . . . . 0.0 109.113 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.1 t -82.77 -47.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.088 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.505 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -61.78 -43.24 99.24 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.966 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.526 ' HB3' ' HB3' ' A' ' 4' ' ' CYS . 6.0 ptp180 -65.41 -28.23 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.095 0.474 . . . . 0.0 110.69 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.514 ' O ' HG22 ' A' ' 15' ' ' VAL . 42.4 m -72.62 -40.59 66.34 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.357 176.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -65.8 -28.69 69.19 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.632 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.24 -50.63 72.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.972 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -66.0 -26.42 67.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.192 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.514 HG22 ' O ' ' A' ' 11' ' ' SER . 84.5 t -68.2 -34.49 66.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.699 -179.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.481 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.0 t -82.26 -24.5 34.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 121.371 0.605 . . . . 0.0 110.393 -178.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -80.5 -13.05 59.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.482 -178.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.432 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 8.2 mt -71.76 -52.1 8.38 Favored Pre-proline 0 N--CA 1.444 -0.745 0 CA-C-N 115.998 -0.547 . . . . 0.0 112.447 -177.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.481 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 6.4 Cg_exo -75.01 18.39 0.54 Allowed 'Trans proline' 0 C--N 1.358 1.051 0 C-N-CA 122.538 2.159 . . . . 0.0 113.11 -178.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 78.9 40.15 18.14 Favored Glycine 0 N--CA 1.443 -0.897 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.526 178.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.458 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 3.0 m -107.08 135.96 19.53 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 175.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.567 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 11.0 Cg_endo -57.24 116.65 3.36 Favored 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 122.938 2.425 . . . . 0.0 111.411 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -39.83 -34.94 0.3 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.903 170.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.62 -49.32 73.76 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.183 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.567 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 45.0 tp -68.55 -36.4 78.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-O 120.852 0.358 . . . . 0.0 110.199 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 36.0 m -66.78 -42.37 86.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.237 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -61.65 -24.64 66.86 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.657 0.741 . . . . 0.0 111.653 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.2 m -76.13 -22.62 55.27 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.984 -178.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -109.52 -42.69 4.25 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.332 0.587 . . . . 0.0 110.784 -177.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.5 m -62.86 -37.88 88.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.186 -178.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 108.65 -15.85 34.49 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.753 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.496 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 34.5 m -71.05 133.4 46.27 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 176.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.4 pt -103.96 141.22 20.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.233 0.539 . . . . 0.0 111.383 -175.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 68.8 mt -108.15 107.73 23.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.977 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.788 HG21 ' H ' ' A' ' 37' ' ' GLY . 5.0 mp -89.86 130.21 43.62 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.05 -179.347 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.55 -13.31 38.61 Favored 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.836 2.357 . . . . 0.0 112.235 175.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.788 ' H ' HG21 ' A' ' 35' ' ' ILE . . . -91.03 -137.35 7.22 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.903 176.013 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.45 15.9 0.26 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.613 0.244 . . . . 0.0 111.387 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.9 m -120.02 105.51 11.11 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.093 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.7 p -134.47 135.96 24.79 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.51 173.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.459 ' HG2' ' OD1' ' A' ' 43' ' ' ASP . 53.3 Cg_endo -67.15 176.6 4.47 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.748 2.299 . . . . 0.0 112.802 -176.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.24 24.94 5.82 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.589 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.459 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 11.3 p-10 -112.22 -18.29 12.57 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 170.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.607 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 17.7 m-85 -98.4 3.6 48.47 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.789 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.56 18.82 21.39 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.824 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 . . . . . 0 C--O 1.246 0.904 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.732 -179.123 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.476 0.827 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -98.26 136.4 38.5 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-O 120.921 0.391 . . . . 0.0 112.017 -176.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 96.9 m -134.18 112.72 11.34 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 173.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 41.4 m -101.56 152.5 38.06 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.911 -173.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -99.74 24.67 0.18 Allowed 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.722 2.282 . . . . 0.0 113.598 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 t -174.03 132.5 0.41 Allowed 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.118 0.485 . . . . 0.0 110.269 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.478 ' HA ' ' HB3' ' A' ' 10' ' ' ARG . 59.3 mt -69.79 -19.97 23.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.154 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -71.36 -41.99 73.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.509 ' HB2' HG23 ' A' ' 30' ' ' THR . . . -66.08 -48.17 71.84 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.8 174.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.478 ' HB3' ' HA ' ' A' ' 7' ' ' ILE . 4.0 tpp180 -50.97 -41.78 59.56 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.167 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.405 ' O ' HG23 ' A' ' 15' ' ' VAL . 41.5 t -58.76 -55.19 38.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.522 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.0 p30 -71.04 -26.89 63.29 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.246 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -62.22 -50.44 71.75 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.615 173.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -54.98 -44.19 74.22 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.674 178.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 11' ' ' SER . 57.7 t -67.5 -27.11 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.455 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.536 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.2 t -83.93 -43.18 15.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 121.01 0.433 . . . . 0.0 111.035 -176.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -76.38 -10.88 59.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.021 0.439 . . . . 0.0 111.409 -177.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.4 mt -69.95 -51.12 15.34 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -176.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.536 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 48.9 Cg_endo -71.8 -8.78 23.72 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.292 1.995 . . . . 0.0 113.131 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.11 19.1 5.27 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.347 -0.93 . . . . 0.0 113.312 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.489 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 3.1 m -83.66 137.33 41.48 Favored Pre-proline 0 N--CA 1.431 -1.383 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 21.0 Cg_endo -63.74 125.93 16.42 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.564 2.176 . . . . 0.0 110.511 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -42.14 -26.5 0.1 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.412 170.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.435 ' HA ' ' CD1' ' A' ' 34' ' ' ILE . . . -51.09 -54.14 27.71 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.769 0.319 . . . . 0.0 110.934 171.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.2 tt -67.69 -41.29 83.88 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 109.85 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.0 m -81.51 9.05 8.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.3 -175.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.422 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -109.64 -49.2 3.13 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.859 0.838 . . . . 0.0 110.302 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -64.37 -33.26 75.45 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 113.859 -1.518 . . . . 0.0 112.37 -173.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -96.57 -15.19 21.73 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.228 1.014 . . . . 0.0 109.527 -176.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.509 HG23 ' HB2' ' A' ' 9' ' ' ALA . 55.7 m -96.32 -25.89 15.59 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 113.791 -1.55 . . . . 0.0 112.279 -172.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.66 7.33 57.89 Favored Glycine 0 C--N 1.328 0.093 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.422 ' HB3' ' HA ' ' A' ' 27' ' ' ALA . 19.8 t -92.92 157.85 16.13 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.2 pt -118.43 160.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.573 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.435 ' CD1' ' HA ' ' A' ' 24' ' ' ALA . 69.9 mt -122.31 137.37 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.599 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.418 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -130.66 157.27 78.19 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 176.268 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.418 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 45.5 Cg_endo -70.54 -28.12 21.89 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.497 2.131 . . . . 0.0 112.263 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.73 -140.5 11.29 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.006 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -152.65 12.93 0.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.685 0.279 . . . . 0.0 111.353 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.2 m -90.54 104.98 17.5 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.254 0.549 . . . . 0.0 110.0 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 94.9 m -129.43 131.68 23.77 Favored Pre-proline 0 C--N 1.311 -1.085 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.954 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -69.81 176.09 7.27 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.697 2.265 . . . . 0.0 112.499 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.51 3.06 26.92 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 116.069 -0.514 . . . . 0.0 113.755 -175.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -94.36 -22.34 18.39 Favored 'General case' 0 CA--C 1.513 -0.481 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -121.17 20.71 11.37 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.273 -1.331 . . . . 0.0 109.661 -176.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -99.37 16.37 23.28 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.031 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.737 -0.649 . . . . 0.0 109.566 -178.7 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 60.2 m . . . . . 0 N--CA 1.476 0.874 0 CA-C-O 120.835 0.35 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.608 HG22 ' CZ ' ' A' ' 13' ' ' PHE . 26.8 m -104.27 118.37 36.46 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.747 178.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 62.6 m -108.87 128.14 54.65 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.344 -174.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.5 m -128.98 132.55 24.44 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.548 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.775 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.2 Cg_endo -90.84 23.82 0.62 Allowed 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.899 2.399 . . . . 0.0 114.245 -177.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.1 p -171.01 149.38 2.92 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 122.07 -0.394 . . . . 0.0 111.438 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 58.7 mt -65.22 -29.45 47.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.156 178.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.5 t -76.63 -38.81 31.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.833 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -72.88 -41.99 64.11 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.463 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 10.7 tpp180 -54.4 -36.76 64.29 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.721 177.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.49 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 4.0 p -79.52 -55.09 5.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.66 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 p30 -60.88 -24.27 65.83 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 121.218 0.533 . . . . 0.0 110.787 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.635 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 71.0 t80 -61.39 -60.51 3.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.586 173.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.49 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 8.5 p30 -69.49 -28.59 66.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.673 -175.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 93.6 t -71.52 -23.61 22.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.394 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.501 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.5 t -76.86 -32.06 57.25 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 121.996 -0.44 . . . . 0.0 110.595 -179.157 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.6 ' HA ' ' O ' ' A' ' 21' ' ' THR . 1.7 ptm180 -87.19 -0.06 56.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.194 0.521 . . . . 0.0 110.697 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HB3' ' HD3' ' A' ' 19' ' ' PRO . 63.9 tp -70.32 -53.32 10.56 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.662 179.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.518 ' HD3' ' HB3' ' A' ' 18' ' ' LEU . 91.1 Cg_endo -82.2 28.03 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.171 1.914 . . . . 0.0 113.759 -177.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.94 39.53 8.57 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.317 175.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.6 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.8 OUTLIER -115.37 136.56 22.74 Favored Pre-proline 0 N--CA 1.437 -1.093 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 174.917 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.836 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 17.7 Cg_endo -63.2 120.99 8.67 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 122.617 2.211 . . . . 0.0 111.047 175.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.635 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 11.0 pt-20 -56.88 -23.71 46.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.243 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.498 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -63.34 -41.95 98.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.729 173.277 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.836 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.5 OUTLIER -71.8 -39.12 70.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 120.903 0.382 . . . . 0.0 110.215 176.795 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 34.3 m -66.97 -36.96 83.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.041 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.4 -36.15 73.13 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.785 0.802 . . . . 0.0 110.898 176.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -69.04 -23.79 64.1 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 114.093 -1.412 . . . . 0.0 111.129 -176.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -102.65 -46.07 4.84 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.626 0.727 . . . . 0.0 110.02 -176.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.5 m -59.95 -44.36 94.45 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 114.626 -1.17 . . . . 0.0 112.172 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.78 -9.16 14.49 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.28 -0.962 . . . . 0.0 112.037 -176.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 94.7 m -71.38 158.8 35.68 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 175.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 26.3 pt -126.39 139.59 51.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.963 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.498 HD11 ' HA ' ' A' ' 24' ' ' ALA . 71.3 mt -112.32 103.28 15.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.791 177.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 34.1 pt -107.83 148.28 37.07 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.142 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -76.93 12.06 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.997 2.465 . . . . 0.0 112.387 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -130.45 -147.39 6.13 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.74 21.86 2.14 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.163 0.506 . . . . 0.0 110.273 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 m -79.98 72.25 6.74 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.396 -175.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 90.9 m -128.29 131.51 23.82 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.287 176.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.411 ' C ' ' H ' ' A' ' 43' ' ' ASP . 55.7 Cg_endo -69.23 174.55 8.88 Favored 'Trans proline' 0 CA--C 1.531 0.348 0 C-N-CA 122.595 2.196 . . . . 0.0 111.903 176.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.98 26.21 1.47 Allowed Glycine 0 CA--C 1.521 0.424 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.236 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.531 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 24.7 t70 -115.38 -29.78 6.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.775 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 10.4 m-85 -105.91 5.18 30.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.967 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.61 17.11 23.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.913 -174.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.0 t30 . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.086 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.591 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 23.5 m . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.465 HG23 ' CZ ' ' A' ' 13' ' ' PHE . 21.9 m -134.16 124.16 25.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.011 -176.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.451 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 82.6 m -128.16 142.84 51.06 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.647 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 0.5 OUTLIER -128.42 151.66 76.96 Favored Pre-proline 0 C--N 1.32 -0.676 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.505 -175.716 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.647 ' HD2' ' SG ' ' A' ' 4' ' ' CYS . 88.8 Cg_endo -82.05 1.66 9.06 Favored 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.955 2.436 . . . . 0.0 113.958 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.8 p -160.9 155.55 23.64 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 121.88 -0.512 . . . . 0.0 110.94 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 59.2 mt -73.05 -28.58 26.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.421 178.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.6 t -67.87 -44.43 85.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.766 -178.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.34 -45.2 81.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.961 177.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -54.2 -39.27 66.53 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.38 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.504 ' O ' HG22 ' A' ' 15' ' ' VAL . 70.4 m -60.5 -55.07 37.88 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.641 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 11.3 p30 -75.28 -22.62 57.62 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.02 0.438 . . . . 0.0 110.906 -176.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.465 ' CZ ' HG23 ' A' ' 2' ' ' THR . 44.8 t80 -58.16 -53.41 58.62 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.086 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -61.96 -29.89 70.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.783 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 11' ' ' SER . 79.5 t -65.26 -33.23 62.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.89 178.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.532 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 39.8 t -75.71 -21.35 57.63 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 121.469 0.652 . . . . 0.0 110.151 -178.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.632 ' HD3' ' HG3' ' A' ' 23' ' ' GLU . 27.3 tpt180 -74.68 -26.45 59.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.013 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.556 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 97.6 mt -62.52 -49.22 84.35 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -175.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.556 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 13.7 Cg_exo -70.54 -5.41 16.62 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.226 1.951 . . . . 0.0 112.995 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.69 28.92 7.62 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.461 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.657 HG21 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -90.68 140.87 26.6 Favored Pre-proline 0 N--CA 1.431 -1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 177.769 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.685 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 14.4 Cg_endo -62.05 121.76 9.95 Favored 'Trans proline' 0 N--CA 1.443 -1.462 0 C-N-CA 122.941 2.427 . . . . 0.0 110.857 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.632 ' HG3' ' HD3' ' A' ' 17' ' ' ARG . 1.1 mp0 -45.93 -32.35 2.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.059 173.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.2 -48.11 82.82 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.066 175.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.685 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.2 tt -66.68 -44.49 81.67 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.095 178.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.483 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 14.0 m -66.76 -40.4 88.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.508 -176.017 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.02 -42.21 93.84 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.519 0.676 . . . . 0.0 111.021 178.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.3 m -68.22 -21.87 64.82 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.353 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -100.7 -38.09 8.45 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.674 0.75 . . . . 0.0 109.847 -174.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.6 m -75.65 -57.68 3.74 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.596 -1.184 . . . . 0.0 112.024 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.0 -20.38 2.14 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 119.705 -1.236 . . . . 0.0 112.527 -176.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 30.7 m -66.83 155.91 37.01 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 175.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 33.1 pt -120.55 148.84 23.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.331 -0.547 . . . . 0.0 111.814 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 50.8 mm -102.13 139.22 23.77 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.344 176.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.591 ' O ' ' HB ' ' A' ' 1' ' ' THR . 3.1 pt -146.31 151.37 43.87 Favored Pre-proline 0 C--N 1.316 -0.859 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.25 -179.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -87.75 30.99 0.44 Allowed 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.498 2.799 . . . . 0.0 112.233 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.51 137.79 4.81 Favored Glycine 0 N--CA 1.446 -0.676 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.699 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.29 30.17 0.34 Allowed 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.057 0.456 . . . . 0.0 111.58 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.8 m -80.38 48.66 1.05 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.511 0.672 . . . . 0.0 111.632 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.574 ' SG ' HD11 ' A' ' 35' ' ' ILE . 76.3 m -94.29 126.38 48.6 Favored Pre-proline 0 C--N 1.313 -1.003 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.699 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -75.03 176.36 10.02 Favored 'Trans proline' 0 CA--C 1.531 0.352 0 C-N-CA 122.762 2.308 . . . . 0.0 112.36 176.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.95 -8.69 74.17 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 114.572 0.589 . . . . 0.0 114.572 -171.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -94.99 -22.12 18.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.831 0.824 . . . . 0.0 109.294 -179.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.451 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 20.8 m-85 -107.23 18.07 22.12 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.278 -178.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.01 33.46 0.79 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.261 -177.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.412 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 16.6 m-80 . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.791 -0.623 . . . . 0.0 109.497 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.521 ' HB ' HG13 ' A' ' 35' ' ' ILE . 7.5 m . . . . . 0 N--CA 1.475 0.798 0 CA-C-O 120.782 0.325 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.414 HG22 ' CZ ' ' A' ' 13' ' ' PHE . 7.3 m -90.57 115.02 27.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.103 0.478 . . . . 0.0 110.785 178.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.4 m -115.08 144.56 43.45 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.599 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.4 t -156.28 110.82 2.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.012 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.568 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 96.7 Cg_endo -84.61 45.4 1.68 Allowed 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.971 2.447 . . . . 0.0 113.881 -173.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.411 ' HG ' ' C ' ' A' ' 5' ' ' PRO . 19.8 m -158.17 127.28 5.69 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.4 mp -64.85 -36.96 78.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.9 t -62.59 -38.8 82.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.326 -1.307 . . . . 0.0 110.251 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.4 22.07 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.26 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.3 tpp180 -50.89 -43.45 59.65 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.833 175.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.503 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.7 m -53.7 -55.01 29.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.423 0.154 . . . . 0.0 111.378 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -76.65 -23.03 53.29 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.398 -0.521 . . . . 0.0 110.608 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.414 ' CZ ' HG22 ' A' ' 2' ' ' THR . 34.7 t80 -65.48 -49.07 70.44 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.114 175.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -59.97 -32.64 71.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.127 0.489 . . . . 0.0 109.843 174.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 11' ' ' SER . 92.8 t -72.82 -24.0 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.99 177.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -86.26 5.71 33.09 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-O 121.753 0.787 . . . . 0.0 109.62 -178.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.46 ' NE ' ' HG3' ' A' ' 23' ' ' GLU . 13.7 mmm180 -106.3 -23.53 12.53 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.556 0.693 . . . . 0.0 109.185 178.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -56.92 -47.62 98.77 Favored Pre-proline 0 CA--C 1.547 0.846 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.131 175.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.425 ' HG2' ' OG1' ' A' ' 21' ' ' THR . 82.3 Cg_endo -79.61 4.16 6.91 Favored 'Trans proline' 0 C--N 1.36 1.17 0 C-N-CA 121.779 1.653 . . . . 0.0 113.037 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.72 20.86 45.64 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.505 176.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.709 HG21 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -81.06 142.46 51.62 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.206 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.709 ' HD2' HG21 ' A' ' 21' ' ' THR . 38.2 Cg_endo -70.85 130.44 17.99 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 C-N-CA 123.156 2.571 . . . . 0.0 111.494 176.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.46 ' HG3' ' NE ' ' A' ' 17' ' ' ARG . 51.4 mt-10 -41.83 -36.08 0.96 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.485 171.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.71 -52.1 50.96 Favored 'General case' 0 C--N 1.33 -0.266 0 O-C-N 123.381 0.426 . . . . 0.0 110.857 175.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.503 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -68.19 -41.62 81.12 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.167 179.063 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.577 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 7.5 m -80.57 12.17 3.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.523 -176.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -108.05 -48.28 3.41 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 121.894 0.854 . . . . 0.0 110.104 173.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.0 m -62.73 -29.62 70.81 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 113.817 -1.538 . . . . 0.0 112.117 -174.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -95.86 -22.5 17.42 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.885 0.85 . . . . 0.0 110.117 -175.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -93.21 -38.61 11.46 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.528 -1.214 . . . . 0.0 111.82 -171.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.74 -18.68 8.58 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.433 -177.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 6.6 m -64.9 150.48 47.73 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 32.9 pt -122.3 149.09 25.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.085 0.469 . . . . 0.0 111.495 -177.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.5 mt -111.28 110.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.829 176.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.873 HD12 ' HB2' ' A' ' 38' ' ' ALA . 5.7 pt -108.52 129.36 24.11 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.907 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.09 -32.31 17.43 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.435 2.09 . . . . 0.0 112.68 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.07 117.91 0.83 Allowed Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.873 ' HB2' HD12 ' A' ' 35' ' ' ILE . . . 165.2 102.0 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.741 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -172.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.41 94.39 0.01 OUTLIER 'General case' 0 N--CA 1.435 -1.216 0 O-C-N 123.884 0.74 . . . . 0.0 110.377 172.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.41 ' SG ' ' HB2' ' A' ' 45' ' ' ALA . 4.2 t -65.92 120.52 69.8 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.356 -175.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.41 170.27 20.66 Favored 'Trans proline' 0 C--O 1.236 0.379 0 C-N-CA 122.766 2.311 . . . . 0.0 112.473 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.75 20.7 7.39 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.008 -173.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -119.1 -11.53 9.61 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 174.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.568 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 19.6 m-85 -113.81 0.11 14.38 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.756 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.41 ' HB2' ' SG ' ' A' ' 40' ' ' CYS . . . -135.9 64.99 1.55 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 120.962 0.41 . . . . 0.0 110.431 -177.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.7 m120 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.582 -0.723 . . . . 0.0 109.304 175.608 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.0 m . . . . . 0 N--CA 1.477 0.897 0 CA-C-O 120.554 0.216 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.444 ' OG1' HG12 ' A' ' 34' ' ' ILE . 31.1 m -97.33 112.49 24.28 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.129 0.49 . . . . 0.0 110.274 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.625 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 74.3 m -105.98 146.63 29.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.082 -176.821 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.426 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 2.1 t -136.8 141.99 37.13 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 5.4 Cg_exo -78.59 17.12 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.789 2.326 . . . . 0.0 115.043 -171.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -170.29 150.78 3.66 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 118.975 0.807 . . . . 0.0 110.755 177.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.736 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 3.3 mp -64.66 -33.52 63.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.893 0.854 . . . . 0.0 109.107 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.16 -51.09 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.754 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.84 -34.15 69.03 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.4 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.736 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -68.21 -25.22 65.11 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 109.93 -179.675 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.471 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 69.8 m -67.91 -47.42 68.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.903 172.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -55.27 -39.66 70.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.195 0.522 . . . . 0.0 109.879 176.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.424 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 5.8 t80 -53.0 -56.65 14.47 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 114.954 -1.021 . . . . 0.0 112.097 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.471 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 11.9 p30 -74.8 -31.39 61.71 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 121.2 -0.2 . . . . 0.0 111.213 -174.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 11' ' ' SER . 96.6 t -70.52 -30.9 44.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 111.131 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.41 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.2 t -74.64 -22.9 58.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.935 -178.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.671 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 74.2 mtm180 -77.98 -22.22 49.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.579 0.228 . . . . 0.0 111.172 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.6 mt -54.45 -50.58 84.37 Favored Pre-proline 0 N--CA 1.443 -0.816 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 -176.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.41 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 55.6 Cg_endo -72.14 5.0 2.87 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.099 1.866 . . . . 0.0 113.089 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.71 28.14 9.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.936 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.67 133.48 24.48 Favored Pre-proline 0 N--CA 1.438 -1.037 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.672 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 18.2 Cg_endo -62.01 124.44 14.44 Favored 'Trans proline' 0 N--CA 1.445 -1.381 0 C-N-CA 122.755 2.304 . . . . 0.0 109.798 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.671 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 9.4 pt-20 -53.63 -20.2 4.94 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.269 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -64.56 -47.09 80.03 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 173.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.672 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.5 tt -63.74 -44.12 94.47 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 120.871 0.367 . . . . 0.0 110.347 176.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 14.9 m -69.21 -30.97 69.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.309 -177.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.461 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -65.71 -31.14 71.97 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.749 0.785 . . . . 0.0 110.334 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 m -74.75 -20.59 59.76 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.78 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -98.12 -52.99 3.51 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-O 121.91 0.862 . . . . 0.0 110.244 -176.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 52.0 m -70.58 -47.47 60.07 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 114.013 -1.448 . . . . 0.0 112.161 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.1 0.79 10.56 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.953 -1.117 . . . . 0.0 112.753 -177.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.461 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 25.5 m -71.46 161.34 31.2 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 174.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.1 pt -132.42 141.25 45.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.967 0.413 . . . . 0.0 111.301 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.444 HG12 ' OG1' ' A' ' 2' ' ' THR . 77.4 mt -97.0 112.66 29.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.817 177.154 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.578 HG12 ' HB3' ' A' ' 40' ' ' CYS . 2.4 pp -105.72 147.53 34.87 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.869 0.366 . . . . 0.0 111.5 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -78.56 28.91 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 123.409 2.739 . . . . 0.0 112.999 -176.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -133.27 -151.08 6.49 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 177.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -148.39 22.38 1.05 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.608 0.24 . . . . 0.0 111.361 -177.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.0 m -133.0 -46.48 0.85 Allowed 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.828 -179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.651 ' HB2' ' HD2' ' A' ' 41' ' ' PRO . 24.1 p 48.92 164.92 0.03 OUTLIER Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 124.904 1.378 . . . . 0.0 113.187 -174.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.651 ' HD2' ' HB2' ' A' ' 40' ' ' CYS . 31.6 Cg_endo -65.82 152.55 81.24 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.253 1.969 . . . . 0.0 112.682 176.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.11 12.2 7.1 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.753 -0.658 . . . . 0.0 113.997 -172.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.44 ' OD1' ' HB2' ' A' ' 41' ' ' PRO . 19.1 p-10 -106.49 -12.31 15.66 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.625 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.9 m-85 -117.67 5.53 12.35 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.616 175.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.06 35.5 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.06 -172.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.8 m120 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.579 176.712 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.477 ' HB ' ' HB ' ' A' ' 35' ' ' ILE . 9.1 m . . . . . 0 N--CA 1.475 0.819 0 CA-C-O 121.041 0.448 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 31.7 m -135.54 142.14 45.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.804 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 58.9 m -125.06 132.27 53.2 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -172.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.0 m -126.47 123.28 24.03 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.377 174.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -80.74 19.67 1.08 Allowed 'Trans proline' 0 CA--C 1.532 0.406 0 C-N-CA 122.416 2.077 . . . . 0.0 113.441 -174.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -157.97 136.42 11.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.786 HD13 ' H ' ' A' ' 7' ' ' ILE . 4.1 mp -57.51 -38.66 64.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.326 0.584 . . . . 0.0 109.672 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.6 t -72.88 -36.78 52.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.271 -177.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.13 82.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.477 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -71.64 -39.68 70.21 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.23 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.579 ' O ' HG22 ' A' ' 15' ' ' VAL . 5.9 p -66.38 -37.39 85.17 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.557 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -66.25 -41.98 89.21 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.379 0.609 . . . . 0.0 109.834 175.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 23' ' ' GLU . 13.1 t80 -60.86 -42.99 98.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.123 179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -61.54 -34.29 75.29 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.156 177.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.579 HG22 ' O ' ' A' ' 11' ' ' SER . 47.2 t -78.57 -6.18 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.475 178.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.665 ' O ' ' HB ' ' A' ' 21' ' ' THR . 1.8 t -108.96 14.94 23.79 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-O 121.888 0.851 . . . . 0.0 108.855 176.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 21' ' ' THR . 6.2 tpt180 -120.9 -42.84 2.48 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 114.979 -1.01 . . . . 0.0 108.365 175.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.14 -51.35 57.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 CA-C-N 113.727 -1.578 . . . . 0.0 113.372 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.05 35.46 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.813 0 C-N-CA 122.641 2.227 . . . . 0.0 113.203 -175.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 66.51 46.68 75.1 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.935 178.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.665 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.57 132.23 24.27 Favored Pre-proline 0 N--CA 1.441 -0.899 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.857 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.684 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 30.1 Cg_endo -63.83 122.45 10.51 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.745 2.297 . . . . 0.0 111.156 177.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 13' ' ' PHE . 1.1 mp0 -51.9 -31.48 28.49 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.142 174.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.63 -48.82 79.72 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.573 177.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.684 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.9 OUTLIER -67.26 -41.9 84.8 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.204 0.526 . . . . 0.0 110.177 179.219 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 86.2 m -74.52 -14.12 60.77 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.82 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -70.27 -32.47 70.29 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 122.052 0.93 . . . . 0.0 109.883 174.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.6 m -72.05 -23.21 61.33 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 113.885 -1.507 . . . . 0.0 110.418 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -99.57 -49.42 4.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.352 0.596 . . . . 0.0 110.608 -176.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m -66.7 -44.92 80.41 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.567 -178.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.51 -15.17 14.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.429 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 82.6 m -65.89 145.43 55.94 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 176.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.8 pt -116.62 153.59 18.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.74 0.305 . . . . 0.0 111.487 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 67.7 mt -102.06 133.54 45.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.956 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.477 ' HB ' ' HB ' ' A' ' 1' ' ' THR . 45.7 mm -93.13 123.43 60.94 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.843 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -55.76 -40.04 87.59 Favored 'Trans proline' 0 CA--C 1.528 0.195 0 C-N-CA 122.829 2.353 . . . . 0.0 112.073 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.41 -125.4 4.67 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.999 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.24 72.8 1.34 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.561 0.696 . . . . 0.0 110.376 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.419 ' H ' HG23 ' A' ' 35' ' ' ILE . 11.2 m -145.78 108.94 4.6 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.112 174.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 16.8 t -153.89 123.01 3.15 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.129 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.54 164.83 34.47 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.918 2.412 . . . . 0.0 112.84 179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -74.41 6.72 21.69 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.584 -0.734 . . . . 0.0 113.314 -175.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -92.8 -21.28 20.0 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -108.44 5.99 25.82 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.892 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -122.88 18.88 10.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.872 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.307 -0.854 . . . . 0.0 110.909 -174.719 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.414 ' O ' HG21 ' A' ' 34' ' ' ILE . 8.5 m . . . . . 0 N--CA 1.477 0.914 0 CA-C-O 120.958 0.408 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 35.5 m -118.19 132.68 56.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.456 -175.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.556 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 98.3 m -106.82 126.38 52.23 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.702 174.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.456 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 1.8 t -115.15 140.45 25.68 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -91.74 22.79 0.64 Allowed 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.646 2.23 . . . . 0.0 113.652 -175.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 51.5 m -150.86 143.0 24.11 Favored 'General case' 0 C--N 1.332 -0.18 0 O-C-N 122.044 -0.41 . . . . 0.0 110.71 -179.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.0 mt -71.16 -27.01 28.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.256 0.55 . . . . 0.0 110.547 -175.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 80.0 t -87.27 -51.91 12.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.709 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -50.16 -42.53 51.16 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.348 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -26.3 68.31 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.286 0.565 . . . . 0.0 110.881 -176.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.514 ' O ' HG21 ' A' ' 15' ' ' VAL . 22.2 t -77.81 -56.16 4.73 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.464 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -68.03 -21.76 65.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.067 0.46 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.448 ' HZ ' ' HB2' ' A' ' 23' ' ' GLU . 21.7 t80 -57.97 -56.01 27.54 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.033 170.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.416 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 12.1 p30 -69.59 -25.16 63.84 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.679 -177.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.514 HG21 ' O ' ' A' ' 11' ' ' SER . 84.8 t -66.99 -22.83 29.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.758 173.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.6 t -83.64 -22.92 32.04 Favored 'General case' 0 C--O 1.221 -0.431 0 CA-C-O 121.35 0.595 . . . . 0.0 109.892 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.559 ' HG2' ' O ' ' A' ' 21' ' ' THR . 3.5 tmt_? -92.26 -29.57 16.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.902 -172.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.663 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -54.87 -44.83 99.7 Favored Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 114.599 -1.182 . . . . 0.0 113.179 -177.802 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.663 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 64.7 Cg_endo -73.52 14.0 0.67 Allowed 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 122.046 1.83 . . . . 0.0 113.808 -177.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.96 27.08 8.03 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.779 -0.724 . . . . 0.0 113.096 176.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.559 ' O ' ' HG2' ' A' ' 17' ' ' ARG . 4.5 m -104.73 138.34 19.48 Favored Pre-proline 0 N--CA 1.429 -1.49 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 17.4 Cg_endo -62.02 123.53 12.73 Favored 'Trans proline' 0 N--CA 1.441 -1.58 0 C-N-CA 122.335 2.024 . . . . 0.0 109.889 176.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.448 ' HB2' ' HZ ' ' A' ' 13' ' ' PHE . 14.8 pt-20 -45.22 -30.2 1.15 Allowed 'General case' 0 C--N 1.324 -0.54 0 O-C-N 123.816 0.697 . . . . 0.0 110.03 174.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.506 ' HA ' HD13 ' A' ' 34' ' ' ILE . . . -58.13 -46.74 85.11 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.704 177.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.62 -37.77 73.86 Favored 'General case' 0 N--CA 1.444 -0.765 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 85.9 m -71.55 -33.44 69.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.651 -177.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.84 -46.12 91.8 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 122.073 0.94 . . . . 0.0 110.245 176.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.7 m -67.18 -20.43 65.72 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 113.607 -1.633 . . . . 0.0 111.729 -178.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -100.45 -45.88 5.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.599 0.714 . . . . 0.0 110.175 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.432 HG22 ' HB2' ' A' ' 13' ' ' PHE . 99.8 m -72.58 -40.73 66.37 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.616 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.64 16.39 4.6 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.082 -1.056 . . . . 0.0 112.67 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.3 m -98.44 170.81 8.58 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -129.86 148.1 33.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.818 -0.353 . . . . 0.0 111.569 -177.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.506 HD13 ' HA ' ' A' ' 24' ' ' ALA . 31.3 mt -101.5 140.64 19.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.231 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.8 pt -129.83 142.78 46.54 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.758 0.313 . . . . 0.0 110.99 177.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.53 39.85 0.85 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.255 2.637 . . . . 0.0 112.331 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.25 149.05 20.34 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -176.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.71 -1.83 58.22 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 120.847 0.356 . . . . 0.0 111.143 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.2 m -99.72 106.29 18.18 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.494 176.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 14.3 t -123.5 131.2 24.29 Favored Pre-proline 0 C--N 1.309 -1.17 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.931 179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -59.36 143.14 99.82 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.791 2.327 . . . . 0.0 112.127 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.57 -8.35 25.87 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 114.563 -173.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -83.86 -24.17 30.99 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.556 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 7.9 m-85 -117.86 3.79 12.21 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.313 -176.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.43 34.31 0.52 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.41 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.456 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 22.3 m-80 . . . . . 0 C--O 1.245 0.823 0 CA-C-O 118.457 -0.783 . . . . 0.0 108.896 176.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 41.1 m . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 120.711 0.291 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.664 HG23 HG13 ' A' ' 34' ' ' ILE . 27.4 m -105.03 125.19 50.71 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.524 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 59.4 m -128.96 120.15 25.59 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.048 0.452 . . . . 0.0 111.288 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.563 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 78.8 m -107.36 166.31 11.27 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.386 179.177 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.516 ' HD2' ' HB3' ' A' ' 4' ' ' CYS . 83.6 Cg_endo -82.21 8.78 4.3 Favored 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 122.507 2.138 . . . . 0.0 114.574 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.4 t -176.09 145.13 0.62 Allowed 'General case' 0 CA--C 1.518 -0.281 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.667 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.872 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 46.2 mm -65.76 -27.24 40.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.561 0.695 . . . . 0.0 109.293 176.114 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.2 t -74.16 -49.75 31.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.844 177.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.93 -40.39 94.98 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.298 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.872 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -65.59 -27.72 68.62 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.111 0.481 . . . . 0.0 110.434 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.558 ' O ' HG22 ' A' ' 15' ' ' VAL . 6.3 t -64.86 -47.59 77.38 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.669 177.275 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 54.4 m-80 -67.26 -26.69 66.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.567 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.479 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 57.4 t80 -66.6 -51.63 54.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.578 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.442 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 10.9 p30 -66.82 -23.79 66.08 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.908 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.558 HG22 ' O ' ' A' ' 11' ' ' SER . 55.7 t -62.57 -34.53 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.792 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.536 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 75.8 m -66.41 -25.03 66.57 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.432 0.634 . . . . 0.0 111.319 177.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.635 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 18.2 mmm180 -75.04 -31.71 61.37 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.722 -175.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.987 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -66.72 -42.87 47.44 Favored Pre-proline 0 CA--C 1.546 0.825 0 N-CA-C 114.054 1.131 . . . . 0.0 114.054 -173.761 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.987 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 94.9 Cg_endo -87.55 -6.18 7.02 Favored 'Trans proline' 0 C--N 1.356 0.939 0 C-N-CA 121.806 1.67 . . . . 0.0 113.22 -177.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.03 23.0 7.95 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.074 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.459 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 5.6 m -84.53 126.42 69.01 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 175.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.772 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.32 120.48 8.36 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.404 2.069 . . . . 0.0 110.557 177.404 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.635 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -45.98 -35.33 4.64 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.035 169.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.08 -51.41 67.97 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.989 174.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.772 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.0 tt -62.39 -53.36 56.08 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 120.685 0.279 . . . . 0.0 110.355 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 13' ' ' PHE . 33.7 t -63.27 -38.26 90.48 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.593 -174.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' A' ' 32' ' ' CYS . . . -64.76 -34.33 78.08 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.356 0.598 . . . . 0.0 111.626 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 23.4 m -76.55 -20.71 56.56 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.306 -177.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -97.54 -46.17 6.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.94 0.876 . . . . 0.0 109.678 -175.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 55.5 m -70.59 -34.86 72.62 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.748 -1.569 . . . . 0.0 111.755 178.52 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.18 30.49 7.38 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.352 -0.928 . . . . 0.0 111.331 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.524 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 42.4 t -109.31 159.44 16.97 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.8 141.26 44.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.878 0.371 . . . . 0.0 111.587 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.664 HG13 HG23 ' A' ' 2' ' ' THR . 4.3 mp -109.95 132.08 59.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.892 174.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.464 HD12 ' SG ' ' A' ' 40' ' ' CYS . 24.5 pt -134.82 156.8 78.25 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.848 -178.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.51 -25.49 41.18 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 122.855 2.37 . . . . 0.0 112.689 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -113.06 -147.12 9.91 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.803 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -135.05 30.22 3.35 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.373 0.606 . . . . 0.0 110.386 -176.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.1 m -79.73 54.51 1.83 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.865 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.464 ' SG ' HD12 ' A' ' 35' ' ' ILE . 30.2 m -98.82 135.0 21.1 Favored Pre-proline 0 C--N 1.309 -1.176 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.81 -178.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.859 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 30.2 Cg_endo -65.1 165.96 20.25 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.779 2.319 . . . . 0.0 111.875 174.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -66.23 -37.9 93.33 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 121.283 -0.484 . . . . 0.0 113.788 -171.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -84.03 -18.24 37.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 122.022 0.915 . . . . 0.0 109.44 -174.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.859 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 16.3 m-85 -112.13 23.91 13.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.797 -176.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.5 22.47 12.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.048 0.452 . . . . 0.0 110.908 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 27.9 m-80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.459 -0.782 . . . . 0.0 109.524 -178.385 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 N--CA 1.478 0.928 0 CA-C-O 121.131 0.491 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.523 ' HB ' HG13 ' A' ' 34' ' ' ILE . 8.9 t -115.62 145.63 42.53 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.425 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 m -136.96 115.67 12.1 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -175.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.407 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 85.1 m -103.58 125.3 35.22 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 121.137 0.494 . . . . 0.0 111.219 -177.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.617 ' HA ' ' CB ' ' A' ' 44' ' ' TYR . 18.8 Cg_endo -60.24 -7.12 6.09 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.892 3.061 . . . . 0.0 115.606 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 p -161.55 162.14 30.12 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 118.771 0.714 . . . . 0.0 111.17 -177.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.577 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 60.2 mt -67.63 -34.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.115 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.03 -50.27 55.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.25 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.57 -32.63 74.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.253 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.577 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.41 -29.48 62.62 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.825 0.345 . . . . 0.0 110.533 -178.662 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.479 ' O ' HG21 ' A' ' 15' ' ' VAL . 70.1 m -68.67 -53.04 24.75 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -55.13 -40.11 70.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.099 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -57.0 -62.92 1.41 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.083 175.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 35.5 m-80 -59.41 -39.0 82.02 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.479 HG21 ' O ' ' A' ' 11' ' ' SER . 69.9 t -60.95 -37.46 77.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-O 120.551 0.215 . . . . 0.0 111.363 -178.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.457 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 18.2 t -70.28 -42.21 72.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.787 0.327 . . . . 0.0 110.808 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.71 ' HD2' ' HG2' ' A' ' 23' ' ' GLU . 0.0 OUTLIER -91.3 20.62 5.01 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.961 0.41 . . . . 0.0 111.811 -177.597 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 15' ' ' VAL . 4.5 mt -73.02 -50.33 6.81 Favored Pre-proline 0 N--CA 1.445 -0.71 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.693 177.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.65 25.96 0.63 Allowed 'Trans proline' 0 C--N 1.36 1.152 0 C-N-CA 122.221 1.948 . . . . 0.0 113.208 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.24 37.78 6.99 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.113 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.478 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 1.7 m -97.65 141.01 22.34 Favored Pre-proline 0 N--CA 1.43 -1.432 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.628 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.3 116.34 3.12 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.905 2.403 . . . . 0.0 111.178 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.71 ' HG2' ' HD2' ' A' ' 17' ' ' ARG . 36.8 mt-10 -51.11 -28.8 11.57 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.901 172.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.73 79.6 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.763 173.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.628 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.1 tt -65.36 -42.97 92.22 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.246 0.546 . . . . 0.0 109.927 178.504 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.457 ' HB3' ' HB3' ' A' ' 16' ' ' CYS . 61.0 m -77.34 -0.4 25.47 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.021 -175.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.53 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -101.57 -41.02 6.75 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.686 0.755 . . . . 0.0 111.113 175.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.0 m -65.82 -23.91 66.79 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.184 -1.371 . . . . 0.0 111.61 -174.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -100.47 -15.23 17.97 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 122.176 0.989 . . . . 0.0 109.88 -176.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 89.1 m -99.93 -46.81 5.24 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.075 -1.42 . . . . 0.0 111.874 -172.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.12 -20.96 6.23 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 119.944 -1.122 . . . . 0.0 112.287 -178.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.53 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 42.3 t -73.61 158.54 34.58 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.25 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.0 pt -131.64 143.68 39.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.441 0.639 . . . . 0.0 112.104 -175.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.523 HG13 ' HB ' ' A' ' 2' ' ' THR . 4.5 mp -104.25 136.16 38.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 168.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 46.7 pt -120.64 142.23 33.81 Favored Pre-proline 0 C--N 1.317 -0.807 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.035 -178.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.1 38.48 0.69 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 123.081 2.521 . . . . 0.0 112.304 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.72 -138.64 2.64 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -178.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -150.62 13.68 0.74 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.661 0.267 . . . . 0.0 111.244 -178.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.9 t -91.74 103.07 15.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 122.159 0.981 . . . . 0.0 111.991 -177.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.453 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 34.1 m -149.92 112.62 3.36 Favored Pre-proline 0 C--N 1.305 -1.351 0 CA-C-N 113.806 -1.543 . . . . 0.0 110.688 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.453 ' HD2' ' HA ' ' A' ' 40' ' ' CYS . 33.7 Cg_endo -63.89 160.59 36.55 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.49 2.126 . . . . 0.0 111.114 172.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.37 32.55 3.85 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.916 -0.659 . . . . 0.0 113.574 -171.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -108.19 -29.8 8.72 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.617 ' CB ' ' HA ' ' A' ' 5' ' ' PRO . 4.5 p90 -128.13 22.11 6.19 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.462 173.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.96 37.76 1.14 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.312 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 6.0 t30 . . . . . 0 C--O 1.252 1.19 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.234 -179.248 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.411 ' HB ' HD13 ' A' ' 35' ' ' ILE . 17.0 m . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.835 0.35 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.1 t -113.33 119.2 36.87 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.457 0.646 . . . . 0.0 110.138 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.415 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 33.6 m -104.91 108.88 20.61 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.747 -176.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 13.9 t -136.72 99.86 10.23 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.209 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.879 ' HG3' ' HA ' ' A' ' 44' ' ' TYR . 64.0 Cg_endo -85.35 61.24 5.58 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.954 2.436 . . . . 0.0 113.975 -169.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.731 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 1.4 p -167.39 120.96 0.96 Allowed 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.218 -178.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 68.0 mt -48.11 -38.63 8.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.604 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.5 t -77.53 -48.6 23.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.701 -175.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.97 -37.67 88.28 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.27 -178.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.731 ' HG3' ' O ' ' A' ' 6' ' ' SER . 60.5 mtt180 -54.27 -51.69 63.78 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 121.151 0.501 . . . . 0.0 110.284 179.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.517 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.9 m -70.63 -42.27 71.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.261 -177.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -62.69 -38.25 89.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 120.81 0.338 . . . . 0.0 110.581 -178.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -51.39 -51.34 55.51 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.412 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 36.6 m-80 -65.11 -37.87 88.85 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.452 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 11' ' ' SER . 90.7 t -61.98 -41.89 92.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.378 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.516 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 26.1 t -71.52 -32.11 67.82 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.398 0.618 . . . . 0.0 110.018 -179.225 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 17' ' ' ARG . 39.5 ttt180 -73.3 -21.86 60.48 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.342 -176.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 19.3 mt -64.61 -52.89 48.68 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -174.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.518 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 16.5 Cg_exo -69.9 0.5 5.65 Favored 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.427 2.085 . . . . 0.0 113.137 -178.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.25 26.27 7.87 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.182 -1.008 . . . . 0.0 112.407 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.487 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 1.3 m -89.89 137.88 28.07 Favored Pre-proline 0 N--CA 1.428 -1.55 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 176.113 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.482 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 8.3 Cg_endo -55.45 117.49 4.11 Favored 'Trans proline' 0 N--CA 1.444 -1.408 0 C-N-CA 122.869 2.38 . . . . 0.0 111.058 -179.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -47.21 -28.76 2.0 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.457 170.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.47 -42.16 98.6 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.885 174.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.482 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 41.3 tp -76.69 -36.17 57.43 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.053 0.454 . . . . 0.0 110.52 178.444 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.487 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 17.4 m -78.28 3.03 16.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.976 -179.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -101.2 -56.44 2.31 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.852 0.834 . . . . 0.0 110.328 174.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 m -62.77 -25.41 68.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.047 -174.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -94.39 -17.75 22.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 122.087 0.946 . . . . 0.0 109.551 -175.1 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 84.5 m -97.61 -44.62 6.71 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.542 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.25 -7.34 6.33 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.62 -175.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.524 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 5.3 m -82.39 148.13 28.41 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.8 pt -123.4 143.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.451 -0.5 . . . . 0.0 110.683 176.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 78.9 mt -112.95 120.83 63.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.022 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.411 HD13 ' HB ' ' A' ' 1' ' ' THR . 2.1 pp -120.08 139.85 28.99 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.637 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -82.09 22.42 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.234 2.623 . . . . 0.0 113.145 -175.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.48 -139.96 3.74 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.214 178.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.21 62.39 1.53 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.049 0.452 . . . . 0.0 109.943 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 m -152.44 106.05 3.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.275 0.559 . . . . 0.0 111.099 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.0 p -148.46 140.83 14.81 Favored Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.064 171.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.479 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 11.0 Cg_endo -53.81 143.71 58.1 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 123.005 2.47 . . . . 0.0 112.568 -174.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.13 -13.07 47.18 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.841 -0.618 . . . . 0.0 113.674 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.85 -17.37 41.11 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.879 ' HA ' ' HG3' ' A' ' 5' ' ' PRO . 16.9 m-85 -121.67 5.94 10.01 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.094 -175.022 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -105.3 38.0 2.06 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -171.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.692 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 2.9 t30 . . . . . 0 C--O 1.246 0.893 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.07 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.564 ' HB ' HG13 ' A' ' 35' ' ' ILE . 22.7 m . . . . . 0 N--CA 1.477 0.887 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -120.55 147.49 45.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.806 0.336 . . . . 0.0 111.605 -174.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.492 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 2.1 m -151.34 123.29 8.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.886 176.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.548 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 40.0 m -110.2 162.12 21.72 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.044 -175.705 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -91.13 13.95 2.03 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.394 2.062 . . . . 0.0 114.825 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.5 p -167.3 144.02 4.41 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 118.505 0.593 . . . . 0.0 111.115 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.444 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 35.9 mt -60.27 -29.32 43.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.763 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.5 t -72.55 -51.51 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.475 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.53 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -69.77 -30.35 67.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.725 -177.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.548 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -69.94 -26.09 63.96 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.149 0.499 . . . . 0.0 110.339 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.424 ' O ' HG21 ' A' ' 15' ' ' VAL . 25.0 m -79.79 -42.25 24.82 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.434 175.324 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -59.88 -30.26 68.87 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.541 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -52.9 -61.38 2.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.664 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.3 m-80 -63.21 -33.1 74.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.267 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.424 HG21 ' O ' ' A' ' 11' ' ' SER . 72.2 t -63.99 -34.84 71.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.079 178.272 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 41.8 t -77.5 -16.72 58.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.436 0.636 . . . . 0.0 110.67 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.473 ' HD2' ' O ' ' A' ' 21' ' ' THR . 7.8 mmm180 -82.66 -19.32 38.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.027 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.586 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 85.2 mt -67.14 -48.84 47.73 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.586 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 22.9 Cg_exo -65.58 -19.01 60.35 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.927 1.752 . . . . 0.0 112.391 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.4 24.44 5.64 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.586 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.553 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -90.56 134.06 31.6 Favored Pre-proline 0 N--CA 1.438 -1.054 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 177.615 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -66.46 129.55 21.61 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 123.065 2.51 . . . . 0.0 111.168 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -46.35 -25.58 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.197 171.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.95 -47.65 71.09 Favored 'General case' 0 C--N 1.327 -0.398 0 O-C-N 123.293 0.371 . . . . 0.0 110.629 172.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.8 mt -79.08 -38.46 36.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-O 120.93 0.395 . . . . 0.0 111.0 177.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.553 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 5.0 m -80.28 10.41 4.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.285 -176.15 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.73 -43.98 5.43 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.96 0.886 . . . . 0.0 109.731 170.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.2 m -69.76 -24.89 63.59 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 113.96 -1.473 . . . . 0.0 111.517 -177.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -91.36 -31.12 16.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.72 0.772 . . . . 0.0 109.759 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.53 HG22 ' HB1' ' A' ' 9' ' ' ALA . 0.3 OUTLIER -99.12 -14.78 19.23 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.555 -1.202 . . . . 0.0 112.596 -171.469 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.93 16.48 63.19 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.462 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 19.7 t -94.25 159.43 15.13 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.25 148.97 33.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.125 0.488 . . . . 0.0 111.871 -176.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 4.4 mp -96.42 135.32 30.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.898 176.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.565 HD12 ' SG ' ' A' ' 40' ' ' CYS . 5.5 pt -129.64 164.25 41.27 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.716 -179.627 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.41 -57.24 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.995 2.463 . . . . 0.0 111.252 169.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 171.47 137.69 2.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 116.098 -0.501 . . . . 0.0 112.028 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 64.43 18.08 11.15 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.256 0.622 . . . . 0.0 111.373 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -98.18 27.93 4.34 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.685 0.755 . . . . 0.0 110.904 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.565 ' SG ' HD12 ' A' ' 35' ' ' ILE . 16.9 m -112.86 107.28 54.69 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.466 -175.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.439 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 43.6 Cg_endo -71.3 174.27 11.05 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.59 2.193 . . . . 0.0 111.142 173.015 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.97 -34.74 66.22 Favored Glycine 0 CA--C 1.521 0.408 0 N-CA-C 114.754 0.662 . . . . 0.0 114.754 -172.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -83.98 -22.84 31.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.849 0.825 . . . . 0.0 109.772 -172.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.492 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 16.2 m-85 -108.75 20.09 18.91 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.314 -175.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.83 27.11 6.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.847 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 37.8 m-80 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.116 -177.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 37' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 121.004 0.43 . . . . 0.0 110.226 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.492 ' HB ' ' CZ ' ' A' ' 13' ' ' PHE . 86.3 m -137.97 140.38 40.18 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.928 -176.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -114.98 111.14 20.69 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.053 -178.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.558 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 100.0 m -102.0 111.84 64.67 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.202 174.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.666 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 91.1 Cg_endo -86.98 35.89 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.851 2.367 . . . . 0.0 112.923 -177.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.1 m -155.43 131.28 9.95 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 61.2 mt -56.18 -36.8 46.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 123.537 0.523 . . . . 0.0 111.143 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.9 t -83.28 -31.12 8.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.223 0.535 . . . . 0.0 110.382 -174.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.52 -37.21 71.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.394 178.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.558 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -83.78 -22.86 31.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.15 -175.468 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 61.3 p -74.24 -30.1 62.0 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.318 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -92.88 -26.48 17.61 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.876 177.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.492 ' CZ ' ' HB ' ' A' ' 2' ' ' THR . 27.4 t80 -55.05 -52.4 63.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.551 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -61.71 -29.08 69.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.65 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.605 ' HA ' HD23 ' A' ' 18' ' ' LEU . 57.3 t -75.73 -24.28 16.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.711 176.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.815 ' O ' ' HB ' ' A' ' 21' ' ' THR . 48.6 t -88.37 0.38 56.26 Favored 'General case' 0 C--O 1.214 -0.782 0 CA-C-O 121.684 0.754 . . . . 0.0 109.623 -178.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -109.32 -21.95 12.29 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -175.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.759 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 3.4 pp -74.5 -36.54 2.58 Favored Pre-proline 0 N--CA 1.436 -1.16 0 N-CA-C 113.785 1.031 . . . . 0.0 113.785 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.759 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 5.8 Cg_exo -78.62 7.24 4.31 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 121.835 1.69 . . . . 0.0 112.604 -175.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.97 33.05 8.47 Favored Glycine 0 N--CA 1.444 -0.81 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.042 -178.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.815 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 1.1 m -106.11 134.14 19.9 Favored Pre-proline 0 N--CA 1.434 -1.253 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.065 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.763 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.9 Cg_endo -56.29 117.22 3.84 Favored 'Trans proline' 0 N--CA 1.446 -1.285 0 C-N-CA 123.167 2.578 . . . . 0.0 112.183 -179.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -46.34 -31.52 2.63 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.839 168.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.09 -49.99 75.77 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.17 174.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.763 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tt -65.28 -44.31 88.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 18.8 m -76.17 -0.07 20.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.765 -177.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.512 ' HA ' ' HB2' ' A' ' 32' ' ' CYS . . . -94.68 -56.8 2.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.934 0.873 . . . . 0.0 109.885 168.423 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.1 m -58.28 -33.17 69.12 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 113.531 -1.668 . . . . 0.0 113.302 -173.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -96.43 -19.58 19.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 122.073 0.94 . . . . 0.0 110.324 -171.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 m -92.46 -25.1 18.59 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.518 -172.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.28 10.71 27.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.958 -177.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.512 ' HB2' ' HA ' ' A' ' 27' ' ' ALA . 44.1 m -95.11 167.69 11.22 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 176.171 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.2 pt -123.82 131.57 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.233 0.54 . . . . 0.0 111.334 176.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 16.2 tt -94.55 138.5 20.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.227 178.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.698 HD13 ' HB2' ' A' ' 40' ' ' CYS . 14.1 pt -119.58 160.85 40.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.348 -174.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -92.2 24.18 0.52 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.125 2.55 . . . . 0.0 113.176 178.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 1' ' ' THR . . . 177.01 -135.98 3.0 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.514 -0.851 . . . . 0.0 112.26 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.41 13.69 17.75 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 120.635 0.255 . . . . 0.0 111.534 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -77.64 88.25 3.93 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.296 0.569 . . . . 0.0 110.509 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.698 ' HB2' HD13 ' A' ' 35' ' ' ILE . 23.4 t -155.43 125.01 3.15 Favored Pre-proline 0 C--N 1.31 -1.135 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.321 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.31 167.98 25.92 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 123.003 2.469 . . . . 0.0 112.056 177.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.21 5.19 51.62 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 116.033 -0.531 . . . . 0.0 112.941 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -88.6 -20.85 24.45 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.666 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 14.7 m-85 -108.9 7.89 26.24 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.971 -178.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -116.53 52.32 0.94 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.736 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.8 t30 . . . . . 0 C--O 1.251 1.157 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.758 -176.574 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.53 HG21 ' HA2' ' A' ' 37' ' ' GLY . 12.2 m . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.775 HG22 ' SG ' ' A' ' 32' ' ' CYS . 3.9 m -139.5 134.03 31.69 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.019 -174.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.6 m -129.26 129.23 44.67 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.2 m -111.2 127.44 26.89 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.254 -171.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.811 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 75.8 Cg_endo -92.35 43.94 0.36 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.108 2.539 . . . . 0.0 114.113 -176.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.682 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 6.8 p -173.02 135.17 0.59 Allowed 'General case' 0 CA--C 1.517 -0.301 0 O-C-N 122.11 -0.369 . . . . 0.0 110.187 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.574 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 49.0 mt -56.29 -31.01 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.216 0.531 . . . . 0.0 111.003 -171.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.86 -53.09 28.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.956 177.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -62.06 -40.14 94.75 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.708 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.682 ' HG3' ' O ' ' A' ' 6' ' ' SER . 4.5 mtp-105 -59.01 -37.54 77.12 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.53 178.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.7 t -76.05 -35.72 59.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.565 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.9 m-20 -57.72 -42.87 84.7 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.994 174.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.627 ' CE1' ' HB ' ' A' ' 2' ' ' THR . 40.6 t80 -47.56 -46.01 27.59 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.202 -179.019 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -61.76 -48.61 79.9 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.33 0.586 . . . . 0.0 110.116 177.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -72.8 -12.55 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.026 -176.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.705 ' O ' ' HB ' ' A' ' 21' ' ' THR . 69.3 m -100.63 14.83 30.15 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.547 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.552 ' HD2' ' CE1' ' A' ' 13' ' ' PHE . 36.1 mtp180 -134.27 -39.87 0.83 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.325 0.583 . . . . 0.0 110.011 176.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 tp -49.62 -54.79 27.58 Favored Pre-proline 0 CA--C 1.553 1.086 0 CA-C-N 114.709 -1.132 . . . . 0.0 113.427 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -88.5 39.29 0.49 Allowed 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 122.075 1.85 . . . . 0.0 113.794 -174.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.57 50.29 26.43 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.302 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.705 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.82 138.25 31.03 Favored Pre-proline 0 N--CA 1.435 -1.186 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.665 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.528 ' HG2' ' CB ' ' A' ' 25' ' ' LEU . 38.0 Cg_endo -70.1 126.47 13.12 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 122.763 2.309 . . . . 0.0 111.544 174.366 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.47 ' HB3' ' HE ' ' A' ' 17' ' ' ARG . 11.2 pt-20 -50.75 -32.27 19.2 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.064 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.506 ' HA ' HD13 ' A' ' 34' ' ' ILE . . . -64.7 -39.26 93.35 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.255 -178.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.528 ' CB ' ' HG2' ' A' ' 22' ' ' PRO . 34.1 tp -69.63 -46.79 65.4 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.683 0.278 . . . . 0.0 110.831 -177.273 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 17.1 t -67.98 -29.41 68.43 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.258 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.53 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -56.9 -46.89 81.61 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.643 0.735 . . . . 0.0 110.906 177.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 47.2 m -67.07 -28.43 68.19 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.924 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -102.7 -35.11 8.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.311 0.577 . . . . 0.0 111.435 -171.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.481 ' HB ' ' O ' ' A' ' 26' ' ' CYS . 4.6 m -87.01 -19.79 28.17 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.144 -175.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.94 25.86 8.23 Favored Glycine 0 C--N 1.331 0.292 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.355 177.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.775 ' SG ' HG22 ' A' ' 2' ' ' THR . 5.8 t -102.6 161.74 13.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.6 pt -112.25 140.92 29.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 C-N-CA 119.928 -0.709 . . . . 0.0 112.644 -174.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.506 HD13 ' HA ' ' A' ' 24' ' ' ALA . 25.3 mm -98.91 132.7 43.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.274 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.459 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 44.5 pt -141.88 159.5 59.22 Favored Pre-proline 0 C--N 1.32 -0.682 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 53.8 Cg_endo -71.06 -16.02 32.19 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.71 2.273 . . . . 0.0 111.801 175.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.53 ' HA2' HG21 ' A' ' 1' ' ' THR . . . 111.59 130.21 5.54 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.811 176.044 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.55 -87.46 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.333 -0.434 . . . . 0.0 110.008 176.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.5 m -140.91 -15.17 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.944 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.461 ' HA ' ' HD3' ' A' ' 41' ' ' PRO . 91.4 m 64.91 139.5 0.05 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.521 -171.421 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.809 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 17.4 Cg_exo -65.09 156.95 59.94 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.934 2.423 . . . . 0.0 112.503 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -27.65 63.8 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.264 -174.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.7 -31.65 13.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.678 0.752 . . . . 0.0 110.075 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.811 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 20.1 m-85 -91.75 -7.99 48.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.968 -174.125 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.442 ' HB2' ' CB ' ' A' ' 40' ' ' CYS . . . -105.97 30.35 5.93 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.608 174.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 5.7 t30 . . . . . 0 C--O 1.247 0.929 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.996 -177.341 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.57 ' HB ' HG13 ' A' ' 35' ' ' ILE . 92.3 m . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 120.831 0.348 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.2 t -101.53 108.12 19.6 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-O 121.914 0.864 . . . . 0.0 110.656 -179.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.563 ' HB3' HG13 ' A' ' 33' ' ' ILE . 15.9 t -103.65 81.82 1.94 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.438 -173.38 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.43 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 60.2 m -105.54 134.35 19.74 Favored Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.436 178.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 61.2 Cg_endo -94.91 30.83 0.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.545 2.163 . . . . 0.0 115.245 -172.587 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.6 p -179.04 139.55 0.15 Allowed 'General case' 0 C--O 1.235 0.327 0 CA-C-N 118.846 0.748 . . . . 0.0 111.395 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.477 HG13 ' OD1' ' A' ' 46' ' ' ASN . 75.1 mt -58.37 -30.38 40.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.068 170.389 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 67.0 t -54.39 -58.66 3.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.52 175.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.04 -43.15 96.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.041 0.448 . . . . 0.0 110.666 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.421 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 21.4 tpp180 -55.06 -38.57 68.19 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.211 178.286 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 31.7 m -78.62 -10.44 59.74 Favored 'General case' 0 N--CA 1.466 0.375 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -94.55 -17.09 22.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.414 0.626 . . . . 0.0 109.778 175.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -69.22 -37.15 77.88 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.855 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -63.94 -26.05 68.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.955 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.9 t -64.81 -48.92 82.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.549 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.823 ' HB3' ' HB ' ' A' ' 21' ' ' THR . 55.8 m -67.2 -24.76 65.88 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -176.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.472 ' HD3' ' HG2' ' A' ' 23' ' ' GLU . 22.3 mmm180 -79.15 -8.76 59.25 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.976 -0.452 . . . . 0.0 111.703 -178.204 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.567 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 72.7 mt -78.02 -56.95 1.0 Allowed Pre-proline 0 N--CA 1.436 -1.148 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.281 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.567 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 81.2 Cg_endo -85.52 -4.99 9.23 Favored 'Trans proline' 0 C--N 1.359 1.131 0 C-N-CA 122.117 1.878 . . . . 0.0 113.451 -176.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.29 28.37 7.66 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.088 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.823 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 1.4 m -74.07 133.79 78.23 Favored Pre-proline 0 N--CA 1.441 -0.887 0 CA-C-O 121.208 0.528 . . . . 0.0 110.016 176.341 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.864 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.1 Cg_endo -62.61 120.82 8.51 Favored 'Trans proline' 0 N--CA 1.444 -1.415 0 C-N-CA 122.941 2.427 . . . . 0.0 111.008 177.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.472 ' HG2' ' HD3' ' A' ' 17' ' ' ARG . 24.2 mt-10 -45.49 -33.99 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.613 172.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.83 -47.78 84.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.405 176.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.864 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -65.06 -41.03 95.48 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -179.923 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 29.9 m -87.91 23.95 1.91 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.443 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.33 -46.25 3.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 122.171 0.986 . . . . 0.0 109.245 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -65.89 -29.24 69.64 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.259 -1.791 . . . . 0.0 112.388 -175.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 t80 -99.73 -21.51 15.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.872 0.844 . . . . 0.0 110.123 -173.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.22 -6.62 37.68 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.949 -172.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.32 36.0 28.27 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.465 178.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.3 t -127.61 153.01 46.93 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.563 HG13 ' HB3' ' A' ' 3' ' ' CYS . 25.2 pt -122.66 148.89 26.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.326 0.584 . . . . 0.0 112.033 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.2 mt -106.4 116.85 51.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.552 177.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.57 HG13 ' HB ' ' A' ' 1' ' ' THR . 25.3 pt -121.97 131.34 24.44 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.898 -178.589 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.86 -12.14 23.96 Favored 'Trans proline' 0 CA--C 1.529 0.259 0 C-N-CA 122.903 2.402 . . . . 0.0 112.282 177.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.92 -141.24 9.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.133 177.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.66 12.95 1.17 Allowed 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 -176.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.5 m -86.02 97.55 10.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.377 0.608 . . . . 0.0 110.818 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 39.6 t -158.38 107.39 1.68 Allowed Pre-proline 0 C--N 1.311 -1.103 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.536 -178.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.498 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 15.1 Cg_endo -59.55 161.92 16.38 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.851 2.368 . . . . 0.0 112.851 -177.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -69.97 1.14 18.4 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.723 -0.671 . . . . 0.0 113.594 -174.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.03 -15.49 18.23 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 19.3 m-85 -115.44 8.05 15.16 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.029 179.307 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.05 39.56 1.77 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.347 0.594 . . . . 0.0 109.573 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.477 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.4 t-20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.03 -175.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 120.77 0.319 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 28.5 m -132.65 121.22 22.83 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 174.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.579 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.5 m -124.53 117.19 23.8 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.254 0.55 . . . . 0.0 111.244 -173.006 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 20.8 m -108.55 166.74 10.31 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.704 -177.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -91.33 6.02 3.76 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 122.104 1.87 . . . . 0.0 113.351 169.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.1 m -155.62 141.5 18.12 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 121.914 -0.491 . . . . 0.0 110.993 -172.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.4 mm -61.38 -32.19 52.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 121.187 0.518 . . . . 0.0 109.74 174.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.4 t -62.78 -43.27 98.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.889 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.559 ' HA ' ' ND2' ' A' ' 12' ' ' ASN . . . -69.4 -39.84 77.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.671 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.419 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 19.6 ttm180 -64.73 -27.93 69.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.658 176.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -79.03 -48.18 14.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.368 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.559 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.1 p30 -73.78 -15.99 61.18 Favored 'General case' 0 N--CA 1.464 0.271 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.168 -178.159 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 23.9 t80 -48.81 -44.36 39.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 122.02 0.914 . . . . 0.0 109.286 165.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.37 -39.4 53.92 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.345 -1.298 . . . . 0.0 109.941 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.51 ' CG2' ' HA ' ' A' ' 12' ' ' ASN . 92.0 t -57.92 -46.51 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.748 -176.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.563 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 68.2 m -61.07 -38.05 84.87 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.644 ' HD2' ' HB3' ' A' ' 23' ' ' GLU . 45.9 mtp180 -79.27 -5.62 54.81 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.574 -172.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.607 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 31.9 mt -75.94 -53.6 2.32 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.607 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 6.1 Cg_exo -76.18 -24.34 11.11 Favored 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.178 1.919 . . . . 0.0 112.517 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.53 13.49 2.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.051 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.422 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 2.4 m -80.96 124.27 81.51 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.777 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.5 Cg_endo -59.94 123.54 13.44 Favored 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.236 1.958 . . . . 0.0 110.765 177.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.644 ' HB3' ' HD2' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -51.26 -27.94 10.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.738 169.866 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.79 -46.42 89.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.92 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.777 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.7 tt -66.63 -51.61 54.33 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 120.664 0.269 . . . . 0.0 110.426 178.321 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 26.6 m -66.82 -25.43 66.44 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.28 72.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.984 0.897 . . . . 0.0 110.435 174.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.4 m -81.85 -22.11 37.16 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.358 -174.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 19.9 t80 -106.18 -39.5 5.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.348 0.594 . . . . 0.0 110.707 -174.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.0 m -72.2 -31.93 66.33 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.498 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.3 18.59 38.55 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.24 -0.981 . . . . 0.0 112.287 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.6 t -105.5 139.59 39.89 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.409 HD12 HD13 ' A' ' 35' ' ' ILE . 22.6 pt -104.79 139.98 24.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.286 0.565 . . . . 0.0 111.794 -172.353 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 80.3 mt -100.6 124.92 54.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.917 176.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.79 HG22 ' HB ' ' A' ' 39' ' ' THR . 96.7 mt -129.18 137.4 30.91 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.372 -175.509 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -47.25 -48.51 14.82 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.697 2.265 . . . . 0.0 112.384 176.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.77 137.71 2.3 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.6 177.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.01 65.29 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 123.45 0.7 . . . . 0.0 112.401 175.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.79 ' HB ' HG22 ' A' ' 35' ' ' ILE . 8.9 m -151.03 26.21 0.72 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 122.224 1.012 . . . . 0.0 110.091 175.115 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.487 ' SG ' HD12 ' A' ' 35' ' ' ILE . 62.9 m -108.64 116.42 56.13 Favored Pre-proline 0 C--N 1.314 -0.965 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.342 -172.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.428 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 40.3 Cg_endo -69.38 162.35 42.23 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.391 2.061 . . . . 0.0 111.963 175.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.61 -28.4 67.74 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 114.947 0.739 . . . . 0.0 114.947 -172.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -87.78 -20.05 26.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.734 0.778 . . . . 0.0 109.778 -174.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.579 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.5 m-85 -114.16 25.31 11.22 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.185 -176.09 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.33 23.7 13.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.812 177.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 65.9 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-O 118.096 -0.954 . . . . 0.0 109.681 -177.602 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.929 ' HB ' HG23 ' A' ' 35' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.473 0.711 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.91 110.59 16.49 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -171.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.567 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 46.5 m -150.38 156.25 41.14 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.102 0.477 . . . . 0.0 111.768 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.1 t -144.82 143.01 19.59 Favored Pre-proline 0 N--CA 1.453 -0.301 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 47.6 Cg_exo -58.82 -27.91 85.41 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.138 2.558 . . . . 0.0 114.205 -177.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.0 m -142.01 141.93 32.89 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 -176.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.687 HG13 ' OD1' ' A' ' 46' ' ' ASN . 87.8 mt -53.39 -40.35 39.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.956 175.481 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -67.49 -34.3 67.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.099 0.476 . . . . 0.0 110.49 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -74.53 -36.23 63.16 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.245 0.545 . . . . 0.0 109.775 177.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -63.97 -42.13 97.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.4 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.499 ' O ' HG22 ' A' ' 15' ' ' VAL . 6.7 p -67.73 -37.65 82.48 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.032 178.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -66.86 -34.38 77.67 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.277 0.561 . . . . 0.0 110.734 179.144 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.593 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 50.6 t80 -58.85 -53.24 60.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.117 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -55.39 -30.85 61.18 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.398 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 11' ' ' SER . 90.0 t -63.57 -34.18 66.05 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.476 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.52 -23.36 42.97 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.946 -0.471 . . . . 0.0 111.176 -175.386 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -74.61 -18.27 60.58 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 177.155 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.465 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 95.3 mt -63.77 -53.21 52.09 Favored Pre-proline 0 N--CA 1.442 -0.839 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -177.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 61.2 Cg_endo -73.25 2.99 5.01 Favored 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.054 1.836 . . . . 0.0 113.181 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.32 36.76 7.96 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.485 178.28 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.57 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -97.6 141.05 22.41 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 176.621 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.57 ' HD2' HG22 ' A' ' 21' ' ' THR . 13.3 Cg_endo -61.07 117.74 4.55 Favored 'Trans proline' 0 N--CA 1.446 -1.309 0 C-N-CA 122.962 2.441 . . . . 0.0 110.944 178.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.593 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 9.7 pt-20 -51.81 -29.75 20.46 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.854 175.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.18 -41.74 97.34 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.554 174.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.556 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 50.7 tp -77.52 -39.44 46.15 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-O 120.737 0.303 . . . . 0.0 110.427 179.591 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.502 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 26.6 m -64.69 -39.74 94.18 Favored 'General case' 0 C--O 1.22 -0.455 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.041 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.561 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -64.98 -23.59 67.26 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.57 0.7 . . . . 0.0 111.58 -178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.5 m -75.59 -22.35 57.0 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.673 -1.149 . . . . 0.0 110.316 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -104.03 -43.46 5.27 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.862 0.839 . . . . 0.0 110.13 -178.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 93.9 m -64.89 -55.37 19.74 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.24 -1.346 . . . . 0.0 111.849 -178.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 131.1 -24.92 4.18 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.547 -178.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.561 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 38.2 m -64.34 158.85 22.44 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.3 pt -130.16 139.55 51.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.427 -0.509 . . . . 0.0 112.293 -175.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.0 mp -85.68 125.7 40.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.929 HG23 ' HB ' ' A' ' 1' ' ' THR . 9.2 tt -129.65 110.35 17.44 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.46 0.648 . . . . 0.0 110.784 -171.057 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 34.9 Cg_exo -62.24 -32.38 82.3 Favored 'Trans proline' 0 N--CA 1.477 0.544 0 C-N-CA 123.785 2.99 . . . . 0.0 114.331 -174.248 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -153.41 -163.4 11.75 Favored Glycine 0 N--CA 1.44 -1.071 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.434 -177.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.56 25.97 12.22 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 123.06 0.544 . . . . 0.0 111.634 -178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 49.3 m 42.28 -99.48 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.0 -176.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 79.8 m -158.51 137.86 8.33 Favored Pre-proline 0 C--N 1.314 -0.949 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.32 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.573 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 52.5 Cg_endo -72.55 148.23 47.43 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.865 1.71 . . . . 0.0 110.796 169.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.04 10.39 14.97 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 121.364 -0.446 . . . . 0.0 113.529 -173.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -112.67 -16.28 12.83 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.628 0.728 . . . . 0.0 109.252 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.573 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 21.4 m-85 -119.93 18.67 12.48 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.352 -178.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -113.19 45.85 1.32 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.672 177.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.687 ' OD1' HG13 ' A' ' 7' ' ' ILE . 15.6 t-20 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.211 -0.899 . . . . 0.0 110.481 -175.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.517 ' HB ' HG13 ' A' ' 35' ' ' ILE . 86.1 m . . . . . 0 N--CA 1.475 0.794 0 CA-C-O 121.061 0.457 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -123.37 142.42 50.98 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.023 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 44' ' ' TYR . 22.1 p -152.48 147.96 26.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.912 0.387 . . . . 0.0 110.682 175.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.652 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 15.2 t -141.36 144.03 32.54 Favored Pre-proline 0 C--N 1.328 -0.331 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.699 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 3.6 Cg_exo -39.25 -51.86 2.5 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 124.474 3.45 . . . . 0.0 114.694 -177.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.464 ' HA ' ' HB3' ' A' ' 46' ' ' ASN . 3.8 p -147.74 160.6 42.53 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 122.29 -0.256 . . . . 0.0 111.394 -176.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.485 HG13 ' OD1' ' A' ' 46' ' ' ASN . 80.2 mt -53.82 -39.59 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.429 178.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 84.5 t -59.87 -52.92 55.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.652 0.263 . . . . 0.0 110.611 178.248 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.27 -35.46 80.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.746 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.527 ' HA ' ' HD2' ' A' ' 13' ' ' PHE . 1.0 OUTLIER -67.27 -41.01 86.23 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-O 121.231 0.539 . . . . 0.0 110.103 178.194 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.509 ' O ' HG23 ' A' ' 15' ' ' VAL . 29.7 t -57.87 -42.55 84.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.867 174.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -46.03 79.37 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.313 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.538 ' HB3' HG23 ' A' ' 30' ' ' THR . 0.8 OUTLIER -72.54 -35.19 67.99 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.856 -175.699 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -59.85 -43.15 94.8 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.921 0.391 . . . . 0.0 110.019 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.509 HG23 ' O ' ' A' ' 11' ' ' SER . 63.3 t -67.26 -21.37 27.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.046 177.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.426 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 14.0 t -80.99 -25.4 37.29 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 120.929 0.395 . . . . 0.0 110.749 -176.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -72.0 -41.51 67.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.052 0.453 . . . . 0.0 110.741 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.949 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -56.55 -40.5 85.42 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -171.093 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.949 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 59.6 Cg_endo -74.1 0.6 8.21 Favored 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 121.522 1.481 . . . . 0.0 113.377 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.29 34.08 4.63 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.476 178.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.528 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -104.36 135.82 19.27 Favored Pre-proline 0 N--CA 1.436 -1.143 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.677 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.633 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.0 Cg_endo -63.74 127.71 20.33 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 122.848 2.366 . . . . 0.0 111.053 176.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.411 ' H ' ' CD ' ' A' ' 23' ' ' GLU . 1.5 mp0 -37.56 -40.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.346 172.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.43 -50.07 72.72 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.162 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.633 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -63.98 -36.42 83.91 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.107 0.479 . . . . 0.0 110.088 177.812 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.528 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 21.5 m -79.02 10.83 3.11 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.249 -179.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.25 -38.85 5.86 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.847 0.832 . . . . 0.0 110.359 171.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -69.59 -29.56 67.12 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.975 -1.466 . . . . 0.0 112.324 -173.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -103.77 -31.74 9.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.732 0.777 . . . . 0.0 109.913 -175.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.538 HG23 ' HB3' ' A' ' 13' ' ' PHE . 15.6 m -78.51 -33.1 48.3 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 114.426 -1.261 . . . . 0.0 111.684 -175.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.85 0.55 36.39 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.913 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.1 m -85.69 155.02 21.26 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.412 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.6 pt -120.43 144.98 27.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.398 0.618 . . . . 0.0 111.965 -176.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 79.5 mt -107.87 127.44 63.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.178 175.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.524 HD12 ' HB2' ' A' ' 40' ' ' CYS . 24.3 pt -132.32 134.11 24.55 Favored Pre-proline 0 C--N 1.319 -0.76 0 CA-C-O 120.936 0.398 . . . . 0.0 111.476 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 -9.81 15.7 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.625 2.217 . . . . 0.0 111.176 173.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.01 -142.34 7.76 Favored Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.62 15.34 7.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 120.732 0.301 . . . . 0.0 111.181 -177.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.5 m -80.29 86.32 5.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.51 0.672 . . . . 0.0 110.751 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.524 ' HB2' HD12 ' A' ' 35' ' ' ILE . 42.1 t -158.29 116.26 1.78 Allowed Pre-proline 0 C--N 1.311 -1.108 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.672 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.96 166.65 28.94 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.415 2.076 . . . . 0.0 112.692 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.46 10.9 14.9 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.084 -177.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -98.43 -18.84 18.04 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.699 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 17.4 m-85 -120.0 18.4 12.44 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.827 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -115.09 47.25 1.31 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.212 -175.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.485 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.3 t-20 . . . . . 0 C--O 1.246 0.885 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.389 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' THR . . . . . 0.487 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 88.7 m . . . . . 0 N--CA 1.473 0.685 0 CA-C-O 121.131 0.491 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.408 HG22 HG12 ' A' ' 34' ' ' ILE . 40.2 m -128.92 112.01 13.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.729 -176.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.572 ' O ' ' HB2' ' A' ' 32' ' ' CYS . 73.2 m -75.5 90.82 2.75 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 176.124 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.52 ' SG ' HG22 ' A' ' 30' ' ' THR . 1.4 t -125.35 87.8 55.11 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -177.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.63 78.73 2.99 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 123.418 2.745 . . . . 0.0 114.025 -167.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.67 ' HB3' ' HB1' ' A' ' 9' ' ' ALA . 29.2 t 172.21 132.87 0.03 OUTLIER 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 171.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.643 ' H ' HD12 ' A' ' 7' ' ' ILE . 3.7 mp -62.93 -31.57 52.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.051 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.2 t -80.08 -47.26 21.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.173 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.67 ' HB1' ' HB3' ' A' ' 6' ' ' SER . . . -60.75 -48.4 81.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.68 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.406 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 1.8 ptp180 -62.75 -25.09 68.03 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.621 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.47 ' O ' HG23 ' A' ' 15' ' ' VAL . 67.6 m -69.09 -56.49 7.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.029 178.195 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.492 ' HA ' ' HB ' ' A' ' 15' ' ' VAL . 11.2 p30 -64.32 -22.38 66.93 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.634 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.406 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 61.8 t80 -59.12 -59.69 5.05 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.653 170.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.434 ' O ' ' HB3' ' A' ' 17' ' ' ARG . 2.3 p-10 -71.73 -27.1 62.77 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.877 0.37 . . . . 0.0 110.903 -178.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.492 ' HB ' ' HA ' ' A' ' 12' ' ' ASN . 78.1 t -70.31 -17.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.006 0.431 . . . . 0.0 110.263 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.655 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 3.8 t -84.66 -29.03 26.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.417 0.627 . . . . 0.0 109.707 177.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.434 ' HB3' ' O ' ' A' ' 14' ' ' ASN . 6.9 tpt180 -58.42 -40.72 83.23 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.383 175.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.564 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 86.1 mt -61.08 -50.29 85.09 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 113.775 1.028 . . . . 0.0 113.775 -172.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.655 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 7.9 Cg_exo -73.39 13.56 0.69 Allowed 'Trans proline' 0 C--N 1.358 1.079 0 C-N-CA 122.581 2.187 . . . . 0.0 113.507 -177.712 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.23 36.85 9.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.897 176.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.58 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -108.79 134.9 20.17 Favored Pre-proline 0 N--CA 1.434 -1.27 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 176.887 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.726 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -60.18 122.51 11.48 Favored 'Trans proline' 0 N--CA 1.446 -1.29 0 C-N-CA 122.951 2.434 . . . . 0.0 111.121 178.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -35.84 -39.56 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.398 169.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.56 -53.39 58.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.192 176.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.726 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tm? -63.71 -37.2 86.46 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-O 121.004 0.431 . . . . 0.0 110.782 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 23.9 m -65.04 -37.43 87.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.358 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.52 -32.4 74.02 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.804 0.811 . . . . 0.0 110.462 176.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.8 m -74.89 -22.5 58.6 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 114.47 -1.241 . . . . 0.0 110.761 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -89.45 -45.58 9.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.864 0.84 . . . . 0.0 109.024 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.52 HG22 ' SG ' ' A' ' 4' ' ' CYS . 85.0 m -70.89 -37.79 73.01 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.002 -1.454 . . . . 0.0 111.061 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.04 16.89 17.65 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.904 -0.665 . . . . 0.0 113.017 179.11 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 3' ' ' CYS . 10.7 p -114.24 179.53 3.93 Favored 'General case' 0 C--N 1.327 -0.395 0 O-C-N 122.725 -0.279 . . . . 0.0 110.721 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.4 ' H ' HD12 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -127.77 141.88 45.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 111.563 -173.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.408 HG12 HG22 ' A' ' 2' ' ' THR . 60.3 mt -99.44 140.17 19.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.777 176.477 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.841 HD12 ' HB3' ' A' ' 38' ' ' ALA . 11.2 pt -137.91 129.14 15.94 Favored Pre-proline 0 N--CA 1.448 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 111.388 -177.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 32.6 Cg_exo -61.62 -27.77 81.94 Favored 'Trans proline' 0 CA--C 1.53 0.307 0 C-N-CA 123.029 2.486 . . . . 0.0 112.639 176.608 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 39' ' ' THR . . . -132.94 -153.46 7.22 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.927 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.841 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 71.69 -29.04 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.904 0.881 . . . . 0.0 111.898 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.482 ' H ' ' C ' ' A' ' 37' ' ' GLY . 52.2 m 65.81 5.45 3.41 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.331 0.652 . . . . 0.0 112.512 176.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 66.9 m 65.59 137.46 0.05 OUTLIER Pre-proline 0 N--CA 1.468 0.465 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.141 -175.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -74.62 175.85 10.54 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.418 2.079 . . . . 0.0 111.698 175.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -73.94 -0.82 57.49 Favored Glycine 0 CA--C 1.518 0.235 0 C-N-CA 121.363 -0.446 . . . . 0.0 113.12 -175.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -98.07 -22.25 16.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.193 0.52 . . . . 0.0 109.612 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.528 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 16.0 m-85 -121.44 19.95 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.679 -173.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.11 14.8 29.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.393 0.616 . . . . 0.0 110.77 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 18.3 m120 . . . . . 0 C--O 1.247 0.971 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.681 179.404 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.421 ' HB ' HG13 ' A' ' 35' ' ' ILE . 13.0 m . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 121.016 0.436 . . . . 0.0 109.933 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.7 t -98.99 122.65 42.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.518 0.675 . . . . 0.0 110.526 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 61.9 m -121.43 122.49 39.89 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.08 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.9 t -147.52 141.0 15.3 Favored Pre-proline 0 N--CA 1.448 -0.561 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -103.0 40.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.05 2.5 . . . . 0.0 113.957 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.9 t -158.26 135.52 10.09 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.622 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.8 mt -69.34 -28.0 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.356 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.7 t -83.5 -25.29 7.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.875 -175.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.36 -50.23 8.01 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.055 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.508 ' NH2' ' H ' ' A' ' 4' ' ' CYS . 7.3 tpp180 -53.5 -39.83 64.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.358 177.773 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.4 p -62.41 -61.71 2.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.644 0.259 . . . . 0.0 111.222 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -64.52 -24.07 67.48 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.469 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.429 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 56.7 t80 -59.17 -58.14 9.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.064 173.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -70.2 -30.56 67.7 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.898 -179.116 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 11' ' ' SER . 72.0 t -65.2 -30.16 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.351 . . . . 0.0 110.707 176.594 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -71.74 -27.16 62.8 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.297 0.57 . . . . 0.0 110.574 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.596 ' HA ' ' O ' ' A' ' 21' ' ' THR . 46.5 tpt85 -76.49 -17.71 59.14 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.205 -178.566 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.417 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 77.9 mt -68.57 -52.29 19.94 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -175.252 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.417 ' HD2' ' N ' ' A' ' 18' ' ' LEU . 56.4 Cg_endo -69.72 -6.28 18.19 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.262 1.975 . . . . 0.0 113.271 -177.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.92 25.87 4.94 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.2 OUTLIER -103.19 128.65 27.15 Favored Pre-proline 0 N--CA 1.439 -0.99 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.457 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.772 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 12.7 Cg_endo -58.43 121.99 10.9 Favored 'Trans proline' 0 N--CA 1.449 -1.146 0 C-N-CA 122.577 2.184 . . . . 0.0 110.752 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.57 ' H ' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -50.67 -29.19 10.5 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.937 173.459 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.16 -46.95 87.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.976 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.772 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -67.5 -46.69 72.16 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 120.971 0.415 . . . . 0.0 109.992 177.841 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 6.9 m -62.66 -35.54 79.97 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.828 -177.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.541 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -58.41 -40.45 82.46 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 111.266 178.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.6 m -66.28 -22.75 66.31 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.528 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -86.11 -47.03 9.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.124 176.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.464 ' HB ' ' SG ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -69.39 -36.99 77.31 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 -177.28 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.67 -22.24 36.28 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.141 -172.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.541 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 3.2 m -60.94 116.31 4.38 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.217 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.2 pt -91.68 150.5 3.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.925 0.393 . . . . 0.0 111.866 -172.043 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 69.4 mt -116.14 107.93 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.37 0.605 . . . . 0.0 109.617 174.471 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.726 HD12 ' HB3' ' A' ' 38' ' ' ALA . 15.3 pt -116.0 152.81 48.06 Favored Pre-proline 0 C--N 1.314 -0.95 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.91 -175.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.38 -64.71 0.1 OUTLIER 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 123.049 2.499 . . . . 0.0 112.41 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.39 -142.47 8.94 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 62.52 80.37 0.23 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.388 0.613 . . . . 0.0 110.939 177.571 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.63 96.63 0.13 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.745 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 44' ' ' TYR . 62.5 m -59.59 144.11 85.3 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.181 177.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.582 ' HD2' ' HD2' ' A' ' 44' ' ' TYR . 57.2 Cg_endo -70.96 -175.13 1.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.974 2.449 . . . . 0.0 113.25 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.41 7.1 33.4 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.488 -0.778 . . . . 0.0 114.428 -170.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.549 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 16.7 p-10 -108.45 -17.51 13.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 176.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.674 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . 22.2 m-85 -102.74 0.73 33.35 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.612 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.01 18.38 18.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.424 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.5 t-20 . . . . . 0 C--O 1.253 1.252 0 CA-C-O 118.251 -0.88 . . . . 0.0 110.215 -179.213 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.1 m . . . . . 0 N--CA 1.476 0.844 0 CA-C-O 120.782 0.325 . . . . 0.0 110.375 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 22.8 m -89.08 123.92 33.81 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.817 0.341 . . . . 0.0 110.47 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 63.8 m -124.25 106.7 10.49 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.559 ' HB3' ' HB3' ' A' ' 10' ' ' ARG . 7.8 t -100.76 132.6 21.97 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.054 -178.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.615 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.7 Cg_endo -86.05 34.21 0.47 Allowed 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.97 2.447 . . . . 0.0 112.982 -177.051 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.62 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 38.6 t -164.88 133.28 3.35 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 120.983 0.42 . . . . 0.0 110.573 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.31 -26.7 34.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.186 -0.916 . . . . 0.0 109.113 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.1 t -82.77 -47.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.088 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.62 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -61.78 -43.24 99.24 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.966 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.559 ' HB3' ' HB3' ' A' ' 4' ' ' CYS . 6.0 ptp180 -65.41 -28.23 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.095 0.474 . . . . 0.0 110.69 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.515 ' O ' HG23 ' A' ' 15' ' ' VAL . 42.4 m -72.62 -40.59 66.34 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.357 176.349 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -65.8 -28.69 69.19 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.632 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.24 -50.63 72.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.972 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -66.0 -26.42 67.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.192 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 11' ' ' SER . 84.5 t -68.2 -34.49 66.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.699 -179.185 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.499 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.0 t -82.26 -24.5 34.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 121.371 0.605 . . . . 0.0 110.393 -178.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 17' ' ' ARG . 23.6 ttt180 -80.5 -13.05 59.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.482 -178.229 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 8.2 mt -71.76 -52.1 8.38 Favored Pre-proline 0 N--CA 1.444 -0.745 0 CA-C-N 115.998 -0.547 . . . . 0.0 112.447 -177.177 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 6.4 Cg_exo -75.01 18.39 0.54 Allowed 'Trans proline' 0 C--N 1.358 1.051 0 C-N-CA 122.538 2.159 . . . . 0.0 113.11 -178.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 78.9 40.15 18.14 Favored Glycine 0 N--CA 1.443 -0.897 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.526 178.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.45 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 3.0 m -107.08 135.96 19.53 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 175.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.579 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 11.0 Cg_endo -57.24 116.65 3.36 Favored 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 122.938 2.425 . . . . 0.0 111.411 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -39.83 -34.94 0.3 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.903 170.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.62 -49.32 73.76 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.183 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.579 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 45.0 tp -68.55 -36.4 78.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-O 120.852 0.358 . . . . 0.0 110.199 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 36.0 m -66.78 -42.37 86.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.237 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -61.65 -24.64 66.86 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.657 0.741 . . . . 0.0 111.653 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.2 m -76.13 -22.62 55.27 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.984 -178.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -109.52 -42.69 4.25 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.332 0.587 . . . . 0.0 110.784 -177.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.5 m -62.86 -37.88 88.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.186 -178.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 108.65 -15.85 34.49 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.753 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.464 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 34.5 m -71.05 133.4 46.27 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 176.48 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.4 pt -103.96 141.22 20.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.233 0.539 . . . . 0.0 111.383 -175.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 68.8 mt -108.15 107.73 23.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.977 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.88 HG22 ' H ' ' A' ' 37' ' ' GLY . 5.0 mp -89.86 130.21 43.62 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.05 -179.347 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.55 -13.31 38.61 Favored 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.836 2.357 . . . . 0.0 112.235 175.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.88 ' H ' HG22 ' A' ' 35' ' ' ILE . . . -91.03 -137.35 7.22 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.903 176.013 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.45 15.9 0.26 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.613 0.244 . . . . 0.0 111.387 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.9 m -120.02 105.51 11.11 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.093 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.7 p -134.47 135.96 24.79 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.51 173.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.47 ' HG2' ' OD1' ' A' ' 43' ' ' ASP . 53.3 Cg_endo -67.15 176.6 4.47 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.748 2.299 . . . . 0.0 112.802 -176.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.24 24.94 5.82 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.589 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.47 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 11.3 p-10 -112.22 -18.29 12.57 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 170.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.615 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 17.7 m-85 -98.4 3.6 48.47 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.789 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.56 18.82 21.39 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.824 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 . . . . . 0 C--O 1.246 0.904 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.732 -179.123 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.476 0.827 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -98.26 136.4 38.5 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-O 120.921 0.391 . . . . 0.0 112.017 -176.297 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 96.9 m -134.18 112.72 11.34 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 173.435 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 41.4 m -101.56 152.5 38.06 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.911 -173.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -99.74 24.67 0.18 Allowed 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.722 2.282 . . . . 0.0 113.598 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 t -174.03 132.5 0.41 Allowed 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.118 0.485 . . . . 0.0 110.269 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.489 ' HA ' ' HB3' ' A' ' 10' ' ' ARG . 59.3 mt -69.79 -19.97 23.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.154 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -71.36 -41.99 73.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.525 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -66.08 -48.17 71.84 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.8 174.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.489 ' HB3' ' HA ' ' A' ' 7' ' ' ILE . 4.0 tpp180 -50.97 -41.78 59.56 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.167 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 15' ' ' VAL . 41.5 t -58.76 -55.19 38.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.522 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.406 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.0 p30 -71.04 -26.89 63.29 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.246 -178.276 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -62.22 -50.44 71.75 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.615 173.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -54.98 -44.19 74.22 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.674 178.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 11' ' ' SER . 57.7 t -67.5 -27.11 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.455 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.2 t -83.93 -43.18 15.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 121.01 0.433 . . . . 0.0 111.035 -176.176 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -76.38 -10.88 59.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.021 0.439 . . . . 0.0 111.409 -177.463 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.406 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 5.4 mt -69.95 -51.12 15.34 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -176.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 48.9 Cg_endo -71.8 -8.78 23.72 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.292 1.995 . . . . 0.0 113.131 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.11 19.1 5.27 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.347 -0.93 . . . . 0.0 113.312 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.477 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 3.1 m -83.66 137.33 41.48 Favored Pre-proline 0 N--CA 1.431 -1.383 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 21.0 Cg_endo -63.74 125.93 16.42 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.564 2.176 . . . . 0.0 110.511 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -42.14 -26.5 0.1 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.412 170.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 34' ' ' ILE . . . -51.09 -54.14 27.71 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.769 0.319 . . . . 0.0 110.934 171.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.2 tt -67.69 -41.29 83.88 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 109.85 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.0 m -81.51 9.05 8.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.3 -175.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -109.64 -49.2 3.13 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.859 0.838 . . . . 0.0 110.302 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -64.37 -33.26 75.45 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 113.859 -1.518 . . . . 0.0 112.37 -173.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -96.57 -15.19 21.73 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.228 1.014 . . . . 0.0 109.527 -176.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.525 HG22 ' HB1' ' A' ' 9' ' ' ALA . 55.7 m -96.32 -25.89 15.59 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 113.791 -1.55 . . . . 0.0 112.279 -172.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.66 7.33 57.89 Favored Glycine 0 C--N 1.328 0.093 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.42 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.464 ' HB3' ' HA ' ' A' ' 27' ' ' ALA . 19.8 t -92.92 157.85 16.13 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.2 pt -118.43 160.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.573 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.44 ' CD1' ' HA ' ' A' ' 24' ' ' ALA . 69.9 mt -122.31 137.37 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.599 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.521 HD13 ' H ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -130.66 157.27 78.19 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 176.268 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 45.5 Cg_endo -70.54 -28.12 21.89 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.497 2.131 . . . . 0.0 112.263 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.73 -140.5 11.29 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.006 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -152.65 12.93 0.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.685 0.279 . . . . 0.0 111.353 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.2 m -90.54 104.98 17.5 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.254 0.549 . . . . 0.0 110.0 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 94.9 m -129.43 131.68 23.77 Favored Pre-proline 0 C--N 1.311 -1.085 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.954 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -69.81 176.09 7.27 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.697 2.265 . . . . 0.0 112.499 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.51 3.06 26.92 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 116.069 -0.514 . . . . 0.0 113.755 -175.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -94.36 -22.34 18.39 Favored 'General case' 0 CA--C 1.513 -0.481 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.609 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -121.17 20.71 11.37 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.273 -1.331 . . . . 0.0 109.661 -176.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -99.37 16.37 23.28 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.031 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.737 -0.649 . . . . 0.0 109.566 -178.7 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 60.2 m . . . . . 0 N--CA 1.476 0.874 0 CA-C-O 120.835 0.35 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.624 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 26.8 m -104.27 118.37 36.46 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.747 178.417 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 62.6 m -108.87 128.14 54.65 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.344 -174.252 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.5 m -128.98 132.55 24.44 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.548 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.782 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.2 Cg_endo -90.84 23.82 0.62 Allowed 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.899 2.399 . . . . 0.0 114.245 -177.766 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.1 p -171.01 149.38 2.92 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 122.07 -0.394 . . . . 0.0 111.438 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 58.7 mt -65.22 -29.45 47.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.156 178.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.5 t -76.63 -38.81 31.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.833 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -72.88 -41.99 64.11 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 10.7 tpp180 -54.4 -36.76 64.29 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.721 177.27 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -79.52 -55.09 5.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.66 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 p30 -60.88 -24.27 65.83 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 121.218 0.533 . . . . 0.0 110.787 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.647 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 71.0 t80 -61.39 -60.51 3.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.586 173.66 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -69.49 -28.59 66.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.673 -175.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 93.6 t -71.52 -23.61 22.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.394 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.502 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.5 t -76.86 -32.06 57.25 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 121.996 -0.44 . . . . 0.0 110.595 -179.157 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.616 ' HA ' ' O ' ' A' ' 21' ' ' THR . 1.7 ptm180 -87.19 -0.06 56.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.194 0.521 . . . . 0.0 110.697 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.538 ' HB3' ' HD3' ' A' ' 19' ' ' PRO . 63.9 tp -70.32 -53.32 10.56 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.662 179.098 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.538 ' HD3' ' HB3' ' A' ' 18' ' ' LEU . 91.1 Cg_endo -82.2 28.03 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.171 1.914 . . . . 0.0 113.759 -177.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.94 39.53 8.57 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.317 175.675 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.616 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.8 OUTLIER -115.37 136.56 22.74 Favored Pre-proline 0 N--CA 1.437 -1.093 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 174.917 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.869 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 17.7 Cg_endo -63.2 120.99 8.67 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 122.617 2.211 . . . . 0.0 111.047 175.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 11.0 pt-20 -56.88 -23.71 46.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.243 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.505 ' HA ' HD12 ' A' ' 34' ' ' ILE . . . -63.34 -41.95 98.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.729 173.277 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.869 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.5 OUTLIER -71.8 -39.12 70.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 120.903 0.382 . . . . 0.0 110.215 176.795 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 34.3 m -66.97 -36.96 83.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.041 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.4 -36.15 73.13 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.785 0.802 . . . . 0.0 110.898 176.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -69.04 -23.79 64.1 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 114.093 -1.412 . . . . 0.0 111.129 -176.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -102.65 -46.07 4.84 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.626 0.727 . . . . 0.0 110.02 -176.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.5 m -59.95 -44.36 94.45 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 114.626 -1.17 . . . . 0.0 112.172 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.78 -9.16 14.49 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.28 -0.962 . . . . 0.0 112.037 -176.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 94.7 m -71.38 158.8 35.68 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 175.147 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 26.3 pt -126.39 139.59 51.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.963 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.505 HD12 ' HA ' ' A' ' 24' ' ' ALA . 71.3 mt -112.32 103.28 15.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.791 177.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 34.1 pt -107.83 148.28 37.07 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.142 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -76.93 12.06 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.997 2.465 . . . . 0.0 112.387 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -130.45 -147.39 6.13 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.664 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.74 21.86 2.14 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.163 0.506 . . . . 0.0 110.273 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 m -79.98 72.25 6.74 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.396 -175.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 90.9 m -128.29 131.51 23.82 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.287 176.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.23 174.55 8.88 Favored 'Trans proline' 0 CA--C 1.531 0.348 0 C-N-CA 122.595 2.196 . . . . 0.0 111.903 176.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.98 26.21 1.47 Allowed Glycine 0 CA--C 1.521 0.424 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.236 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 24.7 t70 -115.38 -29.78 6.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.2 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.782 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 10.4 m-85 -105.91 5.18 30.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.967 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.61 17.11 23.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.913 -174.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.0 t30 . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.086 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.598 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 23.5 m . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.483 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 21.9 m -134.16 124.16 25.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.011 -176.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.458 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 82.6 m -128.16 142.84 51.06 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.664 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 0.5 OUTLIER -128.42 151.66 76.96 Favored Pre-proline 0 C--N 1.32 -0.676 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.505 -175.716 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.664 ' HD2' ' SG ' ' A' ' 4' ' ' CYS . 88.8 Cg_endo -82.05 1.66 9.06 Favored 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.955 2.436 . . . . 0.0 113.958 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.8 p -160.9 155.55 23.64 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 121.88 -0.512 . . . . 0.0 110.94 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 59.2 mt -73.05 -28.58 26.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.421 178.478 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.6 t -67.87 -44.43 85.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.766 -178.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.411 ' HA ' HD21 ' A' ' 12' ' ' ASN . . . -66.34 -45.2 81.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.961 177.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -54.2 -39.27 66.53 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.38 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.4 m -60.5 -55.07 37.88 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.641 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.411 HD21 ' HA ' ' A' ' 9' ' ' ALA . 11.3 p30 -75.28 -22.62 57.62 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.02 0.438 . . . . 0.0 110.906 -176.363 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CZ ' HG21 ' A' ' 2' ' ' THR . 44.8 t80 -58.16 -53.41 58.62 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.086 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -61.96 -29.89 70.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.783 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 79.5 t -65.26 -33.23 62.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.89 178.236 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.548 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 39.8 t -75.71 -21.35 57.63 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 121.469 0.652 . . . . 0.0 110.151 -178.088 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.663 ' HD3' ' HG3' ' A' ' 23' ' ' GLU . 27.3 tpt180 -74.68 -26.45 59.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.013 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 97.6 mt -62.52 -49.22 84.35 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -175.385 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 13.7 Cg_exo -70.54 -5.41 16.62 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.226 1.951 . . . . 0.0 112.995 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.69 28.92 7.62 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.461 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.596 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -90.68 140.87 26.6 Favored Pre-proline 0 N--CA 1.431 -1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 177.769 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.706 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 14.4 Cg_endo -62.05 121.76 9.95 Favored 'Trans proline' 0 N--CA 1.443 -1.462 0 C-N-CA 122.941 2.427 . . . . 0.0 110.857 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.663 ' HG3' ' HD3' ' A' ' 17' ' ' ARG . 1.1 mp0 -45.93 -32.35 2.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.059 173.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.2 -48.11 82.82 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.066 175.533 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.706 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.2 tt -66.68 -44.49 81.67 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.095 178.228 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.493 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 14.0 m -66.76 -40.4 88.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.508 -176.017 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.02 -42.21 93.84 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.519 0.676 . . . . 0.0 111.021 178.292 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.3 m -68.22 -21.87 64.82 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.353 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -100.7 -38.09 8.45 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.674 0.75 . . . . 0.0 109.847 -174.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.6 m -75.65 -57.68 3.74 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.596 -1.184 . . . . 0.0 112.024 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.0 -20.38 2.14 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 119.705 -1.236 . . . . 0.0 112.527 -176.415 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 30.7 m -66.83 155.91 37.01 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 175.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 33.1 pt -120.55 148.84 23.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.331 -0.547 . . . . 0.0 111.814 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 50.8 mm -102.13 139.22 23.77 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.344 176.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.598 ' O ' ' HB ' ' A' ' 1' ' ' THR . 3.1 pt -146.31 151.37 43.87 Favored Pre-proline 0 C--N 1.316 -0.859 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.25 -179.016 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -87.75 30.99 0.44 Allowed 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.498 2.799 . . . . 0.0 112.233 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.51 137.79 4.81 Favored Glycine 0 N--CA 1.446 -0.676 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.699 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.29 30.17 0.34 Allowed 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.057 0.456 . . . . 0.0 111.58 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.8 m -80.38 48.66 1.05 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.511 0.672 . . . . 0.0 111.632 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.584 ' SG ' HD11 ' A' ' 35' ' ' ILE . 76.3 m -94.29 126.38 48.6 Favored Pre-proline 0 C--N 1.313 -1.003 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.699 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -75.03 176.36 10.02 Favored 'Trans proline' 0 CA--C 1.531 0.352 0 C-N-CA 122.762 2.308 . . . . 0.0 112.36 176.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.95 -8.69 74.17 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 114.572 0.589 . . . . 0.0 114.572 -171.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -94.99 -22.12 18.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.831 0.824 . . . . 0.0 109.294 -179.049 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.458 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 20.8 m-85 -107.23 18.07 22.12 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.278 -178.459 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.01 33.46 0.79 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.261 -177.181 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.411 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 16.6 m-80 . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.791 -0.623 . . . . 0.0 109.497 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.546 ' HB ' HG13 ' A' ' 35' ' ' ILE . 7.5 m . . . . . 0 N--CA 1.475 0.798 0 CA-C-O 120.782 0.325 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.405 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 7.3 m -90.57 115.02 27.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.103 0.478 . . . . 0.0 110.785 178.444 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.403 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.4 m -115.08 144.56 43.45 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.599 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.4 t -156.28 110.82 2.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.012 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.567 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 96.7 Cg_endo -84.61 45.4 1.68 Allowed 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.971 2.447 . . . . 0.0 113.881 -173.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m -158.17 127.28 5.69 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.4 mp -64.85 -36.96 78.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.9 t -62.59 -38.8 82.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.326 -1.307 . . . . 0.0 110.251 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.4 22.07 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.26 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.3 tpp180 -50.89 -43.45 59.65 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.833 175.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.543 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.7 m -53.7 -55.01 29.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.423 0.154 . . . . 0.0 111.378 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -76.65 -23.03 53.29 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.398 -0.521 . . . . 0.0 110.608 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.405 ' CZ ' HG21 ' A' ' 2' ' ' THR . 34.7 t80 -65.48 -49.07 70.44 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.114 175.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -59.97 -32.64 71.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.127 0.489 . . . . 0.0 109.843 174.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 11' ' ' SER . 92.8 t -72.82 -24.0 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.99 177.592 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -86.26 5.71 33.09 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-O 121.753 0.787 . . . . 0.0 109.62 -178.05 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.479 ' NE ' ' HG3' ' A' ' 23' ' ' GLU . 13.7 mmm180 -106.3 -23.53 12.53 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.556 0.693 . . . . 0.0 109.185 178.241 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -56.92 -47.62 98.77 Favored Pre-proline 0 CA--C 1.547 0.846 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.131 175.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.441 ' HG2' ' OG1' ' A' ' 21' ' ' THR . 82.3 Cg_endo -79.61 4.16 6.91 Favored 'Trans proline' 0 C--N 1.36 1.17 0 C-N-CA 121.779 1.653 . . . . 0.0 113.037 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.72 20.86 45.64 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.505 176.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.685 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -81.06 142.46 51.62 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.206 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.685 ' HD2' HG22 ' A' ' 21' ' ' THR . 38.2 Cg_endo -70.85 130.44 17.99 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 C-N-CA 123.156 2.571 . . . . 0.0 111.494 176.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.479 ' HG3' ' NE ' ' A' ' 17' ' ' ARG . 51.4 mt-10 -41.83 -36.08 0.96 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.485 171.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.71 -52.1 50.96 Favored 'General case' 0 C--N 1.33 -0.266 0 O-C-N 123.381 0.426 . . . . 0.0 110.857 175.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.527 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -68.19 -41.62 81.12 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.167 179.063 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 7.5 m -80.57 12.17 3.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.523 -176.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -108.05 -48.28 3.41 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 121.894 0.854 . . . . 0.0 110.104 173.032 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.0 m -62.73 -29.62 70.81 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 113.817 -1.538 . . . . 0.0 112.117 -174.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -95.86 -22.5 17.42 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.885 0.85 . . . . 0.0 110.117 -175.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -93.21 -38.61 11.46 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.528 -1.214 . . . . 0.0 111.82 -171.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.74 -18.68 8.58 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.433 -177.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 6.6 m -64.9 150.48 47.73 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 32.9 pt -122.3 149.09 25.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.085 0.469 . . . . 0.0 111.495 -177.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.5 mt -111.28 110.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.829 176.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.909 HD12 ' HB3' ' A' ' 38' ' ' ALA . 5.7 pt -108.52 129.36 24.11 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.907 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.09 -32.31 17.43 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.435 2.09 . . . . 0.0 112.68 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.07 117.91 0.83 Allowed Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.909 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 165.2 102.0 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.741 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -172.072 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.41 94.39 0.01 OUTLIER 'General case' 0 N--CA 1.435 -1.216 0 O-C-N 123.884 0.74 . . . . 0.0 110.377 172.54 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 45' ' ' ALA . 4.2 t -65.92 120.52 69.8 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.356 -175.435 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.41 170.27 20.66 Favored 'Trans proline' 0 C--O 1.236 0.379 0 C-N-CA 122.766 2.311 . . . . 0.0 112.473 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.75 20.7 7.39 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.008 -173.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -119.1 -11.53 9.61 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 174.262 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.567 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 19.6 m-85 -113.81 0.11 14.38 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.756 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.402 ' HB2' ' SG ' ' A' ' 40' ' ' CYS . . . -135.9 64.99 1.55 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 120.962 0.41 . . . . 0.0 110.431 -177.441 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.7 m120 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.582 -0.723 . . . . 0.0 109.304 175.608 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.0 m . . . . . 0 N--CA 1.477 0.897 0 CA-C-O 120.554 0.216 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.444 ' OG1' HG12 ' A' ' 34' ' ' ILE . 31.1 m -97.33 112.49 24.28 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.129 0.49 . . . . 0.0 110.274 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.638 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 74.3 m -105.98 146.63 29.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.082 -176.821 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.455 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 2.1 t -136.8 141.99 37.13 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 5.4 Cg_exo -78.59 17.12 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.789 2.326 . . . . 0.0 115.043 -171.531 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -170.29 150.78 3.66 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 118.975 0.807 . . . . 0.0 110.755 177.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.753 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 3.3 mp -64.66 -33.52 63.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.893 0.854 . . . . 0.0 109.107 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.16 -51.09 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.754 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.84 -34.15 69.03 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.4 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.753 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -68.21 -25.22 65.11 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 109.93 -179.675 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.415 ' O ' HG23 ' A' ' 15' ' ' VAL . 69.8 m -67.91 -47.42 68.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.903 172.137 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -55.27 -39.66 70.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.195 0.522 . . . . 0.0 109.879 176.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 5.8 t80 -53.0 -56.65 14.47 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 114.954 -1.021 . . . . 0.0 112.097 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -74.8 -31.39 61.71 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 121.2 -0.2 . . . . 0.0 111.213 -174.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 11' ' ' SER . 96.6 t -70.52 -30.9 44.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 111.131 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.406 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.2 t -74.64 -22.9 58.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.935 -178.229 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.695 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 74.2 mtm180 -77.98 -22.22 49.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.579 0.228 . . . . 0.0 111.172 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.6 mt -54.45 -50.58 84.37 Favored Pre-proline 0 N--CA 1.443 -0.816 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 -176.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.406 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 55.6 Cg_endo -72.14 5.0 2.87 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.099 1.866 . . . . 0.0 113.089 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.71 28.14 9.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.936 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.67 133.48 24.48 Favored Pre-proline 0 N--CA 1.438 -1.037 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.694 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 18.2 Cg_endo -62.01 124.44 14.44 Favored 'Trans proline' 0 N--CA 1.445 -1.381 0 C-N-CA 122.755 2.304 . . . . 0.0 109.798 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.695 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 9.4 pt-20 -53.63 -20.2 4.94 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.269 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -64.56 -47.09 80.03 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 173.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.694 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.5 tt -63.74 -44.12 94.47 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 120.871 0.367 . . . . 0.0 110.347 176.316 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 14.9 m -69.21 -30.97 69.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.309 -177.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.462 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -65.71 -31.14 71.97 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.749 0.785 . . . . 0.0 110.334 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 m -74.75 -20.59 59.76 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.78 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -98.12 -52.99 3.51 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-O 121.91 0.862 . . . . 0.0 110.244 -176.349 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 52.0 m -70.58 -47.47 60.07 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 114.013 -1.448 . . . . 0.0 112.161 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.1 0.79 10.56 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.953 -1.117 . . . . 0.0 112.753 -177.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.462 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 25.5 m -71.46 161.34 31.2 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 174.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.1 pt -132.42 141.25 45.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.967 0.413 . . . . 0.0 111.301 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.444 HG12 ' OG1' ' A' ' 2' ' ' THR . 77.4 mt -97.0 112.66 29.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.817 177.154 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.584 HG12 ' HB3' ' A' ' 40' ' ' CYS . 2.4 pp -105.72 147.53 34.87 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.869 0.366 . . . . 0.0 111.5 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -78.56 28.91 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 123.409 2.739 . . . . 0.0 112.999 -176.609 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -133.27 -151.08 6.49 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 177.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -148.39 22.38 1.05 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.608 0.24 . . . . 0.0 111.361 -177.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.0 m -133.0 -46.48 0.85 Allowed 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.828 -179.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.673 ' HB2' ' HD2' ' A' ' 41' ' ' PRO . 24.1 p 48.92 164.92 0.03 OUTLIER Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 124.904 1.378 . . . . 0.0 113.187 -174.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.673 ' HD2' ' HB2' ' A' ' 40' ' ' CYS . 31.6 Cg_endo -65.82 152.55 81.24 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.253 1.969 . . . . 0.0 112.682 176.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.11 12.2 7.1 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.753 -0.658 . . . . 0.0 113.997 -172.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.443 ' OD1' ' HB2' ' A' ' 41' ' ' PRO . 19.1 p-10 -106.49 -12.31 15.66 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.638 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.9 m-85 -117.67 5.53 12.35 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.616 175.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.06 35.5 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.06 -172.337 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.579 176.712 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.499 ' HB ' ' HB ' ' A' ' 35' ' ' ILE . 9.1 m . . . . . 0 N--CA 1.475 0.819 0 CA-C-O 121.041 0.448 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 31.7 m -135.54 142.14 45.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.804 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 58.9 m -125.06 132.27 53.2 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -172.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.0 m -126.47 123.28 24.03 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.377 174.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -80.74 19.67 1.08 Allowed 'Trans proline' 0 CA--C 1.532 0.406 0 C-N-CA 122.416 2.077 . . . . 0.0 113.441 -174.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -157.97 136.42 11.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.823 HD12 ' H ' ' A' ' 7' ' ' ILE . 4.1 mp -57.51 -38.66 64.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.326 0.584 . . . . 0.0 109.672 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.6 t -72.88 -36.78 52.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.271 -177.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.13 82.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.477 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -71.64 -39.68 70.21 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.23 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.584 ' O ' HG23 ' A' ' 15' ' ' VAL . 5.9 p -66.38 -37.39 85.17 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.557 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -66.25 -41.98 89.21 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.379 0.609 . . . . 0.0 109.834 175.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 23' ' ' GLU . 13.1 t80 -60.86 -42.99 98.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.123 179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -61.54 -34.29 75.29 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.156 177.243 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 11' ' ' SER . 47.2 t -78.57 -6.18 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.475 178.121 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.671 ' O ' ' HB ' ' A' ' 21' ' ' THR . 1.8 t -108.96 14.94 23.79 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-O 121.888 0.851 . . . . 0.0 108.855 176.239 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 21' ' ' THR . 6.2 tpt180 -120.9 -42.84 2.48 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 114.979 -1.01 . . . . 0.0 108.365 175.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.14 -51.35 57.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 CA-C-N 113.727 -1.578 . . . . 0.0 113.372 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.05 35.46 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.813 0 C-N-CA 122.641 2.227 . . . . 0.0 113.203 -175.355 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 66.51 46.68 75.1 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.935 178.443 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.671 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.57 132.23 24.27 Favored Pre-proline 0 N--CA 1.441 -0.899 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.857 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.714 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 30.1 Cg_endo -63.83 122.45 10.51 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.745 2.297 . . . . 0.0 111.156 177.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 13' ' ' PHE . 1.1 mp0 -51.9 -31.48 28.49 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.142 174.483 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.63 -48.82 79.72 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.573 177.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.714 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.9 OUTLIER -67.26 -41.9 84.8 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.204 0.526 . . . . 0.0 110.177 179.219 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 86.2 m -74.52 -14.12 60.77 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.82 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -70.27 -32.47 70.29 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 122.052 0.93 . . . . 0.0 109.883 174.514 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.6 m -72.05 -23.21 61.33 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 113.885 -1.507 . . . . 0.0 110.418 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -99.57 -49.42 4.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.352 0.596 . . . . 0.0 110.608 -176.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m -66.7 -44.92 80.41 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.567 -178.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.51 -15.17 14.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.427 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 82.6 m -65.89 145.43 55.94 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 176.072 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.8 pt -116.62 153.59 18.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.74 0.305 . . . . 0.0 111.487 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 67.7 mt -102.06 133.54 45.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.956 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.499 ' HB ' ' HB ' ' A' ' 1' ' ' THR . 45.7 mm -93.13 123.43 60.94 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.843 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -55.76 -40.04 87.59 Favored 'Trans proline' 0 CA--C 1.528 0.195 0 C-N-CA 122.829 2.353 . . . . 0.0 112.073 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.41 -125.4 4.67 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.999 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.24 72.8 1.34 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.561 0.696 . . . . 0.0 110.376 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.469 ' H ' HG21 ' A' ' 35' ' ' ILE . 11.2 m -145.78 108.94 4.6 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.112 174.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 16.8 t -153.89 123.01 3.15 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.129 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.54 164.83 34.47 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.918 2.412 . . . . 0.0 112.84 179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -74.41 6.72 21.69 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.584 -0.734 . . . . 0.0 113.314 -175.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -92.8 -21.28 20.0 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -108.44 5.99 25.82 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.892 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -122.88 18.88 10.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.872 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 59.9 t30 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.307 -0.854 . . . . 0.0 110.909 -174.719 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 34' ' ' ILE . 8.5 m . . . . . 0 N--CA 1.477 0.914 0 CA-C-O 120.958 0.408 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.405 ' OG1' HG12 ' A' ' 34' ' ' ILE . 35.5 m -118.19 132.68 56.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.456 -175.219 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 98.3 m -106.82 126.38 52.23 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.702 174.055 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 1.8 t -115.15 140.45 25.68 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 88.6 Cg_endo -91.74 22.79 0.64 Allowed 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.646 2.23 . . . . 0.0 113.652 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.444 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . 51.5 m -150.86 143.0 24.11 Favored 'General case' 0 C--N 1.332 -0.18 0 O-C-N 122.044 -0.41 . . . . 0.0 110.71 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.0 mt -71.16 -27.01 28.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.256 0.55 . . . . 0.0 110.547 -175.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 80.0 t -87.27 -51.91 12.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.709 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.444 ' HB3' ' HB2' ' A' ' 6' ' ' SER . . . -50.16 -42.53 51.16 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.348 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -26.3 68.31 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.286 0.565 . . . . 0.0 110.881 -176.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.521 ' O ' HG23 ' A' ' 15' ' ' VAL . 22.2 t -77.81 -56.16 4.73 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.464 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -68.03 -21.76 65.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.067 0.46 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.481 ' HB2' HG21 ' A' ' 30' ' ' THR . 21.7 t80 -57.97 -56.01 27.54 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.033 170.565 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -69.59 -25.16 63.84 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.679 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 11' ' ' SER . 84.8 t -66.99 -22.83 29.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.758 173.581 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.6 t -83.64 -22.92 32.04 Favored 'General case' 0 C--O 1.221 -0.431 0 CA-C-O 121.35 0.595 . . . . 0.0 109.892 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.553 ' HG2' ' O ' ' A' ' 21' ' ' THR . 3.5 tmt_? -92.26 -29.57 16.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.902 -172.293 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.662 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -54.87 -44.83 99.7 Favored Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 114.599 -1.182 . . . . 0.0 113.179 -177.802 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.662 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 64.7 Cg_endo -73.52 14.0 0.67 Allowed 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 122.046 1.83 . . . . 0.0 113.808 -177.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.96 27.08 8.03 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.779 -0.724 . . . . 0.0 113.096 176.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.553 ' O ' ' HG2' ' A' ' 17' ' ' ARG . 4.5 m -104.73 138.34 19.48 Favored Pre-proline 0 N--CA 1.429 -1.49 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 17.4 Cg_endo -62.02 123.53 12.73 Favored 'Trans proline' 0 N--CA 1.441 -1.58 0 C-N-CA 122.335 2.024 . . . . 0.0 109.889 176.248 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.461 ' HB2' ' HZ ' ' A' ' 13' ' ' PHE . 14.8 pt-20 -45.22 -30.2 1.15 Allowed 'General case' 0 C--N 1.324 -0.54 0 O-C-N 123.816 0.697 . . . . 0.0 110.03 174.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -58.13 -46.74 85.11 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.704 177.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.62 -37.77 73.86 Favored 'General case' 0 N--CA 1.444 -0.765 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 85.9 m -71.55 -33.44 69.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.651 -177.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.84 -46.12 91.8 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 122.073 0.94 . . . . 0.0 110.245 176.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.7 m -67.18 -20.43 65.72 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 113.607 -1.633 . . . . 0.0 111.729 -178.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -100.45 -45.88 5.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.599 0.714 . . . . 0.0 110.175 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.481 HG21 ' HB2' ' A' ' 13' ' ' PHE . 99.8 m -72.58 -40.73 66.37 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.616 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.64 16.39 4.6 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.082 -1.056 . . . . 0.0 112.67 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.3 m -98.44 170.81 8.58 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -129.86 148.1 33.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.818 -0.353 . . . . 0.0 111.569 -177.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.604 HD11 ' HA ' ' A' ' 24' ' ' ALA . 31.3 mt -101.5 140.64 19.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.231 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.8 pt -129.83 142.78 46.54 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.758 0.313 . . . . 0.0 110.99 177.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.53 39.85 0.85 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.255 2.637 . . . . 0.0 112.331 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.25 149.05 20.34 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -176.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.71 -1.83 58.22 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 120.847 0.356 . . . . 0.0 111.143 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.2 m -99.72 106.29 18.18 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.494 176.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 14.3 t -123.5 131.2 24.29 Favored Pre-proline 0 C--N 1.309 -1.17 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.931 179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.41 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 17.0 Cg_endo -59.36 143.14 99.82 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.791 2.327 . . . . 0.0 112.127 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.57 -8.35 25.87 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 114.563 -173.5 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -83.86 -24.17 30.99 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.557 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 7.9 m-85 -117.86 3.79 12.21 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.313 -176.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.43 34.31 0.52 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.41 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.45 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 22.3 m-80 . . . . . 0 C--O 1.245 0.823 0 CA-C-O 118.457 -0.783 . . . . 0.0 108.896 176.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 41.1 m . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 120.711 0.291 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.67 HG23 HG13 ' A' ' 34' ' ' ILE . 27.4 m -105.03 125.19 50.71 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.547 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 59.4 m -128.96 120.15 25.59 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.048 0.452 . . . . 0.0 111.288 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 78.8 m -107.36 166.31 11.27 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.386 179.177 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.543 ' HD2' ' HB3' ' A' ' 4' ' ' CYS . 83.6 Cg_endo -82.21 8.78 4.3 Favored 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 122.507 2.138 . . . . 0.0 114.574 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.4 t -176.09 145.13 0.62 Allowed 'General case' 0 CA--C 1.518 -0.281 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.667 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.878 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 46.2 mm -65.76 -27.24 40.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.561 0.695 . . . . 0.0 109.293 176.114 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.2 t -74.16 -49.75 31.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.844 177.643 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.93 -40.39 94.98 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.298 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.878 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -65.59 -27.72 68.62 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.111 0.481 . . . . 0.0 110.434 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.568 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.3 t -64.86 -47.59 77.38 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.669 177.275 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 54.4 m-80 -67.26 -26.69 66.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.567 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.49 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 57.4 t80 -66.6 -51.63 54.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.578 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -66.82 -23.79 66.08 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.908 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.568 HG23 ' O ' ' A' ' 11' ' ' SER . 55.7 t -62.57 -34.53 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.792 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.545 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 75.8 m -66.41 -25.03 66.57 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.432 0.634 . . . . 0.0 111.319 177.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.664 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 18.2 mmm180 -75.04 -31.71 61.37 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.722 -175.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 1.003 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -66.72 -42.87 47.44 Favored Pre-proline 0 CA--C 1.546 0.825 0 N-CA-C 114.054 1.131 . . . . 0.0 114.054 -173.761 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 1.003 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 94.9 Cg_endo -87.55 -6.18 7.02 Favored 'Trans proline' 0 C--N 1.356 0.939 0 C-N-CA 121.806 1.67 . . . . 0.0 113.22 -177.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.03 23.0 7.95 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.074 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.46 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 5.6 m -84.53 126.42 69.01 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 175.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.804 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.32 120.48 8.36 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.404 2.069 . . . . 0.0 110.557 177.404 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.664 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -45.98 -35.33 4.64 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.035 169.749 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.08 -51.41 67.97 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.989 174.112 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.804 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.0 tt -62.39 -53.36 56.08 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 120.685 0.279 . . . . 0.0 110.355 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 13' ' ' PHE . 33.7 t -63.27 -38.26 90.48 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.593 -174.412 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.538 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.76 -34.33 78.08 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.356 0.598 . . . . 0.0 111.626 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 23.4 m -76.55 -20.71 56.56 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.306 -177.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -97.54 -46.17 6.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.94 0.876 . . . . 0.0 109.678 -175.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 55.5 m -70.59 -34.86 72.62 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.748 -1.569 . . . . 0.0 111.755 178.52 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.18 30.49 7.38 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.352 -0.928 . . . . 0.0 111.331 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.538 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.4 t -109.31 159.44 16.97 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.8 141.26 44.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.878 0.371 . . . . 0.0 111.587 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.67 HG13 HG23 ' A' ' 2' ' ' THR . 4.3 mp -109.95 132.08 59.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.892 174.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.49 HD11 ' SG ' ' A' ' 40' ' ' CYS . 24.5 pt -134.82 156.8 78.25 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.848 -178.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.51 -25.49 41.18 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 122.855 2.37 . . . . 0.0 112.689 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -113.06 -147.12 9.91 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.803 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -135.05 30.22 3.35 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.373 0.606 . . . . 0.0 110.386 -176.009 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.1 m -79.73 54.51 1.83 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.865 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD11 ' A' ' 35' ' ' ILE . 30.2 m -98.82 135.0 21.1 Favored Pre-proline 0 C--N 1.309 -1.176 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.81 -178.344 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.871 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 30.2 Cg_endo -65.1 165.96 20.25 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.779 2.319 . . . . 0.0 111.875 174.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -66.23 -37.9 93.33 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 121.283 -0.484 . . . . 0.0 113.788 -171.142 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -84.03 -18.24 37.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 122.022 0.915 . . . . 0.0 109.44 -174.369 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.871 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 16.3 m-85 -112.13 23.91 13.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.797 -176.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.5 22.47 12.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.048 0.452 . . . . 0.0 110.908 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.407 ' C ' ' HE ' ' A' ' 10' ' ' ARG . 27.9 m-80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.459 -0.782 . . . . 0.0 109.524 -178.385 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.408 HG21 ' HA ' ' A' ' 38' ' ' ALA . 21.5 m . . . . . 0 N--CA 1.478 0.928 0 CA-C-O 121.131 0.491 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.536 ' HB ' HG13 ' A' ' 34' ' ' ILE . 8.9 t -115.62 145.63 42.53 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.425 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 m -136.96 115.67 12.1 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -175.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.432 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 85.1 m -103.58 125.3 35.22 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 121.137 0.494 . . . . 0.0 111.219 -177.664 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.585 ' HA ' ' CB ' ' A' ' 44' ' ' TYR . 18.8 Cg_endo -60.24 -7.12 6.09 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.892 3.061 . . . . 0.0 115.606 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 p -161.55 162.14 30.12 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 118.771 0.714 . . . . 0.0 111.17 -177.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.612 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 60.2 mt -67.63 -34.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.115 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.03 -50.27 55.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.25 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.57 -32.63 74.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.253 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.612 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.41 -29.48 62.62 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.825 0.345 . . . . 0.0 110.533 -178.662 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.465 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.1 m -68.67 -53.04 24.75 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -55.13 -40.11 70.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.099 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -57.0 -62.92 1.41 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.083 175.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 35.5 m-80 -59.41 -39.0 82.02 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 11' ' ' SER . 69.9 t -60.95 -37.46 77.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-O 120.551 0.215 . . . . 0.0 111.363 -178.656 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 18.2 t -70.28 -42.21 72.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.787 0.327 . . . . 0.0 110.808 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.721 ' HD2' ' HG2' ' A' ' 23' ' ' GLU . 0.0 OUTLIER -91.3 20.62 5.01 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.961 0.41 . . . . 0.0 111.811 -177.597 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.431 ' HB2' ' O ' ' A' ' 15' ' ' VAL . 4.5 mt -73.02 -50.33 6.81 Favored Pre-proline 0 N--CA 1.445 -0.71 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.693 177.225 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.65 25.96 0.63 Allowed 'Trans proline' 0 C--N 1.36 1.152 0 C-N-CA 122.221 1.948 . . . . 0.0 113.208 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.24 37.78 6.99 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.113 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 1.7 m -97.65 141.01 22.34 Favored Pre-proline 0 N--CA 1.43 -1.432 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.211 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.656 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.3 116.34 3.12 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.905 2.403 . . . . 0.0 111.178 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.721 ' HG2' ' HD2' ' A' ' 17' ' ' ARG . 36.8 mt-10 -51.11 -28.8 11.57 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.901 172.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.73 79.6 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.763 173.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.656 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.1 tt -65.36 -42.97 92.22 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.246 0.546 . . . . 0.0 109.927 178.504 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 16' ' ' CYS . 61.0 m -77.34 -0.4 25.47 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.021 -175.238 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.546 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -101.57 -41.02 6.75 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.686 0.755 . . . . 0.0 111.113 175.812 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.0 m -65.82 -23.91 66.79 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.184 -1.371 . . . . 0.0 111.61 -174.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -100.47 -15.23 17.97 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 122.176 0.989 . . . . 0.0 109.88 -176.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 89.1 m -99.93 -46.81 5.24 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.075 -1.42 . . . . 0.0 111.874 -172.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.12 -20.96 6.23 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 119.944 -1.122 . . . . 0.0 112.287 -178.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.546 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.3 t -73.61 158.54 34.58 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.25 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.0 pt -131.64 143.68 39.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.441 0.639 . . . . 0.0 112.104 -175.098 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.536 HG13 ' HB ' ' A' ' 2' ' ' THR . 4.5 mp -104.25 136.16 38.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 168.191 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 46.7 pt -120.64 142.23 33.81 Favored Pre-proline 0 C--N 1.317 -0.807 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.035 -178.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.1 38.48 0.69 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 123.081 2.521 . . . . 0.0 112.304 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.72 -138.64 2.64 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -178.368 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.408 ' HA ' HG21 ' A' ' 1' ' ' THR . . . -150.62 13.68 0.74 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.661 0.267 . . . . 0.0 111.244 -178.796 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.9 t -91.74 103.07 15.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 122.159 0.981 . . . . 0.0 111.991 -177.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.463 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 34.1 m -149.92 112.62 3.36 Favored Pre-proline 0 C--N 1.305 -1.351 0 CA-C-N 113.806 -1.543 . . . . 0.0 110.688 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 40' ' ' CYS . 33.7 Cg_endo -63.89 160.59 36.55 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.49 2.126 . . . . 0.0 111.114 172.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.37 32.55 3.85 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.916 -0.659 . . . . 0.0 113.574 -171.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -108.19 -29.8 8.72 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.585 ' CB ' ' HA ' ' A' ' 5' ' ' PRO . 4.5 p90 -128.13 22.11 6.19 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.462 173.75 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.96 37.76 1.14 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.312 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 . . . . . 0 C--O 1.252 1.19 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.234 -179.248 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.449 ' HB ' HD12 ' A' ' 35' ' ' ILE . 17.0 m . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.835 0.35 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.1 t -113.33 119.2 36.87 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.457 0.646 . . . . 0.0 110.138 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 33.6 m -104.91 108.88 20.61 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.747 -176.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.509 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 13.9 t -136.72 99.86 10.23 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.209 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.865 ' HG3' ' HA ' ' A' ' 44' ' ' TYR . 64.0 Cg_endo -85.35 61.24 5.58 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.954 2.436 . . . . 0.0 113.975 -169.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.738 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 1.4 p -167.39 120.96 0.96 Allowed 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.218 -178.17 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 68.0 mt -48.11 -38.63 8.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.604 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.5 t -77.53 -48.6 23.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.701 -175.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.97 -37.67 88.28 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.27 -178.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.738 ' HG3' ' O ' ' A' ' 6' ' ' SER . 60.5 mtt180 -54.27 -51.69 63.78 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 121.151 0.501 . . . . 0.0 110.284 179.142 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.528 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.9 m -70.63 -42.27 71.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.261 -177.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -62.69 -38.25 89.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 120.81 0.338 . . . . 0.0 110.581 -178.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -51.39 -51.34 55.51 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASN . . . . . 0.423 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 36.6 m-80 -65.11 -37.87 88.85 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.452 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 11' ' ' SER . 90.7 t -61.98 -41.89 92.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.378 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.535 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 26.1 t -71.52 -32.11 67.82 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.398 0.618 . . . . 0.0 110.018 -179.225 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 17' ' ' ARG . 39.5 ttt180 -73.3 -21.86 60.48 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.342 -176.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 19.3 mt -64.61 -52.89 48.68 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -174.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.535 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 16.5 Cg_exo -69.9 0.5 5.65 Favored 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.427 2.085 . . . . 0.0 113.137 -178.39 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.25 26.27 7.87 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.182 -1.008 . . . . 0.0 112.407 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.492 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 1.3 m -89.89 137.88 28.07 Favored Pre-proline 0 N--CA 1.428 -1.55 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 176.113 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 8.3 Cg_endo -55.45 117.49 4.11 Favored 'Trans proline' 0 N--CA 1.444 -1.408 0 C-N-CA 122.869 2.38 . . . . 0.0 111.058 -179.346 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -47.21 -28.76 2.0 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.457 170.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.47 -42.16 98.6 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.885 174.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.489 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 41.3 tp -76.69 -36.17 57.43 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.053 0.454 . . . . 0.0 110.52 178.444 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 17.4 m -78.28 3.03 16.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.976 -179.336 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -101.2 -56.44 2.31 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.852 0.834 . . . . 0.0 110.328 174.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 m -62.77 -25.41 68.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.047 -174.407 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -94.39 -17.75 22.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 122.087 0.946 . . . . 0.0 109.551 -175.1 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 84.5 m -97.61 -44.62 6.71 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.542 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.25 -7.34 6.33 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.62 -175.251 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 5.3 m -82.39 148.13 28.41 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.8 pt -123.4 143.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.451 -0.5 . . . . 0.0 110.683 176.236 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 78.9 mt -112.95 120.83 63.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.022 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.449 HD12 ' HB ' ' A' ' 1' ' ' THR . 2.1 pp -120.08 139.85 28.99 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.637 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -82.09 22.42 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.234 2.623 . . . . 0.0 113.145 -175.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.48 -139.96 3.74 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.214 178.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.21 62.39 1.53 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.049 0.452 . . . . 0.0 109.943 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 m -152.44 106.05 3.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.275 0.559 . . . . 0.0 111.099 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.0 p -148.46 140.83 14.81 Favored Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.064 171.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.504 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 11.0 Cg_endo -53.81 143.71 58.1 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 123.005 2.47 . . . . 0.0 112.568 -174.305 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.13 -13.07 47.18 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.841 -0.618 . . . . 0.0 113.674 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.85 -17.37 41.11 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.865 ' HA ' ' HG3' ' A' ' 5' ' ' PRO . 16.9 m-85 -121.67 5.94 10.01 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.094 -175.022 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -105.3 38.0 2.06 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -171.368 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.71 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 10.2 t-20 . . . . . 0 C--O 1.246 0.893 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.07 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.593 ' HB ' HG13 ' A' ' 35' ' ' ILE . 22.7 m . . . . . 0 N--CA 1.477 0.887 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -120.55 147.49 45.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.806 0.336 . . . . 0.0 111.605 -174.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.493 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 2.1 m -151.34 123.29 8.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.886 176.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.575 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 40.0 m -110.2 162.12 21.72 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.044 -175.705 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -91.13 13.95 2.03 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.394 2.062 . . . . 0.0 114.825 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.5 p -167.3 144.02 4.41 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 118.505 0.593 . . . . 0.0 111.115 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.455 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 35.9 mt -60.27 -29.32 43.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.763 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.5 t -72.55 -51.51 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.475 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.564 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -69.77 -30.35 67.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.725 -177.292 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.575 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -69.94 -26.09 63.96 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.149 0.499 . . . . 0.0 110.339 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.435 ' O ' HG23 ' A' ' 15' ' ' VAL . 25.0 m -79.79 -42.25 24.82 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.434 175.324 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -59.88 -30.26 68.87 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.541 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -52.9 -61.38 2.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.664 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.3 m-80 -63.21 -33.1 74.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.267 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 11' ' ' SER . 72.2 t -63.99 -34.84 71.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.079 178.272 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 41.8 t -77.5 -16.72 58.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.436 0.636 . . . . 0.0 110.67 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.487 ' HD2' ' O ' ' A' ' 21' ' ' THR . 7.8 mmm180 -82.66 -19.32 38.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.027 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.606 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 85.2 mt -67.14 -48.84 47.73 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.606 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 22.9 Cg_exo -65.58 -19.01 60.35 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.927 1.752 . . . . 0.0 112.391 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.4 24.44 5.64 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.586 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.556 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -90.56 134.06 31.6 Favored Pre-proline 0 N--CA 1.438 -1.054 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 177.615 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -66.46 129.55 21.61 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 123.065 2.51 . . . . 0.0 111.168 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -46.35 -25.58 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.197 171.674 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.95 -47.65 71.09 Favored 'General case' 0 C--N 1.327 -0.398 0 O-C-N 123.293 0.371 . . . . 0.0 110.629 172.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.8 mt -79.08 -38.46 36.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-O 120.93 0.395 . . . . 0.0 111.0 177.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.556 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 5.0 m -80.28 10.41 4.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.285 -176.15 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.73 -43.98 5.43 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.96 0.886 . . . . 0.0 109.731 170.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.2 m -69.76 -24.89 63.59 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 113.96 -1.473 . . . . 0.0 111.517 -177.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -91.36 -31.12 16.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.72 0.772 . . . . 0.0 109.759 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.564 HG22 ' HB1' ' A' ' 9' ' ' ALA . 0.3 OUTLIER -99.12 -14.78 19.23 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.555 -1.202 . . . . 0.0 112.596 -171.469 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.93 16.48 63.19 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.462 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 19.7 t -94.25 159.43 15.13 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.25 148.97 33.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.125 0.488 . . . . 0.0 111.871 -176.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.403 ' N ' HD12 ' A' ' 34' ' ' ILE . 4.4 mp -96.42 135.32 30.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.898 176.673 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.593 HG13 ' HB ' ' A' ' 1' ' ' THR . 5.5 pt -129.64 164.25 41.27 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.716 -179.627 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.41 -57.24 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.995 2.463 . . . . 0.0 111.252 169.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 171.47 137.69 2.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 116.098 -0.501 . . . . 0.0 112.028 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 64.43 18.08 11.15 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.256 0.622 . . . . 0.0 111.373 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -98.18 27.93 4.34 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.685 0.755 . . . . 0.0 110.904 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.532 ' SG ' HD13 ' A' ' 35' ' ' ILE . 16.9 m -112.86 107.28 54.69 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.466 -175.774 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.465 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 43.6 Cg_endo -71.3 174.27 11.05 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.59 2.193 . . . . 0.0 111.142 173.015 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.97 -34.74 66.22 Favored Glycine 0 CA--C 1.521 0.408 0 N-CA-C 114.754 0.662 . . . . 0.0 114.754 -172.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -83.98 -22.84 31.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.849 0.825 . . . . 0.0 109.772 -172.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.493 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 16.2 m-85 -108.75 20.09 18.91 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.314 -175.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.83 27.11 6.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.847 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.484 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 37.8 m-80 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.116 -177.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.497 HG21 ' O ' ' A' ' 37' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 121.004 0.43 . . . . 0.0 110.226 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.491 ' HB ' ' CZ ' ' A' ' 13' ' ' PHE . 86.3 m -137.97 140.38 40.18 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.928 -176.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -114.98 111.14 20.69 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.053 -178.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.6 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 100.0 m -102.0 111.84 64.67 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.202 174.182 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.698 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 91.1 Cg_endo -86.98 35.89 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.851 2.367 . . . . 0.0 112.923 -177.557 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.1 m -155.43 131.28 9.95 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 61.2 mt -56.18 -36.8 46.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 123.537 0.523 . . . . 0.0 111.143 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.9 t -83.28 -31.12 8.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.223 0.535 . . . . 0.0 110.382 -174.612 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.52 -37.21 71.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.394 178.46 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.6 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -83.78 -22.86 31.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.15 -175.468 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 61.3 p -74.24 -30.1 62.0 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.318 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -92.88 -26.48 17.61 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.876 177.054 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.491 ' CZ ' ' HB ' ' A' ' 2' ' ' THR . 27.4 t80 -55.05 -52.4 63.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.551 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -61.71 -29.08 69.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.65 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.646 ' HA ' HD23 ' A' ' 18' ' ' LEU . 57.3 t -75.73 -24.28 16.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.711 176.744 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.818 ' O ' ' HB ' ' A' ' 21' ' ' THR . 48.6 t -88.37 0.38 56.26 Favored 'General case' 0 C--O 1.214 -0.782 0 CA-C-O 121.684 0.754 . . . . 0.0 109.623 -178.22 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -109.32 -21.95 12.29 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -175.123 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.752 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 3.4 pp -74.5 -36.54 2.58 Favored Pre-proline 0 N--CA 1.436 -1.16 0 N-CA-C 113.785 1.031 . . . . 0.0 113.785 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.752 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 5.8 Cg_exo -78.62 7.24 4.31 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 121.835 1.69 . . . . 0.0 112.604 -175.799 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.97 33.05 8.47 Favored Glycine 0 N--CA 1.444 -0.81 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.042 -178.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.818 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 1.1 m -106.11 134.14 19.9 Favored Pre-proline 0 N--CA 1.434 -1.253 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.065 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.776 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.9 Cg_endo -56.29 117.22 3.84 Favored 'Trans proline' 0 N--CA 1.446 -1.285 0 C-N-CA 123.167 2.578 . . . . 0.0 112.183 -179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -46.34 -31.52 2.63 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.839 168.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.09 -49.99 75.77 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.17 174.343 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.776 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tt -65.28 -44.31 88.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.776 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 18.8 m -76.17 -0.07 20.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.765 -177.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.535 ' HA ' ' HB2' ' A' ' 32' ' ' CYS . . . -94.68 -56.8 2.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.934 0.873 . . . . 0.0 109.885 168.423 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.1 m -58.28 -33.17 69.12 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 113.531 -1.668 . . . . 0.0 113.302 -173.037 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -96.43 -19.58 19.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 122.073 0.94 . . . . 0.0 110.324 -171.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 m -92.46 -25.1 18.59 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.518 -172.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.28 10.71 27.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.958 -177.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.535 ' HB2' ' HA ' ' A' ' 27' ' ' ALA . 44.1 m -95.11 167.69 11.22 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 176.171 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.2 pt -123.82 131.57 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.233 0.54 . . . . 0.0 111.334 176.041 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 16.2 tt -94.55 138.5 20.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.227 178.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.712 HD13 ' HB2' ' A' ' 40' ' ' CYS . 14.1 pt -119.58 160.85 40.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.348 -174.92 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -92.2 24.18 0.52 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.125 2.55 . . . . 0.0 113.176 178.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.497 ' O ' HG21 ' A' ' 1' ' ' THR . . . 177.01 -135.98 3.0 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.514 -0.851 . . . . 0.0 112.26 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.41 13.69 17.75 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 120.635 0.255 . . . . 0.0 111.534 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -77.64 88.25 3.93 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.296 0.569 . . . . 0.0 110.509 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.712 ' HB2' HD13 ' A' ' 35' ' ' ILE . 23.4 t -155.43 125.01 3.15 Favored Pre-proline 0 C--N 1.31 -1.135 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.321 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.31 167.98 25.92 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 123.003 2.469 . . . . 0.0 112.056 177.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.21 5.19 51.62 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 116.033 -0.531 . . . . 0.0 112.941 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -88.6 -20.85 24.45 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.698 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 14.7 m-85 -108.9 7.89 26.24 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.971 -178.094 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -116.53 52.32 0.94 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.736 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.8 t30 . . . . . 0 C--O 1.251 1.157 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.758 -176.574 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.555 HG21 ' HA2' ' A' ' 37' ' ' GLY . 12.2 m . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.787 HG22 ' SG ' ' A' ' 32' ' ' CYS . 3.9 m -139.5 134.03 31.69 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.019 -174.316 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.6 m -129.26 129.23 44.67 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.2 m -111.2 127.44 26.89 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.254 -171.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.805 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 75.8 Cg_endo -92.35 43.94 0.36 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.108 2.539 . . . . 0.0 114.113 -176.271 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.674 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 6.8 p -173.02 135.17 0.59 Allowed 'General case' 0 CA--C 1.517 -0.301 0 O-C-N 122.11 -0.369 . . . . 0.0 110.187 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.606 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 49.0 mt -56.29 -31.01 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.216 0.531 . . . . 0.0 111.003 -171.329 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.86 -53.09 28.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.956 177.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -62.06 -40.14 94.75 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.708 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.674 ' HG3' ' O ' ' A' ' 6' ' ' SER . 4.5 mtp-105 -59.01 -37.54 77.12 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.53 178.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.7 t -76.05 -35.72 59.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.565 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.9 m-20 -57.72 -42.87 84.7 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.994 174.38 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 2' ' ' THR . 40.6 t80 -47.56 -46.01 27.59 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.202 -179.019 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -61.76 -48.61 79.9 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.33 0.586 . . . . 0.0 110.116 177.625 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -72.8 -12.55 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.026 -176.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.71 ' O ' ' HB ' ' A' ' 21' ' ' THR . 69.3 m -100.63 14.83 30.15 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.547 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.56 ' HD2' ' CE1' ' A' ' 13' ' ' PHE . 36.1 mtp180 -134.27 -39.87 0.83 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.325 0.583 . . . . 0.0 110.011 176.505 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 tp -49.62 -54.79 27.58 Favored Pre-proline 0 CA--C 1.553 1.086 0 CA-C-N 114.709 -1.132 . . . . 0.0 113.427 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -88.5 39.29 0.49 Allowed 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 122.075 1.85 . . . . 0.0 113.794 -174.368 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.57 50.29 26.43 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.302 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.71 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.82 138.25 31.03 Favored Pre-proline 0 N--CA 1.435 -1.186 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.665 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.538 ' HG2' ' CB ' ' A' ' 25' ' ' LEU . 38.0 Cg_endo -70.1 126.47 13.12 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 122.763 2.309 . . . . 0.0 111.544 174.366 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.444 ' HB3' ' HE ' ' A' ' 17' ' ' ARG . 11.2 pt-20 -50.75 -32.27 19.2 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.064 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.554 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -64.7 -39.26 93.35 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.255 -178.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.538 ' CB ' ' HG2' ' A' ' 22' ' ' PRO . 34.1 tp -69.63 -46.79 65.4 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.683 0.278 . . . . 0.0 110.831 -177.273 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.514 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 17.1 t -67.98 -29.41 68.43 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.258 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.574 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -56.9 -46.89 81.61 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.643 0.735 . . . . 0.0 110.906 177.603 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 47.2 m -67.07 -28.43 68.19 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.924 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -102.7 -35.11 8.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.311 0.577 . . . . 0.0 111.435 -171.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.476 ' HB ' ' O ' ' A' ' 26' ' ' CYS . 4.6 m -87.01 -19.79 28.17 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.144 -175.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.94 25.86 8.23 Favored Glycine 0 C--N 1.331 0.292 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.355 177.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.787 ' SG ' HG22 ' A' ' 2' ' ' THR . 5.8 t -102.6 161.74 13.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.6 pt -112.25 140.92 29.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 C-N-CA 119.928 -0.709 . . . . 0.0 112.644 -174.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 24' ' ' ALA . 25.3 mm -98.91 132.7 43.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.274 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 44.5 pt -141.88 159.5 59.22 Favored Pre-proline 0 C--N 1.32 -0.682 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 53.8 Cg_endo -71.06 -16.02 32.19 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.71 2.273 . . . . 0.0 111.801 175.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.555 ' HA2' HG21 ' A' ' 1' ' ' THR . . . 111.59 130.21 5.54 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.811 176.044 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.55 -87.46 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.333 -0.434 . . . . 0.0 110.008 176.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.5 m -140.91 -15.17 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.944 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HA ' ' HD3' ' A' ' 41' ' ' PRO . 91.4 m 64.91 139.5 0.05 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.521 -171.421 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.799 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 17.4 Cg_exo -65.09 156.95 59.94 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.934 2.423 . . . . 0.0 112.503 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -27.65 63.8 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.264 -174.224 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.7 -31.65 13.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.678 0.752 . . . . 0.0 110.075 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.805 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 20.1 m-85 -91.75 -7.99 48.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.968 -174.125 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.478 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . . . -105.97 30.35 5.93 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.608 174.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 5.7 t30 . . . . . 0 C--O 1.247 0.929 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.996 -177.341 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.597 ' HB ' HG13 ' A' ' 35' ' ' ILE . 92.3 m . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 120.831 0.348 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.2 t -101.53 108.12 19.6 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-O 121.914 0.864 . . . . 0.0 110.656 -179.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' HG13 ' A' ' 33' ' ' ILE . 15.9 t -103.65 81.82 1.94 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.438 -173.38 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.429 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 60.2 m -105.54 134.35 19.74 Favored Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.436 178.61 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 61.2 Cg_endo -94.91 30.83 0.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.545 2.163 . . . . 0.0 115.245 -172.587 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.6 p -179.04 139.55 0.15 Allowed 'General case' 0 C--O 1.235 0.327 0 CA-C-N 118.846 0.748 . . . . 0.0 111.395 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.496 HG13 ' OD1' ' A' ' 46' ' ' ASN . 75.1 mt -58.37 -30.38 40.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.068 170.389 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 67.0 t -54.39 -58.66 3.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.52 175.384 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.04 -43.15 96.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.041 0.448 . . . . 0.0 110.666 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.476 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 21.4 tpp180 -55.06 -38.57 68.19 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.211 178.286 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 31.7 m -78.62 -10.44 59.74 Favored 'General case' 0 N--CA 1.466 0.375 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -94.55 -17.09 22.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.414 0.626 . . . . 0.0 109.778 175.341 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -69.22 -37.15 77.88 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.855 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -63.94 -26.05 68.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.955 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.9 t -64.81 -48.92 82.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.549 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.844 ' HB3' ' HB ' ' A' ' 21' ' ' THR . 55.8 m -67.2 -24.76 65.88 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -176.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.503 ' HD3' ' HG2' ' A' ' 23' ' ' GLU . 22.3 mmm180 -79.15 -8.76 59.25 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.976 -0.452 . . . . 0.0 111.703 -178.204 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.603 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 72.7 mt -78.02 -56.95 1.0 Allowed Pre-proline 0 N--CA 1.436 -1.148 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.281 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.603 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 81.2 Cg_endo -85.52 -4.99 9.23 Favored 'Trans proline' 0 C--N 1.359 1.131 0 C-N-CA 122.117 1.878 . . . . 0.0 113.451 -176.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.29 28.37 7.66 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.088 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.844 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 1.4 m -74.07 133.79 78.23 Favored Pre-proline 0 N--CA 1.441 -0.887 0 CA-C-O 121.208 0.528 . . . . 0.0 110.016 176.341 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.883 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.1 Cg_endo -62.61 120.82 8.51 Favored 'Trans proline' 0 N--CA 1.444 -1.415 0 C-N-CA 122.941 2.427 . . . . 0.0 111.008 177.696 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.503 ' HG2' ' HD3' ' A' ' 17' ' ' ARG . 24.2 mt-10 -45.49 -33.99 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.613 172.271 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.83 -47.78 84.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.405 176.241 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.883 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -65.06 -41.03 95.48 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -179.923 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 29.9 m -87.91 23.95 1.91 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.443 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.33 -46.25 3.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 122.171 0.986 . . . . 0.0 109.245 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -65.89 -29.24 69.64 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.259 -1.791 . . . . 0.0 112.388 -175.378 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 t80 -99.73 -21.51 15.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.872 0.844 . . . . 0.0 110.123 -173.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.22 -6.62 37.68 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.949 -172.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.32 36.0 28.27 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.465 178.367 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.3 t -127.61 153.01 46.93 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.596 HG13 ' HB3' ' A' ' 3' ' ' CYS . 25.2 pt -122.66 148.89 26.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.326 0.584 . . . . 0.0 112.033 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.2 mt -106.4 116.85 51.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.552 177.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.597 HG13 ' HB ' ' A' ' 1' ' ' THR . 25.3 pt -121.97 131.34 24.44 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.898 -178.589 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.86 -12.14 23.96 Favored 'Trans proline' 0 CA--C 1.529 0.259 0 C-N-CA 122.903 2.402 . . . . 0.0 112.282 177.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.92 -141.24 9.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.133 177.569 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.66 12.95 1.17 Allowed 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 -176.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.5 m -86.02 97.55 10.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.377 0.608 . . . . 0.0 110.818 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 39.6 t -158.38 107.39 1.68 Allowed Pre-proline 0 C--N 1.311 -1.103 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.536 -178.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 15.1 Cg_endo -59.55 161.92 16.38 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.851 2.368 . . . . 0.0 112.851 -177.625 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -69.97 1.14 18.4 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.723 -0.671 . . . . 0.0 113.594 -174.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.03 -15.49 18.23 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.518 ' CD2' ' HG2' ' A' ' 41' ' ' PRO . 19.3 m-85 -115.44 8.05 15.16 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.029 179.307 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.05 39.56 1.77 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.347 0.594 . . . . 0.0 109.573 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.4 t-20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.03 -175.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 120.77 0.319 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 28.5 m -132.65 121.22 22.83 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 174.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.597 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.5 m -124.53 117.19 23.8 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.254 0.55 . . . . 0.0 111.244 -173.006 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 20.8 m -108.55 166.74 10.31 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.704 -177.392 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -91.33 6.02 3.76 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 122.104 1.87 . . . . 0.0 113.351 169.261 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.1 m -155.62 141.5 18.12 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 121.914 -0.491 . . . . 0.0 110.993 -172.322 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.4 mm -61.38 -32.19 52.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 121.187 0.518 . . . . 0.0 109.74 174.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.4 t -62.78 -43.27 98.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.889 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.576 ' HA ' ' ND2' ' A' ' 12' ' ' ASN . . . -69.4 -39.84 77.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.671 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 19.6 ttm180 -64.73 -27.93 69.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.658 176.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -79.03 -48.18 14.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.368 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.576 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.1 p30 -73.78 -15.99 61.18 Favored 'General case' 0 N--CA 1.464 0.271 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.168 -178.159 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 23.9 t80 -48.81 -44.36 39.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 122.02 0.914 . . . . 0.0 109.286 165.342 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -76.37 -39.4 53.92 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.345 -1.298 . . . . 0.0 109.941 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.524 ' CG2' ' HA ' ' A' ' 12' ' ' ASN . 92.0 t -57.92 -46.51 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.748 -176.739 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 68.2 m -61.07 -38.05 84.87 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.647 ' HD2' ' HB3' ' A' ' 23' ' ' GLU . 45.9 mtp180 -79.27 -5.62 54.81 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.574 -172.717 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.633 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 31.9 mt -75.94 -53.6 2.32 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 6.1 Cg_exo -76.18 -24.34 11.11 Favored 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.178 1.919 . . . . 0.0 112.517 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.53 13.49 2.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.051 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 2.4 m -80.96 124.27 81.51 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.667 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.802 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.5 Cg_endo -59.94 123.54 13.44 Favored 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.236 1.958 . . . . 0.0 110.765 177.371 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB3' ' HD2' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -51.26 -27.94 10.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.738 169.866 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.79 -46.42 89.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.92 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.802 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.7 tt -66.63 -51.61 54.33 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 120.664 0.269 . . . . 0.0 110.426 178.321 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 26.6 m -66.82 -25.43 66.44 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.28 72.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.984 0.897 . . . . 0.0 110.435 174.229 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.4 m -81.85 -22.11 37.16 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.358 -174.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 19.9 t80 -106.18 -39.5 5.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.348 0.594 . . . . 0.0 110.707 -174.314 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.0 m -72.2 -31.93 66.33 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.498 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.3 18.59 38.55 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.24 -0.981 . . . . 0.0 112.287 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.6 t -105.5 139.59 39.89 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.416 HD12 HD11 ' A' ' 35' ' ' ILE . 22.6 pt -104.79 139.98 24.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.286 0.565 . . . . 0.0 111.794 -172.353 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 80.3 mt -100.6 124.92 54.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.917 176.178 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.827 HG21 ' HB ' ' A' ' 39' ' ' THR . 96.7 mt -129.18 137.4 30.91 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.372 -175.509 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -47.25 -48.51 14.82 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.697 2.265 . . . . 0.0 112.384 176.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.77 137.71 2.3 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.6 177.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.01 65.29 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 123.45 0.7 . . . . 0.0 112.401 175.091 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.827 ' HB ' HG21 ' A' ' 35' ' ' ILE . 8.9 m -151.03 26.21 0.72 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 122.224 1.012 . . . . 0.0 110.091 175.115 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD12 ' A' ' 35' ' ' ILE . 62.9 m -108.64 116.42 56.13 Favored Pre-proline 0 C--N 1.314 -0.965 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.342 -172.294 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 40.3 Cg_endo -69.38 162.35 42.23 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.391 2.061 . . . . 0.0 111.963 175.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.61 -28.4 67.74 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 114.947 0.739 . . . . 0.0 114.947 -172.559 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -87.78 -20.05 26.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.734 0.778 . . . . 0.0 109.778 -174.804 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.597 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.5 m-85 -114.16 25.31 11.22 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.185 -176.09 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.33 23.7 13.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.812 177.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 65.9 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-O 118.096 -0.954 . . . . 0.0 109.681 -177.602 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.954 ' HB ' HG23 ' A' ' 35' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.473 0.711 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.91 110.59 16.49 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -171.588 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.576 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 46.5 m -150.38 156.25 41.14 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.102 0.477 . . . . 0.0 111.768 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 10.1 t -144.82 143.01 19.59 Favored Pre-proline 0 N--CA 1.453 -0.301 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 47.6 Cg_exo -58.82 -27.91 85.41 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.138 2.558 . . . . 0.0 114.205 -177.238 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.0 m -142.01 141.93 32.89 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 -176.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.697 HG13 ' OD1' ' A' ' 46' ' ' ASN . 87.8 mt -53.39 -40.35 39.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.956 175.481 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -67.49 -34.3 67.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.099 0.476 . . . . 0.0 110.49 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -74.53 -36.23 63.16 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.245 0.545 . . . . 0.0 109.775 177.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -63.97 -42.13 97.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.4 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.7 p -67.73 -37.65 82.48 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.032 178.411 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -66.86 -34.38 77.67 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.277 0.561 . . . . 0.0 110.734 179.144 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.616 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 50.6 t80 -58.85 -53.24 60.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.117 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -55.39 -30.85 61.18 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.398 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 90.0 t -63.57 -34.18 66.05 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.476 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.52 -23.36 42.97 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.946 -0.471 . . . . 0.0 111.176 -175.386 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -74.61 -18.27 60.58 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 177.155 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 95.3 mt -63.77 -53.21 52.09 Favored Pre-proline 0 N--CA 1.442 -0.839 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -177.206 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.49 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 61.2 Cg_endo -73.25 2.99 5.01 Favored 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.054 1.836 . . . . 0.0 113.181 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.32 36.76 7.96 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.485 178.28 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.565 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -97.6 141.05 22.41 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 176.621 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.566 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -61.07 117.74 4.55 Favored 'Trans proline' 0 N--CA 1.446 -1.309 0 C-N-CA 122.962 2.441 . . . . 0.0 110.944 178.571 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.616 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 9.7 pt-20 -51.81 -29.75 20.46 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.854 175.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.18 -41.74 97.34 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.554 174.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.566 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 50.7 tp -77.52 -39.44 46.15 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-O 120.737 0.303 . . . . 0.0 110.427 179.591 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.509 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 26.6 m -64.69 -39.74 94.18 Favored 'General case' 0 C--O 1.22 -0.455 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.041 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.98 -23.59 67.26 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.57 0.7 . . . . 0.0 111.58 -178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.5 m -75.59 -22.35 57.0 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.673 -1.149 . . . . 0.0 110.316 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -104.03 -43.46 5.27 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.862 0.839 . . . . 0.0 110.13 -178.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.405 HG21 ' HB2' ' A' ' 13' ' ' PHE . 93.9 m -64.89 -55.37 19.74 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.24 -1.346 . . . . 0.0 111.849 -178.225 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 131.1 -24.92 4.18 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.547 -178.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.556 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 38.2 m -64.34 158.85 22.44 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.3 pt -130.16 139.55 51.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.427 -0.509 . . . . 0.0 112.293 -175.305 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.0 mp -85.68 125.7 40.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.954 HG23 ' HB ' ' A' ' 1' ' ' THR . 9.2 tt -129.65 110.35 17.44 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.46 0.648 . . . . 0.0 110.784 -171.057 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 34.9 Cg_exo -62.24 -32.38 82.3 Favored 'Trans proline' 0 N--CA 1.477 0.544 0 C-N-CA 123.785 2.99 . . . . 0.0 114.331 -174.248 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -153.41 -163.4 11.75 Favored Glycine 0 N--CA 1.44 -1.071 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.434 -177.229 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.56 25.97 12.22 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 123.06 0.544 . . . . 0.0 111.634 -178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 49.3 m 42.28 -99.48 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.0 -176.072 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 79.8 m -158.51 137.86 8.33 Favored Pre-proline 0 C--N 1.314 -0.949 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.32 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.591 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 52.5 Cg_endo -72.55 148.23 47.43 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.865 1.71 . . . . 0.0 110.796 169.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.04 10.39 14.97 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 121.364 -0.446 . . . . 0.0 113.529 -173.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -112.67 -16.28 12.83 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.628 0.728 . . . . 0.0 109.252 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.591 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 21.4 m-85 -119.93 18.67 12.48 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.352 -178.041 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -113.19 45.85 1.32 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.672 177.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.697 ' OD1' HG13 ' A' ' 7' ' ' ILE . 15.6 t-20 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.211 -0.899 . . . . 0.0 110.481 -175.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.535 ' HB ' HG13 ' A' ' 35' ' ' ILE . 86.1 m . . . . . 0 N--CA 1.475 0.794 0 CA-C-O 121.061 0.457 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -123.37 142.42 50.98 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.023 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 44' ' ' TYR . 22.1 p -152.48 147.96 26.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.912 0.387 . . . . 0.0 110.682 175.634 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.633 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 15.2 t -141.36 144.03 32.54 Favored Pre-proline 0 C--N 1.328 -0.331 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.746 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 3.6 Cg_exo -39.25 -51.86 2.5 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 124.474 3.45 . . . . 0.0 114.694 -177.363 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.488 ' HA ' ' HB3' ' A' ' 46' ' ' ASN . 3.8 p -147.74 160.6 42.53 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 122.29 -0.256 . . . . 0.0 111.394 -176.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.495 HG13 ' OD1' ' A' ' 46' ' ' ASN . 80.2 mt -53.82 -39.59 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.429 178.648 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 84.5 t -59.87 -52.92 55.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.652 0.263 . . . . 0.0 110.611 178.248 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.27 -35.46 80.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.746 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.553 ' HA ' ' HD2' ' A' ' 13' ' ' PHE . 1.0 OUTLIER -67.27 -41.01 86.23 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-O 121.231 0.539 . . . . 0.0 110.103 178.194 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.524 ' O ' HG23 ' A' ' 15' ' ' VAL . 29.7 t -57.87 -42.55 84.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.867 174.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -56.14 -46.03 79.37 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.313 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.556 ' HB3' HG21 ' A' ' 30' ' ' THR . 0.8 OUTLIER -72.54 -35.19 67.99 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.856 -175.699 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -59.85 -43.15 94.8 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.921 0.391 . . . . 0.0 110.019 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 11' ' ' SER . 63.3 t -67.26 -21.37 27.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.046 177.802 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.424 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 14.0 t -80.99 -25.4 37.29 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 120.929 0.395 . . . . 0.0 110.749 -176.47 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -72.0 -41.51 67.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.052 0.453 . . . . 0.0 110.741 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.955 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -56.55 -40.5 85.42 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -171.093 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.955 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 59.6 Cg_endo -74.1 0.6 8.21 Favored 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 121.522 1.481 . . . . 0.0 113.377 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.29 34.08 4.63 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.476 178.181 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.532 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -104.36 135.82 19.27 Favored Pre-proline 0 N--CA 1.436 -1.143 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.677 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.654 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.0 Cg_endo -63.74 127.71 20.33 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 122.848 2.366 . . . . 0.0 111.053 176.345 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.536 ' H ' ' CD ' ' A' ' 23' ' ' GLU . 1.5 mp0 -37.56 -40.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.346 172.312 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.43 -50.07 72.72 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.162 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.654 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -63.98 -36.42 83.91 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.107 0.479 . . . . 0.0 110.088 177.812 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 21.5 m -79.02 10.83 3.11 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.249 -179.525 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.25 -38.85 5.86 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.847 0.832 . . . . 0.0 110.359 171.119 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -69.59 -29.56 67.12 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.975 -1.466 . . . . 0.0 112.324 -173.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -103.77 -31.74 9.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.732 0.777 . . . . 0.0 109.913 -175.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.556 HG21 ' HB3' ' A' ' 13' ' ' PHE . 15.6 m -78.51 -33.1 48.3 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 114.426 -1.261 . . . . 0.0 111.684 -175.359 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.85 0.55 36.39 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.913 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.1 m -85.69 155.02 21.26 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.412 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.6 pt -120.43 144.98 27.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.398 0.618 . . . . 0.0 111.965 -176.576 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 79.5 mt -107.87 127.44 63.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.178 175.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HB2' ' A' ' 40' ' ' CYS . 24.3 pt -132.32 134.11 24.55 Favored Pre-proline 0 C--N 1.319 -0.76 0 CA-C-O 120.936 0.398 . . . . 0.0 111.476 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 -9.81 15.7 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.625 2.217 . . . . 0.0 111.176 173.377 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.01 -142.34 7.76 Favored Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.62 15.34 7.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 120.732 0.301 . . . . 0.0 111.181 -177.29 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.5 m -80.29 86.32 5.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.51 0.672 . . . . 0.0 110.751 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.545 ' HB2' HD13 ' A' ' 35' ' ' ILE . 42.1 t -158.29 116.26 1.78 Allowed Pre-proline 0 C--N 1.311 -1.108 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.672 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.96 166.65 28.94 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.415 2.076 . . . . 0.0 112.692 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.46 10.9 14.9 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.084 -177.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -98.43 -18.84 18.04 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.746 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 17.4 m-85 -120.0 18.4 12.44 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.827 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -115.09 47.25 1.31 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.212 -175.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.495 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.3 t-20 . . . . . 0 C--O 1.246 0.885 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.389 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' THR . . . . . 0.497 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 88.7 m . . . . . 0 N--CA 1.473 0.685 0 CA-C-O 121.131 0.491 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.46 HG23 HG12 ' A' ' 34' ' ' ILE . 40.2 m -128.92 112.01 13.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.729 -176.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' CYS . 73.2 m -75.5 90.82 2.75 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 176.124 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.506 ' SG ' HG21 ' A' ' 30' ' ' THR . 1.4 t -125.35 87.8 55.11 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -177.197 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.63 78.73 2.99 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 123.418 2.745 . . . . 0.0 114.025 -167.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.742 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 29.2 t 172.21 132.87 0.03 OUTLIER 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 171.248 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.667 ' H ' HD12 ' A' ' 7' ' ' ILE . 3.7 mp -62.93 -31.57 52.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.051 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.2 t -80.08 -47.26 21.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.173 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.742 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -60.75 -48.4 81.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.68 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 1.8 ptp180 -62.75 -25.09 68.03 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.621 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.471 ' O ' HG23 ' A' ' 15' ' ' VAL . 67.6 m -69.09 -56.49 7.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.029 178.195 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.474 ' HA ' ' HB ' ' A' ' 15' ' ' VAL . 11.2 p30 -64.32 -22.38 66.93 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.634 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.42 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 61.8 t80 -59.12 -59.69 5.05 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.653 170.601 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 17' ' ' ARG . 2.3 p-10 -71.73 -27.1 62.77 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.877 0.37 . . . . 0.0 110.903 -178.496 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.474 ' HB ' ' HA ' ' A' ' 12' ' ' ASN . 78.1 t -70.31 -17.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.006 0.431 . . . . 0.0 110.263 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.676 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 3.8 t -84.66 -29.03 26.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.417 0.627 . . . . 0.0 109.707 177.636 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.451 ' HB3' ' O ' ' A' ' 14' ' ' ASN . 6.9 tpt180 -58.42 -40.72 83.23 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.383 175.188 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.566 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 86.1 mt -61.08 -50.29 85.09 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 113.775 1.028 . . . . 0.0 113.775 -172.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.676 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 7.9 Cg_exo -73.39 13.56 0.69 Allowed 'Trans proline' 0 C--N 1.358 1.079 0 C-N-CA 122.581 2.187 . . . . 0.0 113.507 -177.712 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.23 36.85 9.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.897 176.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -108.79 134.9 20.17 Favored Pre-proline 0 N--CA 1.434 -1.27 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 176.887 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.752 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -60.18 122.51 11.48 Favored 'Trans proline' 0 N--CA 1.446 -1.29 0 C-N-CA 122.951 2.434 . . . . 0.0 111.121 178.803 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -35.84 -39.56 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.398 169.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.56 -53.39 58.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.192 176.314 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.752 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tm? -63.71 -37.2 86.46 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-O 121.004 0.431 . . . . 0.0 110.782 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 23.9 m -65.04 -37.43 87.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.358 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.52 -32.4 74.02 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.804 0.811 . . . . 0.0 110.462 176.253 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.8 m -74.89 -22.5 58.6 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 114.47 -1.241 . . . . 0.0 110.761 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -89.45 -45.58 9.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.864 0.84 . . . . 0.0 109.024 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.506 HG21 ' SG ' ' A' ' 4' ' ' CYS . 85.0 m -70.89 -37.79 73.01 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.002 -1.454 . . . . 0.0 111.061 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.04 16.89 17.65 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.904 -0.665 . . . . 0.0 113.017 179.11 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.592 ' HB2' ' O ' ' A' ' 3' ' ' CYS . 10.7 p -114.24 179.53 3.93 Favored 'General case' 0 C--N 1.327 -0.395 0 O-C-N 122.725 -0.279 . . . . 0.0 110.721 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.46 ' H ' HD13 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -127.77 141.88 45.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 111.563 -173.948 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.46 HG12 HG23 ' A' ' 2' ' ' THR . 60.3 mt -99.44 140.17 19.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.777 176.477 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' HB3' ' A' ' 38' ' ' ALA . 11.2 pt -137.91 129.14 15.94 Favored Pre-proline 0 N--CA 1.448 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 111.388 -177.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 32.6 Cg_exo -61.62 -27.77 81.94 Favored 'Trans proline' 0 CA--C 1.53 0.307 0 C-N-CA 123.029 2.486 . . . . 0.0 112.639 176.608 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.457 ' C ' ' H ' ' A' ' 39' ' ' THR . . . -132.94 -153.46 7.22 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.927 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.845 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 71.69 -29.04 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.904 0.881 . . . . 0.0 111.898 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' C ' ' A' ' 37' ' ' GLY . 52.2 m 65.81 5.45 3.41 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.331 0.652 . . . . 0.0 112.512 176.758 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 66.9 m 65.59 137.46 0.05 OUTLIER Pre-proline 0 N--CA 1.468 0.465 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.141 -175.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -74.62 175.85 10.54 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.418 2.079 . . . . 0.0 111.698 175.054 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -73.94 -0.82 57.49 Favored Glycine 0 CA--C 1.518 0.235 0 C-N-CA 121.363 -0.446 . . . . 0.0 113.12 -175.227 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -98.07 -22.25 16.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.193 0.52 . . . . 0.0 109.612 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.541 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 16.0 m-85 -121.44 19.95 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.679 -173.642 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.11 14.8 29.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.393 0.616 . . . . 0.0 110.77 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 18.3 m120 . . . . . 0 C--O 1.247 0.971 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.681 179.404 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.421 ' HB ' HG13 ' A' ' 35' ' ' ILE . 13.0 m . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 121.016 0.436 . . . . 0.0 109.933 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.7 t -98.99 122.65 42.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.518 0.675 . . . . 0.0 110.526 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 61.9 m -121.43 122.49 39.89 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.08 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.9 t -147.52 141.0 15.3 Favored Pre-proline 0 N--CA 1.448 -0.561 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -103.0 40.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.05 2.5 . . . . 0.0 113.957 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.9 t -158.26 135.52 10.09 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.622 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.8 mt -69.34 -28.0 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.356 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.7 t -83.5 -25.29 7.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.875 -175.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.36 -50.23 8.01 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.055 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.508 ' NH2' ' H ' ' A' ' 4' ' ' CYS . 7.3 tpp180 -53.5 -39.83 64.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.358 177.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.4 p -62.41 -61.71 2.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.644 0.259 . . . . 0.0 111.222 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -64.52 -24.07 67.48 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.469 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.429 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 56.7 t80 -59.17 -58.14 9.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.064 173.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -70.2 -30.56 67.7 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.898 -179.116 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 11' ' ' SER . 72.0 t -65.2 -30.16 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.351 . . . . 0.0 110.707 176.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -71.74 -27.16 62.8 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.297 0.57 . . . . 0.0 110.574 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.596 ' HA ' ' O ' ' A' ' 21' ' ' THR . 46.5 tpt85 -76.49 -17.71 59.14 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.205 -178.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.417 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 77.9 mt -68.57 -52.29 19.94 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -175.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.417 ' HD2' ' N ' ' A' ' 18' ' ' LEU . 56.4 Cg_endo -69.72 -6.28 18.19 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.262 1.975 . . . . 0.0 113.271 -177.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.92 25.87 4.94 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.2 OUTLIER -103.19 128.65 27.15 Favored Pre-proline 0 N--CA 1.439 -0.99 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.457 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.772 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 12.7 Cg_endo -58.43 121.99 10.9 Favored 'Trans proline' 0 N--CA 1.449 -1.146 0 C-N-CA 122.577 2.184 . . . . 0.0 110.752 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.57 ' H ' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -50.67 -29.19 10.5 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.937 173.459 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.16 -46.95 87.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.976 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.772 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -67.5 -46.69 72.16 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 120.971 0.415 . . . . 0.0 109.992 177.841 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 6.9 m -62.66 -35.54 79.97 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.828 -177.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.541 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -58.41 -40.45 82.46 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 111.266 178.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.6 m -66.28 -22.75 66.31 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.528 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -86.11 -47.03 9.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.124 176.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.464 ' HB ' ' SG ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -69.39 -36.99 77.31 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 -177.28 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.67 -22.24 36.28 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.141 -172.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.541 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 3.2 m -60.94 116.31 4.38 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.2 pt -91.68 150.5 3.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.925 0.393 . . . . 0.0 111.866 -172.043 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 69.4 mt -116.14 107.93 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.37 0.605 . . . . 0.0 109.617 174.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.726 HD12 ' HB3' ' A' ' 38' ' ' ALA . 15.3 pt -116.0 152.81 48.06 Favored Pre-proline 0 C--N 1.314 -0.95 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.91 -175.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.38 -64.71 0.1 OUTLIER 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 123.049 2.499 . . . . 0.0 112.41 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.39 -142.47 8.94 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 62.52 80.37 0.23 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.388 0.613 . . . . 0.0 110.939 177.571 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.63 96.63 0.13 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.745 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 44' ' ' TYR . 62.5 m -59.59 144.11 85.3 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.181 177.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.582 ' HD2' ' HD2' ' A' ' 44' ' ' TYR . 57.2 Cg_endo -70.96 -175.13 1.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.974 2.449 . . . . 0.0 113.25 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.41 7.1 33.4 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.488 -0.778 . . . . 0.0 114.428 -170.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.549 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 16.7 p-10 -108.45 -17.51 13.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 176.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.674 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . 22.2 m-85 -102.74 0.73 33.35 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.612 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.01 18.38 18.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.424 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.5 t-20 . . . . . 0 C--O 1.253 1.252 0 CA-C-O 118.251 -0.88 . . . . 0.0 110.215 -179.213 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.1 m . . . . . 0 N--CA 1.476 0.844 0 CA-C-O 120.782 0.325 . . . . 0.0 110.375 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 22.8 m -89.08 123.92 33.81 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.817 0.341 . . . . 0.0 110.47 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 63.8 m -124.25 106.7 10.49 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.559 ' HB3' ' HB3' ' A' ' 10' ' ' ARG . 7.8 t -100.76 132.6 21.97 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.054 -178.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.615 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.7 Cg_endo -86.05 34.21 0.47 Allowed 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.97 2.447 . . . . 0.0 112.982 -177.051 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.62 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 38.6 t -164.88 133.28 3.35 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 120.983 0.42 . . . . 0.0 110.573 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.31 -26.7 34.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.186 -0.916 . . . . 0.0 109.113 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.1 t -82.77 -47.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.088 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.62 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -61.78 -43.24 99.24 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.966 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.559 ' HB3' ' HB3' ' A' ' 4' ' ' CYS . 6.0 ptp180 -65.41 -28.23 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.095 0.474 . . . . 0.0 110.69 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.515 ' O ' HG23 ' A' ' 15' ' ' VAL . 42.4 m -72.62 -40.59 66.34 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.357 176.349 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -65.8 -28.69 69.19 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.632 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.24 -50.63 72.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.972 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -66.0 -26.42 67.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.192 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 11' ' ' SER . 84.5 t -68.2 -34.49 66.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.699 -179.185 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.499 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.0 t -82.26 -24.5 34.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 121.371 0.605 . . . . 0.0 110.393 -178.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 17' ' ' ARG . 23.6 ttt180 -80.5 -13.05 59.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.482 -178.229 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 8.2 mt -71.76 -52.1 8.38 Favored Pre-proline 0 N--CA 1.444 -0.745 0 CA-C-N 115.998 -0.547 . . . . 0.0 112.447 -177.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 6.4 Cg_exo -75.01 18.39 0.54 Allowed 'Trans proline' 0 C--N 1.358 1.051 0 C-N-CA 122.538 2.159 . . . . 0.0 113.11 -178.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 78.9 40.15 18.14 Favored Glycine 0 N--CA 1.443 -0.897 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.526 178.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.45 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 3.0 m -107.08 135.96 19.53 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 175.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.579 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 11.0 Cg_endo -57.24 116.65 3.36 Favored 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 122.938 2.425 . . . . 0.0 111.411 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -39.83 -34.94 0.3 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.903 170.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.62 -49.32 73.76 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.183 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.579 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 45.0 tp -68.55 -36.4 78.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-O 120.852 0.358 . . . . 0.0 110.199 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 36.0 m -66.78 -42.37 86.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.237 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -61.65 -24.64 66.86 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.657 0.741 . . . . 0.0 111.653 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.2 m -76.13 -22.62 55.27 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.984 -178.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -109.52 -42.69 4.25 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.332 0.587 . . . . 0.0 110.784 -177.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.5 m -62.86 -37.88 88.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.186 -178.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 108.65 -15.85 34.49 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.753 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.464 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 34.5 m -71.05 133.4 46.27 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 176.48 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.4 pt -103.96 141.22 20.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.233 0.539 . . . . 0.0 111.383 -175.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 68.8 mt -108.15 107.73 23.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.977 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.88 HG22 ' H ' ' A' ' 37' ' ' GLY . 5.0 mp -89.86 130.21 43.62 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.05 -179.347 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.55 -13.31 38.61 Favored 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.836 2.357 . . . . 0.0 112.235 175.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.88 ' H ' HG22 ' A' ' 35' ' ' ILE . . . -91.03 -137.35 7.22 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.903 176.013 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.45 15.9 0.26 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.613 0.244 . . . . 0.0 111.387 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.9 m -120.02 105.51 11.11 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.093 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.7 p -134.47 135.96 24.79 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.51 173.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.47 ' HG2' ' OD1' ' A' ' 43' ' ' ASP . 53.3 Cg_endo -67.15 176.6 4.47 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.748 2.299 . . . . 0.0 112.802 -176.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.24 24.94 5.82 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.589 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.47 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 11.3 p-10 -112.22 -18.29 12.57 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 170.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.615 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 17.7 m-85 -98.4 3.6 48.47 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.789 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.56 18.82 21.39 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.824 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 . . . . . 0 C--O 1.246 0.904 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.732 -179.123 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.476 0.827 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -98.26 136.4 38.5 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-O 120.921 0.391 . . . . 0.0 112.017 -176.297 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 96.9 m -134.18 112.72 11.34 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 173.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 41.4 m -101.56 152.5 38.06 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.911 -173.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -99.74 24.67 0.18 Allowed 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.722 2.282 . . . . 0.0 113.598 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 t -174.03 132.5 0.41 Allowed 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.118 0.485 . . . . 0.0 110.269 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.489 ' HA ' ' HB3' ' A' ' 10' ' ' ARG . 59.3 mt -69.79 -19.97 23.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.154 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -71.36 -41.99 73.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.525 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -66.08 -48.17 71.84 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.8 174.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.489 ' HB3' ' HA ' ' A' ' 7' ' ' ILE . 4.0 tpp180 -50.97 -41.78 59.56 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.167 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 15' ' ' VAL . 41.5 t -58.76 -55.19 38.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.522 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.406 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.0 p30 -71.04 -26.89 63.29 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.246 -178.276 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -62.22 -50.44 71.75 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.615 173.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -54.98 -44.19 74.22 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.674 178.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 11' ' ' SER . 57.7 t -67.5 -27.11 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.455 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.2 t -83.93 -43.18 15.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 121.01 0.433 . . . . 0.0 111.035 -176.176 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -76.38 -10.88 59.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.021 0.439 . . . . 0.0 111.409 -177.463 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.406 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 5.4 mt -69.95 -51.12 15.34 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -176.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 48.9 Cg_endo -71.8 -8.78 23.72 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.292 1.995 . . . . 0.0 113.131 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.11 19.1 5.27 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.347 -0.93 . . . . 0.0 113.312 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.477 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 3.1 m -83.66 137.33 41.48 Favored Pre-proline 0 N--CA 1.431 -1.383 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 21.0 Cg_endo -63.74 125.93 16.42 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.564 2.176 . . . . 0.0 110.511 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -42.14 -26.5 0.1 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.412 170.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 34' ' ' ILE . . . -51.09 -54.14 27.71 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.769 0.319 . . . . 0.0 110.934 171.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.2 tt -67.69 -41.29 83.88 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 109.85 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.0 m -81.51 9.05 8.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.3 -175.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -109.64 -49.2 3.13 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.859 0.838 . . . . 0.0 110.302 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -64.37 -33.26 75.45 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 113.859 -1.518 . . . . 0.0 112.37 -173.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -96.57 -15.19 21.73 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.228 1.014 . . . . 0.0 109.527 -176.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.525 HG22 ' HB1' ' A' ' 9' ' ' ALA . 55.7 m -96.32 -25.89 15.59 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 113.791 -1.55 . . . . 0.0 112.279 -172.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.66 7.33 57.89 Favored Glycine 0 C--N 1.328 0.093 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.42 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.464 ' HB3' ' HA ' ' A' ' 27' ' ' ALA . 19.8 t -92.92 157.85 16.13 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.2 pt -118.43 160.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.573 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.44 ' CD1' ' HA ' ' A' ' 24' ' ' ALA . 69.9 mt -122.31 137.37 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.599 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.521 HD13 ' H ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -130.66 157.27 78.19 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 176.268 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 45.5 Cg_endo -70.54 -28.12 21.89 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.497 2.131 . . . . 0.0 112.263 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.73 -140.5 11.29 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.006 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -152.65 12.93 0.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.685 0.279 . . . . 0.0 111.353 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.2 m -90.54 104.98 17.5 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.254 0.549 . . . . 0.0 110.0 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 94.9 m -129.43 131.68 23.77 Favored Pre-proline 0 C--N 1.311 -1.085 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.954 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -69.81 176.09 7.27 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.697 2.265 . . . . 0.0 112.499 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.51 3.06 26.92 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 116.069 -0.514 . . . . 0.0 113.755 -175.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -94.36 -22.34 18.39 Favored 'General case' 0 CA--C 1.513 -0.481 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.609 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -121.17 20.71 11.37 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.273 -1.331 . . . . 0.0 109.661 -176.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -99.37 16.37 23.28 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.031 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.737 -0.649 . . . . 0.0 109.566 -178.7 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 60.2 m . . . . . 0 N--CA 1.476 0.874 0 CA-C-O 120.835 0.35 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.624 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 26.8 m -104.27 118.37 36.46 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.747 178.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 62.6 m -108.87 128.14 54.65 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.344 -174.252 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.5 m -128.98 132.55 24.44 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.548 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.782 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.2 Cg_endo -90.84 23.82 0.62 Allowed 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.899 2.399 . . . . 0.0 114.245 -177.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.1 p -171.01 149.38 2.92 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 122.07 -0.394 . . . . 0.0 111.438 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 58.7 mt -65.22 -29.45 47.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.156 178.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.5 t -76.63 -38.81 31.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.833 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -72.88 -41.99 64.11 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 10.7 tpp180 -54.4 -36.76 64.29 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.721 177.27 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -79.52 -55.09 5.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.66 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 p30 -60.88 -24.27 65.83 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 121.218 0.533 . . . . 0.0 110.787 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.647 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 71.0 t80 -61.39 -60.51 3.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.586 173.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -69.49 -28.59 66.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.673 -175.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 93.6 t -71.52 -23.61 22.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.394 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.502 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.5 t -76.86 -32.06 57.25 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 121.996 -0.44 . . . . 0.0 110.595 -179.157 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.616 ' HA ' ' O ' ' A' ' 21' ' ' THR . 1.7 ptm180 -87.19 -0.06 56.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.194 0.521 . . . . 0.0 110.697 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.538 ' HB3' ' HD3' ' A' ' 19' ' ' PRO . 63.9 tp -70.32 -53.32 10.56 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.662 179.098 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.538 ' HD3' ' HB3' ' A' ' 18' ' ' LEU . 91.1 Cg_endo -82.2 28.03 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.171 1.914 . . . . 0.0 113.759 -177.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.94 39.53 8.57 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.317 175.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.616 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.8 OUTLIER -115.37 136.56 22.74 Favored Pre-proline 0 N--CA 1.437 -1.093 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 174.917 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.869 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 17.7 Cg_endo -63.2 120.99 8.67 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 122.617 2.211 . . . . 0.0 111.047 175.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 11.0 pt-20 -56.88 -23.71 46.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.243 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.505 ' HA ' HD12 ' A' ' 34' ' ' ILE . . . -63.34 -41.95 98.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.729 173.277 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.869 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.5 OUTLIER -71.8 -39.12 70.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 120.903 0.382 . . . . 0.0 110.215 176.795 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 34.3 m -66.97 -36.96 83.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.041 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.4 -36.15 73.13 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.785 0.802 . . . . 0.0 110.898 176.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -69.04 -23.79 64.1 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 114.093 -1.412 . . . . 0.0 111.129 -176.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -102.65 -46.07 4.84 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.626 0.727 . . . . 0.0 110.02 -176.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.5 m -59.95 -44.36 94.45 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 114.626 -1.17 . . . . 0.0 112.172 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.78 -9.16 14.49 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.28 -0.962 . . . . 0.0 112.037 -176.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 94.7 m -71.38 158.8 35.68 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 175.147 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 26.3 pt -126.39 139.59 51.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.963 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.505 HD12 ' HA ' ' A' ' 24' ' ' ALA . 71.3 mt -112.32 103.28 15.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.791 177.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 34.1 pt -107.83 148.28 37.07 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.142 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -76.93 12.06 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.997 2.465 . . . . 0.0 112.387 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -130.45 -147.39 6.13 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.74 21.86 2.14 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.163 0.506 . . . . 0.0 110.273 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 m -79.98 72.25 6.74 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.396 -175.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 90.9 m -128.29 131.51 23.82 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.287 176.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.23 174.55 8.88 Favored 'Trans proline' 0 CA--C 1.531 0.348 0 C-N-CA 122.595 2.196 . . . . 0.0 111.903 176.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.98 26.21 1.47 Allowed Glycine 0 CA--C 1.521 0.424 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.236 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 24.7 t70 -115.38 -29.78 6.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.2 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.782 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 10.4 m-85 -105.91 5.18 30.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.967 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.61 17.11 23.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.913 -174.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.0 t30 . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.086 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.598 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 23.5 m . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.483 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 21.9 m -134.16 124.16 25.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.011 -176.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.458 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 82.6 m -128.16 142.84 51.06 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.664 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 0.5 OUTLIER -128.42 151.66 76.96 Favored Pre-proline 0 C--N 1.32 -0.676 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.505 -175.716 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.664 ' HD2' ' SG ' ' A' ' 4' ' ' CYS . 88.8 Cg_endo -82.05 1.66 9.06 Favored 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.955 2.436 . . . . 0.0 113.958 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.8 p -160.9 155.55 23.64 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 121.88 -0.512 . . . . 0.0 110.94 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 59.2 mt -73.05 -28.58 26.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.421 178.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.6 t -67.87 -44.43 85.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.766 -178.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.411 ' HA ' HD21 ' A' ' 12' ' ' ASN . . . -66.34 -45.2 81.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.961 177.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -54.2 -39.27 66.53 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.38 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.4 m -60.5 -55.07 37.88 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.641 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.411 HD21 ' HA ' ' A' ' 9' ' ' ALA . 11.3 p30 -75.28 -22.62 57.62 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.02 0.438 . . . . 0.0 110.906 -176.363 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CZ ' HG21 ' A' ' 2' ' ' THR . 44.8 t80 -58.16 -53.41 58.62 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.086 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -61.96 -29.89 70.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.783 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 79.5 t -65.26 -33.23 62.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.89 178.236 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.548 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 39.8 t -75.71 -21.35 57.63 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 121.469 0.652 . . . . 0.0 110.151 -178.088 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.663 ' HD3' ' HG3' ' A' ' 23' ' ' GLU . 27.3 tpt180 -74.68 -26.45 59.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.013 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 97.6 mt -62.52 -49.22 84.35 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -175.385 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 13.7 Cg_exo -70.54 -5.41 16.62 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.226 1.951 . . . . 0.0 112.995 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.69 28.92 7.62 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.461 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.596 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -90.68 140.87 26.6 Favored Pre-proline 0 N--CA 1.431 -1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 177.769 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.706 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 14.4 Cg_endo -62.05 121.76 9.95 Favored 'Trans proline' 0 N--CA 1.443 -1.462 0 C-N-CA 122.941 2.427 . . . . 0.0 110.857 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.663 ' HG3' ' HD3' ' A' ' 17' ' ' ARG . 1.1 mp0 -45.93 -32.35 2.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.059 173.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.2 -48.11 82.82 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.066 175.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.706 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.2 tt -66.68 -44.49 81.67 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.095 178.228 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.493 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 14.0 m -66.76 -40.4 88.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.508 -176.017 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.02 -42.21 93.84 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.519 0.676 . . . . 0.0 111.021 178.292 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.3 m -68.22 -21.87 64.82 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.353 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -100.7 -38.09 8.45 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.674 0.75 . . . . 0.0 109.847 -174.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.6 m -75.65 -57.68 3.74 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.596 -1.184 . . . . 0.0 112.024 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.0 -20.38 2.14 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 119.705 -1.236 . . . . 0.0 112.527 -176.415 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 30.7 m -66.83 155.91 37.01 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 175.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 33.1 pt -120.55 148.84 23.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.331 -0.547 . . . . 0.0 111.814 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 50.8 mm -102.13 139.22 23.77 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.344 176.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.598 ' O ' ' HB ' ' A' ' 1' ' ' THR . 3.1 pt -146.31 151.37 43.87 Favored Pre-proline 0 C--N 1.316 -0.859 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.25 -179.016 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -87.75 30.99 0.44 Allowed 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.498 2.799 . . . . 0.0 112.233 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.51 137.79 4.81 Favored Glycine 0 N--CA 1.446 -0.676 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.699 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.29 30.17 0.34 Allowed 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.057 0.456 . . . . 0.0 111.58 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.8 m -80.38 48.66 1.05 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.511 0.672 . . . . 0.0 111.632 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.584 ' SG ' HD11 ' A' ' 35' ' ' ILE . 76.3 m -94.29 126.38 48.6 Favored Pre-proline 0 C--N 1.313 -1.003 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.699 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -75.03 176.36 10.02 Favored 'Trans proline' 0 CA--C 1.531 0.352 0 C-N-CA 122.762 2.308 . . . . 0.0 112.36 176.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.95 -8.69 74.17 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 114.572 0.589 . . . . 0.0 114.572 -171.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -94.99 -22.12 18.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.831 0.824 . . . . 0.0 109.294 -179.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.458 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 20.8 m-85 -107.23 18.07 22.12 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.278 -178.459 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.01 33.46 0.79 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.261 -177.181 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.411 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 16.6 m-80 . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.791 -0.623 . . . . 0.0 109.497 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.546 ' HB ' HG13 ' A' ' 35' ' ' ILE . 7.5 m . . . . . 0 N--CA 1.475 0.798 0 CA-C-O 120.782 0.325 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.405 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 7.3 m -90.57 115.02 27.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.103 0.478 . . . . 0.0 110.785 178.444 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.403 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.4 m -115.08 144.56 43.45 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.599 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.4 t -156.28 110.82 2.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.012 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.567 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 96.7 Cg_endo -84.61 45.4 1.68 Allowed 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.971 2.447 . . . . 0.0 113.881 -173.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m -158.17 127.28 5.69 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.4 mp -64.85 -36.96 78.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.9 t -62.59 -38.8 82.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.326 -1.307 . . . . 0.0 110.251 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.4 22.07 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.26 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.3 tpp180 -50.89 -43.45 59.65 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.833 175.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.543 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.7 m -53.7 -55.01 29.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.423 0.154 . . . . 0.0 111.378 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -76.65 -23.03 53.29 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.398 -0.521 . . . . 0.0 110.608 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.405 ' CZ ' HG21 ' A' ' 2' ' ' THR . 34.7 t80 -65.48 -49.07 70.44 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.114 175.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -59.97 -32.64 71.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.127 0.489 . . . . 0.0 109.843 174.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 11' ' ' SER . 92.8 t -72.82 -24.0 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.99 177.592 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -86.26 5.71 33.09 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-O 121.753 0.787 . . . . 0.0 109.62 -178.05 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.479 ' NE ' ' HG3' ' A' ' 23' ' ' GLU . 13.7 mmm180 -106.3 -23.53 12.53 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.556 0.693 . . . . 0.0 109.185 178.241 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -56.92 -47.62 98.77 Favored Pre-proline 0 CA--C 1.547 0.846 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.131 175.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.441 ' HG2' ' OG1' ' A' ' 21' ' ' THR . 82.3 Cg_endo -79.61 4.16 6.91 Favored 'Trans proline' 0 C--N 1.36 1.17 0 C-N-CA 121.779 1.653 . . . . 0.0 113.037 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.72 20.86 45.64 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.505 176.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.685 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -81.06 142.46 51.62 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.206 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.685 ' HD2' HG22 ' A' ' 21' ' ' THR . 38.2 Cg_endo -70.85 130.44 17.99 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 C-N-CA 123.156 2.571 . . . . 0.0 111.494 176.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.479 ' HG3' ' NE ' ' A' ' 17' ' ' ARG . 51.4 mt-10 -41.83 -36.08 0.96 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.485 171.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.71 -52.1 50.96 Favored 'General case' 0 C--N 1.33 -0.266 0 O-C-N 123.381 0.426 . . . . 0.0 110.857 175.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.527 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -68.19 -41.62 81.12 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.167 179.063 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 7.5 m -80.57 12.17 3.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.523 -176.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -108.05 -48.28 3.41 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 121.894 0.854 . . . . 0.0 110.104 173.032 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.0 m -62.73 -29.62 70.81 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 113.817 -1.538 . . . . 0.0 112.117 -174.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -95.86 -22.5 17.42 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.885 0.85 . . . . 0.0 110.117 -175.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -93.21 -38.61 11.46 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.528 -1.214 . . . . 0.0 111.82 -171.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.74 -18.68 8.58 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.433 -177.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 6.6 m -64.9 150.48 47.73 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 32.9 pt -122.3 149.09 25.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.085 0.469 . . . . 0.0 111.495 -177.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.5 mt -111.28 110.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.829 176.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.909 HD12 ' HB3' ' A' ' 38' ' ' ALA . 5.7 pt -108.52 129.36 24.11 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.907 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.09 -32.31 17.43 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.435 2.09 . . . . 0.0 112.68 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.07 117.91 0.83 Allowed Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.909 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 165.2 102.0 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.741 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -172.072 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.41 94.39 0.01 OUTLIER 'General case' 0 N--CA 1.435 -1.216 0 O-C-N 123.884 0.74 . . . . 0.0 110.377 172.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 45' ' ' ALA . 4.2 t -65.92 120.52 69.8 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.356 -175.435 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.41 170.27 20.66 Favored 'Trans proline' 0 C--O 1.236 0.379 0 C-N-CA 122.766 2.311 . . . . 0.0 112.473 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.75 20.7 7.39 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.008 -173.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -119.1 -11.53 9.61 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 174.262 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.567 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 19.6 m-85 -113.81 0.11 14.38 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.756 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.402 ' HB2' ' SG ' ' A' ' 40' ' ' CYS . . . -135.9 64.99 1.55 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 120.962 0.41 . . . . 0.0 110.431 -177.441 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.7 m120 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.582 -0.723 . . . . 0.0 109.304 175.608 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.0 m . . . . . 0 N--CA 1.477 0.897 0 CA-C-O 120.554 0.216 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.444 ' OG1' HG12 ' A' ' 34' ' ' ILE . 31.1 m -97.33 112.49 24.28 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.129 0.49 . . . . 0.0 110.274 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.638 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 74.3 m -105.98 146.63 29.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.082 -176.821 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.455 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 2.1 t -136.8 141.99 37.13 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 5.4 Cg_exo -78.59 17.12 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.789 2.326 . . . . 0.0 115.043 -171.531 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -170.29 150.78 3.66 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 118.975 0.807 . . . . 0.0 110.755 177.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.753 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 3.3 mp -64.66 -33.52 63.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.893 0.854 . . . . 0.0 109.107 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.16 -51.09 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.754 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.84 -34.15 69.03 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.4 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.753 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -68.21 -25.22 65.11 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 109.93 -179.675 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.415 ' O ' HG23 ' A' ' 15' ' ' VAL . 69.8 m -67.91 -47.42 68.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.903 172.137 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -55.27 -39.66 70.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.195 0.522 . . . . 0.0 109.879 176.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 5.8 t80 -53.0 -56.65 14.47 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 114.954 -1.021 . . . . 0.0 112.097 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -74.8 -31.39 61.71 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 121.2 -0.2 . . . . 0.0 111.213 -174.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 11' ' ' SER . 96.6 t -70.52 -30.9 44.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 111.131 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.406 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.2 t -74.64 -22.9 58.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.935 -178.229 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.695 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 74.2 mtm180 -77.98 -22.22 49.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.579 0.228 . . . . 0.0 111.172 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.6 mt -54.45 -50.58 84.37 Favored Pre-proline 0 N--CA 1.443 -0.816 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 -176.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.406 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 55.6 Cg_endo -72.14 5.0 2.87 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.099 1.866 . . . . 0.0 113.089 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.71 28.14 9.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.936 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.67 133.48 24.48 Favored Pre-proline 0 N--CA 1.438 -1.037 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.694 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 18.2 Cg_endo -62.01 124.44 14.44 Favored 'Trans proline' 0 N--CA 1.445 -1.381 0 C-N-CA 122.755 2.304 . . . . 0.0 109.798 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.695 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 9.4 pt-20 -53.63 -20.2 4.94 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.269 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -64.56 -47.09 80.03 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 173.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.694 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.5 tt -63.74 -44.12 94.47 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 120.871 0.367 . . . . 0.0 110.347 176.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 14.9 m -69.21 -30.97 69.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.309 -177.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.462 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -65.71 -31.14 71.97 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.749 0.785 . . . . 0.0 110.334 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 m -74.75 -20.59 59.76 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.78 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -98.12 -52.99 3.51 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-O 121.91 0.862 . . . . 0.0 110.244 -176.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 52.0 m -70.58 -47.47 60.07 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 114.013 -1.448 . . . . 0.0 112.161 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.1 0.79 10.56 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.953 -1.117 . . . . 0.0 112.753 -177.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.462 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 25.5 m -71.46 161.34 31.2 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 174.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.1 pt -132.42 141.25 45.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.967 0.413 . . . . 0.0 111.301 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.444 HG12 ' OG1' ' A' ' 2' ' ' THR . 77.4 mt -97.0 112.66 29.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.817 177.154 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.584 HG12 ' HB3' ' A' ' 40' ' ' CYS . 2.4 pp -105.72 147.53 34.87 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.869 0.366 . . . . 0.0 111.5 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -78.56 28.91 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 123.409 2.739 . . . . 0.0 112.999 -176.609 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -133.27 -151.08 6.49 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 177.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -148.39 22.38 1.05 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.608 0.24 . . . . 0.0 111.361 -177.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.0 m -133.0 -46.48 0.85 Allowed 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.828 -179.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.673 ' HB2' ' HD2' ' A' ' 41' ' ' PRO . 24.1 p 48.92 164.92 0.03 OUTLIER Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 124.904 1.378 . . . . 0.0 113.187 -174.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.673 ' HD2' ' HB2' ' A' ' 40' ' ' CYS . 31.6 Cg_endo -65.82 152.55 81.24 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.253 1.969 . . . . 0.0 112.682 176.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.11 12.2 7.1 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.753 -0.658 . . . . 0.0 113.997 -172.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.443 ' OD1' ' HB2' ' A' ' 41' ' ' PRO . 19.1 p-10 -106.49 -12.31 15.66 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.638 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.9 m-85 -117.67 5.53 12.35 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.616 175.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.06 35.5 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.06 -172.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.579 176.712 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.499 ' HB ' ' HB ' ' A' ' 35' ' ' ILE . 9.1 m . . . . . 0 N--CA 1.475 0.819 0 CA-C-O 121.041 0.448 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 31.7 m -135.54 142.14 45.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.804 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 58.9 m -125.06 132.27 53.2 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -172.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.0 m -126.47 123.28 24.03 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.377 174.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -80.74 19.67 1.08 Allowed 'Trans proline' 0 CA--C 1.532 0.406 0 C-N-CA 122.416 2.077 . . . . 0.0 113.441 -174.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -157.97 136.42 11.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.823 HD12 ' H ' ' A' ' 7' ' ' ILE . 4.1 mp -57.51 -38.66 64.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.326 0.584 . . . . 0.0 109.672 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.6 t -72.88 -36.78 52.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.271 -177.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.13 82.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.477 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -71.64 -39.68 70.21 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.23 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.584 ' O ' HG23 ' A' ' 15' ' ' VAL . 5.9 p -66.38 -37.39 85.17 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.557 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -66.25 -41.98 89.21 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.379 0.609 . . . . 0.0 109.834 175.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 23' ' ' GLU . 13.1 t80 -60.86 -42.99 98.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.123 179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -61.54 -34.29 75.29 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.156 177.243 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 11' ' ' SER . 47.2 t -78.57 -6.18 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.475 178.121 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.671 ' O ' ' HB ' ' A' ' 21' ' ' THR . 1.8 t -108.96 14.94 23.79 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-O 121.888 0.851 . . . . 0.0 108.855 176.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 21' ' ' THR . 6.2 tpt180 -120.9 -42.84 2.48 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 114.979 -1.01 . . . . 0.0 108.365 175.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.14 -51.35 57.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 CA-C-N 113.727 -1.578 . . . . 0.0 113.372 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.05 35.46 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.813 0 C-N-CA 122.641 2.227 . . . . 0.0 113.203 -175.355 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 66.51 46.68 75.1 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.935 178.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.671 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.57 132.23 24.27 Favored Pre-proline 0 N--CA 1.441 -0.899 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.857 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.714 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 30.1 Cg_endo -63.83 122.45 10.51 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.745 2.297 . . . . 0.0 111.156 177.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 13' ' ' PHE . 1.1 mp0 -51.9 -31.48 28.49 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.142 174.483 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.63 -48.82 79.72 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.573 177.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.714 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.9 OUTLIER -67.26 -41.9 84.8 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.204 0.526 . . . . 0.0 110.177 179.219 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 86.2 m -74.52 -14.12 60.77 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.82 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -70.27 -32.47 70.29 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 122.052 0.93 . . . . 0.0 109.883 174.514 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.6 m -72.05 -23.21 61.33 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 113.885 -1.507 . . . . 0.0 110.418 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -99.57 -49.42 4.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.352 0.596 . . . . 0.0 110.608 -176.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m -66.7 -44.92 80.41 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.567 -178.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.51 -15.17 14.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.427 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 82.6 m -65.89 145.43 55.94 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 176.072 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.8 pt -116.62 153.59 18.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.74 0.305 . . . . 0.0 111.487 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 67.7 mt -102.06 133.54 45.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.956 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.499 ' HB ' ' HB ' ' A' ' 1' ' ' THR . 45.7 mm -93.13 123.43 60.94 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.843 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -55.76 -40.04 87.59 Favored 'Trans proline' 0 CA--C 1.528 0.195 0 C-N-CA 122.829 2.353 . . . . 0.0 112.073 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.41 -125.4 4.67 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.999 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.24 72.8 1.34 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.561 0.696 . . . . 0.0 110.376 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.469 ' H ' HG21 ' A' ' 35' ' ' ILE . 11.2 m -145.78 108.94 4.6 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.112 174.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 16.8 t -153.89 123.01 3.15 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.129 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.54 164.83 34.47 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.918 2.412 . . . . 0.0 112.84 179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -74.41 6.72 21.69 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.584 -0.734 . . . . 0.0 113.314 -175.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -92.8 -21.28 20.0 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -108.44 5.99 25.82 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.892 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -122.88 18.88 10.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.872 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 59.9 t30 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.307 -0.854 . . . . 0.0 110.909 -174.719 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 34' ' ' ILE . 8.5 m . . . . . 0 N--CA 1.477 0.914 0 CA-C-O 120.958 0.408 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.405 ' OG1' HG12 ' A' ' 34' ' ' ILE . 35.5 m -118.19 132.68 56.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.456 -175.219 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 98.3 m -106.82 126.38 52.23 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.702 174.055 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 1.8 t -115.15 140.45 25.68 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 88.6 Cg_endo -91.74 22.79 0.64 Allowed 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.646 2.23 . . . . 0.0 113.652 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.444 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . 51.5 m -150.86 143.0 24.11 Favored 'General case' 0 C--N 1.332 -0.18 0 O-C-N 122.044 -0.41 . . . . 0.0 110.71 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.0 mt -71.16 -27.01 28.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.256 0.55 . . . . 0.0 110.547 -175.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 80.0 t -87.27 -51.91 12.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.709 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.444 ' HB3' ' HB2' ' A' ' 6' ' ' SER . . . -50.16 -42.53 51.16 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.348 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -26.3 68.31 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.286 0.565 . . . . 0.0 110.881 -176.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.521 ' O ' HG23 ' A' ' 15' ' ' VAL . 22.2 t -77.81 -56.16 4.73 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.464 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -68.03 -21.76 65.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.067 0.46 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.481 ' HB2' HG21 ' A' ' 30' ' ' THR . 21.7 t80 -57.97 -56.01 27.54 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.033 170.565 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -69.59 -25.16 63.84 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.679 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 11' ' ' SER . 84.8 t -66.99 -22.83 29.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.758 173.581 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.6 t -83.64 -22.92 32.04 Favored 'General case' 0 C--O 1.221 -0.431 0 CA-C-O 121.35 0.595 . . . . 0.0 109.892 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.553 ' HG2' ' O ' ' A' ' 21' ' ' THR . 3.5 tmt_? -92.26 -29.57 16.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.902 -172.293 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.662 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -54.87 -44.83 99.7 Favored Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 114.599 -1.182 . . . . 0.0 113.179 -177.802 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.662 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 64.7 Cg_endo -73.52 14.0 0.67 Allowed 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 122.046 1.83 . . . . 0.0 113.808 -177.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.96 27.08 8.03 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.779 -0.724 . . . . 0.0 113.096 176.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.553 ' O ' ' HG2' ' A' ' 17' ' ' ARG . 4.5 m -104.73 138.34 19.48 Favored Pre-proline 0 N--CA 1.429 -1.49 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 17.4 Cg_endo -62.02 123.53 12.73 Favored 'Trans proline' 0 N--CA 1.441 -1.58 0 C-N-CA 122.335 2.024 . . . . 0.0 109.889 176.248 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.461 ' HB2' ' HZ ' ' A' ' 13' ' ' PHE . 14.8 pt-20 -45.22 -30.2 1.15 Allowed 'General case' 0 C--N 1.324 -0.54 0 O-C-N 123.816 0.697 . . . . 0.0 110.03 174.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -58.13 -46.74 85.11 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.704 177.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.62 -37.77 73.86 Favored 'General case' 0 N--CA 1.444 -0.765 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 85.9 m -71.55 -33.44 69.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.651 -177.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.84 -46.12 91.8 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 122.073 0.94 . . . . 0.0 110.245 176.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.7 m -67.18 -20.43 65.72 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 113.607 -1.633 . . . . 0.0 111.729 -178.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -100.45 -45.88 5.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.599 0.714 . . . . 0.0 110.175 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.481 HG21 ' HB2' ' A' ' 13' ' ' PHE . 99.8 m -72.58 -40.73 66.37 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.616 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.64 16.39 4.6 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.082 -1.056 . . . . 0.0 112.67 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.3 m -98.44 170.81 8.58 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -129.86 148.1 33.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.818 -0.353 . . . . 0.0 111.569 -177.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.604 HD11 ' HA ' ' A' ' 24' ' ' ALA . 31.3 mt -101.5 140.64 19.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.231 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.8 pt -129.83 142.78 46.54 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.758 0.313 . . . . 0.0 110.99 177.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.53 39.85 0.85 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.255 2.637 . . . . 0.0 112.331 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.25 149.05 20.34 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -176.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.71 -1.83 58.22 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 120.847 0.356 . . . . 0.0 111.143 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.2 m -99.72 106.29 18.18 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.494 176.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 14.3 t -123.5 131.2 24.29 Favored Pre-proline 0 C--N 1.309 -1.17 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.931 179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.41 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 17.0 Cg_endo -59.36 143.14 99.82 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.791 2.327 . . . . 0.0 112.127 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.57 -8.35 25.87 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 114.563 -173.5 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -83.86 -24.17 30.99 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.557 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 7.9 m-85 -117.86 3.79 12.21 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.313 -176.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.43 34.31 0.52 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.41 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.45 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 22.3 m-80 . . . . . 0 C--O 1.245 0.823 0 CA-C-O 118.457 -0.783 . . . . 0.0 108.896 176.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 41.1 m . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 120.711 0.291 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.67 HG23 HG13 ' A' ' 34' ' ' ILE . 27.4 m -105.03 125.19 50.71 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.547 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 59.4 m -128.96 120.15 25.59 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.048 0.452 . . . . 0.0 111.288 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 78.8 m -107.36 166.31 11.27 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.386 179.177 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.543 ' HD2' ' HB3' ' A' ' 4' ' ' CYS . 83.6 Cg_endo -82.21 8.78 4.3 Favored 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 122.507 2.138 . . . . 0.0 114.574 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.4 t -176.09 145.13 0.62 Allowed 'General case' 0 CA--C 1.518 -0.281 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.667 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.878 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 46.2 mm -65.76 -27.24 40.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.561 0.695 . . . . 0.0 109.293 176.114 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.2 t -74.16 -49.75 31.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.844 177.643 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.93 -40.39 94.98 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.298 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.878 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -65.59 -27.72 68.62 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.111 0.481 . . . . 0.0 110.434 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.568 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.3 t -64.86 -47.59 77.38 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.669 177.275 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 54.4 m-80 -67.26 -26.69 66.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.567 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.49 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 57.4 t80 -66.6 -51.63 54.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.578 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -66.82 -23.79 66.08 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.908 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.568 HG23 ' O ' ' A' ' 11' ' ' SER . 55.7 t -62.57 -34.53 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.792 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.545 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 75.8 m -66.41 -25.03 66.57 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.432 0.634 . . . . 0.0 111.319 177.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.664 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 18.2 mmm180 -75.04 -31.71 61.37 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.722 -175.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 1.003 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -66.72 -42.87 47.44 Favored Pre-proline 0 CA--C 1.546 0.825 0 N-CA-C 114.054 1.131 . . . . 0.0 114.054 -173.761 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 1.003 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 94.9 Cg_endo -87.55 -6.18 7.02 Favored 'Trans proline' 0 C--N 1.356 0.939 0 C-N-CA 121.806 1.67 . . . . 0.0 113.22 -177.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.03 23.0 7.95 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.074 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.46 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 5.6 m -84.53 126.42 69.01 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 175.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.804 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.32 120.48 8.36 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.404 2.069 . . . . 0.0 110.557 177.404 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.664 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -45.98 -35.33 4.64 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.035 169.749 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.08 -51.41 67.97 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.989 174.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.804 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.0 tt -62.39 -53.36 56.08 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 120.685 0.279 . . . . 0.0 110.355 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 13' ' ' PHE . 33.7 t -63.27 -38.26 90.48 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.593 -174.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.538 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.76 -34.33 78.08 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.356 0.598 . . . . 0.0 111.626 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 23.4 m -76.55 -20.71 56.56 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.306 -177.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -97.54 -46.17 6.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.94 0.876 . . . . 0.0 109.678 -175.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 55.5 m -70.59 -34.86 72.62 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.748 -1.569 . . . . 0.0 111.755 178.52 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.18 30.49 7.38 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.352 -0.928 . . . . 0.0 111.331 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.538 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.4 t -109.31 159.44 16.97 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.8 141.26 44.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.878 0.371 . . . . 0.0 111.587 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.67 HG13 HG23 ' A' ' 2' ' ' THR . 4.3 mp -109.95 132.08 59.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.892 174.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.49 HD11 ' SG ' ' A' ' 40' ' ' CYS . 24.5 pt -134.82 156.8 78.25 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.848 -178.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.51 -25.49 41.18 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 122.855 2.37 . . . . 0.0 112.689 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -113.06 -147.12 9.91 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.803 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -135.05 30.22 3.35 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.373 0.606 . . . . 0.0 110.386 -176.009 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.1 m -79.73 54.51 1.83 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.865 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD11 ' A' ' 35' ' ' ILE . 30.2 m -98.82 135.0 21.1 Favored Pre-proline 0 C--N 1.309 -1.176 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.81 -178.344 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.871 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 30.2 Cg_endo -65.1 165.96 20.25 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.779 2.319 . . . . 0.0 111.875 174.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -66.23 -37.9 93.33 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 121.283 -0.484 . . . . 0.0 113.788 -171.142 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -84.03 -18.24 37.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 122.022 0.915 . . . . 0.0 109.44 -174.369 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.871 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 16.3 m-85 -112.13 23.91 13.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.797 -176.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.5 22.47 12.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.048 0.452 . . . . 0.0 110.908 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.407 ' C ' ' HE ' ' A' ' 10' ' ' ARG . 27.9 m-80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.459 -0.782 . . . . 0.0 109.524 -178.385 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.408 HG21 ' HA ' ' A' ' 38' ' ' ALA . 21.5 m . . . . . 0 N--CA 1.478 0.928 0 CA-C-O 121.131 0.491 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.536 ' HB ' HG13 ' A' ' 34' ' ' ILE . 8.9 t -115.62 145.63 42.53 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.425 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 m -136.96 115.67 12.1 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -175.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.432 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 85.1 m -103.58 125.3 35.22 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 121.137 0.494 . . . . 0.0 111.219 -177.664 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.585 ' HA ' ' CB ' ' A' ' 44' ' ' TYR . 18.8 Cg_endo -60.24 -7.12 6.09 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.892 3.061 . . . . 0.0 115.606 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 p -161.55 162.14 30.12 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 118.771 0.714 . . . . 0.0 111.17 -177.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.612 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 60.2 mt -67.63 -34.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.115 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.03 -50.27 55.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.25 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.57 -32.63 74.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.253 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.612 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.41 -29.48 62.62 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.825 0.345 . . . . 0.0 110.533 -178.662 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.465 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.1 m -68.67 -53.04 24.75 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -55.13 -40.11 70.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.099 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -57.0 -62.92 1.41 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.083 175.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 35.5 m-80 -59.41 -39.0 82.02 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 11' ' ' SER . 69.9 t -60.95 -37.46 77.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-O 120.551 0.215 . . . . 0.0 111.363 -178.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 18.2 t -70.28 -42.21 72.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.787 0.327 . . . . 0.0 110.808 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.721 ' HD2' ' HG2' ' A' ' 23' ' ' GLU . 0.0 OUTLIER -91.3 20.62 5.01 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.961 0.41 . . . . 0.0 111.811 -177.597 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.431 ' HB2' ' O ' ' A' ' 15' ' ' VAL . 4.5 mt -73.02 -50.33 6.81 Favored Pre-proline 0 N--CA 1.445 -0.71 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.693 177.225 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.65 25.96 0.63 Allowed 'Trans proline' 0 C--N 1.36 1.152 0 C-N-CA 122.221 1.948 . . . . 0.0 113.208 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.24 37.78 6.99 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.113 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 1.7 m -97.65 141.01 22.34 Favored Pre-proline 0 N--CA 1.43 -1.432 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.211 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.656 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.3 116.34 3.12 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.905 2.403 . . . . 0.0 111.178 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.721 ' HG2' ' HD2' ' A' ' 17' ' ' ARG . 36.8 mt-10 -51.11 -28.8 11.57 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.901 172.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.73 79.6 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.763 173.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.656 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.1 tt -65.36 -42.97 92.22 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.246 0.546 . . . . 0.0 109.927 178.504 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 16' ' ' CYS . 61.0 m -77.34 -0.4 25.47 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.021 -175.238 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.546 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -101.57 -41.02 6.75 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.686 0.755 . . . . 0.0 111.113 175.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.0 m -65.82 -23.91 66.79 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.184 -1.371 . . . . 0.0 111.61 -174.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -100.47 -15.23 17.97 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 122.176 0.989 . . . . 0.0 109.88 -176.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 89.1 m -99.93 -46.81 5.24 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.075 -1.42 . . . . 0.0 111.874 -172.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.12 -20.96 6.23 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 119.944 -1.122 . . . . 0.0 112.287 -178.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.546 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.3 t -73.61 158.54 34.58 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.25 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.0 pt -131.64 143.68 39.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.441 0.639 . . . . 0.0 112.104 -175.098 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.536 HG13 ' HB ' ' A' ' 2' ' ' THR . 4.5 mp -104.25 136.16 38.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 168.191 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 46.7 pt -120.64 142.23 33.81 Favored Pre-proline 0 C--N 1.317 -0.807 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.035 -178.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.1 38.48 0.69 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 123.081 2.521 . . . . 0.0 112.304 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.72 -138.64 2.64 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -178.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.408 ' HA ' HG21 ' A' ' 1' ' ' THR . . . -150.62 13.68 0.74 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.661 0.267 . . . . 0.0 111.244 -178.796 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.9 t -91.74 103.07 15.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 122.159 0.981 . . . . 0.0 111.991 -177.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.463 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 34.1 m -149.92 112.62 3.36 Favored Pre-proline 0 C--N 1.305 -1.351 0 CA-C-N 113.806 -1.543 . . . . 0.0 110.688 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 40' ' ' CYS . 33.7 Cg_endo -63.89 160.59 36.55 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.49 2.126 . . . . 0.0 111.114 172.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.37 32.55 3.85 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.916 -0.659 . . . . 0.0 113.574 -171.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -108.19 -29.8 8.72 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.585 ' CB ' ' HA ' ' A' ' 5' ' ' PRO . 4.5 p90 -128.13 22.11 6.19 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.462 173.75 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.96 37.76 1.14 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.312 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 . . . . . 0 C--O 1.252 1.19 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.234 -179.248 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.449 ' HB ' HD12 ' A' ' 35' ' ' ILE . 17.0 m . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.835 0.35 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.1 t -113.33 119.2 36.87 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.457 0.646 . . . . 0.0 110.138 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 33.6 m -104.91 108.88 20.61 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.747 -176.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.509 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 13.9 t -136.72 99.86 10.23 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.209 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.865 ' HG3' ' HA ' ' A' ' 44' ' ' TYR . 64.0 Cg_endo -85.35 61.24 5.58 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.954 2.436 . . . . 0.0 113.975 -169.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.738 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 1.4 p -167.39 120.96 0.96 Allowed 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.218 -178.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 68.0 mt -48.11 -38.63 8.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.604 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.5 t -77.53 -48.6 23.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.701 -175.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.97 -37.67 88.28 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.27 -178.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.738 ' HG3' ' O ' ' A' ' 6' ' ' SER . 60.5 mtt180 -54.27 -51.69 63.78 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 121.151 0.501 . . . . 0.0 110.284 179.142 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.528 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.9 m -70.63 -42.27 71.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.261 -177.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -62.69 -38.25 89.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 120.81 0.338 . . . . 0.0 110.581 -178.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -51.39 -51.34 55.51 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASN . . . . . 0.423 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 36.6 m-80 -65.11 -37.87 88.85 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.452 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 11' ' ' SER . 90.7 t -61.98 -41.89 92.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.378 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.535 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 26.1 t -71.52 -32.11 67.82 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.398 0.618 . . . . 0.0 110.018 -179.225 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 17' ' ' ARG . 39.5 ttt180 -73.3 -21.86 60.48 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.342 -176.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 19.3 mt -64.61 -52.89 48.68 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -174.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.535 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 16.5 Cg_exo -69.9 0.5 5.65 Favored 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.427 2.085 . . . . 0.0 113.137 -178.39 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.25 26.27 7.87 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.182 -1.008 . . . . 0.0 112.407 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.492 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 1.3 m -89.89 137.88 28.07 Favored Pre-proline 0 N--CA 1.428 -1.55 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 176.113 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 8.3 Cg_endo -55.45 117.49 4.11 Favored 'Trans proline' 0 N--CA 1.444 -1.408 0 C-N-CA 122.869 2.38 . . . . 0.0 111.058 -179.346 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -47.21 -28.76 2.0 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.457 170.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.47 -42.16 98.6 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.885 174.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.489 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 41.3 tp -76.69 -36.17 57.43 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.053 0.454 . . . . 0.0 110.52 178.444 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 17.4 m -78.28 3.03 16.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.976 -179.336 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -101.2 -56.44 2.31 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.852 0.834 . . . . 0.0 110.328 174.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 m -62.77 -25.41 68.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.047 -174.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -94.39 -17.75 22.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 122.087 0.946 . . . . 0.0 109.551 -175.1 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 84.5 m -97.61 -44.62 6.71 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.542 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.25 -7.34 6.33 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.62 -175.251 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 5.3 m -82.39 148.13 28.41 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.8 pt -123.4 143.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.451 -0.5 . . . . 0.0 110.683 176.236 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 78.9 mt -112.95 120.83 63.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.022 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.449 HD12 ' HB ' ' A' ' 1' ' ' THR . 2.1 pp -120.08 139.85 28.99 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.637 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -82.09 22.42 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.234 2.623 . . . . 0.0 113.145 -175.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.48 -139.96 3.74 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.214 178.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.21 62.39 1.53 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.049 0.452 . . . . 0.0 109.943 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 m -152.44 106.05 3.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.275 0.559 . . . . 0.0 111.099 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.0 p -148.46 140.83 14.81 Favored Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.064 171.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.504 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 11.0 Cg_endo -53.81 143.71 58.1 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 123.005 2.47 . . . . 0.0 112.568 -174.305 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.13 -13.07 47.18 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.841 -0.618 . . . . 0.0 113.674 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.85 -17.37 41.11 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.865 ' HA ' ' HG3' ' A' ' 5' ' ' PRO . 16.9 m-85 -121.67 5.94 10.01 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.094 -175.022 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -105.3 38.0 2.06 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -171.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.71 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 10.2 t-20 . . . . . 0 C--O 1.246 0.893 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.07 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.593 ' HB ' HG13 ' A' ' 35' ' ' ILE . 22.7 m . . . . . 0 N--CA 1.477 0.887 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -120.55 147.49 45.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.806 0.336 . . . . 0.0 111.605 -174.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.493 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 2.1 m -151.34 123.29 8.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.886 176.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.575 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 40.0 m -110.2 162.12 21.72 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.044 -175.705 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -91.13 13.95 2.03 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.394 2.062 . . . . 0.0 114.825 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.5 p -167.3 144.02 4.41 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 118.505 0.593 . . . . 0.0 111.115 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.455 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 35.9 mt -60.27 -29.32 43.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.763 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.5 t -72.55 -51.51 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.475 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.564 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -69.77 -30.35 67.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.725 -177.292 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.575 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -69.94 -26.09 63.96 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.149 0.499 . . . . 0.0 110.339 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.435 ' O ' HG23 ' A' ' 15' ' ' VAL . 25.0 m -79.79 -42.25 24.82 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.434 175.324 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -59.88 -30.26 68.87 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.541 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -52.9 -61.38 2.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.664 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.3 m-80 -63.21 -33.1 74.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.267 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 11' ' ' SER . 72.2 t -63.99 -34.84 71.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.079 178.272 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 41.8 t -77.5 -16.72 58.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.436 0.636 . . . . 0.0 110.67 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.487 ' HD2' ' O ' ' A' ' 21' ' ' THR . 7.8 mmm180 -82.66 -19.32 38.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.027 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.606 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 85.2 mt -67.14 -48.84 47.73 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.606 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 22.9 Cg_exo -65.58 -19.01 60.35 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.927 1.752 . . . . 0.0 112.391 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.4 24.44 5.64 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.586 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.556 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -90.56 134.06 31.6 Favored Pre-proline 0 N--CA 1.438 -1.054 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 177.615 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -66.46 129.55 21.61 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 123.065 2.51 . . . . 0.0 111.168 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -46.35 -25.58 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.197 171.674 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.95 -47.65 71.09 Favored 'General case' 0 C--N 1.327 -0.398 0 O-C-N 123.293 0.371 . . . . 0.0 110.629 172.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.8 mt -79.08 -38.46 36.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-O 120.93 0.395 . . . . 0.0 111.0 177.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.556 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 5.0 m -80.28 10.41 4.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.285 -176.15 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.73 -43.98 5.43 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.96 0.886 . . . . 0.0 109.731 170.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.2 m -69.76 -24.89 63.59 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 113.96 -1.473 . . . . 0.0 111.517 -177.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -91.36 -31.12 16.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.72 0.772 . . . . 0.0 109.759 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.564 HG22 ' HB1' ' A' ' 9' ' ' ALA . 0.3 OUTLIER -99.12 -14.78 19.23 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.555 -1.202 . . . . 0.0 112.596 -171.469 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.93 16.48 63.19 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.462 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 19.7 t -94.25 159.43 15.13 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.25 148.97 33.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.125 0.488 . . . . 0.0 111.871 -176.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.403 ' N ' HD12 ' A' ' 34' ' ' ILE . 4.4 mp -96.42 135.32 30.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.898 176.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.593 HG13 ' HB ' ' A' ' 1' ' ' THR . 5.5 pt -129.64 164.25 41.27 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.716 -179.627 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.41 -57.24 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.995 2.463 . . . . 0.0 111.252 169.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 171.47 137.69 2.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 116.098 -0.501 . . . . 0.0 112.028 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 64.43 18.08 11.15 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.256 0.622 . . . . 0.0 111.373 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -98.18 27.93 4.34 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.685 0.755 . . . . 0.0 110.904 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.532 ' SG ' HD13 ' A' ' 35' ' ' ILE . 16.9 m -112.86 107.28 54.69 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.466 -175.774 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.465 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 43.6 Cg_endo -71.3 174.27 11.05 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.59 2.193 . . . . 0.0 111.142 173.015 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.97 -34.74 66.22 Favored Glycine 0 CA--C 1.521 0.408 0 N-CA-C 114.754 0.662 . . . . 0.0 114.754 -172.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -83.98 -22.84 31.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.849 0.825 . . . . 0.0 109.772 -172.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.493 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 16.2 m-85 -108.75 20.09 18.91 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.314 -175.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.83 27.11 6.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.847 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.484 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 37.8 m-80 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.116 -177.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.497 HG21 ' O ' ' A' ' 37' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 121.004 0.43 . . . . 0.0 110.226 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.491 ' HB ' ' CZ ' ' A' ' 13' ' ' PHE . 86.3 m -137.97 140.38 40.18 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.928 -176.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -114.98 111.14 20.69 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.053 -178.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.6 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 100.0 m -102.0 111.84 64.67 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.202 174.182 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.698 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 91.1 Cg_endo -86.98 35.89 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.851 2.367 . . . . 0.0 112.923 -177.557 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.1 m -155.43 131.28 9.95 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 61.2 mt -56.18 -36.8 46.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 123.537 0.523 . . . . 0.0 111.143 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.9 t -83.28 -31.12 8.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.223 0.535 . . . . 0.0 110.382 -174.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.52 -37.21 71.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.394 178.46 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.6 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -83.78 -22.86 31.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.15 -175.468 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 61.3 p -74.24 -30.1 62.0 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.318 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -92.88 -26.48 17.61 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.876 177.054 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.491 ' CZ ' ' HB ' ' A' ' 2' ' ' THR . 27.4 t80 -55.05 -52.4 63.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.551 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -61.71 -29.08 69.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.65 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.646 ' HA ' HD23 ' A' ' 18' ' ' LEU . 57.3 t -75.73 -24.28 16.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.711 176.744 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.818 ' O ' ' HB ' ' A' ' 21' ' ' THR . 48.6 t -88.37 0.38 56.26 Favored 'General case' 0 C--O 1.214 -0.782 0 CA-C-O 121.684 0.754 . . . . 0.0 109.623 -178.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -109.32 -21.95 12.29 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -175.123 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.752 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 3.4 pp -74.5 -36.54 2.58 Favored Pre-proline 0 N--CA 1.436 -1.16 0 N-CA-C 113.785 1.031 . . . . 0.0 113.785 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.752 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 5.8 Cg_exo -78.62 7.24 4.31 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 121.835 1.69 . . . . 0.0 112.604 -175.799 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.97 33.05 8.47 Favored Glycine 0 N--CA 1.444 -0.81 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.042 -178.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.818 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 1.1 m -106.11 134.14 19.9 Favored Pre-proline 0 N--CA 1.434 -1.253 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.065 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.776 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.9 Cg_endo -56.29 117.22 3.84 Favored 'Trans proline' 0 N--CA 1.446 -1.285 0 C-N-CA 123.167 2.578 . . . . 0.0 112.183 -179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -46.34 -31.52 2.63 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.839 168.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.09 -49.99 75.77 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.17 174.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.776 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tt -65.28 -44.31 88.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 18.8 m -76.17 -0.07 20.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.765 -177.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.535 ' HA ' ' HB2' ' A' ' 32' ' ' CYS . . . -94.68 -56.8 2.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.934 0.873 . . . . 0.0 109.885 168.423 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.1 m -58.28 -33.17 69.12 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 113.531 -1.668 . . . . 0.0 113.302 -173.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -96.43 -19.58 19.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 122.073 0.94 . . . . 0.0 110.324 -171.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 m -92.46 -25.1 18.59 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.518 -172.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.28 10.71 27.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.958 -177.398 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.535 ' HB2' ' HA ' ' A' ' 27' ' ' ALA . 44.1 m -95.11 167.69 11.22 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 176.171 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.2 pt -123.82 131.57 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.233 0.54 . . . . 0.0 111.334 176.041 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 16.2 tt -94.55 138.5 20.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.227 178.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.712 HD13 ' HB2' ' A' ' 40' ' ' CYS . 14.1 pt -119.58 160.85 40.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.348 -174.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -92.2 24.18 0.52 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.125 2.55 . . . . 0.0 113.176 178.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.497 ' O ' HG21 ' A' ' 1' ' ' THR . . . 177.01 -135.98 3.0 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.514 -0.851 . . . . 0.0 112.26 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.41 13.69 17.75 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 120.635 0.255 . . . . 0.0 111.534 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -77.64 88.25 3.93 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.296 0.569 . . . . 0.0 110.509 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.712 ' HB2' HD13 ' A' ' 35' ' ' ILE . 23.4 t -155.43 125.01 3.15 Favored Pre-proline 0 C--N 1.31 -1.135 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.321 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.31 167.98 25.92 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 123.003 2.469 . . . . 0.0 112.056 177.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.21 5.19 51.62 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 116.033 -0.531 . . . . 0.0 112.941 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -88.6 -20.85 24.45 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.698 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 14.7 m-85 -108.9 7.89 26.24 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.971 -178.094 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -116.53 52.32 0.94 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.736 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.8 t30 . . . . . 0 C--O 1.251 1.157 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.758 -176.574 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.555 HG21 ' HA2' ' A' ' 37' ' ' GLY . 12.2 m . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.787 HG22 ' SG ' ' A' ' 32' ' ' CYS . 3.9 m -139.5 134.03 31.69 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.019 -174.316 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.6 m -129.26 129.23 44.67 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.2 m -111.2 127.44 26.89 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.254 -171.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.805 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 75.8 Cg_endo -92.35 43.94 0.36 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.108 2.539 . . . . 0.0 114.113 -176.271 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.674 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 6.8 p -173.02 135.17 0.59 Allowed 'General case' 0 CA--C 1.517 -0.301 0 O-C-N 122.11 -0.369 . . . . 0.0 110.187 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.606 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 49.0 mt -56.29 -31.01 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.216 0.531 . . . . 0.0 111.003 -171.329 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.86 -53.09 28.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.956 177.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -62.06 -40.14 94.75 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.708 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.674 ' HG3' ' O ' ' A' ' 6' ' ' SER . 4.5 mtp-105 -59.01 -37.54 77.12 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.53 178.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.7 t -76.05 -35.72 59.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.565 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.9 m-20 -57.72 -42.87 84.7 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.994 174.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 2' ' ' THR . 40.6 t80 -47.56 -46.01 27.59 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.202 -179.019 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -61.76 -48.61 79.9 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.33 0.586 . . . . 0.0 110.116 177.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -72.8 -12.55 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.026 -176.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.71 ' O ' ' HB ' ' A' ' 21' ' ' THR . 69.3 m -100.63 14.83 30.15 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.547 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.56 ' HD2' ' CE1' ' A' ' 13' ' ' PHE . 36.1 mtp180 -134.27 -39.87 0.83 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.325 0.583 . . . . 0.0 110.011 176.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 tp -49.62 -54.79 27.58 Favored Pre-proline 0 CA--C 1.553 1.086 0 CA-C-N 114.709 -1.132 . . . . 0.0 113.427 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -88.5 39.29 0.49 Allowed 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 122.075 1.85 . . . . 0.0 113.794 -174.368 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.57 50.29 26.43 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.302 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.71 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.82 138.25 31.03 Favored Pre-proline 0 N--CA 1.435 -1.186 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.665 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.538 ' HG2' ' CB ' ' A' ' 25' ' ' LEU . 38.0 Cg_endo -70.1 126.47 13.12 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 122.763 2.309 . . . . 0.0 111.544 174.366 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.444 ' HB3' ' HE ' ' A' ' 17' ' ' ARG . 11.2 pt-20 -50.75 -32.27 19.2 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.064 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.554 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -64.7 -39.26 93.35 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.255 -178.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.538 ' CB ' ' HG2' ' A' ' 22' ' ' PRO . 34.1 tp -69.63 -46.79 65.4 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.683 0.278 . . . . 0.0 110.831 -177.273 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.514 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 17.1 t -67.98 -29.41 68.43 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.258 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.574 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -56.9 -46.89 81.61 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.643 0.735 . . . . 0.0 110.906 177.603 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 47.2 m -67.07 -28.43 68.19 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.924 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -102.7 -35.11 8.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.311 0.577 . . . . 0.0 111.435 -171.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.476 ' HB ' ' O ' ' A' ' 26' ' ' CYS . 4.6 m -87.01 -19.79 28.17 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.144 -175.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.94 25.86 8.23 Favored Glycine 0 C--N 1.331 0.292 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.355 177.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.787 ' SG ' HG22 ' A' ' 2' ' ' THR . 5.8 t -102.6 161.74 13.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.6 pt -112.25 140.92 29.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 C-N-CA 119.928 -0.709 . . . . 0.0 112.644 -174.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 24' ' ' ALA . 25.3 mm -98.91 132.7 43.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.274 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 44.5 pt -141.88 159.5 59.22 Favored Pre-proline 0 C--N 1.32 -0.682 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 53.8 Cg_endo -71.06 -16.02 32.19 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.71 2.273 . . . . 0.0 111.801 175.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.555 ' HA2' HG21 ' A' ' 1' ' ' THR . . . 111.59 130.21 5.54 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.811 176.044 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.55 -87.46 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.333 -0.434 . . . . 0.0 110.008 176.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.5 m -140.91 -15.17 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.944 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HA ' ' HD3' ' A' ' 41' ' ' PRO . 91.4 m 64.91 139.5 0.05 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.521 -171.421 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.799 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 17.4 Cg_exo -65.09 156.95 59.94 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.934 2.423 . . . . 0.0 112.503 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -27.65 63.8 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.264 -174.224 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.7 -31.65 13.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.678 0.752 . . . . 0.0 110.075 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.805 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 20.1 m-85 -91.75 -7.99 48.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.968 -174.125 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.478 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . . . -105.97 30.35 5.93 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.608 174.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 5.7 t30 . . . . . 0 C--O 1.247 0.929 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.996 -177.341 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.597 ' HB ' HG13 ' A' ' 35' ' ' ILE . 92.3 m . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 120.831 0.348 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.2 t -101.53 108.12 19.6 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-O 121.914 0.864 . . . . 0.0 110.656 -179.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' HG13 ' A' ' 33' ' ' ILE . 15.9 t -103.65 81.82 1.94 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.438 -173.38 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.429 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 60.2 m -105.54 134.35 19.74 Favored Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.436 178.61 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 61.2 Cg_endo -94.91 30.83 0.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.545 2.163 . . . . 0.0 115.245 -172.587 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.6 p -179.04 139.55 0.15 Allowed 'General case' 0 C--O 1.235 0.327 0 CA-C-N 118.846 0.748 . . . . 0.0 111.395 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.496 HG13 ' OD1' ' A' ' 46' ' ' ASN . 75.1 mt -58.37 -30.38 40.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.068 170.389 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 67.0 t -54.39 -58.66 3.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.52 175.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.04 -43.15 96.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.041 0.448 . . . . 0.0 110.666 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.476 ' HD3' ' HA ' ' A' ' 10' ' ' ARG . 21.4 tpp180 -55.06 -38.57 68.19 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.211 178.286 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 31.7 m -78.62 -10.44 59.74 Favored 'General case' 0 N--CA 1.466 0.375 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -94.55 -17.09 22.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.414 0.626 . . . . 0.0 109.778 175.341 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -69.22 -37.15 77.88 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.855 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -63.94 -26.05 68.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.955 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.9 t -64.81 -48.92 82.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.549 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.844 ' HB3' ' HB ' ' A' ' 21' ' ' THR . 55.8 m -67.2 -24.76 65.88 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -176.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.503 ' HD3' ' HG2' ' A' ' 23' ' ' GLU . 22.3 mmm180 -79.15 -8.76 59.25 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.976 -0.452 . . . . 0.0 111.703 -178.204 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.603 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 72.7 mt -78.02 -56.95 1.0 Allowed Pre-proline 0 N--CA 1.436 -1.148 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.281 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.603 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 81.2 Cg_endo -85.52 -4.99 9.23 Favored 'Trans proline' 0 C--N 1.359 1.131 0 C-N-CA 122.117 1.878 . . . . 0.0 113.451 -176.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.29 28.37 7.66 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.088 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.844 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 1.4 m -74.07 133.79 78.23 Favored Pre-proline 0 N--CA 1.441 -0.887 0 CA-C-O 121.208 0.528 . . . . 0.0 110.016 176.341 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.883 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.1 Cg_endo -62.61 120.82 8.51 Favored 'Trans proline' 0 N--CA 1.444 -1.415 0 C-N-CA 122.941 2.427 . . . . 0.0 111.008 177.696 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.503 ' HG2' ' HD3' ' A' ' 17' ' ' ARG . 24.2 mt-10 -45.49 -33.99 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.613 172.271 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.83 -47.78 84.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.405 176.241 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.883 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -65.06 -41.03 95.48 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -179.923 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 29.9 m -87.91 23.95 1.91 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.443 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.33 -46.25 3.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 122.171 0.986 . . . . 0.0 109.245 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -65.89 -29.24 69.64 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.259 -1.791 . . . . 0.0 112.388 -175.378 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 t80 -99.73 -21.51 15.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.872 0.844 . . . . 0.0 110.123 -173.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.22 -6.62 37.68 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.949 -172.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.32 36.0 28.27 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.465 178.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.3 t -127.61 153.01 46.93 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.596 HG13 ' HB3' ' A' ' 3' ' ' CYS . 25.2 pt -122.66 148.89 26.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.326 0.584 . . . . 0.0 112.033 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.2 mt -106.4 116.85 51.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.552 177.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.597 HG13 ' HB ' ' A' ' 1' ' ' THR . 25.3 pt -121.97 131.34 24.44 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.898 -178.589 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.86 -12.14 23.96 Favored 'Trans proline' 0 CA--C 1.529 0.259 0 C-N-CA 122.903 2.402 . . . . 0.0 112.282 177.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.92 -141.24 9.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.133 177.569 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.66 12.95 1.17 Allowed 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 -176.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.5 m -86.02 97.55 10.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.377 0.608 . . . . 0.0 110.818 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 39.6 t -158.38 107.39 1.68 Allowed Pre-proline 0 C--N 1.311 -1.103 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.536 -178.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 15.1 Cg_endo -59.55 161.92 16.38 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.851 2.368 . . . . 0.0 112.851 -177.625 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -69.97 1.14 18.4 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.723 -0.671 . . . . 0.0 113.594 -174.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.03 -15.49 18.23 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.518 ' CD2' ' HG2' ' A' ' 41' ' ' PRO . 19.3 m-85 -115.44 8.05 15.16 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.029 179.307 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.05 39.56 1.77 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.347 0.594 . . . . 0.0 109.573 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.496 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.4 t-20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.03 -175.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 120.77 0.319 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 28.5 m -132.65 121.22 22.83 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 174.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.597 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.5 m -124.53 117.19 23.8 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.254 0.55 . . . . 0.0 111.244 -173.006 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 20.8 m -108.55 166.74 10.31 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.704 -177.392 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -91.33 6.02 3.76 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 122.104 1.87 . . . . 0.0 113.351 169.261 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.1 m -155.62 141.5 18.12 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 121.914 -0.491 . . . . 0.0 110.993 -172.322 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.4 mm -61.38 -32.19 52.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 121.187 0.518 . . . . 0.0 109.74 174.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.4 t -62.78 -43.27 98.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.889 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.576 ' HA ' ' ND2' ' A' ' 12' ' ' ASN . . . -69.4 -39.84 77.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.671 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 19.6 ttm180 -64.73 -27.93 69.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.658 176.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -79.03 -48.18 14.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.368 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.576 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.1 p30 -73.78 -15.99 61.18 Favored 'General case' 0 N--CA 1.464 0.271 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.168 -178.159 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 23.9 t80 -48.81 -44.36 39.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 122.02 0.914 . . . . 0.0 109.286 165.342 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -76.37 -39.4 53.92 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.345 -1.298 . . . . 0.0 109.941 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.524 ' CG2' ' HA ' ' A' ' 12' ' ' ASN . 92.0 t -57.92 -46.51 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.748 -176.739 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 68.2 m -61.07 -38.05 84.87 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.647 ' HD2' ' HB3' ' A' ' 23' ' ' GLU . 45.9 mtp180 -79.27 -5.62 54.81 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.574 -172.717 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.633 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 31.9 mt -75.94 -53.6 2.32 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 6.1 Cg_exo -76.18 -24.34 11.11 Favored 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.178 1.919 . . . . 0.0 112.517 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.53 13.49 2.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.051 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 2.4 m -80.96 124.27 81.51 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.667 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.802 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.5 Cg_endo -59.94 123.54 13.44 Favored 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.236 1.958 . . . . 0.0 110.765 177.371 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB3' ' HD2' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -51.26 -27.94 10.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.738 169.866 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.79 -46.42 89.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.92 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.802 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.7 tt -66.63 -51.61 54.33 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 120.664 0.269 . . . . 0.0 110.426 178.321 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 26.6 m -66.82 -25.43 66.44 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.28 72.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.984 0.897 . . . . 0.0 110.435 174.229 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.4 m -81.85 -22.11 37.16 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.358 -174.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 19.9 t80 -106.18 -39.5 5.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.348 0.594 . . . . 0.0 110.707 -174.314 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.0 m -72.2 -31.93 66.33 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.498 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.3 18.59 38.55 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.24 -0.981 . . . . 0.0 112.287 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.6 t -105.5 139.59 39.89 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.416 HD12 HD11 ' A' ' 35' ' ' ILE . 22.6 pt -104.79 139.98 24.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.286 0.565 . . . . 0.0 111.794 -172.353 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 80.3 mt -100.6 124.92 54.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.917 176.178 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.827 HG21 ' HB ' ' A' ' 39' ' ' THR . 96.7 mt -129.18 137.4 30.91 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.372 -175.509 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -47.25 -48.51 14.82 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.697 2.265 . . . . 0.0 112.384 176.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.77 137.71 2.3 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.6 177.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.01 65.29 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 123.45 0.7 . . . . 0.0 112.401 175.091 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.827 ' HB ' HG21 ' A' ' 35' ' ' ILE . 8.9 m -151.03 26.21 0.72 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 122.224 1.012 . . . . 0.0 110.091 175.115 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD12 ' A' ' 35' ' ' ILE . 62.9 m -108.64 116.42 56.13 Favored Pre-proline 0 C--N 1.314 -0.965 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.342 -172.294 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 40.3 Cg_endo -69.38 162.35 42.23 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.391 2.061 . . . . 0.0 111.963 175.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.61 -28.4 67.74 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 114.947 0.739 . . . . 0.0 114.947 -172.559 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -87.78 -20.05 26.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.734 0.778 . . . . 0.0 109.778 -174.804 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.597 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.5 m-85 -114.16 25.31 11.22 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.185 -176.09 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.33 23.7 13.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.812 177.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 65.9 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-O 118.096 -0.954 . . . . 0.0 109.681 -177.602 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.954 ' HB ' HG23 ' A' ' 35' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.473 0.711 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.91 110.59 16.49 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -171.588 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.576 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 46.5 m -150.38 156.25 41.14 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.102 0.477 . . . . 0.0 111.768 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 10.1 t -144.82 143.01 19.59 Favored Pre-proline 0 N--CA 1.453 -0.301 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 47.6 Cg_exo -58.82 -27.91 85.41 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.138 2.558 . . . . 0.0 114.205 -177.238 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.0 m -142.01 141.93 32.89 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 -176.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.697 HG13 ' OD1' ' A' ' 46' ' ' ASN . 87.8 mt -53.39 -40.35 39.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.956 175.481 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -67.49 -34.3 67.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.099 0.476 . . . . 0.0 110.49 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -74.53 -36.23 63.16 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.245 0.545 . . . . 0.0 109.775 177.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -63.97 -42.13 97.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.4 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.7 p -67.73 -37.65 82.48 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.032 178.411 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -66.86 -34.38 77.67 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.277 0.561 . . . . 0.0 110.734 179.144 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.616 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 50.6 t80 -58.85 -53.24 60.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.117 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -55.39 -30.85 61.18 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.398 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 90.0 t -63.57 -34.18 66.05 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.476 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.52 -23.36 42.97 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.946 -0.471 . . . . 0.0 111.176 -175.386 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -74.61 -18.27 60.58 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 177.155 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 95.3 mt -63.77 -53.21 52.09 Favored Pre-proline 0 N--CA 1.442 -0.839 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -177.206 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.49 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 61.2 Cg_endo -73.25 2.99 5.01 Favored 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.054 1.836 . . . . 0.0 113.181 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.32 36.76 7.96 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.485 178.28 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.565 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -97.6 141.05 22.41 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 176.621 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.566 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -61.07 117.74 4.55 Favored 'Trans proline' 0 N--CA 1.446 -1.309 0 C-N-CA 122.962 2.441 . . . . 0.0 110.944 178.571 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.616 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 9.7 pt-20 -51.81 -29.75 20.46 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.854 175.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.18 -41.74 97.34 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.554 174.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.566 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 50.7 tp -77.52 -39.44 46.15 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-O 120.737 0.303 . . . . 0.0 110.427 179.591 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.509 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 26.6 m -64.69 -39.74 94.18 Favored 'General case' 0 C--O 1.22 -0.455 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.041 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.98 -23.59 67.26 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.57 0.7 . . . . 0.0 111.58 -178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.5 m -75.59 -22.35 57.0 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.673 -1.149 . . . . 0.0 110.316 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -104.03 -43.46 5.27 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.862 0.839 . . . . 0.0 110.13 -178.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.405 HG21 ' HB2' ' A' ' 13' ' ' PHE . 93.9 m -64.89 -55.37 19.74 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.24 -1.346 . . . . 0.0 111.849 -178.225 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 131.1 -24.92 4.18 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.547 -178.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.556 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 38.2 m -64.34 158.85 22.44 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.3 pt -130.16 139.55 51.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.427 -0.509 . . . . 0.0 112.293 -175.305 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.0 mp -85.68 125.7 40.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.954 HG23 ' HB ' ' A' ' 1' ' ' THR . 9.2 tt -129.65 110.35 17.44 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.46 0.648 . . . . 0.0 110.784 -171.057 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 34.9 Cg_exo -62.24 -32.38 82.3 Favored 'Trans proline' 0 N--CA 1.477 0.544 0 C-N-CA 123.785 2.99 . . . . 0.0 114.331 -174.248 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -153.41 -163.4 11.75 Favored Glycine 0 N--CA 1.44 -1.071 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.434 -177.229 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.56 25.97 12.22 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 123.06 0.544 . . . . 0.0 111.634 -178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 49.3 m 42.28 -99.48 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.0 -176.072 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 79.8 m -158.51 137.86 8.33 Favored Pre-proline 0 C--N 1.314 -0.949 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.32 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.591 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 52.5 Cg_endo -72.55 148.23 47.43 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.865 1.71 . . . . 0.0 110.796 169.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.04 10.39 14.97 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 121.364 -0.446 . . . . 0.0 113.529 -173.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -112.67 -16.28 12.83 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.628 0.728 . . . . 0.0 109.252 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.591 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 21.4 m-85 -119.93 18.67 12.48 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.352 -178.041 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -113.19 45.85 1.32 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.672 177.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.697 ' OD1' HG13 ' A' ' 7' ' ' ILE . 15.6 t-20 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.211 -0.899 . . . . 0.0 110.481 -175.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.535 ' HB ' HG13 ' A' ' 35' ' ' ILE . 86.1 m . . . . . 0 N--CA 1.475 0.794 0 CA-C-O 121.061 0.457 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -123.37 142.42 50.98 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.023 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 44' ' ' TYR . 22.1 p -152.48 147.96 26.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.912 0.387 . . . . 0.0 110.682 175.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.633 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 15.2 t -141.36 144.03 32.54 Favored Pre-proline 0 C--N 1.328 -0.331 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.746 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 3.6 Cg_exo -39.25 -51.86 2.5 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 124.474 3.45 . . . . 0.0 114.694 -177.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.488 ' HA ' ' HB3' ' A' ' 46' ' ' ASN . 3.8 p -147.74 160.6 42.53 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 122.29 -0.256 . . . . 0.0 111.394 -176.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.495 HG13 ' OD1' ' A' ' 46' ' ' ASN . 80.2 mt -53.82 -39.59 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.429 178.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 84.5 t -59.87 -52.92 55.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.652 0.263 . . . . 0.0 110.611 178.248 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.27 -35.46 80.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.746 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.553 ' HA ' ' HD2' ' A' ' 13' ' ' PHE . 1.0 OUTLIER -67.27 -41.01 86.23 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-O 121.231 0.539 . . . . 0.0 110.103 178.194 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.524 ' O ' HG23 ' A' ' 15' ' ' VAL . 29.7 t -57.87 -42.55 84.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.867 174.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -56.14 -46.03 79.37 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.313 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.556 ' HB3' HG21 ' A' ' 30' ' ' THR . 0.8 OUTLIER -72.54 -35.19 67.99 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.856 -175.699 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -59.85 -43.15 94.8 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.921 0.391 . . . . 0.0 110.019 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 11' ' ' SER . 63.3 t -67.26 -21.37 27.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.046 177.802 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.424 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 14.0 t -80.99 -25.4 37.29 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 120.929 0.395 . . . . 0.0 110.749 -176.47 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -72.0 -41.51 67.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.052 0.453 . . . . 0.0 110.741 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.955 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -56.55 -40.5 85.42 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -171.093 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.955 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 59.6 Cg_endo -74.1 0.6 8.21 Favored 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 121.522 1.481 . . . . 0.0 113.377 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.29 34.08 4.63 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.476 178.181 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.532 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -104.36 135.82 19.27 Favored Pre-proline 0 N--CA 1.436 -1.143 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.677 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.654 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.0 Cg_endo -63.74 127.71 20.33 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 122.848 2.366 . . . . 0.0 111.053 176.345 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.536 ' H ' ' CD ' ' A' ' 23' ' ' GLU . 1.5 mp0 -37.56 -40.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.346 172.312 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.43 -50.07 72.72 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.162 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.654 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -63.98 -36.42 83.91 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.107 0.479 . . . . 0.0 110.088 177.812 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 21.5 m -79.02 10.83 3.11 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.249 -179.525 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.25 -38.85 5.86 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.847 0.832 . . . . 0.0 110.359 171.119 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -69.59 -29.56 67.12 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.975 -1.466 . . . . 0.0 112.324 -173.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -103.77 -31.74 9.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.732 0.777 . . . . 0.0 109.913 -175.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.556 HG21 ' HB3' ' A' ' 13' ' ' PHE . 15.6 m -78.51 -33.1 48.3 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 114.426 -1.261 . . . . 0.0 111.684 -175.359 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.85 0.55 36.39 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.913 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.1 m -85.69 155.02 21.26 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.412 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.6 pt -120.43 144.98 27.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.398 0.618 . . . . 0.0 111.965 -176.576 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 79.5 mt -107.87 127.44 63.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.178 175.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HB2' ' A' ' 40' ' ' CYS . 24.3 pt -132.32 134.11 24.55 Favored Pre-proline 0 C--N 1.319 -0.76 0 CA-C-O 120.936 0.398 . . . . 0.0 111.476 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 -9.81 15.7 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.625 2.217 . . . . 0.0 111.176 173.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.01 -142.34 7.76 Favored Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.62 15.34 7.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 120.732 0.301 . . . . 0.0 111.181 -177.29 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.5 m -80.29 86.32 5.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.51 0.672 . . . . 0.0 110.751 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.545 ' HB2' HD13 ' A' ' 35' ' ' ILE . 42.1 t -158.29 116.26 1.78 Allowed Pre-proline 0 C--N 1.311 -1.108 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.672 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.96 166.65 28.94 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.415 2.076 . . . . 0.0 112.692 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.46 10.9 14.9 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.084 -177.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -98.43 -18.84 18.04 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.746 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 17.4 m-85 -120.0 18.4 12.44 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.827 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -115.09 47.25 1.31 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.212 -175.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.495 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.3 t-20 . . . . . 0 C--O 1.246 0.885 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.389 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.497 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 88.7 m . . . . . 0 N--CA 1.473 0.685 0 CA-C-O 121.131 0.491 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.46 HG23 HG12 ' A' ' 34' ' ' ILE . 40.2 m -128.92 112.01 13.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.729 -176.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' CYS . 73.2 m -75.5 90.82 2.75 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 176.124 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.506 ' SG ' HG21 ' A' ' 30' ' ' THR . 1.4 t -125.35 87.8 55.11 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -177.197 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.63 78.73 2.99 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 123.418 2.745 . . . . 0.0 114.025 -167.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.742 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 29.2 t 172.21 132.87 0.03 OUTLIER 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 171.248 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.667 ' H ' HD12 ' A' ' 7' ' ' ILE . 3.7 mp -62.93 -31.57 52.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.051 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.2 t -80.08 -47.26 21.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.173 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.742 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -60.75 -48.4 81.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.68 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 1.8 ptp180 -62.75 -25.09 68.03 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.621 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.471 ' O ' HG23 ' A' ' 15' ' ' VAL . 67.6 m -69.09 -56.49 7.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.029 178.195 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.474 ' HA ' ' HB ' ' A' ' 15' ' ' VAL . 11.2 p30 -64.32 -22.38 66.93 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.634 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.42 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 61.8 t80 -59.12 -59.69 5.05 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.653 170.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 17' ' ' ARG . 2.3 p-10 -71.73 -27.1 62.77 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.877 0.37 . . . . 0.0 110.903 -178.496 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.474 ' HB ' ' HA ' ' A' ' 12' ' ' ASN . 78.1 t -70.31 -17.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.006 0.431 . . . . 0.0 110.263 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.676 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 3.8 t -84.66 -29.03 26.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.417 0.627 . . . . 0.0 109.707 177.636 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.451 ' HB3' ' O ' ' A' ' 14' ' ' ASN . 6.9 tpt180 -58.42 -40.72 83.23 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.383 175.188 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.566 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 86.1 mt -61.08 -50.29 85.09 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 113.775 1.028 . . . . 0.0 113.775 -172.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.676 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 7.9 Cg_exo -73.39 13.56 0.69 Allowed 'Trans proline' 0 C--N 1.358 1.079 0 C-N-CA 122.581 2.187 . . . . 0.0 113.507 -177.712 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.23 36.85 9.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.897 176.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -108.79 134.9 20.17 Favored Pre-proline 0 N--CA 1.434 -1.27 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 176.887 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.752 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -60.18 122.51 11.48 Favored 'Trans proline' 0 N--CA 1.446 -1.29 0 C-N-CA 122.951 2.434 . . . . 0.0 111.121 178.803 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -35.84 -39.56 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.398 169.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.56 -53.39 58.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.192 176.314 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.752 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tm? -63.71 -37.2 86.46 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-O 121.004 0.431 . . . . 0.0 110.782 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 23.9 m -65.04 -37.43 87.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.358 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.52 -32.4 74.02 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.804 0.811 . . . . 0.0 110.462 176.253 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.8 m -74.89 -22.5 58.6 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 114.47 -1.241 . . . . 0.0 110.761 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -89.45 -45.58 9.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.864 0.84 . . . . 0.0 109.024 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.506 HG21 ' SG ' ' A' ' 4' ' ' CYS . 85.0 m -70.89 -37.79 73.01 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.002 -1.454 . . . . 0.0 111.061 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.04 16.89 17.65 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.904 -0.665 . . . . 0.0 113.017 179.11 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.592 ' HB2' ' O ' ' A' ' 3' ' ' CYS . 10.7 p -114.24 179.53 3.93 Favored 'General case' 0 C--N 1.327 -0.395 0 O-C-N 122.725 -0.279 . . . . 0.0 110.721 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.46 ' H ' HD13 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -127.77 141.88 45.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 111.563 -173.948 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.46 HG12 HG23 ' A' ' 2' ' ' THR . 60.3 mt -99.44 140.17 19.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.777 176.477 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' HB3' ' A' ' 38' ' ' ALA . 11.2 pt -137.91 129.14 15.94 Favored Pre-proline 0 N--CA 1.448 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 111.388 -177.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 32.6 Cg_exo -61.62 -27.77 81.94 Favored 'Trans proline' 0 CA--C 1.53 0.307 0 C-N-CA 123.029 2.486 . . . . 0.0 112.639 176.608 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.457 ' C ' ' H ' ' A' ' 39' ' ' THR . . . -132.94 -153.46 7.22 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.927 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.845 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 71.69 -29.04 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.904 0.881 . . . . 0.0 111.898 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' C ' ' A' ' 37' ' ' GLY . 52.2 m 65.81 5.45 3.41 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.331 0.652 . . . . 0.0 112.512 176.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 66.9 m 65.59 137.46 0.05 OUTLIER Pre-proline 0 N--CA 1.468 0.465 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.141 -175.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -74.62 175.85 10.54 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.418 2.079 . . . . 0.0 111.698 175.054 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -73.94 -0.82 57.49 Favored Glycine 0 CA--C 1.518 0.235 0 C-N-CA 121.363 -0.446 . . . . 0.0 113.12 -175.227 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -98.07 -22.25 16.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.193 0.52 . . . . 0.0 109.612 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.541 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 16.0 m-85 -121.44 19.95 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.679 -173.642 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.11 14.8 29.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.393 0.616 . . . . 0.0 110.77 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 18.3 m120 . . . . . 0 C--O 1.247 0.971 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.681 179.404 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.421 ' HB ' HG13 ' A' ' 35' ' ' ILE . 13.0 m . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 121.016 0.436 . . . . 0.0 109.933 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.7 t -98.99 122.65 42.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.518 0.675 . . . . 0.0 110.526 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 61.9 m -121.43 122.49 39.89 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.08 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.9 t -147.52 141.0 15.3 Favored Pre-proline 0 N--CA 1.448 -0.561 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -103.0 40.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.05 2.5 . . . . 0.0 113.957 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.9 t -158.26 135.52 10.09 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.622 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.8 mt -69.34 -28.0 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.356 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.7 t -83.5 -25.29 7.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.875 -175.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.36 -50.23 8.01 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.055 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.508 ' NH2' ' H ' ' A' ' 4' ' ' CYS . 7.3 tpp180 -53.5 -39.83 64.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.358 177.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.4 p -62.41 -61.71 2.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.644 0.259 . . . . 0.0 111.222 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -64.52 -24.07 67.48 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.469 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.429 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 56.7 t80 -59.17 -58.14 9.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.064 173.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -70.2 -30.56 67.7 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.898 -179.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 11' ' ' SER . 72.0 t -65.2 -30.16 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.351 . . . . 0.0 110.707 176.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -71.74 -27.16 62.8 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.297 0.57 . . . . 0.0 110.574 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.596 ' HA ' ' O ' ' A' ' 21' ' ' THR . 46.5 tpt85 -76.49 -17.71 59.14 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.205 -178.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.417 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 77.9 mt -68.57 -52.29 19.94 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -175.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.417 ' HD2' ' N ' ' A' ' 18' ' ' LEU . 56.4 Cg_endo -69.72 -6.28 18.19 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.262 1.975 . . . . 0.0 113.271 -177.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.92 25.87 4.94 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.2 OUTLIER -103.19 128.65 27.15 Favored Pre-proline 0 N--CA 1.439 -0.99 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.457 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.772 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 12.7 Cg_endo -58.43 121.99 10.9 Favored 'Trans proline' 0 N--CA 1.449 -1.146 0 C-N-CA 122.577 2.184 . . . . 0.0 110.752 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.57 ' H ' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -50.67 -29.19 10.5 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.937 173.459 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.16 -46.95 87.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.976 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.772 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -67.5 -46.69 72.16 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 120.971 0.415 . . . . 0.0 109.992 177.841 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 6.9 m -62.66 -35.54 79.97 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.828 -177.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.541 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -58.41 -40.45 82.46 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 111.266 178.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.6 m -66.28 -22.75 66.31 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.528 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -86.11 -47.03 9.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.124 176.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.464 ' HB ' ' SG ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -69.39 -36.99 77.31 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 -177.28 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.67 -22.24 36.28 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.141 -172.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 3.2 m -60.94 116.31 4.38 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.2 pt -91.68 150.5 3.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.925 0.393 . . . . 0.0 111.866 -172.043 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 69.4 mt -116.14 107.93 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.37 0.605 . . . . 0.0 109.617 174.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.726 HD12 ' HB3' ' A' ' 38' ' ' ALA . 15.3 pt -116.0 152.81 48.06 Favored Pre-proline 0 C--N 1.314 -0.95 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.91 -175.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.38 -64.71 0.1 OUTLIER 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 123.049 2.499 . . . . 0.0 112.41 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.39 -142.47 8.94 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 62.52 80.37 0.23 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.388 0.613 . . . . 0.0 110.939 177.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.63 96.63 0.13 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.745 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 44' ' ' TYR . 62.5 m -59.59 144.11 85.3 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.181 177.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.582 ' HD2' ' HD2' ' A' ' 44' ' ' TYR . 57.2 Cg_endo -70.96 -175.13 1.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.974 2.449 . . . . 0.0 113.25 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.41 7.1 33.4 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.488 -0.778 . . . . 0.0 114.428 -170.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.549 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 16.7 p-10 -108.45 -17.51 13.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 176.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.674 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . 22.2 m-85 -102.74 0.73 33.35 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.612 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.01 18.38 18.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.424 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.5 t-20 . . . . . 0 C--O 1.253 1.252 0 CA-C-O 118.251 -0.88 . . . . 0.0 110.215 -179.213 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.1 m . . . . . 0 N--CA 1.476 0.844 0 CA-C-O 120.782 0.325 . . . . 0.0 110.375 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 22.8 m -89.08 123.92 33.81 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.817 0.341 . . . . 0.0 110.47 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 63.8 m -124.25 106.7 10.49 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.559 ' HB3' ' HB3' ' A' ' 10' ' ' ARG . 7.8 t -100.76 132.6 21.97 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.054 -178.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.615 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.7 Cg_endo -86.05 34.21 0.47 Allowed 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.97 2.447 . . . . 0.0 112.982 -177.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.62 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 38.6 t -164.88 133.28 3.35 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 120.983 0.42 . . . . 0.0 110.573 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.31 -26.7 34.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.186 -0.916 . . . . 0.0 109.113 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.1 t -82.77 -47.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.088 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.62 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -61.78 -43.24 99.24 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.966 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.559 ' HB3' ' HB3' ' A' ' 4' ' ' CYS . 6.0 ptp180 -65.41 -28.23 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.095 0.474 . . . . 0.0 110.69 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.515 ' O ' HG23 ' A' ' 15' ' ' VAL . 42.4 m -72.62 -40.59 66.34 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.357 176.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -65.8 -28.69 69.19 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.632 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.24 -50.63 72.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.972 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -66.0 -26.42 67.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.192 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 11' ' ' SER . 84.5 t -68.2 -34.49 66.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.699 -179.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.499 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.0 t -82.26 -24.5 34.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 121.371 0.605 . . . . 0.0 110.393 -178.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 17' ' ' ARG . 23.6 ttt180 -80.5 -13.05 59.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.482 -178.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 8.2 mt -71.76 -52.1 8.38 Favored Pre-proline 0 N--CA 1.444 -0.745 0 CA-C-N 115.998 -0.547 . . . . 0.0 112.447 -177.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 6.4 Cg_exo -75.01 18.39 0.54 Allowed 'Trans proline' 0 C--N 1.358 1.051 0 C-N-CA 122.538 2.159 . . . . 0.0 113.11 -178.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 78.9 40.15 18.14 Favored Glycine 0 N--CA 1.443 -0.897 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.526 178.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.45 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 3.0 m -107.08 135.96 19.53 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 175.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.579 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 11.0 Cg_endo -57.24 116.65 3.36 Favored 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 122.938 2.425 . . . . 0.0 111.411 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -39.83 -34.94 0.3 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.903 170.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.62 -49.32 73.76 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.183 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.579 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 45.0 tp -68.55 -36.4 78.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-O 120.852 0.358 . . . . 0.0 110.199 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 36.0 m -66.78 -42.37 86.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.237 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -61.65 -24.64 66.86 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.657 0.741 . . . . 0.0 111.653 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.2 m -76.13 -22.62 55.27 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.984 -178.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -109.52 -42.69 4.25 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.332 0.587 . . . . 0.0 110.784 -177.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.5 m -62.86 -37.88 88.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.186 -178.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 108.65 -15.85 34.49 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.753 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.464 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 34.5 m -71.05 133.4 46.27 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 176.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.4 pt -103.96 141.22 20.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.233 0.539 . . . . 0.0 111.383 -175.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 68.8 mt -108.15 107.73 23.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.977 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.88 HG22 ' H ' ' A' ' 37' ' ' GLY . 5.0 mp -89.86 130.21 43.62 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.05 -179.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.55 -13.31 38.61 Favored 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.836 2.357 . . . . 0.0 112.235 175.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.88 ' H ' HG22 ' A' ' 35' ' ' ILE . . . -91.03 -137.35 7.22 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.903 176.013 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.45 15.9 0.26 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.613 0.244 . . . . 0.0 111.387 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.9 m -120.02 105.51 11.11 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.093 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.7 p -134.47 135.96 24.79 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.51 173.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.47 ' HG2' ' OD1' ' A' ' 43' ' ' ASP . 53.3 Cg_endo -67.15 176.6 4.47 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.748 2.299 . . . . 0.0 112.802 -176.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.24 24.94 5.82 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.589 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.47 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 11.3 p-10 -112.22 -18.29 12.57 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 170.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.615 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 17.7 m-85 -98.4 3.6 48.47 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.789 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.56 18.82 21.39 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.824 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 . . . . . 0 C--O 1.246 0.904 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.732 -179.123 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.476 0.827 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -98.26 136.4 38.5 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-O 120.921 0.391 . . . . 0.0 112.017 -176.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 96.9 m -134.18 112.72 11.34 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 173.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 41.4 m -101.56 152.5 38.06 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.911 -173.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -99.74 24.67 0.18 Allowed 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.722 2.282 . . . . 0.0 113.598 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 t -174.03 132.5 0.41 Allowed 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.118 0.485 . . . . 0.0 110.269 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.489 ' HA ' ' HB3' ' A' ' 10' ' ' ARG . 59.3 mt -69.79 -19.97 23.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.154 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -71.36 -41.99 73.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.525 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -66.08 -48.17 71.84 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.8 174.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.489 ' HB3' ' HA ' ' A' ' 7' ' ' ILE . 4.0 tpp180 -50.97 -41.78 59.56 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.167 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 15' ' ' VAL . 41.5 t -58.76 -55.19 38.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.522 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.406 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.0 p30 -71.04 -26.89 63.29 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.246 -178.276 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -62.22 -50.44 71.75 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.615 173.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -54.98 -44.19 74.22 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.674 178.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 11' ' ' SER . 57.7 t -67.5 -27.11 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.455 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.2 t -83.93 -43.18 15.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 121.01 0.433 . . . . 0.0 111.035 -176.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -76.38 -10.88 59.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.021 0.439 . . . . 0.0 111.409 -177.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.406 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 5.4 mt -69.95 -51.12 15.34 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -176.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 48.9 Cg_endo -71.8 -8.78 23.72 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.292 1.995 . . . . 0.0 113.131 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.11 19.1 5.27 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.347 -0.93 . . . . 0.0 113.312 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.477 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 3.1 m -83.66 137.33 41.48 Favored Pre-proline 0 N--CA 1.431 -1.383 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 21.0 Cg_endo -63.74 125.93 16.42 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.564 2.176 . . . . 0.0 110.511 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -42.14 -26.5 0.1 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.412 170.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 34' ' ' ILE . . . -51.09 -54.14 27.71 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.769 0.319 . . . . 0.0 110.934 171.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.2 tt -67.69 -41.29 83.88 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 109.85 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.0 m -81.51 9.05 8.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.3 -175.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -109.64 -49.2 3.13 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.859 0.838 . . . . 0.0 110.302 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -64.37 -33.26 75.45 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 113.859 -1.518 . . . . 0.0 112.37 -173.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -96.57 -15.19 21.73 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.228 1.014 . . . . 0.0 109.527 -176.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.525 HG22 ' HB1' ' A' ' 9' ' ' ALA . 55.7 m -96.32 -25.89 15.59 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 113.791 -1.55 . . . . 0.0 112.279 -172.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.66 7.33 57.89 Favored Glycine 0 C--N 1.328 0.093 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.464 ' HB3' ' HA ' ' A' ' 27' ' ' ALA . 19.8 t -92.92 157.85 16.13 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.2 pt -118.43 160.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.573 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.44 ' CD1' ' HA ' ' A' ' 24' ' ' ALA . 69.9 mt -122.31 137.37 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.599 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.521 ' H ' HD13 ' A' ' 35' ' ' ILE . 0.2 OUTLIER -130.66 157.27 78.19 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 176.268 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 45.5 Cg_endo -70.54 -28.12 21.89 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.497 2.131 . . . . 0.0 112.263 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.73 -140.5 11.29 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.006 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -152.65 12.93 0.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.685 0.279 . . . . 0.0 111.353 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.2 m -90.54 104.98 17.5 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.254 0.549 . . . . 0.0 110.0 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 94.9 m -129.43 131.68 23.77 Favored Pre-proline 0 C--N 1.311 -1.085 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.954 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -69.81 176.09 7.27 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.697 2.265 . . . . 0.0 112.499 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.51 3.06 26.92 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 116.069 -0.514 . . . . 0.0 113.755 -175.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -94.36 -22.34 18.39 Favored 'General case' 0 CA--C 1.513 -0.481 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.609 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -121.17 20.71 11.37 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.273 -1.331 . . . . 0.0 109.661 -176.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -99.37 16.37 23.28 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.031 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.737 -0.649 . . . . 0.0 109.566 -178.7 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 60.2 m . . . . . 0 N--CA 1.476 0.874 0 CA-C-O 120.835 0.35 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.624 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 26.8 m -104.27 118.37 36.46 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.747 178.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 62.6 m -108.87 128.14 54.65 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.344 -174.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.5 m -128.98 132.55 24.44 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.548 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.782 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.2 Cg_endo -90.84 23.82 0.62 Allowed 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.899 2.399 . . . . 0.0 114.245 -177.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.1 p -171.01 149.38 2.92 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 122.07 -0.394 . . . . 0.0 111.438 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 58.7 mt -65.22 -29.45 47.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.156 178.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.5 t -76.63 -38.81 31.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.833 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -72.88 -41.99 64.11 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 10.7 tpp180 -54.4 -36.76 64.29 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.721 177.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.507 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 4.0 p -79.52 -55.09 5.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.66 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 p30 -60.88 -24.27 65.83 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 121.218 0.533 . . . . 0.0 110.787 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.647 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 71.0 t80 -61.39 -60.51 3.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.586 173.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.507 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 8.5 p30 -69.49 -28.59 66.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.673 -175.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 93.6 t -71.52 -23.61 22.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.394 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.502 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.5 t -76.86 -32.06 57.25 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 121.996 -0.44 . . . . 0.0 110.595 -179.157 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.616 ' HA ' ' O ' ' A' ' 21' ' ' THR . 1.7 ptm180 -87.19 -0.06 56.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.194 0.521 . . . . 0.0 110.697 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.538 ' HB3' ' HD3' ' A' ' 19' ' ' PRO . 63.9 tp -70.32 -53.32 10.56 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.662 179.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.538 ' HD3' ' HB3' ' A' ' 18' ' ' LEU . 91.1 Cg_endo -82.2 28.03 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.171 1.914 . . . . 0.0 113.759 -177.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.94 39.53 8.57 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.317 175.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.616 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.8 OUTLIER -115.37 136.56 22.74 Favored Pre-proline 0 N--CA 1.437 -1.093 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 174.917 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.869 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 17.7 Cg_endo -63.2 120.99 8.67 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 122.617 2.211 . . . . 0.0 111.047 175.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 11.0 pt-20 -56.88 -23.71 46.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.243 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.505 ' HA ' HD12 ' A' ' 34' ' ' ILE . . . -63.34 -41.95 98.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.729 173.277 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.869 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.5 OUTLIER -71.8 -39.12 70.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 120.903 0.382 . . . . 0.0 110.215 176.795 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 34.3 m -66.97 -36.96 83.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.041 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.4 -36.15 73.13 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.785 0.802 . . . . 0.0 110.898 176.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -69.04 -23.79 64.1 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 114.093 -1.412 . . . . 0.0 111.129 -176.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -102.65 -46.07 4.84 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.626 0.727 . . . . 0.0 110.02 -176.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.5 m -59.95 -44.36 94.45 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 114.626 -1.17 . . . . 0.0 112.172 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.78 -9.16 14.49 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.28 -0.962 . . . . 0.0 112.037 -176.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 94.7 m -71.38 158.8 35.68 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 175.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 26.3 pt -126.39 139.59 51.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.963 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.505 HD12 ' HA ' ' A' ' 24' ' ' ALA . 71.3 mt -112.32 103.28 15.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.791 177.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 34.1 pt -107.83 148.28 37.07 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.142 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -76.93 12.06 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.997 2.465 . . . . 0.0 112.387 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -130.45 -147.39 6.13 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.74 21.86 2.14 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.163 0.506 . . . . 0.0 110.273 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 m -79.98 72.25 6.74 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.396 -175.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 90.9 m -128.29 131.51 23.82 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.287 176.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.23 174.55 8.88 Favored 'Trans proline' 0 CA--C 1.531 0.348 0 C-N-CA 122.595 2.196 . . . . 0.0 111.903 176.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.98 26.21 1.47 Allowed Glycine 0 CA--C 1.521 0.424 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.236 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 24.7 t70 -115.38 -29.78 6.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.782 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 10.4 m-85 -105.91 5.18 30.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.967 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.61 17.11 23.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.913 -174.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.0 t30 . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.086 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.598 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 23.5 m . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.483 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 21.9 m -134.16 124.16 25.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.011 -176.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.458 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 82.6 m -128.16 142.84 51.06 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.664 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 0.5 OUTLIER -128.42 151.66 76.96 Favored Pre-proline 0 C--N 1.32 -0.676 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.505 -175.716 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.664 ' HD2' ' SG ' ' A' ' 4' ' ' CYS . 88.8 Cg_endo -82.05 1.66 9.06 Favored 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.955 2.436 . . . . 0.0 113.958 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.8 p -160.9 155.55 23.64 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 121.88 -0.512 . . . . 0.0 110.94 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 59.2 mt -73.05 -28.58 26.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.421 178.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.6 t -67.87 -44.43 85.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.766 -178.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.411 ' HA ' HD21 ' A' ' 12' ' ' ASN . . . -66.34 -45.2 81.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.961 177.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -54.2 -39.27 66.53 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.38 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.4 m -60.5 -55.07 37.88 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.641 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.411 HD21 ' HA ' ' A' ' 9' ' ' ALA . 11.3 p30 -75.28 -22.62 57.62 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.02 0.438 . . . . 0.0 110.906 -176.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CZ ' HG21 ' A' ' 2' ' ' THR . 44.8 t80 -58.16 -53.41 58.62 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.086 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -61.96 -29.89 70.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.783 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 79.5 t -65.26 -33.23 62.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.89 178.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.548 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 39.8 t -75.71 -21.35 57.63 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 121.469 0.652 . . . . 0.0 110.151 -178.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.663 ' HD3' ' HG3' ' A' ' 23' ' ' GLU . 27.3 tpt180 -74.68 -26.45 59.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.013 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 97.6 mt -62.52 -49.22 84.35 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -175.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 13.7 Cg_exo -70.54 -5.41 16.62 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.226 1.951 . . . . 0.0 112.995 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.69 28.92 7.62 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.461 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.596 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -90.68 140.87 26.6 Favored Pre-proline 0 N--CA 1.431 -1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 177.769 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.706 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 14.4 Cg_endo -62.05 121.76 9.95 Favored 'Trans proline' 0 N--CA 1.443 -1.462 0 C-N-CA 122.941 2.427 . . . . 0.0 110.857 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.663 ' HG3' ' HD3' ' A' ' 17' ' ' ARG . 1.1 mp0 -45.93 -32.35 2.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.059 173.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.2 -48.11 82.82 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.066 175.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.706 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.2 tt -66.68 -44.49 81.67 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.095 178.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.493 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 14.0 m -66.76 -40.4 88.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.508 -176.017 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.02 -42.21 93.84 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.519 0.676 . . . . 0.0 111.021 178.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.3 m -68.22 -21.87 64.82 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.353 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -100.7 -38.09 8.45 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.674 0.75 . . . . 0.0 109.847 -174.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.6 m -75.65 -57.68 3.74 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.596 -1.184 . . . . 0.0 112.024 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.0 -20.38 2.14 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 119.705 -1.236 . . . . 0.0 112.527 -176.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 30.7 m -66.83 155.91 37.01 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 175.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 33.1 pt -120.55 148.84 23.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.331 -0.547 . . . . 0.0 111.814 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 50.8 mm -102.13 139.22 23.77 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.344 176.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.598 ' O ' ' HB ' ' A' ' 1' ' ' THR . 3.1 pt -146.31 151.37 43.87 Favored Pre-proline 0 C--N 1.316 -0.859 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.25 -179.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -87.75 30.99 0.44 Allowed 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.498 2.799 . . . . 0.0 112.233 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.51 137.79 4.81 Favored Glycine 0 N--CA 1.446 -0.676 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.699 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.29 30.17 0.34 Allowed 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.057 0.456 . . . . 0.0 111.58 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.8 m -80.38 48.66 1.05 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.511 0.672 . . . . 0.0 111.632 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.584 ' SG ' HD11 ' A' ' 35' ' ' ILE . 76.3 m -94.29 126.38 48.6 Favored Pre-proline 0 C--N 1.313 -1.003 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.699 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -75.03 176.36 10.02 Favored 'Trans proline' 0 CA--C 1.531 0.352 0 C-N-CA 122.762 2.308 . . . . 0.0 112.36 176.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.95 -8.69 74.17 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 114.572 0.589 . . . . 0.0 114.572 -171.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -94.99 -22.12 18.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.831 0.824 . . . . 0.0 109.294 -179.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.458 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 20.8 m-85 -107.23 18.07 22.12 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.278 -178.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.01 33.46 0.79 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.261 -177.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.411 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 16.6 m-80 . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.791 -0.623 . . . . 0.0 109.497 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.546 ' HB ' HG13 ' A' ' 35' ' ' ILE . 7.5 m . . . . . 0 N--CA 1.475 0.798 0 CA-C-O 120.782 0.325 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.405 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 7.3 m -90.57 115.02 27.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.103 0.478 . . . . 0.0 110.785 178.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.403 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.4 m -115.08 144.56 43.45 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.599 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.4 t -156.28 110.82 2.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.012 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.567 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 96.7 Cg_endo -84.61 45.4 1.68 Allowed 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.971 2.447 . . . . 0.0 113.881 -173.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m -158.17 127.28 5.69 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.4 mp -64.85 -36.96 78.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.9 t -62.59 -38.8 82.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.326 -1.307 . . . . 0.0 110.251 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.4 22.07 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.26 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.3 tpp180 -50.89 -43.45 59.65 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.833 175.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.543 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.7 m -53.7 -55.01 29.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.423 0.154 . . . . 0.0 111.378 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -76.65 -23.03 53.29 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.398 -0.521 . . . . 0.0 110.608 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.405 ' CZ ' HG21 ' A' ' 2' ' ' THR . 34.7 t80 -65.48 -49.07 70.44 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.114 175.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -59.97 -32.64 71.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.127 0.489 . . . . 0.0 109.843 174.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 11' ' ' SER . 92.8 t -72.82 -24.0 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.99 177.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -86.26 5.71 33.09 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-O 121.753 0.787 . . . . 0.0 109.62 -178.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.479 ' NE ' ' HG3' ' A' ' 23' ' ' GLU . 13.7 mmm180 -106.3 -23.53 12.53 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.556 0.693 . . . . 0.0 109.185 178.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -56.92 -47.62 98.77 Favored Pre-proline 0 CA--C 1.547 0.846 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.131 175.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.441 ' HG2' ' OG1' ' A' ' 21' ' ' THR . 82.3 Cg_endo -79.61 4.16 6.91 Favored 'Trans proline' 0 C--N 1.36 1.17 0 C-N-CA 121.779 1.653 . . . . 0.0 113.037 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.72 20.86 45.64 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.505 176.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.685 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -81.06 142.46 51.62 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.206 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.685 ' HD2' HG22 ' A' ' 21' ' ' THR . 38.2 Cg_endo -70.85 130.44 17.99 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 C-N-CA 123.156 2.571 . . . . 0.0 111.494 176.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.479 ' HG3' ' NE ' ' A' ' 17' ' ' ARG . 51.4 mt-10 -41.83 -36.08 0.96 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.485 171.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.71 -52.1 50.96 Favored 'General case' 0 C--N 1.33 -0.266 0 O-C-N 123.381 0.426 . . . . 0.0 110.857 175.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.527 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -68.19 -41.62 81.12 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.167 179.063 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 7.5 m -80.57 12.17 3.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.523 -176.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -108.05 -48.28 3.41 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 121.894 0.854 . . . . 0.0 110.104 173.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.0 m -62.73 -29.62 70.81 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 113.817 -1.538 . . . . 0.0 112.117 -174.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -95.86 -22.5 17.42 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.885 0.85 . . . . 0.0 110.117 -175.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -93.21 -38.61 11.46 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.528 -1.214 . . . . 0.0 111.82 -171.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.74 -18.68 8.58 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.433 -177.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 6.6 m -64.9 150.48 47.73 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 32.9 pt -122.3 149.09 25.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.085 0.469 . . . . 0.0 111.495 -177.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.5 mt -111.28 110.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.829 176.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.909 HD12 ' HB3' ' A' ' 38' ' ' ALA . 5.7 pt -108.52 129.36 24.11 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.907 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.09 -32.31 17.43 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.435 2.09 . . . . 0.0 112.68 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.07 117.91 0.83 Allowed Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.909 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 165.2 102.0 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.741 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -172.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.41 94.39 0.01 OUTLIER 'General case' 0 N--CA 1.435 -1.216 0 O-C-N 123.884 0.74 . . . . 0.0 110.377 172.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 45' ' ' ALA . 4.2 t -65.92 120.52 69.8 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.356 -175.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.41 170.27 20.66 Favored 'Trans proline' 0 C--O 1.236 0.379 0 C-N-CA 122.766 2.311 . . . . 0.0 112.473 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.75 20.7 7.39 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.008 -173.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -119.1 -11.53 9.61 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 174.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.567 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 19.6 m-85 -113.81 0.11 14.38 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.756 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.402 ' HB2' ' SG ' ' A' ' 40' ' ' CYS . . . -135.9 64.99 1.55 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 120.962 0.41 . . . . 0.0 110.431 -177.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.7 m120 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.582 -0.723 . . . . 0.0 109.304 175.608 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.0 m . . . . . 0 N--CA 1.477 0.897 0 CA-C-O 120.554 0.216 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.444 ' OG1' HG12 ' A' ' 34' ' ' ILE . 31.1 m -97.33 112.49 24.28 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.129 0.49 . . . . 0.0 110.274 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.638 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 74.3 m -105.98 146.63 29.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.082 -176.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.455 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 2.1 t -136.8 141.99 37.13 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 5.4 Cg_exo -78.59 17.12 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.789 2.326 . . . . 0.0 115.043 -171.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -170.29 150.78 3.66 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 118.975 0.807 . . . . 0.0 110.755 177.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.753 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 3.3 mp -64.66 -33.52 63.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.893 0.854 . . . . 0.0 109.107 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.16 -51.09 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.754 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.84 -34.15 69.03 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.4 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.753 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -68.21 -25.22 65.11 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 109.93 -179.675 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.473 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 69.8 m -67.91 -47.42 68.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.903 172.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -55.27 -39.66 70.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.195 0.522 . . . . 0.0 109.879 176.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 5.8 t80 -53.0 -56.65 14.47 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 114.954 -1.021 . . . . 0.0 112.097 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.473 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 11.9 p30 -74.8 -31.39 61.71 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 121.2 -0.2 . . . . 0.0 111.213 -174.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 11' ' ' SER . 96.6 t -70.52 -30.9 44.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 111.131 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.406 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.2 t -74.64 -22.9 58.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.935 -178.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.695 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 74.2 mtm180 -77.98 -22.22 49.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.579 0.228 . . . . 0.0 111.172 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.6 mt -54.45 -50.58 84.37 Favored Pre-proline 0 N--CA 1.443 -0.816 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 -176.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.406 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 55.6 Cg_endo -72.14 5.0 2.87 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.099 1.866 . . . . 0.0 113.089 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.71 28.14 9.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.936 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.67 133.48 24.48 Favored Pre-proline 0 N--CA 1.438 -1.037 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.694 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 18.2 Cg_endo -62.01 124.44 14.44 Favored 'Trans proline' 0 N--CA 1.445 -1.381 0 C-N-CA 122.755 2.304 . . . . 0.0 109.798 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.695 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 9.4 pt-20 -53.63 -20.2 4.94 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.269 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -64.56 -47.09 80.03 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 173.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.694 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.5 tt -63.74 -44.12 94.47 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 120.871 0.367 . . . . 0.0 110.347 176.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 14.9 m -69.21 -30.97 69.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.309 -177.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.462 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -65.71 -31.14 71.97 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.749 0.785 . . . . 0.0 110.334 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 m -74.75 -20.59 59.76 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.78 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -98.12 -52.99 3.51 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-O 121.91 0.862 . . . . 0.0 110.244 -176.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 52.0 m -70.58 -47.47 60.07 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 114.013 -1.448 . . . . 0.0 112.161 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.1 0.79 10.56 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.953 -1.117 . . . . 0.0 112.753 -177.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.462 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 25.5 m -71.46 161.34 31.2 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 174.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.1 pt -132.42 141.25 45.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.967 0.413 . . . . 0.0 111.301 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.444 HG12 ' OG1' ' A' ' 2' ' ' THR . 77.4 mt -97.0 112.66 29.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.817 177.154 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.584 HG12 ' HB3' ' A' ' 40' ' ' CYS . 2.4 pp -105.72 147.53 34.87 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.869 0.366 . . . . 0.0 111.5 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -78.56 28.91 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 123.409 2.739 . . . . 0.0 112.999 -176.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -133.27 -151.08 6.49 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 177.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -148.39 22.38 1.05 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.608 0.24 . . . . 0.0 111.361 -177.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.0 m -133.0 -46.48 0.85 Allowed 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.828 -179.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.673 ' HB2' ' HD2' ' A' ' 41' ' ' PRO . 24.1 p 48.92 164.92 0.03 OUTLIER Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 124.904 1.378 . . . . 0.0 113.187 -174.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.673 ' HD2' ' HB2' ' A' ' 40' ' ' CYS . 31.6 Cg_endo -65.82 152.55 81.24 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.253 1.969 . . . . 0.0 112.682 176.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.11 12.2 7.1 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.753 -0.658 . . . . 0.0 113.997 -172.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.443 ' OD1' ' HB2' ' A' ' 41' ' ' PRO . 19.1 p-10 -106.49 -12.31 15.66 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.638 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.9 m-85 -117.67 5.53 12.35 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.616 175.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.06 35.5 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.06 -172.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.8 m120 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.579 176.712 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.499 ' HB ' ' HB ' ' A' ' 35' ' ' ILE . 9.1 m . . . . . 0 N--CA 1.475 0.819 0 CA-C-O 121.041 0.448 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 31.7 m -135.54 142.14 45.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.804 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 58.9 m -125.06 132.27 53.2 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -172.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.0 m -126.47 123.28 24.03 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.377 174.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -80.74 19.67 1.08 Allowed 'Trans proline' 0 CA--C 1.532 0.406 0 C-N-CA 122.416 2.077 . . . . 0.0 113.441 -174.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -157.97 136.42 11.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.823 ' H ' HD12 ' A' ' 7' ' ' ILE . 4.1 mp -57.51 -38.66 64.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.326 0.584 . . . . 0.0 109.672 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.6 t -72.88 -36.78 52.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.271 -177.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.13 82.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.477 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -71.64 -39.68 70.21 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.23 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.584 ' O ' HG23 ' A' ' 15' ' ' VAL . 5.9 p -66.38 -37.39 85.17 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.557 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -66.25 -41.98 89.21 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.379 0.609 . . . . 0.0 109.834 175.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 23' ' ' GLU . 13.1 t80 -60.86 -42.99 98.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.123 179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -61.54 -34.29 75.29 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.156 177.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 11' ' ' SER . 47.2 t -78.57 -6.18 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.475 178.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.671 ' O ' ' HB ' ' A' ' 21' ' ' THR . 1.8 t -108.96 14.94 23.79 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-O 121.888 0.851 . . . . 0.0 108.855 176.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 21' ' ' THR . 6.2 tpt180 -120.9 -42.84 2.48 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 114.979 -1.01 . . . . 0.0 108.365 175.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.14 -51.35 57.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 CA-C-N 113.727 -1.578 . . . . 0.0 113.372 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.05 35.46 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.813 0 C-N-CA 122.641 2.227 . . . . 0.0 113.203 -175.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 66.51 46.68 75.1 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.935 178.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.671 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.57 132.23 24.27 Favored Pre-proline 0 N--CA 1.441 -0.899 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.857 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.714 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 30.1 Cg_endo -63.83 122.45 10.51 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.745 2.297 . . . . 0.0 111.156 177.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 13' ' ' PHE . 1.1 mp0 -51.9 -31.48 28.49 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.142 174.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.63 -48.82 79.72 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.573 177.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.714 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.9 OUTLIER -67.26 -41.9 84.8 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.204 0.526 . . . . 0.0 110.177 179.219 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 86.2 m -74.52 -14.12 60.77 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.82 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -70.27 -32.47 70.29 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 122.052 0.93 . . . . 0.0 109.883 174.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.6 m -72.05 -23.21 61.33 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 113.885 -1.507 . . . . 0.0 110.418 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -99.57 -49.42 4.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.352 0.596 . . . . 0.0 110.608 -176.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m -66.7 -44.92 80.41 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.567 -178.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.51 -15.17 14.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.427 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 82.6 m -65.89 145.43 55.94 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 176.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.8 pt -116.62 153.59 18.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.74 0.305 . . . . 0.0 111.487 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 67.7 mt -102.06 133.54 45.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.956 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.499 ' HB ' ' HB ' ' A' ' 1' ' ' THR . 45.7 mm -93.13 123.43 60.94 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.843 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -55.76 -40.04 87.59 Favored 'Trans proline' 0 CA--C 1.528 0.195 0 C-N-CA 122.829 2.353 . . . . 0.0 112.073 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.41 -125.4 4.67 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.999 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.24 72.8 1.34 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.561 0.696 . . . . 0.0 110.376 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.469 ' H ' HG21 ' A' ' 35' ' ' ILE . 11.2 m -145.78 108.94 4.6 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.112 174.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 16.8 t -153.89 123.01 3.15 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.129 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.54 164.83 34.47 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.918 2.412 . . . . 0.0 112.84 179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -74.41 6.72 21.69 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.584 -0.734 . . . . 0.0 113.314 -175.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -92.8 -21.28 20.0 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -108.44 5.99 25.82 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.892 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -122.88 18.88 10.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.872 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.307 -0.854 . . . . 0.0 110.909 -174.719 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 34' ' ' ILE . 8.5 m . . . . . 0 N--CA 1.477 0.914 0 CA-C-O 120.958 0.408 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.405 ' OG1' HG12 ' A' ' 34' ' ' ILE . 35.5 m -118.19 132.68 56.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.456 -175.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 98.3 m -106.82 126.38 52.23 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.702 174.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 1.8 t -115.15 140.45 25.68 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 88.6 Cg_endo -91.74 22.79 0.64 Allowed 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.646 2.23 . . . . 0.0 113.652 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.444 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . 51.5 m -150.86 143.0 24.11 Favored 'General case' 0 C--N 1.332 -0.18 0 O-C-N 122.044 -0.41 . . . . 0.0 110.71 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.0 mt -71.16 -27.01 28.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.256 0.55 . . . . 0.0 110.547 -175.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 80.0 t -87.27 -51.91 12.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.709 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.444 ' HB3' ' HB2' ' A' ' 6' ' ' SER . . . -50.16 -42.53 51.16 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.348 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -26.3 68.31 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.286 0.565 . . . . 0.0 110.881 -176.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.521 ' O ' HG23 ' A' ' 15' ' ' VAL . 22.2 t -77.81 -56.16 4.73 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.464 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -68.03 -21.76 65.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.067 0.46 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.481 ' HB2' HG21 ' A' ' 30' ' ' THR . 21.7 t80 -57.97 -56.01 27.54 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.033 170.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.425 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 12.1 p30 -69.59 -25.16 63.84 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.679 -177.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 11' ' ' SER . 84.8 t -66.99 -22.83 29.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.758 173.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.6 t -83.64 -22.92 32.04 Favored 'General case' 0 C--O 1.221 -0.431 0 CA-C-O 121.35 0.595 . . . . 0.0 109.892 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.553 ' HG2' ' O ' ' A' ' 21' ' ' THR . 3.5 tmt_? -92.26 -29.57 16.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.902 -172.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.662 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -54.87 -44.83 99.7 Favored Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 114.599 -1.182 . . . . 0.0 113.179 -177.802 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.662 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 64.7 Cg_endo -73.52 14.0 0.67 Allowed 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 122.046 1.83 . . . . 0.0 113.808 -177.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.96 27.08 8.03 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.779 -0.724 . . . . 0.0 113.096 176.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.553 ' O ' ' HG2' ' A' ' 17' ' ' ARG . 4.5 m -104.73 138.34 19.48 Favored Pre-proline 0 N--CA 1.429 -1.49 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 17.4 Cg_endo -62.02 123.53 12.73 Favored 'Trans proline' 0 N--CA 1.441 -1.58 0 C-N-CA 122.335 2.024 . . . . 0.0 109.889 176.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.461 ' HB2' ' HZ ' ' A' ' 13' ' ' PHE . 14.8 pt-20 -45.22 -30.2 1.15 Allowed 'General case' 0 C--N 1.324 -0.54 0 O-C-N 123.816 0.697 . . . . 0.0 110.03 174.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -58.13 -46.74 85.11 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.704 177.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.62 -37.77 73.86 Favored 'General case' 0 N--CA 1.444 -0.765 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 85.9 m -71.55 -33.44 69.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.651 -177.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.84 -46.12 91.8 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 122.073 0.94 . . . . 0.0 110.245 176.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.7 m -67.18 -20.43 65.72 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 113.607 -1.633 . . . . 0.0 111.729 -178.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -100.45 -45.88 5.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.599 0.714 . . . . 0.0 110.175 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.481 HG21 ' HB2' ' A' ' 13' ' ' PHE . 99.8 m -72.58 -40.73 66.37 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.616 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.64 16.39 4.6 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.082 -1.056 . . . . 0.0 112.67 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.3 m -98.44 170.81 8.58 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -129.86 148.1 33.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.818 -0.353 . . . . 0.0 111.569 -177.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.604 HD11 ' HA ' ' A' ' 24' ' ' ALA . 31.3 mt -101.5 140.64 19.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.231 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.8 pt -129.83 142.78 46.54 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.758 0.313 . . . . 0.0 110.99 177.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.53 39.85 0.85 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.255 2.637 . . . . 0.0 112.331 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.25 149.05 20.34 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -176.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.71 -1.83 58.22 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 120.847 0.356 . . . . 0.0 111.143 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.2 m -99.72 106.29 18.18 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.494 176.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 14.3 t -123.5 131.2 24.29 Favored Pre-proline 0 C--N 1.309 -1.17 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.931 179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.41 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 17.0 Cg_endo -59.36 143.14 99.82 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.791 2.327 . . . . 0.0 112.127 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.57 -8.35 25.87 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 114.563 -173.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -83.86 -24.17 30.99 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.557 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 7.9 m-85 -117.86 3.79 12.21 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.313 -176.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.43 34.31 0.52 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.41 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.45 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 22.3 m-80 . . . . . 0 C--O 1.245 0.823 0 CA-C-O 118.457 -0.783 . . . . 0.0 108.896 176.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 41.1 m . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 120.711 0.291 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.67 HG23 HG13 ' A' ' 34' ' ' ILE . 27.4 m -105.03 125.19 50.71 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.547 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 59.4 m -128.96 120.15 25.59 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.048 0.452 . . . . 0.0 111.288 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 78.8 m -107.36 166.31 11.27 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.386 179.177 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.543 ' HD2' ' HB3' ' A' ' 4' ' ' CYS . 83.6 Cg_endo -82.21 8.78 4.3 Favored 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 122.507 2.138 . . . . 0.0 114.574 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.4 t -176.09 145.13 0.62 Allowed 'General case' 0 CA--C 1.518 -0.281 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.667 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.878 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 46.2 mm -65.76 -27.24 40.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.561 0.695 . . . . 0.0 109.293 176.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.2 t -74.16 -49.75 31.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.844 177.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.93 -40.39 94.98 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.298 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.878 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -65.59 -27.72 68.62 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.111 0.481 . . . . 0.0 110.434 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.568 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.3 t -64.86 -47.59 77.38 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.669 177.275 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 54.4 m-80 -67.26 -26.69 66.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.567 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.49 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 57.4 t80 -66.6 -51.63 54.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.578 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.443 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 10.9 p30 -66.82 -23.79 66.08 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.908 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.568 HG23 ' O ' ' A' ' 11' ' ' SER . 55.7 t -62.57 -34.53 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.792 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.545 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 75.8 m -66.41 -25.03 66.57 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.432 0.634 . . . . 0.0 111.319 177.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.664 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 18.2 mmm180 -75.04 -31.71 61.37 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.722 -175.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 1.003 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -66.72 -42.87 47.44 Favored Pre-proline 0 CA--C 1.546 0.825 0 N-CA-C 114.054 1.131 . . . . 0.0 114.054 -173.761 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 1.003 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 94.9 Cg_endo -87.55 -6.18 7.02 Favored 'Trans proline' 0 C--N 1.356 0.939 0 C-N-CA 121.806 1.67 . . . . 0.0 113.22 -177.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.03 23.0 7.95 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.074 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.46 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 5.6 m -84.53 126.42 69.01 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 175.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.804 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.32 120.48 8.36 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.404 2.069 . . . . 0.0 110.557 177.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.664 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -45.98 -35.33 4.64 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.035 169.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.08 -51.41 67.97 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.989 174.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.804 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.0 tt -62.39 -53.36 56.08 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 120.685 0.279 . . . . 0.0 110.355 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 13' ' ' PHE . 33.7 t -63.27 -38.26 90.48 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.593 -174.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.538 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.76 -34.33 78.08 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.356 0.598 . . . . 0.0 111.626 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 23.4 m -76.55 -20.71 56.56 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.306 -177.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -97.54 -46.17 6.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.94 0.876 . . . . 0.0 109.678 -175.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 55.5 m -70.59 -34.86 72.62 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.748 -1.569 . . . . 0.0 111.755 178.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.18 30.49 7.38 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.352 -0.928 . . . . 0.0 111.331 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.538 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.4 t -109.31 159.44 16.97 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.8 141.26 44.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.878 0.371 . . . . 0.0 111.587 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.67 HG13 HG23 ' A' ' 2' ' ' THR . 4.3 mp -109.95 132.08 59.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.892 174.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.49 HD11 ' SG ' ' A' ' 40' ' ' CYS . 24.5 pt -134.82 156.8 78.25 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.848 -178.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.51 -25.49 41.18 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 122.855 2.37 . . . . 0.0 112.689 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -113.06 -147.12 9.91 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.803 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -135.05 30.22 3.35 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.373 0.606 . . . . 0.0 110.386 -176.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.1 m -79.73 54.51 1.83 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.865 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD11 ' A' ' 35' ' ' ILE . 30.2 m -98.82 135.0 21.1 Favored Pre-proline 0 C--N 1.309 -1.176 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.81 -178.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.871 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 30.2 Cg_endo -65.1 165.96 20.25 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.779 2.319 . . . . 0.0 111.875 174.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -66.23 -37.9 93.33 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 121.283 -0.484 . . . . 0.0 113.788 -171.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -84.03 -18.24 37.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 122.022 0.915 . . . . 0.0 109.44 -174.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.871 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 16.3 m-85 -112.13 23.91 13.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.797 -176.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.5 22.47 12.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.048 0.452 . . . . 0.0 110.908 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.407 ' C ' ' HE ' ' A' ' 10' ' ' ARG . 27.9 m-80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.459 -0.782 . . . . 0.0 109.524 -178.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.408 HG21 ' HA ' ' A' ' 38' ' ' ALA . 21.5 m . . . . . 0 N--CA 1.478 0.928 0 CA-C-O 121.131 0.491 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.536 ' HB ' HG13 ' A' ' 34' ' ' ILE . 8.9 t -115.62 145.63 42.53 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 m -136.96 115.67 12.1 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -175.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.432 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 85.1 m -103.58 125.3 35.22 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 121.137 0.494 . . . . 0.0 111.219 -177.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.585 ' HA ' ' CB ' ' A' ' 44' ' ' TYR . 18.8 Cg_endo -60.24 -7.12 6.09 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.892 3.061 . . . . 0.0 115.606 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 p -161.55 162.14 30.12 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 118.771 0.714 . . . . 0.0 111.17 -177.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.612 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 60.2 mt -67.63 -34.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.115 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.03 -50.27 55.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.25 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.57 -32.63 74.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.253 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.612 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.41 -29.48 62.62 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.825 0.345 . . . . 0.0 110.533 -178.662 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.465 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.1 m -68.67 -53.04 24.75 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -55.13 -40.11 70.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.099 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -57.0 -62.92 1.41 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.083 175.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 35.5 m-80 -59.41 -39.0 82.02 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 11' ' ' SER . 69.9 t -60.95 -37.46 77.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-O 120.551 0.215 . . . . 0.0 111.363 -178.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 18.2 t -70.28 -42.21 72.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.787 0.327 . . . . 0.0 110.808 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.721 ' HD2' ' HG2' ' A' ' 23' ' ' GLU . 0.0 OUTLIER -91.3 20.62 5.01 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.961 0.41 . . . . 0.0 111.811 -177.597 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.431 ' HB2' ' O ' ' A' ' 15' ' ' VAL . 4.5 mt -73.02 -50.33 6.81 Favored Pre-proline 0 N--CA 1.445 -0.71 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.693 177.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.65 25.96 0.63 Allowed 'Trans proline' 0 C--N 1.36 1.152 0 C-N-CA 122.221 1.948 . . . . 0.0 113.208 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.24 37.78 6.99 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.113 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 1.7 m -97.65 141.01 22.34 Favored Pre-proline 0 N--CA 1.43 -1.432 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.656 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.3 116.34 3.12 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.905 2.403 . . . . 0.0 111.178 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.721 ' HG2' ' HD2' ' A' ' 17' ' ' ARG . 36.8 mt-10 -51.11 -28.8 11.57 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.901 172.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.73 79.6 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.763 173.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.656 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.1 tt -65.36 -42.97 92.22 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.246 0.546 . . . . 0.0 109.927 178.504 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 16' ' ' CYS . 61.0 m -77.34 -0.4 25.47 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.021 -175.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.546 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -101.57 -41.02 6.75 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.686 0.755 . . . . 0.0 111.113 175.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.0 m -65.82 -23.91 66.79 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.184 -1.371 . . . . 0.0 111.61 -174.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -100.47 -15.23 17.97 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 122.176 0.989 . . . . 0.0 109.88 -176.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 89.1 m -99.93 -46.81 5.24 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.075 -1.42 . . . . 0.0 111.874 -172.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.12 -20.96 6.23 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 119.944 -1.122 . . . . 0.0 112.287 -178.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.546 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.3 t -73.61 158.54 34.58 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.25 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.0 pt -131.64 143.68 39.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.441 0.639 . . . . 0.0 112.104 -175.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.536 HG13 ' HB ' ' A' ' 2' ' ' THR . 4.5 mp -104.25 136.16 38.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 168.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 46.7 pt -120.64 142.23 33.81 Favored Pre-proline 0 C--N 1.317 -0.807 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.035 -178.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.1 38.48 0.69 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 123.081 2.521 . . . . 0.0 112.304 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.72 -138.64 2.64 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -178.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.408 ' HA ' HG21 ' A' ' 1' ' ' THR . . . -150.62 13.68 0.74 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.661 0.267 . . . . 0.0 111.244 -178.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.9 t -91.74 103.07 15.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 122.159 0.981 . . . . 0.0 111.991 -177.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.463 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 34.1 m -149.92 112.62 3.36 Favored Pre-proline 0 C--N 1.305 -1.351 0 CA-C-N 113.806 -1.543 . . . . 0.0 110.688 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 40' ' ' CYS . 33.7 Cg_endo -63.89 160.59 36.55 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.49 2.126 . . . . 0.0 111.114 172.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.37 32.55 3.85 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.916 -0.659 . . . . 0.0 113.574 -171.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -108.19 -29.8 8.72 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.585 ' CB ' ' HA ' ' A' ' 5' ' ' PRO . 4.5 p90 -128.13 22.11 6.19 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.462 173.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.96 37.76 1.14 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.312 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 6.0 t30 . . . . . 0 C--O 1.252 1.19 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.234 -179.248 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.449 ' HB ' HD12 ' A' ' 35' ' ' ILE . 17.0 m . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.835 0.35 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.1 t -113.33 119.2 36.87 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.457 0.646 . . . . 0.0 110.138 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 33.6 m -104.91 108.88 20.61 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.747 -176.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.509 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 13.9 t -136.72 99.86 10.23 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.209 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.865 ' HG3' ' HA ' ' A' ' 44' ' ' TYR . 64.0 Cg_endo -85.35 61.24 5.58 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.954 2.436 . . . . 0.0 113.975 -169.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.738 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 1.4 p -167.39 120.96 0.96 Allowed 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.218 -178.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 68.0 mt -48.11 -38.63 8.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.604 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.5 t -77.53 -48.6 23.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.701 -175.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.97 -37.67 88.28 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.27 -178.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.738 ' HG3' ' O ' ' A' ' 6' ' ' SER . 60.5 mtt180 -54.27 -51.69 63.78 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 121.151 0.501 . . . . 0.0 110.284 179.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.528 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.9 m -70.63 -42.27 71.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.261 -177.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -62.69 -38.25 89.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 120.81 0.338 . . . . 0.0 110.581 -178.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -51.39 -51.34 55.51 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.423 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 36.6 m-80 -65.11 -37.87 88.85 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.452 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 11' ' ' SER . 90.7 t -61.98 -41.89 92.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.378 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.535 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 26.1 t -71.52 -32.11 67.82 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.398 0.618 . . . . 0.0 110.018 -179.225 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 17' ' ' ARG . 39.5 ttt180 -73.3 -21.86 60.48 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.342 -176.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 19.3 mt -64.61 -52.89 48.68 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -174.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.535 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 16.5 Cg_exo -69.9 0.5 5.65 Favored 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.427 2.085 . . . . 0.0 113.137 -178.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.25 26.27 7.87 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.182 -1.008 . . . . 0.0 112.407 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.492 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 1.3 m -89.89 137.88 28.07 Favored Pre-proline 0 N--CA 1.428 -1.55 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 176.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 8.3 Cg_endo -55.45 117.49 4.11 Favored 'Trans proline' 0 N--CA 1.444 -1.408 0 C-N-CA 122.869 2.38 . . . . 0.0 111.058 -179.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -47.21 -28.76 2.0 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.457 170.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.47 -42.16 98.6 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.885 174.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.489 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 41.3 tp -76.69 -36.17 57.43 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.053 0.454 . . . . 0.0 110.52 178.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 17.4 m -78.28 3.03 16.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.976 -179.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -101.2 -56.44 2.31 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.852 0.834 . . . . 0.0 110.328 174.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 m -62.77 -25.41 68.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.047 -174.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -94.39 -17.75 22.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 122.087 0.946 . . . . 0.0 109.551 -175.1 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 84.5 m -97.61 -44.62 6.71 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.542 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.25 -7.34 6.33 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.62 -175.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 5.3 m -82.39 148.13 28.41 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.8 pt -123.4 143.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.451 -0.5 . . . . 0.0 110.683 176.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 78.9 mt -112.95 120.83 63.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.022 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.449 HD12 ' HB ' ' A' ' 1' ' ' THR . 2.1 pp -120.08 139.85 28.99 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.637 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -82.09 22.42 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.234 2.623 . . . . 0.0 113.145 -175.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.48 -139.96 3.74 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.214 178.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.21 62.39 1.53 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.049 0.452 . . . . 0.0 109.943 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 m -152.44 106.05 3.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.275 0.559 . . . . 0.0 111.099 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.0 p -148.46 140.83 14.81 Favored Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.064 171.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.504 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 11.0 Cg_endo -53.81 143.71 58.1 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 123.005 2.47 . . . . 0.0 112.568 -174.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.13 -13.07 47.18 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.841 -0.618 . . . . 0.0 113.674 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.85 -17.37 41.11 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.865 ' HA ' ' HG3' ' A' ' 5' ' ' PRO . 16.9 m-85 -121.67 5.94 10.01 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.094 -175.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -105.3 38.0 2.06 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -171.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.71 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 2.9 t30 . . . . . 0 C--O 1.246 0.893 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.07 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.593 ' HB ' HG13 ' A' ' 35' ' ' ILE . 22.7 m . . . . . 0 N--CA 1.477 0.887 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -120.55 147.49 45.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.806 0.336 . . . . 0.0 111.605 -174.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.493 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 2.1 m -151.34 123.29 8.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.886 176.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.575 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 40.0 m -110.2 162.12 21.72 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.044 -175.705 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -91.13 13.95 2.03 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.394 2.062 . . . . 0.0 114.825 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.5 p -167.3 144.02 4.41 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 118.505 0.593 . . . . 0.0 111.115 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.455 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 35.9 mt -60.27 -29.32 43.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.763 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.5 t -72.55 -51.51 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.475 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.564 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -69.77 -30.35 67.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.725 -177.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.575 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -69.94 -26.09 63.96 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.149 0.499 . . . . 0.0 110.339 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.435 ' O ' HG23 ' A' ' 15' ' ' VAL . 25.0 m -79.79 -42.25 24.82 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.434 175.324 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -59.88 -30.26 68.87 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.541 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -52.9 -61.38 2.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.664 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.3 m-80 -63.21 -33.1 74.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.267 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 11' ' ' SER . 72.2 t -63.99 -34.84 71.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.079 178.272 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 41.8 t -77.5 -16.72 58.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.436 0.636 . . . . 0.0 110.67 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.487 ' HD2' ' O ' ' A' ' 21' ' ' THR . 7.8 mmm180 -82.66 -19.32 38.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.027 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.606 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 85.2 mt -67.14 -48.84 47.73 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.606 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 22.9 Cg_exo -65.58 -19.01 60.35 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.927 1.752 . . . . 0.0 112.391 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.4 24.44 5.64 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.586 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.556 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -90.56 134.06 31.6 Favored Pre-proline 0 N--CA 1.438 -1.054 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 177.615 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -66.46 129.55 21.61 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 123.065 2.51 . . . . 0.0 111.168 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -46.35 -25.58 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.197 171.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.95 -47.65 71.09 Favored 'General case' 0 C--N 1.327 -0.398 0 O-C-N 123.293 0.371 . . . . 0.0 110.629 172.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.8 mt -79.08 -38.46 36.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-O 120.93 0.395 . . . . 0.0 111.0 177.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.556 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 5.0 m -80.28 10.41 4.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.285 -176.15 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.73 -43.98 5.43 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.96 0.886 . . . . 0.0 109.731 170.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.2 m -69.76 -24.89 63.59 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 113.96 -1.473 . . . . 0.0 111.517 -177.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -91.36 -31.12 16.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.72 0.772 . . . . 0.0 109.759 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.564 HG22 ' HB1' ' A' ' 9' ' ' ALA . 0.3 OUTLIER -99.12 -14.78 19.23 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.555 -1.202 . . . . 0.0 112.596 -171.469 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.93 16.48 63.19 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.462 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 19.7 t -94.25 159.43 15.13 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.25 148.97 33.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.125 0.488 . . . . 0.0 111.871 -176.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.403 ' N ' HD12 ' A' ' 34' ' ' ILE . 4.4 mp -96.42 135.32 30.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.898 176.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.593 HG13 ' HB ' ' A' ' 1' ' ' THR . 5.5 pt -129.64 164.25 41.27 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.716 -179.627 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.41 -57.24 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.995 2.463 . . . . 0.0 111.252 169.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 171.47 137.69 2.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 116.098 -0.501 . . . . 0.0 112.028 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 64.43 18.08 11.15 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.256 0.622 . . . . 0.0 111.373 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -98.18 27.93 4.34 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.685 0.755 . . . . 0.0 110.904 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.532 ' SG ' HD13 ' A' ' 35' ' ' ILE . 16.9 m -112.86 107.28 54.69 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.466 -175.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.465 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 43.6 Cg_endo -71.3 174.27 11.05 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.59 2.193 . . . . 0.0 111.142 173.015 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.97 -34.74 66.22 Favored Glycine 0 CA--C 1.521 0.408 0 N-CA-C 114.754 0.662 . . . . 0.0 114.754 -172.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -83.98 -22.84 31.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.849 0.825 . . . . 0.0 109.772 -172.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.493 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 16.2 m-85 -108.75 20.09 18.91 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.314 -175.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.83 27.11 6.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.847 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.484 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 37.8 m-80 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.116 -177.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.497 HG21 ' O ' ' A' ' 37' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 121.004 0.43 . . . . 0.0 110.226 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.491 ' HB ' ' CZ ' ' A' ' 13' ' ' PHE . 86.3 m -137.97 140.38 40.18 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.928 -176.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -114.98 111.14 20.69 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.053 -178.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.6 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 100.0 m -102.0 111.84 64.67 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.202 174.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.698 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 91.1 Cg_endo -86.98 35.89 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.851 2.367 . . . . 0.0 112.923 -177.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.1 m -155.43 131.28 9.95 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 61.2 mt -56.18 -36.8 46.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 123.537 0.523 . . . . 0.0 111.143 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.9 t -83.28 -31.12 8.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.223 0.535 . . . . 0.0 110.382 -174.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.52 -37.21 71.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.394 178.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.6 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -83.78 -22.86 31.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.15 -175.468 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 61.3 p -74.24 -30.1 62.0 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.318 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -92.88 -26.48 17.61 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.876 177.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.491 ' CZ ' ' HB ' ' A' ' 2' ' ' THR . 27.4 t80 -55.05 -52.4 63.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.551 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -61.71 -29.08 69.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.65 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.646 ' HA ' HD23 ' A' ' 18' ' ' LEU . 57.3 t -75.73 -24.28 16.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.711 176.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.818 ' O ' ' HB ' ' A' ' 21' ' ' THR . 48.6 t -88.37 0.38 56.26 Favored 'General case' 0 C--O 1.214 -0.782 0 CA-C-O 121.684 0.754 . . . . 0.0 109.623 -178.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -109.32 -21.95 12.29 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -175.123 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.752 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 3.4 pp -74.5 -36.54 2.58 Favored Pre-proline 0 N--CA 1.436 -1.16 0 N-CA-C 113.785 1.031 . . . . 0.0 113.785 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.752 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 5.8 Cg_exo -78.62 7.24 4.31 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 121.835 1.69 . . . . 0.0 112.604 -175.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.97 33.05 8.47 Favored Glycine 0 N--CA 1.444 -0.81 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.042 -178.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.818 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 1.1 m -106.11 134.14 19.9 Favored Pre-proline 0 N--CA 1.434 -1.253 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.065 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.776 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.9 Cg_endo -56.29 117.22 3.84 Favored 'Trans proline' 0 N--CA 1.446 -1.285 0 C-N-CA 123.167 2.578 . . . . 0.0 112.183 -179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -46.34 -31.52 2.63 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.839 168.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.09 -49.99 75.77 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.17 174.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.776 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tt -65.28 -44.31 88.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 18.8 m -76.17 -0.07 20.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.765 -177.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.535 ' HA ' ' HB2' ' A' ' 32' ' ' CYS . . . -94.68 -56.8 2.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.934 0.873 . . . . 0.0 109.885 168.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.1 m -58.28 -33.17 69.12 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 113.531 -1.668 . . . . 0.0 113.302 -173.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -96.43 -19.58 19.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 122.073 0.94 . . . . 0.0 110.324 -171.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 m -92.46 -25.1 18.59 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.518 -172.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.28 10.71 27.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.958 -177.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.535 ' HB2' ' HA ' ' A' ' 27' ' ' ALA . 44.1 m -95.11 167.69 11.22 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 176.171 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.2 pt -123.82 131.57 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.233 0.54 . . . . 0.0 111.334 176.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 16.2 tt -94.55 138.5 20.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.227 178.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.712 HD13 ' HB2' ' A' ' 40' ' ' CYS . 14.1 pt -119.58 160.85 40.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.348 -174.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -92.2 24.18 0.52 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.125 2.55 . . . . 0.0 113.176 178.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.497 ' O ' HG21 ' A' ' 1' ' ' THR . . . 177.01 -135.98 3.0 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.514 -0.851 . . . . 0.0 112.26 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.41 13.69 17.75 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 120.635 0.255 . . . . 0.0 111.534 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -77.64 88.25 3.93 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.296 0.569 . . . . 0.0 110.509 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.712 ' HB2' HD13 ' A' ' 35' ' ' ILE . 23.4 t -155.43 125.01 3.15 Favored Pre-proline 0 C--N 1.31 -1.135 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.321 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.31 167.98 25.92 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 123.003 2.469 . . . . 0.0 112.056 177.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.21 5.19 51.62 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 116.033 -0.531 . . . . 0.0 112.941 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -88.6 -20.85 24.45 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.698 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 14.7 m-85 -108.9 7.89 26.24 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.971 -178.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -116.53 52.32 0.94 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.736 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.8 t30 . . . . . 0 C--O 1.251 1.157 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.758 -176.574 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.555 HG21 ' HA2' ' A' ' 37' ' ' GLY . 12.2 m . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.787 HG22 ' SG ' ' A' ' 32' ' ' CYS . 3.9 m -139.5 134.03 31.69 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.019 -174.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.6 m -129.26 129.23 44.67 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.2 m -111.2 127.44 26.89 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.254 -171.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.805 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 75.8 Cg_endo -92.35 43.94 0.36 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.108 2.539 . . . . 0.0 114.113 -176.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.674 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 6.8 p -173.02 135.17 0.59 Allowed 'General case' 0 CA--C 1.517 -0.301 0 O-C-N 122.11 -0.369 . . . . 0.0 110.187 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.606 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 49.0 mt -56.29 -31.01 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.216 0.531 . . . . 0.0 111.003 -171.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.86 -53.09 28.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.956 177.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -62.06 -40.14 94.75 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.708 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.674 ' HG3' ' O ' ' A' ' 6' ' ' SER . 4.5 mtp-105 -59.01 -37.54 77.12 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.53 178.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.7 t -76.05 -35.72 59.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.565 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.9 m-20 -57.72 -42.87 84.7 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.994 174.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 2' ' ' THR . 40.6 t80 -47.56 -46.01 27.59 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.202 -179.019 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -61.76 -48.61 79.9 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.33 0.586 . . . . 0.0 110.116 177.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -72.8 -12.55 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.026 -176.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.71 ' O ' ' HB ' ' A' ' 21' ' ' THR . 69.3 m -100.63 14.83 30.15 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.547 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.56 ' HD2' ' CE1' ' A' ' 13' ' ' PHE . 36.1 mtp180 -134.27 -39.87 0.83 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.325 0.583 . . . . 0.0 110.011 176.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 tp -49.62 -54.79 27.58 Favored Pre-proline 0 CA--C 1.553 1.086 0 CA-C-N 114.709 -1.132 . . . . 0.0 113.427 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -88.5 39.29 0.49 Allowed 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 122.075 1.85 . . . . 0.0 113.794 -174.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.57 50.29 26.43 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.302 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.71 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.82 138.25 31.03 Favored Pre-proline 0 N--CA 1.435 -1.186 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.665 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.538 ' HG2' ' CB ' ' A' ' 25' ' ' LEU . 38.0 Cg_endo -70.1 126.47 13.12 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 122.763 2.309 . . . . 0.0 111.544 174.366 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.444 ' HB3' ' HE ' ' A' ' 17' ' ' ARG . 11.2 pt-20 -50.75 -32.27 19.2 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.064 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.554 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -64.7 -39.26 93.35 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.255 -178.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.538 ' CB ' ' HG2' ' A' ' 22' ' ' PRO . 34.1 tp -69.63 -46.79 65.4 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.683 0.278 . . . . 0.0 110.831 -177.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.514 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 17.1 t -67.98 -29.41 68.43 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.258 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.574 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -56.9 -46.89 81.61 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.643 0.735 . . . . 0.0 110.906 177.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 47.2 m -67.07 -28.43 68.19 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.924 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -102.7 -35.11 8.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.311 0.577 . . . . 0.0 111.435 -171.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.476 ' HB ' ' O ' ' A' ' 26' ' ' CYS . 4.6 m -87.01 -19.79 28.17 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.144 -175.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.94 25.86 8.23 Favored Glycine 0 C--N 1.331 0.292 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.355 177.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.787 ' SG ' HG22 ' A' ' 2' ' ' THR . 5.8 t -102.6 161.74 13.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.6 pt -112.25 140.92 29.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 C-N-CA 119.928 -0.709 . . . . 0.0 112.644 -174.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 24' ' ' ALA . 25.3 mm -98.91 132.7 43.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.274 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 44.5 pt -141.88 159.5 59.22 Favored Pre-proline 0 C--N 1.32 -0.682 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 53.8 Cg_endo -71.06 -16.02 32.19 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.71 2.273 . . . . 0.0 111.801 175.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.555 ' HA2' HG21 ' A' ' 1' ' ' THR . . . 111.59 130.21 5.54 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.811 176.044 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.55 -87.46 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.333 -0.434 . . . . 0.0 110.008 176.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.5 m -140.91 -15.17 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.944 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HA ' ' HD3' ' A' ' 41' ' ' PRO . 91.4 m 64.91 139.5 0.05 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.521 -171.421 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.799 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 17.4 Cg_exo -65.09 156.95 59.94 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.934 2.423 . . . . 0.0 112.503 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -27.65 63.8 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.264 -174.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.7 -31.65 13.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.678 0.752 . . . . 0.0 110.075 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.805 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 20.1 m-85 -91.75 -7.99 48.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.968 -174.125 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.478 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . . . -105.97 30.35 5.93 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.608 174.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 5.7 t30 . . . . . 0 C--O 1.247 0.929 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.996 -177.341 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.597 ' HB ' HG13 ' A' ' 35' ' ' ILE . 92.3 m . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 120.831 0.348 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.2 t -101.53 108.12 19.6 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-O 121.914 0.864 . . . . 0.0 110.656 -179.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' HG13 ' A' ' 33' ' ' ILE . 15.9 t -103.65 81.82 1.94 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.438 -173.38 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.429 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 60.2 m -105.54 134.35 19.74 Favored Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.436 178.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 61.2 Cg_endo -94.91 30.83 0.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.545 2.163 . . . . 0.0 115.245 -172.587 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.6 p -179.04 139.55 0.15 Allowed 'General case' 0 C--O 1.235 0.327 0 CA-C-N 118.846 0.748 . . . . 0.0 111.395 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.496 HG13 ' OD1' ' A' ' 46' ' ' ASN . 75.1 mt -58.37 -30.38 40.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.068 170.389 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 67.0 t -54.39 -58.66 3.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.52 175.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.04 -43.15 96.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.041 0.448 . . . . 0.0 110.666 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.476 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 21.4 tpp180 -55.06 -38.57 68.19 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.211 178.286 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 31.7 m -78.62 -10.44 59.74 Favored 'General case' 0 N--CA 1.466 0.375 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -94.55 -17.09 22.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.414 0.626 . . . . 0.0 109.778 175.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -69.22 -37.15 77.88 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.855 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -63.94 -26.05 68.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.955 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.9 t -64.81 -48.92 82.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.549 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.844 ' HB3' ' HB ' ' A' ' 21' ' ' THR . 55.8 m -67.2 -24.76 65.88 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -176.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.503 ' HD3' ' HG2' ' A' ' 23' ' ' GLU . 22.3 mmm180 -79.15 -8.76 59.25 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.976 -0.452 . . . . 0.0 111.703 -178.204 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.603 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 72.7 mt -78.02 -56.95 1.0 Allowed Pre-proline 0 N--CA 1.436 -1.148 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.281 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.603 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 81.2 Cg_endo -85.52 -4.99 9.23 Favored 'Trans proline' 0 C--N 1.359 1.131 0 C-N-CA 122.117 1.878 . . . . 0.0 113.451 -176.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.29 28.37 7.66 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.088 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.844 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 1.4 m -74.07 133.79 78.23 Favored Pre-proline 0 N--CA 1.441 -0.887 0 CA-C-O 121.208 0.528 . . . . 0.0 110.016 176.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.883 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.1 Cg_endo -62.61 120.82 8.51 Favored 'Trans proline' 0 N--CA 1.444 -1.415 0 C-N-CA 122.941 2.427 . . . . 0.0 111.008 177.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.503 ' HG2' ' HD3' ' A' ' 17' ' ' ARG . 24.2 mt-10 -45.49 -33.99 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.613 172.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.83 -47.78 84.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.405 176.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.883 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -65.06 -41.03 95.48 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -179.923 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 29.9 m -87.91 23.95 1.91 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.443 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.33 -46.25 3.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 122.171 0.986 . . . . 0.0 109.245 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -65.89 -29.24 69.64 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.259 -1.791 . . . . 0.0 112.388 -175.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 t80 -99.73 -21.51 15.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.872 0.844 . . . . 0.0 110.123 -173.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.22 -6.62 37.68 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.949 -172.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.32 36.0 28.27 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.465 178.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.3 t -127.61 153.01 46.93 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.596 HG13 ' HB3' ' A' ' 3' ' ' CYS . 25.2 pt -122.66 148.89 26.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.326 0.584 . . . . 0.0 112.033 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.2 mt -106.4 116.85 51.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.552 177.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.597 HG13 ' HB ' ' A' ' 1' ' ' THR . 25.3 pt -121.97 131.34 24.44 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.898 -178.589 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.86 -12.14 23.96 Favored 'Trans proline' 0 CA--C 1.529 0.259 0 C-N-CA 122.903 2.402 . . . . 0.0 112.282 177.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.92 -141.24 9.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.133 177.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.66 12.95 1.17 Allowed 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 -176.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.5 m -86.02 97.55 10.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.377 0.608 . . . . 0.0 110.818 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 39.6 t -158.38 107.39 1.68 Allowed Pre-proline 0 C--N 1.311 -1.103 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.536 -178.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 15.1 Cg_endo -59.55 161.92 16.38 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.851 2.368 . . . . 0.0 112.851 -177.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -69.97 1.14 18.4 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.723 -0.671 . . . . 0.0 113.594 -174.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.03 -15.49 18.23 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.518 ' CD2' ' HG2' ' A' ' 41' ' ' PRO . 19.3 m-85 -115.44 8.05 15.16 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.029 179.307 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.05 39.56 1.77 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.347 0.594 . . . . 0.0 109.573 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.4 t-20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.03 -175.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 120.77 0.319 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 28.5 m -132.65 121.22 22.83 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 174.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.597 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.5 m -124.53 117.19 23.8 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.254 0.55 . . . . 0.0 111.244 -173.006 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 20.8 m -108.55 166.74 10.31 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.704 -177.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -91.33 6.02 3.76 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 122.104 1.87 . . . . 0.0 113.351 169.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.1 m -155.62 141.5 18.12 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 121.914 -0.491 . . . . 0.0 110.993 -172.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.4 mm -61.38 -32.19 52.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 121.187 0.518 . . . . 0.0 109.74 174.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.4 t -62.78 -43.27 98.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.889 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.576 ' HA ' ' ND2' ' A' ' 12' ' ' ASN . . . -69.4 -39.84 77.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.671 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 19.6 ttm180 -64.73 -27.93 69.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.658 176.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -79.03 -48.18 14.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.368 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.576 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.1 p30 -73.78 -15.99 61.18 Favored 'General case' 0 N--CA 1.464 0.271 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.168 -178.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 23.9 t80 -48.81 -44.36 39.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 122.02 0.914 . . . . 0.0 109.286 165.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.37 -39.4 53.92 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.345 -1.298 . . . . 0.0 109.941 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.524 ' CG2' ' HA ' ' A' ' 12' ' ' ASN . 92.0 t -57.92 -46.51 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.748 -176.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 68.2 m -61.07 -38.05 84.87 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.647 ' HD2' ' HB3' ' A' ' 23' ' ' GLU . 45.9 mtp180 -79.27 -5.62 54.81 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.574 -172.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.633 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 31.9 mt -75.94 -53.6 2.32 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 6.1 Cg_exo -76.18 -24.34 11.11 Favored 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.178 1.919 . . . . 0.0 112.517 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.53 13.49 2.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.051 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 2.4 m -80.96 124.27 81.51 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.802 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.5 Cg_endo -59.94 123.54 13.44 Favored 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.236 1.958 . . . . 0.0 110.765 177.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB3' ' HD2' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -51.26 -27.94 10.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.738 169.866 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.79 -46.42 89.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.92 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.802 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.7 tt -66.63 -51.61 54.33 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 120.664 0.269 . . . . 0.0 110.426 178.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 26.6 m -66.82 -25.43 66.44 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.28 72.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.984 0.897 . . . . 0.0 110.435 174.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.4 m -81.85 -22.11 37.16 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.358 -174.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 19.9 t80 -106.18 -39.5 5.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.348 0.594 . . . . 0.0 110.707 -174.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.0 m -72.2 -31.93 66.33 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.498 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.3 18.59 38.55 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.24 -0.981 . . . . 0.0 112.287 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.6 t -105.5 139.59 39.89 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.416 HD12 HD11 ' A' ' 35' ' ' ILE . 22.6 pt -104.79 139.98 24.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.286 0.565 . . . . 0.0 111.794 -172.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 80.3 mt -100.6 124.92 54.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.917 176.178 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.827 HG21 ' HB ' ' A' ' 39' ' ' THR . 96.7 mt -129.18 137.4 30.91 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.372 -175.509 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -47.25 -48.51 14.82 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.697 2.265 . . . . 0.0 112.384 176.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.77 137.71 2.3 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.6 177.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.01 65.29 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 123.45 0.7 . . . . 0.0 112.401 175.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.827 ' HB ' HG21 ' A' ' 35' ' ' ILE . 8.9 m -151.03 26.21 0.72 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 122.224 1.012 . . . . 0.0 110.091 175.115 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD12 ' A' ' 35' ' ' ILE . 62.9 m -108.64 116.42 56.13 Favored Pre-proline 0 C--N 1.314 -0.965 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.342 -172.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 40.3 Cg_endo -69.38 162.35 42.23 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.391 2.061 . . . . 0.0 111.963 175.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.61 -28.4 67.74 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 114.947 0.739 . . . . 0.0 114.947 -172.559 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -87.78 -20.05 26.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.734 0.778 . . . . 0.0 109.778 -174.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.597 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.5 m-85 -114.16 25.31 11.22 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.185 -176.09 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.33 23.7 13.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.812 177.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 65.9 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-O 118.096 -0.954 . . . . 0.0 109.681 -177.602 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.954 ' HB ' HG23 ' A' ' 35' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.473 0.711 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.91 110.59 16.49 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -171.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.576 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 46.5 m -150.38 156.25 41.14 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.102 0.477 . . . . 0.0 111.768 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 10.1 t -144.82 143.01 19.59 Favored Pre-proline 0 N--CA 1.453 -0.301 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 47.6 Cg_exo -58.82 -27.91 85.41 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.138 2.558 . . . . 0.0 114.205 -177.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.0 m -142.01 141.93 32.89 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 -176.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.697 HG13 ' OD1' ' A' ' 46' ' ' ASN . 87.8 mt -53.39 -40.35 39.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.956 175.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -67.49 -34.3 67.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.099 0.476 . . . . 0.0 110.49 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -74.53 -36.23 63.16 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.245 0.545 . . . . 0.0 109.775 177.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -63.97 -42.13 97.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.4 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.7 p -67.73 -37.65 82.48 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.032 178.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -66.86 -34.38 77.67 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.277 0.561 . . . . 0.0 110.734 179.144 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.616 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 50.6 t80 -58.85 -53.24 60.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.117 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -55.39 -30.85 61.18 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.398 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 90.0 t -63.57 -34.18 66.05 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.476 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.52 -23.36 42.97 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.946 -0.471 . . . . 0.0 111.176 -175.386 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -74.61 -18.27 60.58 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 177.155 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 95.3 mt -63.77 -53.21 52.09 Favored Pre-proline 0 N--CA 1.442 -0.839 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -177.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.49 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 61.2 Cg_endo -73.25 2.99 5.01 Favored 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.054 1.836 . . . . 0.0 113.181 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.32 36.76 7.96 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.485 178.28 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.565 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -97.6 141.05 22.41 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 176.621 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.566 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -61.07 117.74 4.55 Favored 'Trans proline' 0 N--CA 1.446 -1.309 0 C-N-CA 122.962 2.441 . . . . 0.0 110.944 178.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.616 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 9.7 pt-20 -51.81 -29.75 20.46 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.854 175.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.18 -41.74 97.34 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.554 174.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.566 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 50.7 tp -77.52 -39.44 46.15 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-O 120.737 0.303 . . . . 0.0 110.427 179.591 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.509 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 26.6 m -64.69 -39.74 94.18 Favored 'General case' 0 C--O 1.22 -0.455 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.041 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.98 -23.59 67.26 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.57 0.7 . . . . 0.0 111.58 -178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.5 m -75.59 -22.35 57.0 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.673 -1.149 . . . . 0.0 110.316 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -104.03 -43.46 5.27 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.862 0.839 . . . . 0.0 110.13 -178.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.405 HG21 ' HB2' ' A' ' 13' ' ' PHE . 93.9 m -64.89 -55.37 19.74 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.24 -1.346 . . . . 0.0 111.849 -178.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 131.1 -24.92 4.18 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.547 -178.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.556 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 38.2 m -64.34 158.85 22.44 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.3 pt -130.16 139.55 51.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.427 -0.509 . . . . 0.0 112.293 -175.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.0 mp -85.68 125.7 40.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.954 HG23 ' HB ' ' A' ' 1' ' ' THR . 9.2 tt -129.65 110.35 17.44 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.46 0.648 . . . . 0.0 110.784 -171.057 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 34.9 Cg_exo -62.24 -32.38 82.3 Favored 'Trans proline' 0 N--CA 1.477 0.544 0 C-N-CA 123.785 2.99 . . . . 0.0 114.331 -174.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -153.41 -163.4 11.75 Favored Glycine 0 N--CA 1.44 -1.071 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.434 -177.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.56 25.97 12.22 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 123.06 0.544 . . . . 0.0 111.634 -178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 49.3 m 42.28 -99.48 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.0 -176.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 79.8 m -158.51 137.86 8.33 Favored Pre-proline 0 C--N 1.314 -0.949 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.32 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.591 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 52.5 Cg_endo -72.55 148.23 47.43 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.865 1.71 . . . . 0.0 110.796 169.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.04 10.39 14.97 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 121.364 -0.446 . . . . 0.0 113.529 -173.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -112.67 -16.28 12.83 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.628 0.728 . . . . 0.0 109.252 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.591 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 21.4 m-85 -119.93 18.67 12.48 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.352 -178.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -113.19 45.85 1.32 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.672 177.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.697 ' OD1' HG13 ' A' ' 7' ' ' ILE . 15.6 t-20 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.211 -0.899 . . . . 0.0 110.481 -175.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.535 ' HB ' HG13 ' A' ' 35' ' ' ILE . 86.1 m . . . . . 0 N--CA 1.475 0.794 0 CA-C-O 121.061 0.457 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -123.37 142.42 50.98 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.023 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 44' ' ' TYR . 22.1 p -152.48 147.96 26.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.912 0.387 . . . . 0.0 110.682 175.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.633 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 15.2 t -141.36 144.03 32.54 Favored Pre-proline 0 C--N 1.328 -0.331 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.746 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 3.6 Cg_exo -39.25 -51.86 2.5 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 124.474 3.45 . . . . 0.0 114.694 -177.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.488 ' HA ' ' HB3' ' A' ' 46' ' ' ASN . 3.8 p -147.74 160.6 42.53 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 122.29 -0.256 . . . . 0.0 111.394 -176.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.495 HG13 ' OD1' ' A' ' 46' ' ' ASN . 80.2 mt -53.82 -39.59 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.429 178.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 84.5 t -59.87 -52.92 55.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.652 0.263 . . . . 0.0 110.611 178.248 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.27 -35.46 80.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.746 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.553 ' HA ' ' HD2' ' A' ' 13' ' ' PHE . 1.0 OUTLIER -67.27 -41.01 86.23 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-O 121.231 0.539 . . . . 0.0 110.103 178.194 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.524 ' O ' HG23 ' A' ' 15' ' ' VAL . 29.7 t -57.87 -42.55 84.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.867 174.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -46.03 79.37 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.313 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.556 ' HB3' HG21 ' A' ' 30' ' ' THR . 0.8 OUTLIER -72.54 -35.19 67.99 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.856 -175.699 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -59.85 -43.15 94.8 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.921 0.391 . . . . 0.0 110.019 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 11' ' ' SER . 63.3 t -67.26 -21.37 27.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.046 177.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.424 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 14.0 t -80.99 -25.4 37.29 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 120.929 0.395 . . . . 0.0 110.749 -176.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -72.0 -41.51 67.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.052 0.453 . . . . 0.0 110.741 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.955 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -56.55 -40.5 85.42 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -171.093 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.955 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 59.6 Cg_endo -74.1 0.6 8.21 Favored 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 121.522 1.481 . . . . 0.0 113.377 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.29 34.08 4.63 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.476 178.181 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.532 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -104.36 135.82 19.27 Favored Pre-proline 0 N--CA 1.436 -1.143 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.677 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.654 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.0 Cg_endo -63.74 127.71 20.33 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 122.848 2.366 . . . . 0.0 111.053 176.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.536 ' CD ' ' H ' ' A' ' 23' ' ' GLU . 1.5 mp0 -37.56 -40.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.346 172.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.43 -50.07 72.72 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.162 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.654 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -63.98 -36.42 83.91 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.107 0.479 . . . . 0.0 110.088 177.812 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 21.5 m -79.02 10.83 3.11 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.249 -179.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.25 -38.85 5.86 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.847 0.832 . . . . 0.0 110.359 171.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -69.59 -29.56 67.12 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.975 -1.466 . . . . 0.0 112.324 -173.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -103.77 -31.74 9.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.732 0.777 . . . . 0.0 109.913 -175.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.556 HG21 ' HB3' ' A' ' 13' ' ' PHE . 15.6 m -78.51 -33.1 48.3 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 114.426 -1.261 . . . . 0.0 111.684 -175.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.85 0.55 36.39 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.913 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.1 m -85.69 155.02 21.26 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.412 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.6 pt -120.43 144.98 27.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.398 0.618 . . . . 0.0 111.965 -176.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 79.5 mt -107.87 127.44 63.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.178 175.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HB2' ' A' ' 40' ' ' CYS . 24.3 pt -132.32 134.11 24.55 Favored Pre-proline 0 C--N 1.319 -0.76 0 CA-C-O 120.936 0.398 . . . . 0.0 111.476 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 -9.81 15.7 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.625 2.217 . . . . 0.0 111.176 173.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.01 -142.34 7.76 Favored Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.62 15.34 7.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 120.732 0.301 . . . . 0.0 111.181 -177.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.5 m -80.29 86.32 5.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.51 0.672 . . . . 0.0 110.751 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.545 ' HB2' HD13 ' A' ' 35' ' ' ILE . 42.1 t -158.29 116.26 1.78 Allowed Pre-proline 0 C--N 1.311 -1.108 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.672 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.96 166.65 28.94 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.415 2.076 . . . . 0.0 112.692 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.46 10.9 14.9 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.084 -177.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -98.43 -18.84 18.04 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.746 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 17.4 m-85 -120.0 18.4 12.44 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.827 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -115.09 47.25 1.31 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.212 -175.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.495 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.3 t-20 . . . . . 0 C--O 1.246 0.885 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.389 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' THR . . . . . 0.497 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 88.7 m . . . . . 0 N--CA 1.473 0.685 0 CA-C-O 121.131 0.491 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.46 HG23 HG12 ' A' ' 34' ' ' ILE . 40.2 m -128.92 112.01 13.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.729 -176.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' CYS . 73.2 m -75.5 90.82 2.75 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 176.124 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.506 ' SG ' HG21 ' A' ' 30' ' ' THR . 1.4 t -125.35 87.8 55.11 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -177.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.63 78.73 2.99 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 123.418 2.745 . . . . 0.0 114.025 -167.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.742 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 29.2 t 172.21 132.87 0.03 OUTLIER 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 171.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.667 ' H ' HD12 ' A' ' 7' ' ' ILE . 3.7 mp -62.93 -31.57 52.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.2 t -80.08 -47.26 21.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.173 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.742 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -60.75 -48.4 81.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.68 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 1.8 ptp180 -62.75 -25.09 68.03 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.621 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.471 ' O ' HG23 ' A' ' 15' ' ' VAL . 67.6 m -69.09 -56.49 7.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.029 178.195 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.474 ' HA ' ' HB ' ' A' ' 15' ' ' VAL . 11.2 p30 -64.32 -22.38 66.93 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.634 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.42 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 61.8 t80 -59.12 -59.69 5.05 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.653 170.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 17' ' ' ARG . 2.3 p-10 -71.73 -27.1 62.77 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.877 0.37 . . . . 0.0 110.903 -178.496 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.474 ' HB ' ' HA ' ' A' ' 12' ' ' ASN . 78.1 t -70.31 -17.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.006 0.431 . . . . 0.0 110.263 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.676 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 3.8 t -84.66 -29.03 26.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.417 0.627 . . . . 0.0 109.707 177.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.451 ' HB3' ' O ' ' A' ' 14' ' ' ASN . 6.9 tpt180 -58.42 -40.72 83.23 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.383 175.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.566 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 86.1 mt -61.08 -50.29 85.09 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 113.775 1.028 . . . . 0.0 113.775 -172.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.676 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 7.9 Cg_exo -73.39 13.56 0.69 Allowed 'Trans proline' 0 C--N 1.358 1.079 0 C-N-CA 122.581 2.187 . . . . 0.0 113.507 -177.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.23 36.85 9.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.897 176.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -108.79 134.9 20.17 Favored Pre-proline 0 N--CA 1.434 -1.27 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 176.887 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.752 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -60.18 122.51 11.48 Favored 'Trans proline' 0 N--CA 1.446 -1.29 0 C-N-CA 122.951 2.434 . . . . 0.0 111.121 178.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -35.84 -39.56 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.398 169.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.56 -53.39 58.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.192 176.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.752 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tm? -63.71 -37.2 86.46 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-O 121.004 0.431 . . . . 0.0 110.782 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 23.9 m -65.04 -37.43 87.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.358 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.52 -32.4 74.02 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.804 0.811 . . . . 0.0 110.462 176.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.8 m -74.89 -22.5 58.6 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 114.47 -1.241 . . . . 0.0 110.761 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -89.45 -45.58 9.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.864 0.84 . . . . 0.0 109.024 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.506 HG21 ' SG ' ' A' ' 4' ' ' CYS . 85.0 m -70.89 -37.79 73.01 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.002 -1.454 . . . . 0.0 111.061 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.04 16.89 17.65 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.904 -0.665 . . . . 0.0 113.017 179.11 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.592 ' HB2' ' O ' ' A' ' 3' ' ' CYS . 10.7 p -114.24 179.53 3.93 Favored 'General case' 0 C--N 1.327 -0.395 0 O-C-N 122.725 -0.279 . . . . 0.0 110.721 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.46 HD13 ' H ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -127.77 141.88 45.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 111.563 -173.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.46 HG12 HG23 ' A' ' 2' ' ' THR . 60.3 mt -99.44 140.17 19.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.777 176.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' HB3' ' A' ' 38' ' ' ALA . 11.2 pt -137.91 129.14 15.94 Favored Pre-proline 0 N--CA 1.448 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 111.388 -177.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 32.6 Cg_exo -61.62 -27.77 81.94 Favored 'Trans proline' 0 CA--C 1.53 0.307 0 C-N-CA 123.029 2.486 . . . . 0.0 112.639 176.608 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.457 ' C ' ' H ' ' A' ' 39' ' ' THR . . . -132.94 -153.46 7.22 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.927 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.845 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 71.69 -29.04 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.904 0.881 . . . . 0.0 111.898 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' C ' ' A' ' 37' ' ' GLY . 52.2 m 65.81 5.45 3.41 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.331 0.652 . . . . 0.0 112.512 176.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 66.9 m 65.59 137.46 0.05 OUTLIER Pre-proline 0 N--CA 1.468 0.465 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.141 -175.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -74.62 175.85 10.54 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.418 2.079 . . . . 0.0 111.698 175.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -73.94 -0.82 57.49 Favored Glycine 0 CA--C 1.518 0.235 0 C-N-CA 121.363 -0.446 . . . . 0.0 113.12 -175.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -98.07 -22.25 16.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.193 0.52 . . . . 0.0 109.612 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.541 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 16.0 m-85 -121.44 19.95 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.679 -173.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.11 14.8 29.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.393 0.616 . . . . 0.0 110.77 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 18.3 m120 . . . . . 0 C--O 1.247 0.971 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.681 179.404 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.421 ' HB ' HG13 ' A' ' 35' ' ' ILE . 13.0 m . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 121.016 0.436 . . . . 0.0 109.933 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.7 t -98.99 122.65 42.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.518 0.675 . . . . 0.0 110.526 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 61.9 m -121.43 122.49 39.89 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.08 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.9 t -147.52 141.0 15.3 Favored Pre-proline 0 N--CA 1.448 -0.561 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -103.0 40.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.05 2.5 . . . . 0.0 113.957 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.9 t -158.26 135.52 10.09 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.622 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.8 mt -69.34 -28.0 36.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.356 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.7 t -83.5 -25.29 7.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.875 -175.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.36 -50.23 8.01 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.055 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.508 ' NH2' ' H ' ' A' ' 4' ' ' CYS . 7.3 tpp180 -53.5 -39.83 64.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.358 177.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.4 p -62.41 -61.71 2.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.644 0.259 . . . . 0.0 111.222 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -64.52 -24.07 67.48 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.469 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.429 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 56.7 t80 -59.17 -58.14 9.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.064 173.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -70.2 -30.56 67.7 Favored 'General case' 0 CA--C 1.529 0.139 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.898 -179.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 11' ' ' SER . 72.0 t -65.2 -30.16 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.351 . . . . 0.0 110.707 176.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -71.74 -27.16 62.8 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.297 0.57 . . . . 0.0 110.574 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.596 ' HA ' ' O ' ' A' ' 21' ' ' THR . 46.5 tpt85 -76.49 -17.71 59.14 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.205 -178.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.417 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 77.9 mt -68.57 -52.29 19.94 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -175.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.417 ' HD2' ' N ' ' A' ' 18' ' ' LEU . 56.4 Cg_endo -69.72 -6.28 18.19 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.262 1.975 . . . . 0.0 113.271 -177.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.92 25.87 4.94 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.2 OUTLIER -103.19 128.65 27.15 Favored Pre-proline 0 N--CA 1.439 -0.99 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.457 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.772 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 12.7 Cg_endo -58.43 121.99 10.9 Favored 'Trans proline' 0 N--CA 1.449 -1.146 0 C-N-CA 122.577 2.184 . . . . 0.0 110.752 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.57 ' H ' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -50.67 -29.19 10.5 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.937 173.459 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.16 -46.95 87.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.976 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.772 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -67.5 -46.69 72.16 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 120.971 0.415 . . . . 0.0 109.992 177.841 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 6.9 m -62.66 -35.54 79.97 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.828 -177.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.541 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -58.41 -40.45 82.46 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 111.266 178.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.6 m -66.28 -22.75 66.31 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.528 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -86.11 -47.03 9.9 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.124 176.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.464 ' HB ' ' SG ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -69.39 -36.99 77.31 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 -177.28 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.67 -22.24 36.28 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.141 -172.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 3.2 m -60.94 116.31 4.38 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.2 pt -91.68 150.5 3.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.925 0.393 . . . . 0.0 111.866 -172.043 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 69.4 mt -116.14 107.93 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.37 0.605 . . . . 0.0 109.617 174.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.726 HD12 ' HB3' ' A' ' 38' ' ' ALA . 15.3 pt -116.0 152.81 48.06 Favored Pre-proline 0 C--N 1.314 -0.95 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.91 -175.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -59.38 -64.71 0.1 OUTLIER 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 123.049 2.499 . . . . 0.0 112.41 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.39 -142.47 8.94 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 62.52 80.37 0.23 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.388 0.613 . . . . 0.0 110.939 177.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.63 96.63 0.13 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.745 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 44' ' ' TYR . 62.5 m -59.59 144.11 85.3 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.181 177.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.582 ' HD2' ' HD2' ' A' ' 44' ' ' TYR . 57.2 Cg_endo -70.96 -175.13 1.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.974 2.449 . . . . 0.0 113.25 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.41 7.1 33.4 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.488 -0.778 . . . . 0.0 114.428 -170.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.549 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 16.7 p-10 -108.45 -17.51 13.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 176.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.674 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . 22.2 m-85 -102.74 0.73 33.35 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.612 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.01 18.38 18.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.424 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.5 t-20 . . . . . 0 C--O 1.253 1.252 0 CA-C-O 118.251 -0.88 . . . . 0.0 110.215 -179.213 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.1 m . . . . . 0 N--CA 1.476 0.844 0 CA-C-O 120.782 0.325 . . . . 0.0 110.375 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 34' ' ' ILE . 22.8 m -89.08 123.92 33.81 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.817 0.341 . . . . 0.0 110.47 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 63.8 m -124.25 106.7 10.49 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.559 ' HB3' ' HB3' ' A' ' 10' ' ' ARG . 7.8 t -100.76 132.6 21.97 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.054 -178.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.615 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.7 Cg_endo -86.05 34.21 0.47 Allowed 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.97 2.447 . . . . 0.0 112.982 -177.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.62 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 38.6 t -164.88 133.28 3.35 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-O 120.983 0.42 . . . . 0.0 110.573 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.31 -26.7 34.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.186 -0.916 . . . . 0.0 109.113 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.1 t -82.77 -47.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.088 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.62 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -61.78 -43.24 99.24 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.966 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.559 ' HB3' ' HB3' ' A' ' 4' ' ' CYS . 6.0 ptp180 -65.41 -28.23 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.095 0.474 . . . . 0.0 110.69 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.515 ' O ' HG23 ' A' ' 15' ' ' VAL . 42.4 m -72.62 -40.59 66.34 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.357 176.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -65.8 -28.69 69.19 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.632 179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.24 -50.63 72.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.972 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -66.0 -26.42 67.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.192 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 11' ' ' SER . 84.5 t -68.2 -34.49 66.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.699 -179.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.499 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.0 t -82.26 -24.5 34.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 121.371 0.605 . . . . 0.0 110.393 -178.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 17' ' ' ARG . 23.6 ttt180 -80.5 -13.05 59.42 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.482 -178.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 8.2 mt -71.76 -52.1 8.38 Favored Pre-proline 0 N--CA 1.444 -0.745 0 CA-C-N 115.998 -0.547 . . . . 0.0 112.447 -177.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 6.4 Cg_exo -75.01 18.39 0.54 Allowed 'Trans proline' 0 C--N 1.358 1.051 0 C-N-CA 122.538 2.159 . . . . 0.0 113.11 -178.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 78.9 40.15 18.14 Favored Glycine 0 N--CA 1.443 -0.897 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.526 178.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.45 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 3.0 m -107.08 135.96 19.53 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 175.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.579 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 11.0 Cg_endo -57.24 116.65 3.36 Favored 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 122.938 2.425 . . . . 0.0 111.411 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -39.83 -34.94 0.3 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.903 170.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.62 -49.32 73.76 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.183 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.579 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 45.0 tp -68.55 -36.4 78.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-O 120.852 0.358 . . . . 0.0 110.199 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 36.0 m -66.78 -42.37 86.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.237 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -61.65 -24.64 66.86 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.657 0.741 . . . . 0.0 111.653 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.2 m -76.13 -22.62 55.27 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.984 -178.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -109.52 -42.69 4.25 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.332 0.587 . . . . 0.0 110.784 -177.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 63.5 m -62.86 -37.88 88.61 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.186 -178.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 108.65 -15.85 34.49 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.753 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.464 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 34.5 m -71.05 133.4 46.27 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 176.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 36.4 pt -103.96 141.22 20.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.233 0.539 . . . . 0.0 111.383 -175.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 68.8 mt -108.15 107.73 23.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.977 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.88 HG22 ' H ' ' A' ' 37' ' ' GLY . 5.0 mp -89.86 130.21 43.62 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.05 -179.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.55 -13.31 38.61 Favored 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.836 2.357 . . . . 0.0 112.235 175.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.88 ' H ' HG22 ' A' ' 35' ' ' ILE . . . -91.03 -137.35 7.22 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.903 176.013 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -157.45 15.9 0.26 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.613 0.244 . . . . 0.0 111.387 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.9 m -120.02 105.51 11.11 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.093 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.7 p -134.47 135.96 24.79 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.51 173.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.47 ' HG2' ' OD1' ' A' ' 43' ' ' ASP . 53.3 Cg_endo -67.15 176.6 4.47 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.748 2.299 . . . . 0.0 112.802 -176.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -84.24 24.94 5.82 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.589 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.47 ' OD1' ' HG2' ' A' ' 41' ' ' PRO . 11.3 p-10 -112.22 -18.29 12.57 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 170.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.615 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 17.7 m-85 -98.4 3.6 48.47 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.789 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.56 18.82 21.39 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.824 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 . . . . . 0 C--O 1.246 0.904 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.732 -179.123 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.476 0.827 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -98.26 136.4 38.5 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-O 120.921 0.391 . . . . 0.0 112.017 -176.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 96.9 m -134.18 112.72 11.34 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 173.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 41.4 m -101.56 152.5 38.06 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.911 -173.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -99.74 24.67 0.18 Allowed 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.722 2.282 . . . . 0.0 113.598 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 t -174.03 132.5 0.41 Allowed 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 121.118 0.485 . . . . 0.0 110.269 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.489 ' HA ' ' HB3' ' A' ' 10' ' ' ARG . 59.3 mt -69.79 -19.97 23.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.154 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -71.36 -41.99 73.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.525 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -66.08 -48.17 71.84 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.8 174.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.489 ' HB3' ' HA ' ' A' ' 7' ' ' ILE . 4.0 tpp180 -50.97 -41.78 59.56 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.167 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.42 ' O ' HG23 ' A' ' 15' ' ' VAL . 41.5 t -58.76 -55.19 38.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.522 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.406 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.0 p30 -71.04 -26.89 63.29 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.246 -178.276 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -62.22 -50.44 71.75 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.615 173.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -54.98 -44.19 74.22 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.674 178.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 11' ' ' SER . 57.7 t -67.5 -27.11 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.455 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 35.2 t -83.93 -43.18 15.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 121.01 0.433 . . . . 0.0 111.035 -176.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -76.38 -10.88 59.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.021 0.439 . . . . 0.0 111.409 -177.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.406 ' N ' ' HD2' ' A' ' 19' ' ' PRO . 5.4 mt -69.95 -51.12 15.34 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -176.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 48.9 Cg_endo -71.8 -8.78 23.72 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.292 1.995 . . . . 0.0 113.131 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.11 19.1 5.27 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.347 -0.93 . . . . 0.0 113.312 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.477 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 3.1 m -83.66 137.33 41.48 Favored Pre-proline 0 N--CA 1.431 -1.383 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.477 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 21.0 Cg_endo -63.74 125.93 16.42 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.564 2.176 . . . . 0.0 110.511 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -42.14 -26.5 0.1 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.298 -0.865 . . . . 0.0 111.412 170.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 34' ' ' ILE . . . -51.09 -54.14 27.71 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.769 0.319 . . . . 0.0 110.934 171.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.2 tt -67.69 -41.29 83.88 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 109.85 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.0 m -81.51 9.05 8.09 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.3 -175.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.464 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -109.64 -49.2 3.13 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.859 0.838 . . . . 0.0 110.302 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -64.37 -33.26 75.45 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 113.859 -1.518 . . . . 0.0 112.37 -173.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -96.57 -15.19 21.73 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.228 1.014 . . . . 0.0 109.527 -176.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.525 HG22 ' HB1' ' A' ' 9' ' ' ALA . 55.7 m -96.32 -25.89 15.59 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 113.791 -1.55 . . . . 0.0 112.279 -172.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.66 7.33 57.89 Favored Glycine 0 C--N 1.328 0.093 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.464 ' HB3' ' HA ' ' A' ' 27' ' ' ALA . 19.8 t -92.92 157.85 16.13 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.2 pt -118.43 160.49 18.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.573 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.44 ' CD1' ' HA ' ' A' ' 24' ' ' ALA . 69.9 mt -122.31 137.37 56.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.599 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.521 ' H ' HD13 ' A' ' 35' ' ' ILE . 0.2 OUTLIER -130.66 157.27 78.19 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 176.268 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 45.5 Cg_endo -70.54 -28.12 21.89 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.497 2.131 . . . . 0.0 112.263 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.73 -140.5 11.29 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.006 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -152.65 12.93 0.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.685 0.279 . . . . 0.0 111.353 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.2 m -90.54 104.98 17.5 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.254 0.549 . . . . 0.0 110.0 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 94.9 m -129.43 131.68 23.77 Favored Pre-proline 0 C--N 1.311 -1.085 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.954 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -69.81 176.09 7.27 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.697 2.265 . . . . 0.0 112.499 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.51 3.06 26.92 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 116.069 -0.514 . . . . 0.0 113.755 -175.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -94.36 -22.34 18.39 Favored 'General case' 0 CA--C 1.513 -0.481 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.609 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -121.17 20.71 11.37 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.273 -1.331 . . . . 0.0 109.661 -176.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -99.37 16.37 23.28 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.031 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.737 -0.649 . . . . 0.0 109.566 -178.7 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 60.2 m . . . . . 0 N--CA 1.476 0.874 0 CA-C-O 120.835 0.35 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.624 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 26.8 m -104.27 118.37 36.46 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.747 178.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 62.6 m -108.87 128.14 54.65 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.344 -174.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.5 m -128.98 132.55 24.44 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.548 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.782 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 67.2 Cg_endo -90.84 23.82 0.62 Allowed 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.899 2.399 . . . . 0.0 114.245 -177.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.1 p -171.01 149.38 2.92 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 122.07 -0.394 . . . . 0.0 111.438 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 58.7 mt -65.22 -29.45 47.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.156 178.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.5 t -76.63 -38.81 31.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.833 -176.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -72.88 -41.99 64.11 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 10.7 tpp180 -54.4 -36.76 64.29 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.721 177.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.507 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 4.0 p -79.52 -55.09 5.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.66 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 p30 -60.88 -24.27 65.83 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 121.218 0.533 . . . . 0.0 110.787 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.647 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 71.0 t80 -61.39 -60.51 3.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.586 173.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.507 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 8.5 p30 -69.49 -28.59 66.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.673 -175.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 93.6 t -71.52 -23.61 22.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.394 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.502 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.5 t -76.86 -32.06 57.25 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 121.996 -0.44 . . . . 0.0 110.595 -179.157 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.616 ' HA ' ' O ' ' A' ' 21' ' ' THR . 1.7 ptm180 -87.19 -0.06 56.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.194 0.521 . . . . 0.0 110.697 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.538 ' HB3' ' HD3' ' A' ' 19' ' ' PRO . 63.9 tp -70.32 -53.32 10.56 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.662 179.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.538 ' HD3' ' HB3' ' A' ' 18' ' ' LEU . 91.1 Cg_endo -82.2 28.03 0.58 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.171 1.914 . . . . 0.0 113.759 -177.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.94 39.53 8.57 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.317 175.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.616 ' O ' ' HA ' ' A' ' 17' ' ' ARG . 0.8 OUTLIER -115.37 136.56 22.74 Favored Pre-proline 0 N--CA 1.437 -1.093 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 174.917 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.869 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 17.7 Cg_endo -63.2 120.99 8.67 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 122.617 2.211 . . . . 0.0 111.047 175.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 11.0 pt-20 -56.88 -23.71 46.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.243 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.505 ' HA ' HD12 ' A' ' 34' ' ' ILE . . . -63.34 -41.95 98.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.729 173.277 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.869 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.5 OUTLIER -71.8 -39.12 70.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 120.903 0.382 . . . . 0.0 110.215 176.795 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 34.3 m -66.97 -36.96 83.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.041 -178.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.4 -36.15 73.13 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.785 0.802 . . . . 0.0 110.898 176.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -69.04 -23.79 64.1 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 114.093 -1.412 . . . . 0.0 111.129 -176.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -102.65 -46.07 4.84 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.626 0.727 . . . . 0.0 110.02 -176.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.5 m -59.95 -44.36 94.45 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 114.626 -1.17 . . . . 0.0 112.172 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.78 -9.16 14.49 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.28 -0.962 . . . . 0.0 112.037 -176.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 94.7 m -71.38 158.8 35.68 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 175.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 26.3 pt -126.39 139.59 51.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.963 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.505 HD12 ' HA ' ' A' ' 24' ' ' ALA . 71.3 mt -112.32 103.28 15.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.791 177.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 34.1 pt -107.83 148.28 37.07 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.142 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -76.93 12.06 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.997 2.465 . . . . 0.0 112.387 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -130.45 -147.39 6.13 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -141.74 21.86 2.14 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.163 0.506 . . . . 0.0 110.273 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 m -79.98 72.25 6.74 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.396 -175.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 90.9 m -128.29 131.51 23.82 Favored Pre-proline 0 C--N 1.309 -1.168 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.287 176.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.23 174.55 8.88 Favored 'Trans proline' 0 CA--C 1.531 0.348 0 C-N-CA 122.595 2.196 . . . . 0.0 111.903 176.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.98 26.21 1.47 Allowed Glycine 0 CA--C 1.521 0.424 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.236 -176.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 24.7 t70 -115.38 -29.78 6.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.782 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 10.4 m-85 -105.91 5.18 30.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.967 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.61 17.11 23.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.913 -174.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.0 t30 . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.086 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.598 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 23.5 m . . . . . 0 N--CA 1.473 0.682 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.483 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 21.9 m -134.16 124.16 25.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.011 -176.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.458 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 82.6 m -128.16 142.84 51.06 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.664 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 0.5 OUTLIER -128.42 151.66 76.96 Favored Pre-proline 0 C--N 1.32 -0.676 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.505 -175.716 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.664 ' HD2' ' SG ' ' A' ' 4' ' ' CYS . 88.8 Cg_endo -82.05 1.66 9.06 Favored 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.955 2.436 . . . . 0.0 113.958 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.8 p -160.9 155.55 23.64 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 121.88 -0.512 . . . . 0.0 110.94 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 59.2 mt -73.05 -28.58 26.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.421 178.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.6 t -67.87 -44.43 85.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.766 -178.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.411 ' HA ' HD21 ' A' ' 12' ' ' ASN . . . -66.34 -45.2 81.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.961 177.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -54.2 -39.27 66.53 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.38 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.4 m -60.5 -55.07 37.88 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.641 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.411 HD21 ' HA ' ' A' ' 9' ' ' ALA . 11.3 p30 -75.28 -22.62 57.62 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.02 0.438 . . . . 0.0 110.906 -176.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CZ ' HG21 ' A' ' 2' ' ' THR . 44.8 t80 -58.16 -53.41 58.62 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.086 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -61.96 -29.89 70.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.783 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 79.5 t -65.26 -33.23 62.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.89 178.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.548 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 39.8 t -75.71 -21.35 57.63 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 121.469 0.652 . . . . 0.0 110.151 -178.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.663 ' HD3' ' HG3' ' A' ' 23' ' ' GLU . 27.3 tpt180 -74.68 -26.45 59.85 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.013 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 97.6 mt -62.52 -49.22 84.35 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -175.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 13.7 Cg_exo -70.54 -5.41 16.62 Favored 'Trans proline' 0 C--N 1.361 1.19 0 C-N-CA 122.226 1.951 . . . . 0.0 112.995 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.69 28.92 7.62 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.461 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.596 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -90.68 140.87 26.6 Favored Pre-proline 0 N--CA 1.431 -1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 177.769 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.706 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 14.4 Cg_endo -62.05 121.76 9.95 Favored 'Trans proline' 0 N--CA 1.443 -1.462 0 C-N-CA 122.941 2.427 . . . . 0.0 110.857 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.663 ' HG3' ' HD3' ' A' ' 17' ' ' ARG . 1.1 mp0 -45.93 -32.35 2.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.059 173.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.2 -48.11 82.82 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.066 175.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.706 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.2 tt -66.68 -44.49 81.67 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.095 178.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.493 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 14.0 m -66.76 -40.4 88.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.508 -176.017 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.02 -42.21 93.84 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.519 0.676 . . . . 0.0 111.021 178.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.3 m -68.22 -21.87 64.82 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.353 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.8 t80 -100.7 -38.09 8.45 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.674 0.75 . . . . 0.0 109.847 -174.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.6 m -75.65 -57.68 3.74 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.596 -1.184 . . . . 0.0 112.024 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.0 -20.38 2.14 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 119.705 -1.236 . . . . 0.0 112.527 -176.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 30.7 m -66.83 155.91 37.01 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 175.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 33.1 pt -120.55 148.84 23.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.331 -0.547 . . . . 0.0 111.814 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 50.8 mm -102.13 139.22 23.77 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.344 176.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.598 ' O ' ' HB ' ' A' ' 1' ' ' THR . 3.1 pt -146.31 151.37 43.87 Favored Pre-proline 0 C--N 1.316 -0.859 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.25 -179.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -87.75 30.99 0.44 Allowed 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.498 2.799 . . . . 0.0 112.233 178.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.51 137.79 4.81 Favored Glycine 0 N--CA 1.446 -0.676 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.699 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.29 30.17 0.34 Allowed 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.057 0.456 . . . . 0.0 111.58 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.8 m -80.38 48.66 1.05 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.511 0.672 . . . . 0.0 111.632 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.584 ' SG ' HD11 ' A' ' 35' ' ' ILE . 76.3 m -94.29 126.38 48.6 Favored Pre-proline 0 C--N 1.313 -1.003 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.699 177.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -75.03 176.36 10.02 Favored 'Trans proline' 0 CA--C 1.531 0.352 0 C-N-CA 122.762 2.308 . . . . 0.0 112.36 176.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -72.95 -8.69 74.17 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 114.572 0.589 . . . . 0.0 114.572 -171.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -94.99 -22.12 18.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.831 0.824 . . . . 0.0 109.294 -179.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.458 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 20.8 m-85 -107.23 18.07 22.12 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.278 -178.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.01 33.46 0.79 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.261 -177.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.411 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 16.6 m-80 . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.791 -0.623 . . . . 0.0 109.497 179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.546 ' HB ' HG13 ' A' ' 35' ' ' ILE . 7.5 m . . . . . 0 N--CA 1.475 0.798 0 CA-C-O 120.782 0.325 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.405 HG21 ' CZ ' ' A' ' 13' ' ' PHE . 7.3 m -90.57 115.02 27.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.103 0.478 . . . . 0.0 110.785 178.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.403 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.4 m -115.08 144.56 43.45 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.599 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.4 t -156.28 110.82 2.07 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.012 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.567 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 96.7 Cg_endo -84.61 45.4 1.68 Allowed 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.971 2.447 . . . . 0.0 113.881 -173.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m -158.17 127.28 5.69 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.4 mp -64.85 -36.96 78.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.9 t -62.59 -38.8 82.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.326 -1.307 . . . . 0.0 110.251 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.4 22.07 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.26 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.3 tpp180 -50.89 -43.45 59.65 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.833 175.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.543 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.7 m -53.7 -55.01 29.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.423 0.154 . . . . 0.0 111.378 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -76.65 -23.03 53.29 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.398 -0.521 . . . . 0.0 110.608 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.405 ' CZ ' HG21 ' A' ' 2' ' ' THR . 34.7 t80 -65.48 -49.07 70.44 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.114 175.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -59.97 -32.64 71.01 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.127 0.489 . . . . 0.0 109.843 174.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 11' ' ' SER . 92.8 t -72.82 -24.0 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.99 177.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.4 t -86.26 5.71 33.09 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-O 121.753 0.787 . . . . 0.0 109.62 -178.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.479 ' NE ' ' HG3' ' A' ' 23' ' ' GLU . 13.7 mmm180 -106.3 -23.53 12.53 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.556 0.693 . . . . 0.0 109.185 178.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -56.92 -47.62 98.77 Favored Pre-proline 0 CA--C 1.547 0.846 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.131 175.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.441 ' HG2' ' OG1' ' A' ' 21' ' ' THR . 82.3 Cg_endo -79.61 4.16 6.91 Favored 'Trans proline' 0 C--N 1.36 1.17 0 C-N-CA 121.779 1.653 . . . . 0.0 113.037 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.72 20.86 45.64 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.505 176.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.685 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -81.06 142.46 51.62 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 177.206 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.685 ' HD2' HG22 ' A' ' 21' ' ' THR . 38.2 Cg_endo -70.85 130.44 17.99 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 C-N-CA 123.156 2.571 . . . . 0.0 111.494 176.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.479 ' HG3' ' NE ' ' A' ' 17' ' ' ARG . 51.4 mt-10 -41.83 -36.08 0.96 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.485 171.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -51.71 -52.1 50.96 Favored 'General case' 0 C--N 1.33 -0.266 0 O-C-N 123.381 0.426 . . . . 0.0 110.857 175.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.527 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -68.19 -41.62 81.12 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.167 179.063 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 7.5 m -80.57 12.17 3.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.523 -176.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -108.05 -48.28 3.41 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 121.894 0.854 . . . . 0.0 110.104 173.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.0 m -62.73 -29.62 70.81 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-N 113.817 -1.538 . . . . 0.0 112.117 -174.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -95.86 -22.5 17.42 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.885 0.85 . . . . 0.0 110.117 -175.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.0 m -93.21 -38.61 11.46 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.528 -1.214 . . . . 0.0 111.82 -171.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.74 -18.68 8.58 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.433 -177.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 6.6 m -64.9 150.48 47.73 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 32.9 pt -122.3 149.09 25.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.085 0.469 . . . . 0.0 111.495 -177.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.5 mt -111.28 110.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.829 176.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.909 HD12 ' HB3' ' A' ' 38' ' ' ALA . 5.7 pt -108.52 129.36 24.11 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.907 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.09 -32.31 17.43 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.435 2.09 . . . . 0.0 112.68 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.07 117.91 0.83 Allowed Glycine 0 N--CA 1.447 -0.617 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.909 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 165.2 102.0 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.741 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -172.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.41 94.39 0.01 OUTLIER 'General case' 0 N--CA 1.435 -1.216 0 O-C-N 123.884 0.74 . . . . 0.0 110.377 172.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 45' ' ' ALA . 4.2 t -65.92 120.52 69.8 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.356 -175.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.41 170.27 20.66 Favored 'Trans proline' 0 C--O 1.236 0.379 0 C-N-CA 122.766 2.311 . . . . 0.0 112.473 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.75 20.7 7.39 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.008 -173.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -119.1 -11.53 9.61 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 174.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.567 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 19.6 m-85 -113.81 0.11 14.38 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.756 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.402 ' HB2' ' SG ' ' A' ' 40' ' ' CYS . . . -135.9 64.99 1.55 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 120.962 0.41 . . . . 0.0 110.431 -177.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.7 m120 . . . . . 0 C--O 1.245 0.861 0 CA-C-O 118.582 -0.723 . . . . 0.0 109.304 175.608 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 87.0 m . . . . . 0 N--CA 1.477 0.897 0 CA-C-O 120.554 0.216 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.444 ' OG1' HG12 ' A' ' 34' ' ' ILE . 31.1 m -97.33 112.49 24.28 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.129 0.49 . . . . 0.0 110.274 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.638 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 74.3 m -105.98 146.63 29.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.082 -176.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.455 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 2.1 t -136.8 141.99 37.13 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 5.4 Cg_exo -78.59 17.12 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.789 2.326 . . . . 0.0 115.043 -171.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -170.29 150.78 3.66 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 118.975 0.807 . . . . 0.0 110.755 177.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.753 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 3.3 mp -64.66 -33.52 63.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.893 0.854 . . . . 0.0 109.107 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 42.9 t -65.16 -51.09 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.754 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.84 -34.15 69.03 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.4 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.753 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -68.21 -25.22 65.11 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.454 0.645 . . . . 0.0 109.93 -179.675 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.473 ' HA ' ' ND2' ' A' ' 14' ' ' ASN . 69.8 m -67.91 -47.42 68.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.903 172.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -55.27 -39.66 70.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.195 0.522 . . . . 0.0 109.879 176.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 5.8 t80 -53.0 -56.65 14.47 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 114.954 -1.021 . . . . 0.0 112.097 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.473 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 11.9 p30 -74.8 -31.39 61.71 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 121.2 -0.2 . . . . 0.0 111.213 -174.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 11' ' ' SER . 96.6 t -70.52 -30.9 44.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 111.131 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.406 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 43.2 t -74.64 -22.9 58.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.935 -178.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.695 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 74.2 mtm180 -77.98 -22.22 49.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.579 0.228 . . . . 0.0 111.172 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.6 mt -54.45 -50.58 84.37 Favored Pre-proline 0 N--CA 1.443 -0.816 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 -176.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.406 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 55.6 Cg_endo -72.14 5.0 2.87 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.099 1.866 . . . . 0.0 113.089 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.71 28.14 9.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.936 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.67 133.48 24.48 Favored Pre-proline 0 N--CA 1.438 -1.037 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.694 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 18.2 Cg_endo -62.01 124.44 14.44 Favored 'Trans proline' 0 N--CA 1.445 -1.381 0 C-N-CA 122.755 2.304 . . . . 0.0 109.798 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.695 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 9.4 pt-20 -53.63 -20.2 4.94 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.269 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -64.56 -47.09 80.03 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 173.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.694 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.5 tt -63.74 -44.12 94.47 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 120.871 0.367 . . . . 0.0 110.347 176.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 14.9 m -69.21 -30.97 69.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.309 -177.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.462 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -65.71 -31.14 71.97 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.749 0.785 . . . . 0.0 110.334 176.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 m -74.75 -20.59 59.76 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.78 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -98.12 -52.99 3.51 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-O 121.91 0.862 . . . . 0.0 110.244 -176.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 52.0 m -70.58 -47.47 60.07 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 114.013 -1.448 . . . . 0.0 112.161 -177.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.1 0.79 10.56 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.953 -1.117 . . . . 0.0 112.753 -177.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.462 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 25.5 m -71.46 161.34 31.2 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 174.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.1 pt -132.42 141.25 45.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.967 0.413 . . . . 0.0 111.301 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.444 HG12 ' OG1' ' A' ' 2' ' ' THR . 77.4 mt -97.0 112.66 29.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.817 177.154 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.584 HG12 ' HB3' ' A' ' 40' ' ' CYS . 2.4 pp -105.72 147.53 34.87 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.869 0.366 . . . . 0.0 111.5 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -78.56 28.91 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 123.409 2.739 . . . . 0.0 112.999 -176.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -133.27 -151.08 6.49 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 177.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -148.39 22.38 1.05 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.608 0.24 . . . . 0.0 111.361 -177.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.0 m -133.0 -46.48 0.85 Allowed 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.617 -0.433 . . . . 0.0 111.828 -179.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.673 ' HB2' ' HD2' ' A' ' 41' ' ' PRO . 24.1 p 48.92 164.92 0.03 OUTLIER Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 124.904 1.378 . . . . 0.0 113.187 -174.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.673 ' HD2' ' HB2' ' A' ' 40' ' ' CYS . 31.6 Cg_endo -65.82 152.55 81.24 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.253 1.969 . . . . 0.0 112.682 176.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.11 12.2 7.1 Favored Glycine 0 N--CA 1.451 -0.356 0 CA-C-N 115.753 -0.658 . . . . 0.0 113.997 -172.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.443 ' OD1' ' HB2' ' A' ' 41' ' ' PRO . 19.1 p-10 -106.49 -12.31 15.66 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.638 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.9 m-85 -117.67 5.53 12.35 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.616 175.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.06 35.5 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.06 -172.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.8 m120 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.579 176.712 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.499 ' HB ' ' HB ' ' A' ' 35' ' ' ILE . 9.1 m . . . . . 0 N--CA 1.475 0.819 0 CA-C-O 121.041 0.448 . . . . 0.0 110.368 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 31.7 m -135.54 142.14 45.35 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.804 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 58.9 m -125.06 132.27 53.2 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.427 0.528 . . . . 0.0 112.427 -172.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 98.0 m -126.47 123.28 24.03 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.377 174.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -80.74 19.67 1.08 Allowed 'Trans proline' 0 CA--C 1.532 0.406 0 C-N-CA 122.416 2.077 . . . . 0.0 113.441 -174.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -157.97 136.42 11.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.823 ' H ' HD12 ' A' ' 7' ' ' ILE . 4.1 mp -57.51 -38.66 64.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.326 0.584 . . . . 0.0 109.672 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 59.6 t -72.88 -36.78 52.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.271 -177.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.13 82.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.477 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -71.64 -39.68 70.21 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.23 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.584 ' O ' HG23 ' A' ' 15' ' ' VAL . 5.9 p -66.38 -37.39 85.17 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.557 178.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -66.25 -41.98 89.21 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.379 0.609 . . . . 0.0 109.834 175.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 23' ' ' GLU . 13.1 t80 -60.86 -42.99 98.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.123 179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -61.54 -34.29 75.29 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.156 177.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 11' ' ' SER . 47.2 t -78.57 -6.18 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.475 178.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.671 ' O ' ' HB ' ' A' ' 21' ' ' THR . 1.8 t -108.96 14.94 23.79 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-O 121.888 0.851 . . . . 0.0 108.855 176.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 21' ' ' THR . 6.2 tpt180 -120.9 -42.84 2.48 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 114.979 -1.01 . . . . 0.0 108.365 175.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.14 -51.35 57.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 CA-C-N 113.727 -1.578 . . . . 0.0 113.372 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.05 35.46 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.813 0 C-N-CA 122.641 2.227 . . . . 0.0 113.203 -175.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 66.51 46.68 75.1 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.935 178.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.671 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.57 132.23 24.27 Favored Pre-proline 0 N--CA 1.441 -0.899 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.857 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.714 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 30.1 Cg_endo -63.83 122.45 10.51 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.745 2.297 . . . . 0.0 111.156 177.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 13' ' ' PHE . 1.1 mp0 -51.9 -31.48 28.49 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.142 174.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.63 -48.82 79.72 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.573 177.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.714 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 0.9 OUTLIER -67.26 -41.9 84.8 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.204 0.526 . . . . 0.0 110.177 179.219 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 86.2 m -74.52 -14.12 60.77 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.82 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -70.27 -32.47 70.29 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 122.052 0.93 . . . . 0.0 109.883 174.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.6 m -72.05 -23.21 61.33 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 113.885 -1.507 . . . . 0.0 110.418 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -99.57 -49.42 4.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.352 0.596 . . . . 0.0 110.608 -176.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m -66.7 -44.92 80.41 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.567 -178.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.51 -15.17 14.94 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.427 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 82.6 m -65.89 145.43 55.94 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 176.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.8 pt -116.62 153.59 18.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.74 0.305 . . . . 0.0 111.487 -177.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 67.7 mt -102.06 133.54 45.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.956 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.499 ' HB ' ' HB ' ' A' ' 1' ' ' THR . 45.7 mm -93.13 123.43 60.94 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 109.843 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -55.76 -40.04 87.59 Favored 'Trans proline' 0 CA--C 1.528 0.195 0 C-N-CA 122.829 2.353 . . . . 0.0 112.073 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.41 -125.4 4.67 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.999 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.24 72.8 1.34 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.561 0.696 . . . . 0.0 110.376 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.469 ' H ' HG21 ' A' ' 35' ' ' ILE . 11.2 m -145.78 108.94 4.6 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.112 174.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 16.8 t -153.89 123.01 3.15 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.129 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.54 164.83 34.47 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.918 2.412 . . . . 0.0 112.84 179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -74.41 6.72 21.69 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.584 -0.734 . . . . 0.0 113.314 -175.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -92.8 -21.28 20.0 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -108.44 5.99 25.82 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.892 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -122.88 18.88 10.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.872 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.307 -0.854 . . . . 0.0 110.909 -174.719 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 34' ' ' ILE . 8.5 m . . . . . 0 N--CA 1.477 0.914 0 CA-C-O 120.958 0.408 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.405 ' OG1' HG12 ' A' ' 34' ' ' ILE . 35.5 m -118.19 132.68 56.31 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.456 -175.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 98.3 m -106.82 126.38 52.23 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.702 174.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 1.8 t -115.15 140.45 25.68 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 4' ' ' CYS . 88.6 Cg_endo -91.74 22.79 0.64 Allowed 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.646 2.23 . . . . 0.0 113.652 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.444 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . 51.5 m -150.86 143.0 24.11 Favored 'General case' 0 C--N 1.332 -0.18 0 O-C-N 122.044 -0.41 . . . . 0.0 110.71 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.0 mt -71.16 -27.01 28.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.256 0.55 . . . . 0.0 110.547 -175.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 80.0 t -87.27 -51.91 12.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.709 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.444 ' HB3' ' HB2' ' A' ' 6' ' ' SER . . . -50.16 -42.53 51.16 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.348 -179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -26.3 68.31 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.286 0.565 . . . . 0.0 110.881 -176.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.521 ' O ' HG23 ' A' ' 15' ' ' VAL . 22.2 t -77.81 -56.16 4.73 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.464 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -68.03 -21.76 65.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.067 0.46 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.481 ' HB2' HG21 ' A' ' 30' ' ' THR . 21.7 t80 -57.97 -56.01 27.54 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.033 170.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.425 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 12.1 p30 -69.59 -25.16 63.84 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.679 -177.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 11' ' ' SER . 84.8 t -66.99 -22.83 29.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.758 173.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.6 t -83.64 -22.92 32.04 Favored 'General case' 0 C--O 1.221 -0.431 0 CA-C-O 121.35 0.595 . . . . 0.0 109.892 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.553 ' HG2' ' O ' ' A' ' 21' ' ' THR . 3.5 tmt_? -92.26 -29.57 16.34 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.902 -172.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.662 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -54.87 -44.83 99.7 Favored Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 114.599 -1.182 . . . . 0.0 113.179 -177.802 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.662 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 64.7 Cg_endo -73.52 14.0 0.67 Allowed 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 122.046 1.83 . . . . 0.0 113.808 -177.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.96 27.08 8.03 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.779 -0.724 . . . . 0.0 113.096 176.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.553 ' O ' ' HG2' ' A' ' 17' ' ' ARG . 4.5 m -104.73 138.34 19.48 Favored Pre-proline 0 N--CA 1.429 -1.49 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' CG2' ' A' ' 21' ' ' THR . 17.4 Cg_endo -62.02 123.53 12.73 Favored 'Trans proline' 0 N--CA 1.441 -1.58 0 C-N-CA 122.335 2.024 . . . . 0.0 109.889 176.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.461 ' HB2' ' HZ ' ' A' ' 13' ' ' PHE . 14.8 pt-20 -45.22 -30.2 1.15 Allowed 'General case' 0 C--N 1.324 -0.54 0 O-C-N 123.816 0.697 . . . . 0.0 110.03 174.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -58.13 -46.74 85.11 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.704 177.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 48.9 tp -70.62 -37.77 73.86 Favored 'General case' 0 N--CA 1.444 -0.765 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 85.9 m -71.55 -33.44 69.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.651 -177.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -60.84 -46.12 91.8 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 122.073 0.94 . . . . 0.0 110.245 176.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.7 m -67.18 -20.43 65.72 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 113.607 -1.633 . . . . 0.0 111.729 -178.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -100.45 -45.88 5.41 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.599 0.714 . . . . 0.0 110.175 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.481 HG21 ' HB2' ' A' ' 13' ' ' PHE . 99.8 m -72.58 -40.73 66.37 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.616 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.64 16.39 4.6 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.082 -1.056 . . . . 0.0 112.67 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.3 m -98.44 170.81 8.58 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -129.86 148.1 33.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.818 -0.353 . . . . 0.0 111.569 -177.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.604 HD11 ' HA ' ' A' ' 24' ' ' ALA . 31.3 mt -101.5 140.64 19.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.231 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.8 pt -129.83 142.78 46.54 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.758 0.313 . . . . 0.0 110.99 177.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.53 39.85 0.85 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.255 2.637 . . . . 0.0 112.331 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.25 149.05 20.34 Favored Glycine 0 N--CA 1.436 -1.304 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -176.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.71 -1.83 58.22 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 120.847 0.356 . . . . 0.0 111.143 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.2 m -99.72 106.29 18.18 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.494 176.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 14.3 t -123.5 131.2 24.29 Favored Pre-proline 0 C--N 1.309 -1.17 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.931 179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.41 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 17.0 Cg_endo -59.36 143.14 99.82 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.791 2.327 . . . . 0.0 112.127 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.57 -8.35 25.87 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 114.563 -173.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -83.86 -24.17 30.99 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.557 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 7.9 m-85 -117.86 3.79 12.21 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.313 -176.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.43 34.31 0.52 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.41 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.45 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 22.3 m-80 . . . . . 0 C--O 1.245 0.823 0 CA-C-O 118.457 -0.783 . . . . 0.0 108.896 176.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 41.1 m . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 120.711 0.291 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.67 HG23 HG13 ' A' ' 34' ' ' ILE . 27.4 m -105.03 125.19 50.71 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.547 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 59.4 m -128.96 120.15 25.59 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.048 0.452 . . . . 0.0 111.288 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 78.8 m -107.36 166.31 11.27 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.386 179.177 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.543 ' HD2' ' HB3' ' A' ' 4' ' ' CYS . 83.6 Cg_endo -82.21 8.78 4.3 Favored 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 122.507 2.138 . . . . 0.0 114.574 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.4 t -176.09 145.13 0.62 Allowed 'General case' 0 CA--C 1.518 -0.281 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.667 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.878 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 46.2 mm -65.76 -27.24 40.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.561 0.695 . . . . 0.0 109.293 176.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.2 t -74.16 -49.75 31.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.844 177.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.93 -40.39 94.98 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.298 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.878 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -65.59 -27.72 68.62 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.111 0.481 . . . . 0.0 110.434 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.568 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.3 t -64.86 -47.59 77.38 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.669 177.275 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 54.4 m-80 -67.26 -26.69 66.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.567 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.49 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 57.4 t80 -66.6 -51.63 54.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.578 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.443 ' ND2' ' HA ' ' A' ' 11' ' ' SER . 10.9 p30 -66.82 -23.79 66.08 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.908 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.568 HG23 ' O ' ' A' ' 11' ' ' SER . 55.7 t -62.57 -34.53 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.792 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.545 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 75.8 m -66.41 -25.03 66.57 Favored 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.432 0.634 . . . . 0.0 111.319 177.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.664 ' HD3' ' HB3' ' A' ' 23' ' ' GLU . 18.2 mmm180 -75.04 -31.71 61.37 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.722 -175.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 1.003 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -66.72 -42.87 47.44 Favored Pre-proline 0 CA--C 1.546 0.825 0 N-CA-C 114.054 1.131 . . . . 0.0 114.054 -173.761 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 1.003 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 94.9 Cg_endo -87.55 -6.18 7.02 Favored 'Trans proline' 0 C--N 1.356 0.939 0 C-N-CA 121.806 1.67 . . . . 0.0 113.22 -177.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.03 23.0 7.95 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.074 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.46 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 5.6 m -84.53 126.42 69.01 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 175.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.804 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.32 120.48 8.36 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.404 2.069 . . . . 0.0 110.557 177.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.664 ' HB3' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -45.98 -35.33 4.64 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.035 169.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.08 -51.41 67.97 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.989 174.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.804 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.0 tt -62.39 -53.36 56.08 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 120.685 0.279 . . . . 0.0 110.355 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 13' ' ' PHE . 33.7 t -63.27 -38.26 90.48 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.593 -174.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.538 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.76 -34.33 78.08 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.356 0.598 . . . . 0.0 111.626 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 23.4 m -76.55 -20.71 56.56 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.306 -177.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -97.54 -46.17 6.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.94 0.876 . . . . 0.0 109.678 -175.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 55.5 m -70.59 -34.86 72.62 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.748 -1.569 . . . . 0.0 111.755 178.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.18 30.49 7.38 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.352 -0.928 . . . . 0.0 111.331 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.538 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.4 t -109.31 159.44 16.97 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.8 141.26 44.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.878 0.371 . . . . 0.0 111.587 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.67 HG13 HG23 ' A' ' 2' ' ' THR . 4.3 mp -109.95 132.08 59.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.892 174.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.49 HD11 ' SG ' ' A' ' 40' ' ' CYS . 24.5 pt -134.82 156.8 78.25 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.848 -178.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.51 -25.49 41.18 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 122.855 2.37 . . . . 0.0 112.689 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -113.06 -147.12 9.91 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.803 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -135.05 30.22 3.35 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.373 0.606 . . . . 0.0 110.386 -176.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.1 m -79.73 54.51 1.83 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.865 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD11 ' A' ' 35' ' ' ILE . 30.2 m -98.82 135.0 21.1 Favored Pre-proline 0 C--N 1.309 -1.176 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.81 -178.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.871 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 30.2 Cg_endo -65.1 165.96 20.25 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.779 2.319 . . . . 0.0 111.875 174.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -66.23 -37.9 93.33 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 121.283 -0.484 . . . . 0.0 113.788 -171.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -84.03 -18.24 37.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 122.022 0.915 . . . . 0.0 109.44 -174.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.871 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 16.3 m-85 -112.13 23.91 13.19 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.797 -176.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -101.5 22.47 12.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.048 0.452 . . . . 0.0 110.908 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.407 ' C ' ' HE ' ' A' ' 10' ' ' ARG . 27.9 m-80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.459 -0.782 . . . . 0.0 109.524 -178.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.408 HG21 ' HA ' ' A' ' 38' ' ' ALA . 21.5 m . . . . . 0 N--CA 1.478 0.928 0 CA-C-O 121.131 0.491 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.536 ' HB ' HG13 ' A' ' 34' ' ' ILE . 8.9 t -115.62 145.63 42.53 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 m -136.96 115.67 12.1 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -175.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.432 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 85.1 m -103.58 125.3 35.22 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 121.137 0.494 . . . . 0.0 111.219 -177.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.585 ' HA ' ' CB ' ' A' ' 44' ' ' TYR . 18.8 Cg_endo -60.24 -7.12 6.09 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.892 3.061 . . . . 0.0 115.606 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 p -161.55 162.14 30.12 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 118.771 0.714 . . . . 0.0 111.17 -177.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.612 ' HA ' ' HG2' ' A' ' 10' ' ' ARG . 60.2 mt -67.63 -34.29 67.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.115 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.03 -50.27 55.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.25 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -66.57 -32.63 74.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.253 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.612 ' HG2' ' HA ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.41 -29.48 62.62 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.825 0.345 . . . . 0.0 110.533 -178.662 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.465 ' O ' HG23 ' A' ' 15' ' ' VAL . 70.1 m -68.67 -53.04 24.75 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -55.13 -40.11 70.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.099 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -57.0 -62.92 1.41 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.083 175.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 35.5 m-80 -59.41 -39.0 82.02 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 11' ' ' SER . 69.9 t -60.95 -37.46 77.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-O 120.551 0.215 . . . . 0.0 111.363 -178.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 18.2 t -70.28 -42.21 72.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.787 0.327 . . . . 0.0 110.808 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.721 ' HD2' ' HG2' ' A' ' 23' ' ' GLU . 0.0 OUTLIER -91.3 20.62 5.01 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.961 0.41 . . . . 0.0 111.811 -177.597 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.431 ' HB2' ' O ' ' A' ' 15' ' ' VAL . 4.5 mt -73.02 -50.33 6.81 Favored Pre-proline 0 N--CA 1.445 -0.71 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.693 177.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.65 25.96 0.63 Allowed 'Trans proline' 0 C--N 1.36 1.152 0 C-N-CA 122.221 1.948 . . . . 0.0 113.208 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.24 37.78 6.99 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.113 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 22' ' ' PRO . 1.7 m -97.65 141.01 22.34 Favored Pre-proline 0 N--CA 1.43 -1.432 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.656 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.2 Cg_endo -56.3 116.34 3.12 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.905 2.403 . . . . 0.0 111.178 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.721 ' HG2' ' HD2' ' A' ' 17' ' ' ARG . 36.8 mt-10 -51.11 -28.8 11.57 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.068 -0.969 . . . . 0.0 109.901 172.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.73 79.6 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.763 173.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.656 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.1 tt -65.36 -42.97 92.22 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.246 0.546 . . . . 0.0 109.927 178.504 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.449 ' HB3' ' HB3' ' A' ' 16' ' ' CYS . 61.0 m -77.34 -0.4 25.47 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.021 -175.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.546 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -101.57 -41.02 6.75 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.686 0.755 . . . . 0.0 111.113 175.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.0 m -65.82 -23.91 66.79 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.184 -1.371 . . . . 0.0 111.61 -174.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -100.47 -15.23 17.97 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 122.176 0.989 . . . . 0.0 109.88 -176.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 89.1 m -99.93 -46.81 5.24 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.075 -1.42 . . . . 0.0 111.874 -172.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.12 -20.96 6.23 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 119.944 -1.122 . . . . 0.0 112.287 -178.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.546 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 42.3 t -73.61 158.54 34.58 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.25 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.0 pt -131.64 143.68 39.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.441 0.639 . . . . 0.0 112.104 -175.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.536 HG13 ' HB ' ' A' ' 2' ' ' THR . 4.5 mp -104.25 136.16 38.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 168.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 46.7 pt -120.64 142.23 33.81 Favored Pre-proline 0 C--N 1.317 -0.807 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.035 -178.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.1 38.48 0.69 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 123.081 2.521 . . . . 0.0 112.304 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -154.72 -138.64 2.64 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -178.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.408 ' HA ' HG21 ' A' ' 1' ' ' THR . . . -150.62 13.68 0.74 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.661 0.267 . . . . 0.0 111.244 -178.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.9 t -91.74 103.07 15.68 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 122.159 0.981 . . . . 0.0 111.991 -177.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.463 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 34.1 m -149.92 112.62 3.36 Favored Pre-proline 0 C--N 1.305 -1.351 0 CA-C-N 113.806 -1.543 . . . . 0.0 110.688 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 40' ' ' CYS . 33.7 Cg_endo -63.89 160.59 36.55 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.49 2.126 . . . . 0.0 111.114 172.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -86.37 32.55 3.85 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.916 -0.659 . . . . 0.0 113.574 -171.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -108.19 -29.8 8.72 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.585 ' CB ' ' HA ' ' A' ' 5' ' ' PRO . 4.5 p90 -128.13 22.11 6.19 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.462 173.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.96 37.76 1.14 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.312 176.136 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 6.0 t30 . . . . . 0 C--O 1.252 1.19 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.234 -179.248 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.449 ' HB ' HD12 ' A' ' 35' ' ' ILE . 17.0 m . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.835 0.35 . . . . 0.0 110.303 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.1 t -113.33 119.2 36.87 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-O 121.457 0.646 . . . . 0.0 110.138 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 33.6 m -104.91 108.88 20.61 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.747 -176.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.509 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 13.9 t -136.72 99.86 10.23 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.209 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.865 ' HG3' ' HA ' ' A' ' 44' ' ' TYR . 64.0 Cg_endo -85.35 61.24 5.58 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.954 2.436 . . . . 0.0 113.975 -169.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.738 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 1.4 p -167.39 120.96 0.96 Allowed 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.218 -178.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 68.0 mt -48.11 -38.63 8.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.604 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.5 t -77.53 -48.6 23.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.701 -175.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.97 -37.67 88.28 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.27 -178.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.738 ' HG3' ' O ' ' A' ' 6' ' ' SER . 60.5 mtt180 -54.27 -51.69 63.78 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 121.151 0.501 . . . . 0.0 110.284 179.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.528 ' O ' HG23 ' A' ' 15' ' ' VAL . 24.9 m -70.63 -42.27 71.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.261 -177.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -62.69 -38.25 89.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 120.81 0.338 . . . . 0.0 110.581 -178.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -51.39 -51.34 55.51 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.423 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 36.6 m-80 -65.11 -37.87 88.85 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.452 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 11' ' ' SER . 90.7 t -61.98 -41.89 92.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.378 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.535 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 26.1 t -71.52 -32.11 67.82 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.398 0.618 . . . . 0.0 110.018 -179.225 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 17' ' ' ARG . 39.5 ttt180 -73.3 -21.86 60.48 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.342 -176.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 19.3 mt -64.61 -52.89 48.68 Favored Pre-proline 0 CA--C 1.54 0.588 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -174.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.535 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 16.5 Cg_exo -69.9 0.5 5.65 Favored 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.427 2.085 . . . . 0.0 113.137 -178.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.25 26.27 7.87 Favored Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.182 -1.008 . . . . 0.0 112.407 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.492 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 1.3 m -89.89 137.88 28.07 Favored Pre-proline 0 N--CA 1.428 -1.55 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 176.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 8.3 Cg_endo -55.45 117.49 4.11 Favored 'Trans proline' 0 N--CA 1.444 -1.408 0 C-N-CA 122.869 2.38 . . . . 0.0 111.058 -179.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -47.21 -28.76 2.0 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.457 170.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.47 -42.16 98.6 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.885 174.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.489 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 41.3 tp -76.69 -36.17 57.43 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-O 121.053 0.454 . . . . 0.0 110.52 178.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 17.4 m -78.28 3.03 16.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.976 -179.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -101.2 -56.44 2.31 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 121.852 0.834 . . . . 0.0 110.328 174.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 m -62.77 -25.41 68.2 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.047 -174.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -94.39 -17.75 22.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 122.087 0.946 . . . . 0.0 109.551 -175.1 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 84.5 m -97.61 -44.62 6.71 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.096 -1.411 . . . . 0.0 111.542 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.25 -7.34 6.33 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.62 -175.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 5.3 m -82.39 148.13 28.41 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.8 pt -123.4 143.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.451 -0.5 . . . . 0.0 110.683 176.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 78.9 mt -112.95 120.83 63.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.022 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.449 HD12 ' HB ' ' A' ' 1' ' ' THR . 2.1 pp -120.08 139.85 28.99 Favored Pre-proline 0 C--N 1.321 -0.668 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.637 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -82.09 22.42 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 123.234 2.623 . . . . 0.0 113.145 -175.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.48 -139.96 3.74 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.214 178.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -139.21 62.39 1.53 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.049 0.452 . . . . 0.0 109.943 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 m -152.44 106.05 3.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.275 0.559 . . . . 0.0 111.099 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 26.0 p -148.46 140.83 14.81 Favored Pre-proline 0 C--N 1.306 -1.31 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.064 171.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.504 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 11.0 Cg_endo -53.81 143.71 58.1 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 123.005 2.47 . . . . 0.0 112.568 -174.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.13 -13.07 47.18 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.841 -0.618 . . . . 0.0 113.674 -174.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.85 -17.37 41.11 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.865 ' HA ' ' HG3' ' A' ' 5' ' ' PRO . 16.9 m-85 -121.67 5.94 10.01 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.094 -175.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -105.3 38.0 2.06 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -171.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.71 ' O ' ' HA ' ' A' ' 5' ' ' PRO . 2.9 t30 . . . . . 0 C--O 1.246 0.893 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.07 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.593 ' HB ' HG13 ' A' ' 35' ' ' ILE . 22.7 m . . . . . 0 N--CA 1.477 0.887 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -120.55 147.49 45.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.806 0.336 . . . . 0.0 111.605 -174.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.493 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 2.1 m -151.34 123.29 8.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.886 176.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.575 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 40.0 m -110.2 162.12 21.72 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.044 -175.705 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -91.13 13.95 2.03 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.394 2.062 . . . . 0.0 114.825 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.5 p -167.3 144.02 4.41 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 118.505 0.593 . . . . 0.0 111.115 -179.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.455 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 35.9 mt -60.27 -29.32 43.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.763 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.5 t -72.55 -51.51 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.475 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.564 ' HB1' HG22 ' A' ' 30' ' ' THR . . . -69.77 -30.35 67.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.725 -177.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.575 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -69.94 -26.09 63.96 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.149 0.499 . . . . 0.0 110.339 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.435 ' O ' HG23 ' A' ' 15' ' ' VAL . 25.0 m -79.79 -42.25 24.82 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.434 175.324 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -59.88 -30.26 68.87 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.541 177.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -52.9 -61.38 2.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.664 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.3 m-80 -63.21 -33.1 74.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.267 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 11' ' ' SER . 72.2 t -63.99 -34.84 71.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.079 178.272 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 41.8 t -77.5 -16.72 58.55 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.436 0.636 . . . . 0.0 110.67 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.487 ' HD2' ' O ' ' A' ' 21' ' ' THR . 7.8 mmm180 -82.66 -19.32 38.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.027 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.606 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 85.2 mt -67.14 -48.84 47.73 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.606 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 22.9 Cg_exo -65.58 -19.01 60.35 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.927 1.752 . . . . 0.0 112.391 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.4 24.44 5.64 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.586 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.556 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -90.56 134.06 31.6 Favored Pre-proline 0 N--CA 1.438 -1.054 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 177.615 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -66.46 129.55 21.61 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 123.065 2.51 . . . . 0.0 111.168 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -46.35 -25.58 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.197 171.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.95 -47.65 71.09 Favored 'General case' 0 C--N 1.327 -0.398 0 O-C-N 123.293 0.371 . . . . 0.0 110.629 172.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.8 mt -79.08 -38.46 36.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-O 120.93 0.395 . . . . 0.0 111.0 177.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.556 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 5.0 m -80.28 10.41 4.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.285 -176.15 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.73 -43.98 5.43 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.96 0.886 . . . . 0.0 109.731 170.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.2 m -69.76 -24.89 63.59 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 113.96 -1.473 . . . . 0.0 111.517 -177.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -91.36 -31.12 16.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.72 0.772 . . . . 0.0 109.759 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.564 HG22 ' HB1' ' A' ' 9' ' ' ALA . 0.3 OUTLIER -99.12 -14.78 19.23 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.555 -1.202 . . . . 0.0 112.596 -171.469 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.93 16.48 63.19 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.462 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 19.7 t -94.25 159.43 15.13 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.25 148.97 33.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.125 0.488 . . . . 0.0 111.871 -176.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.403 ' N ' HD12 ' A' ' 34' ' ' ILE . 4.4 mp -96.42 135.32 30.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.898 176.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.593 HG13 ' HB ' ' A' ' 1' ' ' THR . 5.5 pt -129.64 164.25 41.27 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.716 -179.627 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.41 -57.24 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.995 2.463 . . . . 0.0 111.252 169.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 171.47 137.69 2.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 116.098 -0.501 . . . . 0.0 112.028 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 64.43 18.08 11.15 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.256 0.622 . . . . 0.0 111.373 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -98.18 27.93 4.34 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.685 0.755 . . . . 0.0 110.904 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.532 ' SG ' HD13 ' A' ' 35' ' ' ILE . 16.9 m -112.86 107.28 54.69 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.466 -175.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.465 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 43.6 Cg_endo -71.3 174.27 11.05 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.59 2.193 . . . . 0.0 111.142 173.015 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.97 -34.74 66.22 Favored Glycine 0 CA--C 1.521 0.408 0 N-CA-C 114.754 0.662 . . . . 0.0 114.754 -172.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -83.98 -22.84 31.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.849 0.825 . . . . 0.0 109.772 -172.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.493 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 16.2 m-85 -108.75 20.09 18.91 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.314 -175.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.83 27.11 6.2 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.847 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.484 ' O ' ' HB3' ' A' ' 10' ' ' ARG . 37.8 m-80 . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.116 -177.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.497 HG21 ' O ' ' A' ' 37' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.473 0.692 0 CA-C-O 121.004 0.43 . . . . 0.0 110.226 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.491 ' HB ' ' CZ ' ' A' ' 13' ' ' PHE . 86.3 m -137.97 140.38 40.18 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.928 -176.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -114.98 111.14 20.69 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.053 -178.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.6 ' HB2' ' HB3' ' A' ' 10' ' ' ARG . 100.0 m -102.0 111.84 64.67 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.202 174.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.698 ' HB3' ' HD1' ' A' ' 44' ' ' TYR . 91.1 Cg_endo -86.98 35.89 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.851 2.367 . . . . 0.0 112.923 -177.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.1 m -155.43 131.28 9.95 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 61.2 mt -56.18 -36.8 46.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 123.537 0.523 . . . . 0.0 111.143 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.9 t -83.28 -31.12 8.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.223 0.535 . . . . 0.0 110.382 -174.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -71.52 -37.21 71.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.394 178.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.6 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 0.0 OUTLIER -83.78 -22.86 31.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.15 -175.468 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 61.3 p -74.24 -30.1 62.0 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.318 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -92.88 -26.48 17.61 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.876 177.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.491 ' CZ ' ' HB ' ' A' ' 2' ' ' THR . 27.4 t80 -55.05 -52.4 63.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.551 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -61.71 -29.08 69.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.65 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.646 ' HA ' HD23 ' A' ' 18' ' ' LEU . 57.3 t -75.73 -24.28 16.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.711 176.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.818 ' O ' ' HB ' ' A' ' 21' ' ' THR . 48.6 t -88.37 0.38 56.26 Favored 'General case' 0 C--O 1.214 -0.782 0 CA-C-O 121.684 0.754 . . . . 0.0 109.623 -178.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -109.32 -21.95 12.29 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -175.123 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.752 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 3.4 pp -74.5 -36.54 2.58 Favored Pre-proline 0 N--CA 1.436 -1.16 0 N-CA-C 113.785 1.031 . . . . 0.0 113.785 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.752 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 5.8 Cg_exo -78.62 7.24 4.31 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 121.835 1.69 . . . . 0.0 112.604 -175.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.97 33.05 8.47 Favored Glycine 0 N--CA 1.444 -0.81 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.042 -178.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.818 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 1.1 m -106.11 134.14 19.9 Favored Pre-proline 0 N--CA 1.434 -1.253 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.065 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.776 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 9.9 Cg_endo -56.29 117.22 3.84 Favored 'Trans proline' 0 N--CA 1.446 -1.285 0 C-N-CA 123.167 2.578 . . . . 0.0 112.183 -179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -46.34 -31.52 2.63 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.839 168.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.09 -49.99 75.77 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.17 174.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.776 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tt -65.28 -44.31 88.45 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 18.8 m -76.17 -0.07 20.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.765 -177.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.535 ' HA ' ' HB2' ' A' ' 32' ' ' CYS . . . -94.68 -56.8 2.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.934 0.873 . . . . 0.0 109.885 168.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.1 m -58.28 -33.17 69.12 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 113.531 -1.668 . . . . 0.0 113.302 -173.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -96.43 -19.58 19.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 122.073 0.94 . . . . 0.0 110.324 -171.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.2 m -92.46 -25.1 18.59 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.518 -172.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.28 10.71 27.11 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.958 -177.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.535 ' HB2' ' HA ' ' A' ' 27' ' ' ALA . 44.1 m -95.11 167.69 11.22 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 176.171 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.2 pt -123.82 131.57 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.233 0.54 . . . . 0.0 111.334 176.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 2' ' ' THR . 16.2 tt -94.55 138.5 20.57 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.62 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.227 178.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.712 HD13 ' HB2' ' A' ' 40' ' ' CYS . 14.1 pt -119.58 160.85 40.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.348 -174.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -92.2 24.18 0.52 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.125 2.55 . . . . 0.0 113.176 178.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.497 ' O ' HG21 ' A' ' 1' ' ' THR . . . 177.01 -135.98 3.0 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.514 -0.851 . . . . 0.0 112.26 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.41 13.69 17.75 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 120.635 0.255 . . . . 0.0 111.534 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -77.64 88.25 3.93 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.296 0.569 . . . . 0.0 110.509 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.712 ' HB2' HD13 ' A' ' 35' ' ' ILE . 23.4 t -155.43 125.01 3.15 Favored Pre-proline 0 C--N 1.31 -1.135 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.321 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.31 167.98 25.92 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 123.003 2.469 . . . . 0.0 112.056 177.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -77.21 5.19 51.62 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 116.033 -0.531 . . . . 0.0 112.941 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -88.6 -20.85 24.45 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.698 ' HD1' ' HB3' ' A' ' 5' ' ' PRO . 14.7 m-85 -108.9 7.89 26.24 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.971 -178.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -116.53 52.32 0.94 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.736 179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.8 t30 . . . . . 0 C--O 1.251 1.157 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.758 -176.574 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.555 HG21 ' HA2' ' A' ' 37' ' ' GLY . 12.2 m . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.787 HG22 ' SG ' ' A' ' 32' ' ' CYS . 3.9 m -139.5 134.03 31.69 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.019 -174.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.6 m -129.26 129.23 44.67 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.2 m -111.2 127.44 26.89 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.254 -171.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.805 ' HB3' ' HA ' ' A' ' 44' ' ' TYR . 75.8 Cg_endo -92.35 43.94 0.36 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.108 2.539 . . . . 0.0 114.113 -176.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.674 ' O ' ' HG3' ' A' ' 10' ' ' ARG . 6.8 p -173.02 135.17 0.59 Allowed 'General case' 0 CA--C 1.517 -0.301 0 O-C-N 122.11 -0.369 . . . . 0.0 110.187 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.606 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 49.0 mt -56.29 -31.01 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.216 0.531 . . . . 0.0 111.003 -171.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.86 -53.09 28.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.956 177.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -62.06 -40.14 94.75 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.708 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.674 ' HG3' ' O ' ' A' ' 6' ' ' SER . 4.5 mtp-105 -59.01 -37.54 77.12 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.53 178.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.7 t -76.05 -35.72 59.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.565 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.9 m-20 -57.72 -42.87 84.7 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.994 174.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 2' ' ' THR . 40.6 t80 -47.56 -46.01 27.59 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.202 -179.019 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -61.76 -48.61 79.9 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.33 0.586 . . . . 0.0 110.116 177.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -72.8 -12.55 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.026 -176.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.71 ' O ' ' HB ' ' A' ' 21' ' ' THR . 69.3 m -100.63 14.83 30.15 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.547 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.56 ' HD2' ' CE1' ' A' ' 13' ' ' PHE . 36.1 mtp180 -134.27 -39.87 0.83 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.325 0.583 . . . . 0.0 110.011 176.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 tp -49.62 -54.79 27.58 Favored Pre-proline 0 CA--C 1.553 1.086 0 CA-C-N 114.709 -1.132 . . . . 0.0 113.427 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -88.5 39.29 0.49 Allowed 'Trans proline' 0 C--N 1.353 0.801 0 C-N-CA 122.075 1.85 . . . . 0.0 113.794 -174.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.57 50.29 26.43 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.302 178.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.71 ' HB ' ' O ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -124.82 138.25 31.03 Favored Pre-proline 0 N--CA 1.435 -1.186 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.665 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.538 ' HG2' ' CB ' ' A' ' 25' ' ' LEU . 38.0 Cg_endo -70.1 126.47 13.12 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 122.763 2.309 . . . . 0.0 111.544 174.366 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.444 ' HB3' ' HE ' ' A' ' 17' ' ' ARG . 11.2 pt-20 -50.75 -32.27 19.2 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.064 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.554 ' HA ' HD11 ' A' ' 34' ' ' ILE . . . -64.7 -39.26 93.35 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.255 -178.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.538 ' CB ' ' HG2' ' A' ' 22' ' ' PRO . 34.1 tp -69.63 -46.79 65.4 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.683 0.278 . . . . 0.0 110.831 -177.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.514 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 17.1 t -67.98 -29.41 68.43 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.258 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.574 ' HA ' ' HB3' ' A' ' 32' ' ' CYS . . . -56.9 -46.89 81.61 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.643 0.735 . . . . 0.0 110.906 177.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 47.2 m -67.07 -28.43 68.19 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.36 -1.291 . . . . 0.0 111.924 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -102.7 -35.11 8.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.311 0.577 . . . . 0.0 111.435 -171.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.476 ' HB ' ' O ' ' A' ' 26' ' ' CYS . 4.6 m -87.01 -19.79 28.17 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.144 -175.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.94 25.86 8.23 Favored Glycine 0 C--N 1.331 0.292 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.355 177.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.787 ' SG ' HG22 ' A' ' 2' ' ' THR . 5.8 t -102.6 161.74 13.48 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.6 pt -112.25 140.92 29.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 C-N-CA 119.928 -0.709 . . . . 0.0 112.644 -174.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 24' ' ' ALA . 25.3 mm -98.91 132.7 43.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.274 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 36' ' ' PRO . 44.5 pt -141.88 159.5 59.22 Favored Pre-proline 0 C--N 1.32 -0.682 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 35' ' ' ILE . 53.8 Cg_endo -71.06 -16.02 32.19 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.71 2.273 . . . . 0.0 111.801 175.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.555 ' HA2' HG21 ' A' ' 1' ' ' THR . . . 111.59 130.21 5.54 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.811 176.044 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -165.55 -87.46 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.333 -0.434 . . . . 0.0 110.008 176.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.5 m -140.91 -15.17 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.944 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HA ' ' HD3' ' A' ' 41' ' ' PRO . 91.4 m 64.91 139.5 0.05 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.521 -171.421 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.799 ' HG2' ' HD2' ' A' ' 44' ' ' TYR . 17.4 Cg_exo -65.09 156.95 59.94 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.934 2.423 . . . . 0.0 112.503 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -27.65 63.8 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.264 -174.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.7 -31.65 13.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.678 0.752 . . . . 0.0 110.075 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.805 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 20.1 m-85 -91.75 -7.99 48.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.968 -174.125 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.478 ' HB2' ' HB3' ' A' ' 40' ' ' CYS . . . -105.97 30.35 5.93 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.608 174.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 5.7 t30 . . . . . 0 C--O 1.247 0.929 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.996 -177.341 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.597 ' HB ' HG13 ' A' ' 35' ' ' ILE . 92.3 m . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 120.831 0.348 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.2 t -101.53 108.12 19.6 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-O 121.914 0.864 . . . . 0.0 110.656 -179.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' HG13 ' A' ' 33' ' ' ILE . 15.9 t -103.65 81.82 1.94 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.438 -173.38 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.429 ' HA ' ' HD3' ' A' ' 5' ' ' PRO . 60.2 m -105.54 134.35 19.74 Favored Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.436 178.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 61.2 Cg_endo -94.91 30.83 0.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.545 2.163 . . . . 0.0 115.245 -172.587 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.6 p -179.04 139.55 0.15 Allowed 'General case' 0 C--O 1.235 0.327 0 CA-C-N 118.846 0.748 . . . . 0.0 111.395 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.496 HG13 ' OD1' ' A' ' 46' ' ' ASN . 75.1 mt -58.37 -30.38 40.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.068 170.389 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 67.0 t -54.39 -58.66 3.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.52 175.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -64.04 -43.15 96.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.041 0.448 . . . . 0.0 110.666 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.476 ' HA ' ' HD3' ' A' ' 10' ' ' ARG . 21.4 tpp180 -55.06 -38.57 68.19 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.211 178.286 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 31.7 m -78.62 -10.44 59.74 Favored 'General case' 0 N--CA 1.466 0.375 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -94.55 -17.09 22.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.414 0.626 . . . . 0.0 109.778 175.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -69.22 -37.15 77.88 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.855 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -63.94 -26.05 68.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.955 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.9 t -64.81 -48.92 82.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.549 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.844 ' HB3' ' HB ' ' A' ' 21' ' ' THR . 55.8 m -67.2 -24.76 65.88 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -176.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.503 ' HD3' ' HG2' ' A' ' 23' ' ' GLU . 22.3 mmm180 -79.15 -8.76 59.25 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.976 -0.452 . . . . 0.0 111.703 -178.204 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.603 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 72.7 mt -78.02 -56.95 1.0 Allowed Pre-proline 0 N--CA 1.436 -1.148 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.281 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.603 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 81.2 Cg_endo -85.52 -4.99 9.23 Favored 'Trans proline' 0 C--N 1.359 1.131 0 C-N-CA 122.117 1.878 . . . . 0.0 113.451 -176.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.29 28.37 7.66 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.088 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.844 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 1.4 m -74.07 133.79 78.23 Favored Pre-proline 0 N--CA 1.441 -0.887 0 CA-C-O 121.208 0.528 . . . . 0.0 110.016 176.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.883 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.1 Cg_endo -62.61 120.82 8.51 Favored 'Trans proline' 0 N--CA 1.444 -1.415 0 C-N-CA 122.941 2.427 . . . . 0.0 111.008 177.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.503 ' HG2' ' HD3' ' A' ' 17' ' ' ARG . 24.2 mt-10 -45.49 -33.99 2.98 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.613 172.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.83 -47.78 84.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.405 176.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.883 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -65.06 -41.03 95.48 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -179.923 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 29.9 m -87.91 23.95 1.91 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.443 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.33 -46.25 3.91 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 122.171 0.986 . . . . 0.0 109.245 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -65.89 -29.24 69.64 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.259 -1.791 . . . . 0.0 112.388 -175.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 18.7 t80 -99.73 -21.51 15.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.872 0.844 . . . . 0.0 110.123 -173.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.22 -6.62 37.68 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.949 -172.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 79.32 36.0 28.27 Favored Glycine 0 N--CA 1.454 -0.16 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.465 178.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.3 t -127.61 153.01 46.93 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.596 HG13 ' HB3' ' A' ' 3' ' ' CYS . 25.2 pt -122.66 148.89 26.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.326 0.584 . . . . 0.0 112.033 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 75.2 mt -106.4 116.85 51.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.552 177.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.597 HG13 ' HB ' ' A' ' 1' ' ' THR . 25.3 pt -121.97 131.34 24.44 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.898 -178.589 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.86 -12.14 23.96 Favored 'Trans proline' 0 CA--C 1.529 0.259 0 C-N-CA 122.903 2.402 . . . . 0.0 112.282 177.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.92 -141.24 9.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.133 177.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.66 12.95 1.17 Allowed 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 -176.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.5 m -86.02 97.55 10.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.377 0.608 . . . . 0.0 110.818 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 39.6 t -158.38 107.39 1.68 Allowed Pre-proline 0 C--N 1.311 -1.103 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.536 -178.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 44' ' ' TYR . 15.1 Cg_endo -59.55 161.92 16.38 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.851 2.368 . . . . 0.0 112.851 -177.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -69.97 1.14 18.4 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.723 -0.671 . . . . 0.0 113.594 -174.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.03 -15.49 18.23 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.518 ' CD2' ' HG2' ' A' ' 41' ' ' PRO . 19.3 m-85 -115.44 8.05 15.16 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.029 179.307 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.05 39.56 1.77 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.347 0.594 . . . . 0.0 109.573 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.496 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.4 t-20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.03 -175.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 120.77 0.319 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 28.5 m -132.65 121.22 22.83 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 174.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.597 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 71.5 m -124.53 117.19 23.8 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.254 0.55 . . . . 0.0 111.244 -173.006 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 20.8 m -108.55 166.74 10.31 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.704 -177.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -91.33 6.02 3.76 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 122.104 1.87 . . . . 0.0 113.351 169.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.1 m -155.62 141.5 18.12 Favored 'General case' 0 C--O 1.233 0.193 0 O-C-N 121.914 -0.491 . . . . 0.0 110.993 -172.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.4 mm -61.38 -32.19 52.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 121.187 0.518 . . . . 0.0 109.74 174.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 96.4 t -62.78 -43.27 98.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.889 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.576 ' HA ' ' ND2' ' A' ' 12' ' ' ASN . . . -69.4 -39.84 77.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.671 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 19.6 ttm180 -64.73 -27.93 69.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.658 176.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -79.03 -48.18 14.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.368 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.576 ' ND2' ' HA ' ' A' ' 9' ' ' ALA . 12.1 p30 -73.78 -15.99 61.18 Favored 'General case' 0 N--CA 1.464 0.271 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.168 -178.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.426 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 23.9 t80 -48.81 -44.36 39.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 122.02 0.914 . . . . 0.0 109.286 165.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.37 -39.4 53.92 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.345 -1.298 . . . . 0.0 109.941 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.524 ' CG2' ' HA ' ' A' ' 12' ' ' ASN . 92.0 t -57.92 -46.51 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.748 -176.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 68.2 m -61.07 -38.05 84.87 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.647 ' HD2' ' HB3' ' A' ' 23' ' ' GLU . 45.9 mtp180 -79.27 -5.62 54.81 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.574 -172.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.633 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 31.9 mt -75.94 -53.6 2.32 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 6.1 Cg_exo -76.18 -24.34 11.11 Favored 'Trans proline' 0 C--N 1.358 1.028 0 C-N-CA 122.178 1.919 . . . . 0.0 112.517 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.53 13.49 2.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.051 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 16' ' ' CYS . 2.4 m -80.96 124.27 81.51 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.802 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.5 Cg_endo -59.94 123.54 13.44 Favored 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.236 1.958 . . . . 0.0 110.765 177.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HB3' ' HD2' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -51.26 -27.94 10.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.738 169.866 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.79 -46.42 89.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.92 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.802 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 2.7 tt -66.63 -51.61 54.33 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 120.664 0.269 . . . . 0.0 110.426 178.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 26.6 m -66.82 -25.43 66.44 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.56 -34.28 72.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.984 0.897 . . . . 0.0 110.435 174.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 27.4 m -81.85 -22.11 37.16 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.358 -174.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 19.9 t80 -106.18 -39.5 5.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.348 0.594 . . . . 0.0 110.707 -174.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.0 m -72.2 -31.93 66.33 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.498 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.3 18.59 38.55 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.24 -0.981 . . . . 0.0 112.287 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.6 t -105.5 139.59 39.89 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.416 HD12 HD11 ' A' ' 35' ' ' ILE . 22.6 pt -104.79 139.98 24.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.286 0.565 . . . . 0.0 111.794 -172.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 80.3 mt -100.6 124.92 54.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.917 176.178 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.827 HG21 ' HB ' ' A' ' 39' ' ' THR . 96.7 mt -129.18 137.4 30.91 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.372 -175.509 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -47.25 -48.51 14.82 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.697 2.265 . . . . 0.0 112.384 176.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 167.77 137.71 2.3 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.6 177.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.01 65.29 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 123.45 0.7 . . . . 0.0 112.401 175.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.827 ' HB ' HG21 ' A' ' 35' ' ' ILE . 8.9 m -151.03 26.21 0.72 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 122.224 1.012 . . . . 0.0 110.091 175.115 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.49 ' SG ' HD12 ' A' ' 35' ' ' ILE . 62.9 m -108.64 116.42 56.13 Favored Pre-proline 0 C--N 1.314 -0.965 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.342 -172.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 40.3 Cg_endo -69.38 162.35 42.23 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.391 2.061 . . . . 0.0 111.963 175.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.61 -28.4 67.74 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 114.947 0.739 . . . . 0.0 114.947 -172.559 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -87.78 -20.05 26.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.734 0.778 . . . . 0.0 109.778 -174.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.597 ' O ' ' HB3' ' A' ' 3' ' ' CYS . 17.5 m-85 -114.16 25.31 11.22 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.185 -176.09 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.33 23.7 13.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.812 177.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 65.9 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-O 118.096 -0.954 . . . . 0.0 109.681 -177.602 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.954 ' HB ' HG23 ' A' ' 35' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.473 0.711 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.91 110.59 16.49 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -171.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.576 ' HB3' ' O ' ' A' ' 44' ' ' TYR . 46.5 m -150.38 156.25 41.14 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.102 0.477 . . . . 0.0 111.768 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 10.1 t -144.82 143.01 19.59 Favored Pre-proline 0 N--CA 1.453 -0.301 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 47.6 Cg_exo -58.82 -27.91 85.41 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.138 2.558 . . . . 0.0 114.205 -177.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.0 m -142.01 141.93 32.89 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 -176.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.697 HG13 ' OD1' ' A' ' 46' ' ' ASN . 87.8 mt -53.39 -40.35 39.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.956 175.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -67.49 -34.3 67.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.099 0.476 . . . . 0.0 110.49 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -74.53 -36.23 63.16 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.245 0.545 . . . . 0.0 109.775 177.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -63.97 -42.13 97.35 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.4 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 15' ' ' VAL . 6.7 p -67.73 -37.65 82.48 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.032 178.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -66.86 -34.38 77.67 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.277 0.561 . . . . 0.0 110.734 179.144 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.616 ' CZ ' ' HB2' ' A' ' 23' ' ' GLU . 50.6 t80 -58.85 -53.24 60.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.117 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -55.39 -30.85 61.18 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.398 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 11' ' ' SER . 90.0 t -63.57 -34.18 66.05 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.476 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.52 -23.36 42.97 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.946 -0.471 . . . . 0.0 111.176 -175.386 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -74.61 -18.27 60.58 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 177.155 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 95.3 mt -63.77 -53.21 52.09 Favored Pre-proline 0 N--CA 1.442 -0.839 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -177.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.49 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 61.2 Cg_endo -73.25 2.99 5.01 Favored 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.054 1.836 . . . . 0.0 113.181 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.32 36.76 7.96 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.485 178.28 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.565 HG22 ' HD2' ' A' ' 22' ' ' PRO . 0.4 OUTLIER -97.6 141.05 22.41 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 176.621 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.566 ' HG2' ' HB3' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -61.07 117.74 4.55 Favored 'Trans proline' 0 N--CA 1.446 -1.309 0 C-N-CA 122.962 2.441 . . . . 0.0 110.944 178.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.616 ' HB2' ' CZ ' ' A' ' 13' ' ' PHE . 9.7 pt-20 -51.81 -29.75 20.46 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.854 175.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.18 -41.74 97.34 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.554 174.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.566 ' HB3' ' HG2' ' A' ' 22' ' ' PRO . 50.7 tp -77.52 -39.44 46.15 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-O 120.737 0.303 . . . . 0.0 110.427 179.591 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.509 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 26.6 m -64.69 -39.74 94.18 Favored 'General case' 0 C--O 1.22 -0.455 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.041 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -64.98 -23.59 67.26 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.57 0.7 . . . . 0.0 111.58 -178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 53.5 m -75.59 -22.35 57.0 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 114.673 -1.149 . . . . 0.0 110.316 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -104.03 -43.46 5.27 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.862 0.839 . . . . 0.0 110.13 -178.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.405 HG21 ' HB2' ' A' ' 13' ' ' PHE . 93.9 m -64.89 -55.37 19.74 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.24 -1.346 . . . . 0.0 111.849 -178.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 131.1 -24.92 4.18 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.547 -178.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.556 ' O ' ' HB1' ' A' ' 27' ' ' ALA . 38.2 m -64.34 158.85 22.44 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.3 pt -130.16 139.55 51.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 C-N-CA 120.427 -0.509 . . . . 0.0 112.293 -175.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.0 mp -85.68 125.7 40.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.954 HG23 ' HB ' ' A' ' 1' ' ' THR . 9.2 tt -129.65 110.35 17.44 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.46 0.648 . . . . 0.0 110.784 -171.057 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 34.9 Cg_exo -62.24 -32.38 82.3 Favored 'Trans proline' 0 N--CA 1.477 0.544 0 C-N-CA 123.785 2.99 . . . . 0.0 114.331 -174.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -153.41 -163.4 11.75 Favored Glycine 0 N--CA 1.44 -1.071 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.434 -177.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 57.56 25.97 12.22 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 123.06 0.544 . . . . 0.0 111.634 -178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 49.3 m 42.28 -99.48 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.0 -176.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 79.8 m -158.51 137.86 8.33 Favored Pre-proline 0 C--N 1.314 -0.949 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.32 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.591 ' HG2' ' HB2' ' A' ' 44' ' ' TYR . 52.5 Cg_endo -72.55 148.23 47.43 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.865 1.71 . . . . 0.0 110.796 169.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.04 10.39 14.97 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 121.364 -0.446 . . . . 0.0 113.529 -173.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -112.67 -16.28 12.83 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.628 0.728 . . . . 0.0 109.252 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.591 ' HB2' ' HG2' ' A' ' 41' ' ' PRO . 21.4 m-85 -119.93 18.67 12.48 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.352 -178.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -113.19 45.85 1.32 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.672 177.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.697 ' OD1' HG13 ' A' ' 7' ' ' ILE . 15.6 t-20 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.211 -0.899 . . . . 0.0 110.481 -175.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.535 ' HB ' HG13 ' A' ' 35' ' ' ILE . 86.1 m . . . . . 0 N--CA 1.475 0.794 0 CA-C-O 121.061 0.457 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.8 t -123.37 142.42 50.98 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.023 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 44' ' ' TYR . 22.1 p -152.48 147.96 26.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.912 0.387 . . . . 0.0 110.682 175.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.633 ' SG ' ' HD2' ' A' ' 5' ' ' PRO . 15.2 t -141.36 144.03 32.54 Favored Pre-proline 0 C--N 1.328 -0.331 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.746 ' HA ' ' HA ' ' A' ' 44' ' ' TYR . 3.6 Cg_exo -39.25 -51.86 2.5 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 124.474 3.45 . . . . 0.0 114.694 -177.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.488 ' HA ' ' HB3' ' A' ' 46' ' ' ASN . 3.8 p -147.74 160.6 42.53 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 122.29 -0.256 . . . . 0.0 111.394 -176.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.495 HG13 ' OD1' ' A' ' 46' ' ' ASN . 80.2 mt -53.82 -39.59 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.429 178.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 84.5 t -59.87 -52.92 55.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.652 0.263 . . . . 0.0 110.611 178.248 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -63.27 -35.46 80.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.746 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.553 ' HA ' ' HD2' ' A' ' 13' ' ' PHE . 1.0 OUTLIER -67.27 -41.01 86.23 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-O 121.231 0.539 . . . . 0.0 110.103 178.194 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.524 ' O ' HG23 ' A' ' 15' ' ' VAL . 29.7 t -57.87 -42.55 84.76 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.867 174.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -46.03 79.37 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.313 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.556 ' HB3' HG21 ' A' ' 30' ' ' THR . 0.8 OUTLIER -72.54 -35.19 67.99 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.856 -175.699 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -59.85 -43.15 94.8 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.921 0.391 . . . . 0.0 110.019 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 11' ' ' SER . 63.3 t -67.26 -21.37 27.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.046 177.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.424 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 14.0 t -80.99 -25.4 37.29 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 120.929 0.395 . . . . 0.0 110.749 -176.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -72.0 -41.51 67.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.052 0.453 . . . . 0.0 110.741 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.955 ' HG ' ' HD3' ' A' ' 19' ' ' PRO . 0.4 OUTLIER -56.55 -40.5 85.42 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -171.093 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.955 ' HD3' ' HG ' ' A' ' 18' ' ' LEU . 59.6 Cg_endo -74.1 0.6 8.21 Favored 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 121.522 1.481 . . . . 0.0 113.377 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.29 34.08 4.63 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.476 178.181 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.532 ' HB ' ' SG ' ' A' ' 26' ' ' CYS . 0.8 OUTLIER -104.36 135.82 19.27 Favored Pre-proline 0 N--CA 1.436 -1.143 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.677 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.654 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 19.0 Cg_endo -63.74 127.71 20.33 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 122.848 2.366 . . . . 0.0 111.053 176.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.536 ' CD ' ' H ' ' A' ' 23' ' ' GLU . 1.5 mp0 -37.56 -40.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.346 172.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.43 -50.07 72.72 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.162 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.654 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.0 OUTLIER -63.98 -36.42 83.91 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.107 0.479 . . . . 0.0 110.088 177.812 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB ' ' A' ' 21' ' ' THR . 21.5 m -79.02 10.83 3.11 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.249 -179.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.25 -38.85 5.86 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.847 0.832 . . . . 0.0 110.359 171.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 29.4 m -69.59 -29.56 67.12 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.975 -1.466 . . . . 0.0 112.324 -173.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -103.77 -31.74 9.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.732 0.777 . . . . 0.0 109.913 -175.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.556 HG21 ' HB3' ' A' ' 13' ' ' PHE . 15.6 m -78.51 -33.1 48.3 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 114.426 -1.261 . . . . 0.0 111.684 -175.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.85 0.55 36.39 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.913 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.1 m -85.69 155.02 21.26 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.412 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.6 pt -120.43 144.98 27.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.398 0.618 . . . . 0.0 111.965 -176.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 79.5 mt -107.87 127.44 63.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.178 175.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HB2' ' A' ' 40' ' ' CYS . 24.3 pt -132.32 134.11 24.55 Favored Pre-proline 0 C--N 1.319 -0.76 0 CA-C-O 120.936 0.398 . . . . 0.0 111.476 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 -9.81 15.7 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.625 2.217 . . . . 0.0 111.176 173.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -115.01 -142.34 7.76 Favored Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.62 15.34 7.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 120.732 0.301 . . . . 0.0 111.181 -177.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.5 m -80.29 86.32 5.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.51 0.672 . . . . 0.0 110.751 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.545 ' HB2' HD13 ' A' ' 35' ' ' ILE . 42.1 t -158.29 116.26 1.78 Allowed Pre-proline 0 C--N 1.311 -1.108 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.672 179.05 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.96 166.65 28.94 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.415 2.076 . . . . 0.0 112.692 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -76.46 10.9 14.9 Favored Glycine 0 N--CA 1.451 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.084 -177.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -98.43 -18.84 18.04 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.746 ' HA ' ' HA ' ' A' ' 5' ' ' PRO . 17.4 m-85 -120.0 18.4 12.44 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.827 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -115.09 47.25 1.31 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.212 -175.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.495 ' OD1' HG13 ' A' ' 7' ' ' ILE . 2.3 t-20 . . . . . 0 C--O 1.246 0.885 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.389 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.497 ' HB ' ' O ' ' A' ' 35' ' ' ILE . 88.7 m . . . . . 0 N--CA 1.473 0.685 0 CA-C-O 121.131 0.491 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.46 HG23 HG12 ' A' ' 34' ' ' ILE . 40.2 m -128.92 112.01 13.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.729 -176.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' CYS . 73.2 m -75.5 90.82 2.75 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 176.124 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.506 ' SG ' HG21 ' A' ' 30' ' ' THR . 1.4 t -125.35 87.8 55.11 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -177.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.63 78.73 2.99 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 123.418 2.745 . . . . 0.0 114.025 -167.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.742 ' HB3' ' HB3' ' A' ' 9' ' ' ALA . 29.2 t 172.21 132.87 0.03 OUTLIER 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 171.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.667 ' H ' HD12 ' A' ' 7' ' ' ILE . 3.7 mp -62.93 -31.57 52.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.2 t -80.08 -47.26 21.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.173 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.742 ' HB3' ' HB3' ' A' ' 6' ' ' SER . . . -60.75 -48.4 81.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.68 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 13' ' ' PHE . 1.8 ptp180 -62.75 -25.09 68.03 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.621 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.471 ' O ' HG23 ' A' ' 15' ' ' VAL . 67.6 m -69.09 -56.49 7.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.029 178.195 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.474 ' HA ' ' HB ' ' A' ' 15' ' ' VAL . 11.2 p30 -64.32 -22.38 66.93 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.634 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.42 ' HB3' ' O ' ' A' ' 10' ' ' ARG . 61.8 t80 -59.12 -59.69 5.05 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.653 170.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 17' ' ' ARG . 2.3 p-10 -71.73 -27.1 62.77 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.877 0.37 . . . . 0.0 110.903 -178.496 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.474 ' HB ' ' HA ' ' A' ' 12' ' ' ASN . 78.1 t -70.31 -17.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 121.006 0.431 . . . . 0.0 110.263 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.676 ' O ' ' HD2' ' A' ' 19' ' ' PRO . 3.8 t -84.66 -29.03 26.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.417 0.627 . . . . 0.0 109.707 177.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.451 ' HB3' ' O ' ' A' ' 14' ' ' ASN . 6.9 tpt180 -58.42 -40.72 83.23 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.383 175.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.566 ' HB2' ' HD3' ' A' ' 19' ' ' PRO . 86.1 mt -61.08 -50.29 85.09 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 113.775 1.028 . . . . 0.0 113.775 -172.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.676 ' HD2' ' O ' ' A' ' 16' ' ' CYS . 7.9 Cg_exo -73.39 13.56 0.69 Allowed 'Trans proline' 0 C--N 1.358 1.079 0 C-N-CA 122.581 2.187 . . . . 0.0 113.507 -177.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.23 36.85 9.47 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.897 176.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -108.79 134.9 20.17 Favored Pre-proline 0 N--CA 1.434 -1.27 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 176.887 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.752 ' HG2' ' HB2' ' A' ' 25' ' ' LEU . 13.3 Cg_endo -60.18 122.51 11.48 Favored 'Trans proline' 0 N--CA 1.446 -1.29 0 C-N-CA 122.951 2.434 . . . . 0.0 111.121 178.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -35.84 -39.56 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.398 169.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.56 -53.39 58.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.192 176.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.752 ' HB2' ' HG2' ' A' ' 22' ' ' PRO . 1.3 tm? -63.71 -37.2 86.46 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-O 121.004 0.431 . . . . 0.0 110.782 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 23.9 m -65.04 -37.43 87.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.358 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.52 -32.4 74.02 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.804 0.811 . . . . 0.0 110.462 176.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.8 m -74.89 -22.5 58.6 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 114.47 -1.241 . . . . 0.0 110.761 179.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -89.45 -45.58 9.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.864 0.84 . . . . 0.0 109.024 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.506 HG21 ' SG ' ' A' ' 4' ' ' CYS . 85.0 m -70.89 -37.79 73.01 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.002 -1.454 . . . . 0.0 111.061 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.04 16.89 17.65 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.904 -0.665 . . . . 0.0 113.017 179.11 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.592 ' HB2' ' O ' ' A' ' 3' ' ' CYS . 10.7 p -114.24 179.53 3.93 Favored 'General case' 0 C--N 1.327 -0.395 0 O-C-N 122.725 -0.279 . . . . 0.0 110.721 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.46 HD13 ' H ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -127.77 141.88 45.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 111.563 -173.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.46 HG12 HG23 ' A' ' 2' ' ' THR . 60.3 mt -99.44 140.17 19.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.777 176.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.845 HD12 ' HB3' ' A' ' 38' ' ' ALA . 11.2 pt -137.91 129.14 15.94 Favored Pre-proline 0 N--CA 1.448 -0.545 0 CA-C-O 121.201 0.524 . . . . 0.0 111.388 -177.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 35' ' ' ILE . 32.6 Cg_exo -61.62 -27.77 81.94 Favored 'Trans proline' 0 CA--C 1.53 0.307 0 C-N-CA 123.029 2.486 . . . . 0.0 112.639 176.608 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.457 ' C ' ' H ' ' A' ' 39' ' ' THR . . . -132.94 -153.46 7.22 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.927 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.845 ' HB3' HD12 ' A' ' 35' ' ' ILE . . . 71.69 -29.04 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.904 0.881 . . . . 0.0 111.898 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' C ' ' A' ' 37' ' ' GLY . 52.2 m 65.81 5.45 3.41 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.331 0.652 . . . . 0.0 112.512 176.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 66.9 m 65.59 137.46 0.05 OUTLIER Pre-proline 0 N--CA 1.468 0.465 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.141 -175.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -74.62 175.85 10.54 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.418 2.079 . . . . 0.0 111.698 175.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -73.94 -0.82 57.49 Favored Glycine 0 CA--C 1.518 0.235 0 C-N-CA 121.363 -0.446 . . . . 0.0 113.12 -175.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -98.07 -22.25 16.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.193 0.52 . . . . 0.0 109.612 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.541 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 16.0 m-85 -121.44 19.95 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.679 -173.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.11 14.8 29.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.393 0.616 . . . . 0.0 110.77 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 18.3 m120 . . . . . 0 C--O 1.247 0.971 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.681 179.404 . . . . . . . . 0 0 . 1 stop_ save_